<SEC-DOCUMENT>0001161697-24-000226.txt : 20240501
<SEC-HEADER>0001161697-24-000226.hdr.sgml : 20240501
<ACCEPTANCE-DATETIME>20240501160328
ACCESSION NUMBER:		0001161697-24-000226
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		57
CONFORMED PERIOD OF REPORT:	20240331
FILED AS OF DATE:		20240501
DATE AS OF CHANGE:		20240501

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KORU Medical Systems, Inc.
		CENTRAL INDEX KEY:			0000704440
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				133044880
		STATE OF INCORPORATION:			NY
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39086
		FILM NUMBER:		24902883

	BUSINESS ADDRESS:	
		STREET 1:		100 CORPORATE DRIVE
		CITY:			MAHWAH
		STATE:			NJ
		ZIP:			07430
		BUSINESS PHONE:		845-469-2042

	MAIL ADDRESS:	
		STREET 1:		100 CORPORATE DRIVE
		CITY:			MAHWAH
		STATE:			NJ
		ZIP:			07430

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	REPRO MED SYSTEMS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>form_10-q.htm
<DESCRIPTION>FORM 10-Q QUARTERLY REPORT FOR 03-31-2024
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:krmd="http://korumedical.com/20240331">
<head>
     <title>KORU Medical Systems, Inc. Form 10-Q Quarterly Report for 03-31-2024</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_039_krmd_korumedical.com_20240331 -->
<!-- Field: Set; Name: xdx; ID: xdx_04C_20240101_20240331 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_052_edei%2D%2DDocumentFiscalYearFocus_2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DDocumentFiscalPeriodFocus_Q1 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DEntityCentralIndexKey_0000704440 -->
<!-- Field: Set; Name: xdx; ID: xdx_075_XDX_D%2D%2D\EDGARbiz\Clients (D)\KORU (fka Repro%2DMed)\10%2DQ 2024%2D03%2D31 KORU\form__10%2Dq.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_064_N_0_Number -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2024-01-01to2024-03-31" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-03-31" id="Fact000004" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-03-31" id="Fact000005" name="dei:DocumentFiscalYearFocus">2024</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-03-31" id="Fact000006" name="dei:DocumentFiscalPeriodFocus">Q1</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-03-31" id="Fact000007" name="dei:EntityCentralIndexKey">0000704440</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="AsOf2024-03-31" id="xdx2ixbrl0084" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="AsOf2023-12-31" id="xdx2ixbrl0085" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-01to2024-03-31" id="xdx2ixbrl0213" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DeferredIncomeTaxesAndTaxCredits" contextRef="From2024-01-01to2024-03-31" id="xdx2ixbrl0252" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2024-01-01to2024-03-31" id="xdx2ixbrl0330" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2023-01-012023-03-31" id="xdx2ixbrl0331" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0349" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-01-012024-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0350" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0355" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0357" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-012024-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0358" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0361" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0363" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2024-01-012024-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0364" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0367" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0369" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2024-01-012024-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0370" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0373" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0374" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0376" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0397" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0398" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0403" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0405" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0406" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0417" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0418" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0420" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NumberOfReportableSegments" contextRef="From2024-01-01to2024-03-31" id="xdx2ixbrl0435" decimals="INF" unitRef="N">1</ix:nonFraction>
  <ix:nonFraction name="krmd:AntiDilutiveStockOptions" contextRef="From2024-01-01to2024-03-31" id="xdx2ixbrl0452" decimals="INF" unitRef="Shares">0</ix:nonFraction>
  <ix:nonFraction name="krmd:CommonStockOptions" contextRef="From2024-01-01to2024-03-31" id="xdx2ixbrl0462" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="krmd:PerformanceStockUnits" contextRef="From2023-01-012023-03-31" id="xdx2ixbrl0466" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="krmd:DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock" contextRef="From2024-01-01to2024-03-31" id="xdx2ixbrl0485" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="krmd:DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock" contextRef="From2023-01-012023-03-31" id="xdx2ixbrl0486" unitRef="Shares" xs:nil="true"/>
  <ix:nonNumeric contextRef="From2024-01-012024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" id="xdx2ixbrl0591" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">P10Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-012023-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" id="xdx2ixbrl0593" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">P10Y</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2024-01-012024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" id="xdx2ixbrl0619" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" id="xdx2ixbrl0621" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2023-01-012023-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" id="xdx2ixbrl0623" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" id="xdx2ixbrl0625" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2023-01-012023-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" id="xdx2ixbrl0631" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" id="xdx2ixbrl0633" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonNumeric contextRef="From2024-01-012024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member" id="xdx2ixbrl0667" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">P6Y10M25D</ix:nonNumeric>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementByUnvestedAwardOptions" contextRef="AsOf2022-12-31_custom_PerformanceBasedSharesOptionsMember" id="xdx2ixbrl0689" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_PerformanceBasedSharesOptionsMember" id="xdx2ixbrl0690" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementByUnvestedAwardOptions" contextRef="AsOf2023-03-31_custom_PerformanceBasedSharesOptionsMember" id="xdx2ixbrl0716" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice" contextRef="AsOf2023-03-31_custom_PerformanceBasedSharesOptionsMember" id="xdx2ixbrl0717" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2023-01-012023-03-31_us-gaap_PerformanceSharesMember" id="xdx2ixbrl0721" decimals="0" unitRef="USD">0</ix:nonFraction>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" contextRef="From2024-01-012024-03-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" id="xdx2ixbrl0735" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" contextRef="From2024-01-012024-03-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" id="xdx2ixbrl0737" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" contextRef="From2023-01-012023-03-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" id="xdx2ixbrl0739" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" contextRef="From2023-01-012023-03-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" id="xdx2ixbrl0741" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" contextRef="From2024-01-012024-03-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" id="xdx2ixbrl0743" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-03-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" id="xdx2ixbrl0745" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" contextRef="From2024-01-012024-03-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" id="xdx2ixbrl0751" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" contextRef="From2024-01-012024-03-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" id="xdx2ixbrl0753" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" contextRef="From2023-01-012023-03-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" id="xdx2ixbrl0755" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" contextRef="From2023-01-012023-03-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" id="xdx2ixbrl0757" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" contextRef="AsOf2023-12-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member" id="xdx2ixbrl0778" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" contextRef="AsOf2023-12-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member" id="xdx2ixbrl0780" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" contextRef="AsOf2022-12-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member" id="xdx2ixbrl0782" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" contextRef="AsOf2022-12-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member" id="xdx2ixbrl0784" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" contextRef="From2023-01-012023-03-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member" id="xdx2ixbrl0790" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" contextRef="From2023-01-012023-03-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member" id="xdx2ixbrl0792" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" contextRef="From2023-01-012023-03-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member" id="xdx2ixbrl0798" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-03-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member" id="xdx2ixbrl0800" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" contextRef="From2024-01-012024-03-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member" id="xdx2ixbrl0802" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" contextRef="From2024-01-012024-03-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member" id="xdx2ixbrl0804" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" contextRef="From2023-01-012023-03-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member" id="xdx2ixbrl0806" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" contextRef="From2023-01-012023-03-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member" id="xdx2ixbrl0808" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" contextRef="AsOf2023-03-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member" id="xdx2ixbrl0814" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" contextRef="AsOf2023-03-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member" id="xdx2ixbrl0816" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="krmd:UnrecognizedCompensationCost" contextRef="From2023-01-012023-03-31_custom_CommonStockWarrantsMember" id="xdx2ixbrl0820" decimals="0" unitRef="USD">0</ix:nonFraction>
  <ix:nonNumeric contextRef="From2024-01-012024-03-31_custom_LeaseOneMember" id="xdx2ixbrl0840" name="krmd:LesseeOperatingLeaseRemainingTerm">P8Y4M24D</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-012024-03-31_custom_LeaseTwoMember" id="xdx2ixbrl0842" name="krmd:LesseeOperatingLeaseRemainingTerm">P4Y9M18D</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-012024-03-31_custom_LeaseOneMember" id="xdx2ixbrl0844" name="krmd:LesseeFinanceLeaseRemainingTerm">P3Y2M12D</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-012024-03-31_custom_LeaseTwoMember" id="xdx2ixbrl0846" name="krmd:LesseeFinanceLeaseRemainingTerm">P2Y9M0D</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-012024-03-31_custom_LeaseThreeMember" id="xdx2ixbrl0848" name="krmd:LesseeFinanceLeaseRemainingTerm">P4Y6M0D</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-03-31" id="xdx2ixbrl0923" name="us-gaap:LesseeOperatingLeaseRenewalTerm">P6Y7M6D</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2023-12-31" id="xdx2ixbrl0924" name="us-gaap:LesseeOperatingLeaseRenewalTerm">P6Y10M25D</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-03-31" id="xdx2ixbrl0926" name="us-gaap:LesseeFinanceLeaseRenewalTerm1">P3Y7M6D</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2023-12-31" id="xdx2ixbrl0927" name="us-gaap:LesseeFinanceLeaseRenewalTerm1">P6Y8M12D</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive" contextRef="AsOf2024-03-31" id="xdx2ixbrl0959" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2024-01-01to2024-03-31" id="xdx2ixbrl0975" decimals="0" unitRef="USD">0</ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="krmd-20240331.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2024-01-01to2024-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_NonUsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_NonUsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_FurnitureAndOfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_FurnitureAndOfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_ManufacturingEquipmentAndToolingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:ManufacturingEquipmentAndToolingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ManufacturingEquipmentAndToolingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:ManufacturingEquipmentAndToolingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_StockOptionPlan2021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_StockOptionPlan2021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_NonEmployeeDirectorAndBoardAdvisorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">krmd:NonEmployeeDirectorAndBoardAdvisorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_srt_BoardOfDirectorsChairmanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_StockOptionPlans2015And2021CombinedMember_custom_TimeBasedSharesOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlans2015And2021CombinedMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_StockOptionPlans2015And2021CombinedMember_custom_TimeBasedSharesOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlans2015And2021CombinedMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_StockOptionPlans2015And2021CombinedMember_custom_TimeBasedSharesOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlans2015And2021CombinedMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_StockOptionPlans2015And2021CombinedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlans2015And2021CombinedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_StockOptionPlans2015And2021CombinedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlans2015And2021CombinedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_PerformanceSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_PerformanceSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">krmd:ExercisePrice1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">krmd:ExercisePrice1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_PerformanceBasedSharesOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:PerformanceBasedSharesOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_PerformanceBasedSharesOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:PerformanceBasedSharesOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_PerformanceBasedSharesOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:PerformanceBasedSharesOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_PerformanceBasedSharesOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:PerformanceBasedSharesOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_PerformanceBasedSharesOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:PerformanceBasedSharesOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_PerformanceBasedSharesOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:PerformanceBasedSharesOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:CommonStockWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:CommonStockWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:CommonStockWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:CommonStockWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:CommonStockWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:CommonStockWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-28_custom_AONPremiumFinanceLLCMember_custom_PromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krmd:AONPremiumFinanceLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">krmd:PromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-262023-07-28_custom_AONPremiumFinanceLLCMember_custom_PromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krmd:AONPremiumFinanceLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">krmd:PromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-26</xbrli:startDate>
        <xbrli:endDate>2023-07-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_AONPremiumFinanceLLCMember_custom_PromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krmd:AONPremiumFinanceLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">krmd:PromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_AONPremiumFinanceLLCMember_custom_PromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krmd:AONPremiumFinanceLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">krmd:PromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-08_custom_HSBCVenturesUSAIncMember_us-gaap_RevolvingCreditFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krmd:HSBCVenturesUSAIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-08_custom_HSBCVenturesUSAIncMember_custom_TermLoanFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krmd:HSBCVenturesUSAIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">krmd:TermLoanFacilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_LeaseOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">krmd:LeaseOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_LeaseTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">krmd:LeaseTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_LeaseThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">krmd:LeaseThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="N">
      <xbrli:measure>krmd:Number</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<div style="width: 7.5in">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>FORM <span id="xdx_900_edei--DocumentType_c20240101__20240331_zjOVCmAaNuG6"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" id="Fact000014" name="dei:DocumentType">10-Q</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(Mark One)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_908_edei--DocumentQuarterlyReport_c20240101__20240331_zGNMcjuYCZec"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" format="ixt:booleantrue" id="Fact000015" name="dei:DocumentQuarterlyReport">[X]</ix:nonNumeric></span></b>&#160;&#160;QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Quarterly Period Ended <span style="text-decoration: underline"><span id="xdx_909_edei--DocumentPeriodEndDate_dd_c20240101__20240331_z8WOCft3Suag"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" format="ixt:datemonthdayyearen" id="Fact000016" name="dei:DocumentPeriodEndDate">March 31, 2024</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">or</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_908_edei--DocumentTransitionReport_c20240101__20240331_zPDPUf0A4w8b"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" format="ixt:booleanfalse" id="Fact000017" name="dei:DocumentTransitionReport">[_]</ix:nonNumeric></span>&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the transition period from ________ to ________.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Commission File Number: <b><span style="text-decoration: underline"><span id="xdx_90A_edei--EntityFileNumber_c20240101__20240331_z7v4q9LMBTkd"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" id="Fact000018" name="dei:EntityFileNumber">0-12305</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_903_edei--EntityRegistrantName_c20240101__20240331_zKQOUN8kIDbg"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" id="Fact000019" name="dei:EntityRegistrantName">KORU MEDICAL SYSTEMS, INC.</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3.75in; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_908_edei--EntityIncorporationStateCountryCode_c20240101__20240331_zA14Q5YtGIRa"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" format="ixt-sec:stateprovnameen" id="Fact000020" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></span></b></td>
    <td style="width: 3.75in; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_90C_edei--EntityTaxIdentificationNumber_c20240101__20240331_zhjkyGfPlWA7"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" id="Fact000021" name="dei:EntityTaxIdentificationNumber">13-3044880</ix:nonNumeric></span></span></b></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">(State or other jurisdiction of incorporation or organization)</td>
    <td style="text-align: center">(I.R.S. Employer Identification No.)</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><b><span style="text-decoration: underline"><span id="xdx_907_edei--EntityAddressAddressLine1_c20240101__20240331_zuOhiqqzeoC5"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" id="Fact000022" name="dei:EntityAddressAddressLine1">100 Corporate Drive</ix:nonNumeric></span>, <span id="xdx_907_edei--EntityAddressCityOrTown_c20240101__20240331_zjrxLyaAkKQj"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" id="Fact000023" name="dei:EntityAddressCityOrTown">Mahwah</ix:nonNumeric></span>, <span id="xdx_90A_edei--EntityAddressStateOrProvince_c20240101__20240331_zTGI8DqHTBu7"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" format="ixt-sec:stateprovnameen" id="Fact000024" name="dei:EntityAddressStateOrProvince">New Jersey</ix:nonNumeric></span></span></b></td>
    <td style="text-align: center"><b><span style="text-decoration: underline"><span id="xdx_90F_edei--EntityAddressPostalZipCode_c20240101__20240331_zJxIlh2kT8B8"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" id="Fact000025" name="dei:EntityAddressPostalZipCode">07430</ix:nonNumeric></span></span></b></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">(Address of principal executive offices)</td>
    <td style="text-align: center">(Zip Code)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="text-decoration: underline">(<span id="xdx_907_edei--CityAreaCode_c20240101__20240331_zayjbU6fkgaa"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" id="Fact000026" name="dei:CityAreaCode">845</ix:nonNumeric></span>) <span id="xdx_906_edei--LocalPhoneNumber_c20240101__20240331_zXsqhlLFGHf3"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" id="Fact000027" name="dei:LocalPhoneNumber">469-2042</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Registrant&#8217;s telephone number, including area
code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 2.5in; text-align: center"><span style="text-decoration: underline">Title of each class</span></td>
    <td style="width: 1.5in; text-align: center"><span style="text-decoration: underline">Trading Symbol(s)</span></td>
    <td style="width: 3.5in; text-align: center"><span style="text-decoration: underline">Name of each exchange on which registered</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b><span id="xdx_906_edei--Security12bTitle_c20240101__20240331_zBlT8XpJkA9f"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" id="Fact000028" name="dei:Security12bTitle">Common stock, $0.01 par value</ix:nonNumeric></span></b></td>
    <td style="text-align: center"><b><span id="xdx_908_edei--TradingSymbol_c20240101__20240331_z6WNKE9d5vgf"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" id="Fact000029" name="dei:TradingSymbol">KRMD</ix:nonNumeric></span></b></td>
    <td style="text-align: center"><b><span id="xdx_907_edei--SecurityExchangeName_c20240101__20240331_zYKymK5qke6k"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" format="ixt-sec:exchnameen" id="Fact000030" name="dei:SecurityExchangeName">The Nasdaq Stock Market</ix:nonNumeric></span></b></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
&#160;<b>[X]</b> <span id="xdx_908_edei--EntityCurrentReportingStatus_c20240101__20240331_zew4ell0nWW9"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" id="Fact000031" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#160;[_] No</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant has submitted electronically
every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the
preceding 12 months (or for such shorter period that the registrant was required to submit such files). &#160;<b>[X]</b> <span id="xdx_900_edei--EntityInteractiveDataCurrent_c20240101__20240331_zGlTWdmMAAg"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" id="Fact000032" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#160;[_]
No</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant is a large accelerated filer,
an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of &#8220;large
accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221;
in Rule 12b-2 of the Exchange Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1in">&#160;</td>
    <td style="width: 3.5in">Large accelerated filer [_]</td>
    <td style="width: 3in">Accelerated filer [_]</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span id="xdx_90D_edei--EntityFilerCategory_c20240101__20240331_zZfWcfTFjTbg"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" format="ixt-sec:entityfilercategoryen" id="Fact000033" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric></span> &#160;&#160;<b>[X]</b></td>
    <td>Smaller reporting company <b><span id="xdx_90D_edei--EntitySmallBusiness_c20240101__20240331_zmmLkUqnasrj"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" format="ixt:booleantrue" id="Fact000034" name="dei:EntitySmallBusiness">[X]</ix:nonNumeric></span></b></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>Emerging growth company <span id="xdx_900_edei--EntityEmergingGrowthCompany_c20240101__20240331_zifeEWtK5Bzb"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" format="ixt:booleanfalse" id="Fact000035" name="dei:EntityEmergingGrowthCompany">[_]</ix:nonNumeric></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. [_]</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant is a shell company (as defined
in Rule 12b-2 of the Exchange Act). &#160;[_] Yes &#160;<b>[X]</b> <span id="xdx_902_edei--EntityShellCompany_c20240101__20240331_zgv02TGUMbIf"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" format="ixt:booleanfalse" id="Fact000036" name="dei:EntityShellCompany">No</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of May 1, 2024, <span id="xdx_903_edei--EntityCommonStockSharesOutstanding_iI_pid_uShares_c20240501_zA9eqVRkTgL6"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2024-05-01" id="Fact000037" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">45,764,225</ix:nonFraction></span> shares of common stock, $<span id="xdx_905_edei--EntityListingParValuePerShare_pid_uUSDPShares_c20240101__20240331_zZvtXEzW1eVj" title="Entity Listing, Par Value Per Share"><ix:nonFraction name="dei:EntityListingParValuePerShare" contextRef="From2024-01-01to2024-03-31" id="Fact000039" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span> par value
per share, were outstanding, which excludes <span id="xdx_90D_eus-gaap--TreasuryStockCommonShares_iI_pid_uShares_c20240501_zLoTiiVxbZu2" title="Treasury Stock, Common, Shares"><ix:nonFraction name="us-gaap:TreasuryStockCommonShares" contextRef="AsOf2024-05-01" id="Fact000041" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,420,502</ix:nonFraction></span> shares of treasury stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="toc"></span><b>KORU MEDICAL SYSTEMS, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>FORM 10-Q</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>TABLE OF CONTENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 6.25in">&#160;</td>
    <td style="width: 0.5in; text-align: center"><span style="text-decoration: underline">PAGE</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="3" style="text-align: center">PART I. FINANCIAL INFORMATION</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>ITEM 1.</td>
    <td><a href="#Part_I_Item_1">Financial Statements (Unaudited)</a></td>
    <td style="text-align: center">3</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>&#160;</td>
    <td><a href="#bs">Balance Sheets as of March 31, 2024 (Unaudited) and December 31, 2023</a></td>
    <td style="text-align: center">3</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>&#160;</td>
    <td><a href="#so">Statements of Operations (Unaudited) for the three months ended March 31, 2024 and 2023</a></td>
    <td style="text-align: center">4</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>&#160;</td>
    <td><a href="#scf">Statements of Cash Flows (Unaudited) for the three months ended March 31,2024 and 2023</a></td>
    <td style="text-align: center">5</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>&#160;</td>
    <td><a href="#se">Statements of Stockholders' Equity (Unaudited) for the three months ended March 31, 2024 and 2023</a></td>
    <td style="text-align: center">6</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>&#160;</td>
    <td><a href="#notes">Notes to Financial Statements</a></td>
    <td style="text-align: center">7</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>ITEM 2.</td>
    <td><a href="#Part_I_Item_2">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></td>
    <td style="text-align: center">17</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>ITEM 3.</td>
    <td><a href="#Part_I_Item_3">Quantitative and Qualitative Disclosures About Market Risk</a></td>
    <td style="text-align: center">20</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>ITEM 4.</td>
    <td><a href="#Part_I_Item_4">Controls and Procedures</a></td>
    <td style="text-align: center">20</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="3" style="text-align: center">PART II. OTHER INFORMATION</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>ITEM 1A.</td>
    <td><a href="#Part_II_Item_1A">Risk Factors</a></td>
    <td style="text-align: center">20</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>ITEM 6.</td>
    <td><a href="#Part_II_Item_6">Exhibits</a></td>
    <td style="text-align: center">21</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>&#160;</td>
    <td><a href="#signatures">Signatures</a></td>
    <td style="text-align: center">22</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 2 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc"><span style="color: Blue">Table of Contents</span></a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>PART I &#8212; FINANCIAL INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="Part_I_Item_1"></span><b>Item 1. &#160;Financial Statements (Unaudited)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="bs"></span><b>KORU MEDICAL SYSTEMS, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>BALANCE SHEETS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(UNAUDITED)</b></p>

<table cellspacing="0" cellpadding="0" id="xdx_30E_111_zHXiB3yR5dqe" summary="xdx: Statement - BALANCE SHEETS (UNAUDITED)" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49B_20240331_zhuPEipIuHJ1" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49A_20231231_zy0mPI40hJvf" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>March 31,</b></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>December 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 70%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: right">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsAbstract_iB_zbvY2JrK4YP6" style="vertical-align: bottom; background-color: #E6E6E6">
    <td><b>ASSETS</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AssetsCurrentAbstract_i01B_zMDWobimNMZd" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>CURRENT ASSETS</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maACzL7R_zNUIUE0g0ruk" style="vertical-align: bottom">
    <td style="padding-left: 0.2in; text-indent: -0.1in">Cash and cash equivalents</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-03-31" id="Fact000049" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,820,317</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31" id="Fact000050" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,482,240</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccountsReceivableNetCurrent_i02I_maACzL7R_zfLEhdHx6Lp3" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.2in; text-indent: -0.1in">Accounts receivable less allowance for doubtful accounts of $<span id="xdx_907_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20240331_zGbj5ZMGOA0f" title="Accounts receivable, allowance for credit loss, current"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="AsOf2024-03-31" id="Fact000055" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,777</ix:nonFraction></span> as of March 31, 2024 and $<span id="xdx_90F_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20231231_z8yYs6v5OROf" title="Accounts receivable, allowance for credit loss, current"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="AsOf2023-12-31" id="Fact000057" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,777</ix:nonFraction></span> as of December 31, 2023</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2024-03-31" id="Fact000052" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,392,511</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2023-12-31" id="Fact000053" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,045,211</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--InventoryNet_i02I_maACzL7R_zWZG3cAij3s1" style="vertical-align: bottom">
    <td style="padding-left: 0.2in; text-indent: -0.1in">Inventory</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2024-03-31" id="Fact000059" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,147,312</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2023-12-31" id="Fact000060" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,481,301</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OtherReceivables_i02I_maACzL7R_zIBQo3e8Krm3" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.2in; text-indent: -0.1in">Other receivables</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OtherReceivables" contextRef="AsOf2024-03-31" id="Fact000062" format="ixt:numdotdecimal" decimals="0" unitRef="USD">288,714</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OtherReceivables" contextRef="AsOf2023-12-31" id="Fact000063" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,889</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PrepaidExpenseCurrent_i02I_maACzL7R_zlN3kLilvCya" style="vertical-align: bottom">
    <td style="padding-left: 0.2in; text-indent: -0.1in">Prepaid expenses</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2024-03-31" id="Fact000065" format="ixt:numdotdecimal" decimals="0" unitRef="USD">830,408</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2023-12-31" id="Fact000066" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,218,288</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AssetsCurrent_i02TI_mtACzL7R_maAzzVs_z4RzveDW0D35" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>TOTAL CURRENT ASSETS</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-03-31" id="Fact000068" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,479,262</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000069" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,255,929</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maAzzVs_zCir8RcX4Mx6" style="vertical-align: bottom">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Property and equipment, net</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-03-31" id="Fact000071" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,755,530</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact000072" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,837,657</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsNet_i01I_maAzzVs_z5ZgOMNBBOJl" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Intangible assets, net of accumulated amortization of $<span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20240331_zoB5K4b9A7pd" title="Finite-lived intangible assets, accumulated amortization"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2024-03-31" id="Fact000077" format="ixt:numdotdecimal" decimals="0" unitRef="USD">406,801</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20231231_z2yIe7UcpGdh" title="Finite-lived intangible assets, accumulated amortization"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-12-31" id="Fact000079" format="ixt:numdotdecimal" decimals="0" unitRef="USD">390,341</ix:nonFraction></span> as of March 31, 2024 and December 31, 2023, respectively</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2024-03-31" id="Fact000074" format="ixt:numdotdecimal" decimals="0" unitRef="USD">737,901</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-12-31" id="Fact000075" format="ixt:numdotdecimal" decimals="0" unitRef="USD">754,361</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_maAzzVs_z5sPOOwr3EZg" style="vertical-align: bottom">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Operating lease right-of-use assets</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-03-31" id="Fact000081" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,428,885</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-12-31" id="Fact000082" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,514,055</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredIncomeTaxAssetsNet_i01I_maAzzVs_zquPFrt1tY75" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Deferred income tax assets, net of allowance for non-realization of deferred tax assets of $<span id="xdx_907_eus-gaap--DeferredRentReceivablesNetNoncurrent_iI_c20240331_z7uvyuhyuXV"><ix:nonFraction name="us-gaap:DeferredRentReceivablesNetNoncurrent" contextRef="AsOf2024-03-31" id="Fact000086" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,391,452</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--DeferredRentReceivablesNetNoncurrent_iI_c20231231_zkACCExHVi81"><ix:nonFraction name="us-gaap:DeferredRentReceivablesNetNoncurrent" contextRef="AsOf2023-12-31" id="Fact000087" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,002,777</ix:nonFraction></span> for March 31, 2024 and December 31, 2023, respectively</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0084">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0085">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OtherAssetsNoncurrent_i01I_maAzzVs_zQvlIrrrycI3" style="vertical-align: bottom">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Other assets</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2024-03-31" id="Fact000089" format="ixt:numdotdecimal" decimals="0" unitRef="USD">98,970</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2023-12-31" id="Fact000090" format="ixt:numdotdecimal" decimals="0" unitRef="USD">98,970</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--Assets_i01TI_mtAzzVs_zxtFIlC2pkHe" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>TOTAL ASSETS</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-03-31" id="Fact000092" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,500,548</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31" id="Fact000093" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,460,972</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zae6kxS3kMX7" style="vertical-align: bottom; background-color: #E6E6E6">
    <td><b>LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesCurrentAbstract_i01B_ztEx5Ea0bsvf" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>CURRENT LIABILITIES</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AccountsPayableCurrent_i02I_maLCzFb4_zZUETQMXn25c" style="vertical-align: bottom">
    <td style="padding-left: 0.2in; text-indent: -0.1in">Accounts payable</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-03-31" id="Fact000101" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,774,185</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-12-31" id="Fact000102" format="ixt:numdotdecimal" decimals="0" unitRef="USD">975,193</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AccruedLiabilitiesCurrent_i02I_maLCzFb4_zuKaIRJFBo28" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.2in; text-indent: -0.1in">Accrued expenses</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-03-31" id="Fact000104" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,459,405</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000105" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,711,427</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NotesPayableCurrent_i02I_maLCzFb4_zyGh8Zy7PQl2" style="vertical-align: bottom">
    <td style="padding-left: 0.2in; text-indent: -0.1in">Note payable</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2024-03-31" id="Fact000107" format="ixt:numdotdecimal" decimals="0" unitRef="USD">159,031</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2023-12-31" id="Fact000108" format="ixt:numdotdecimal" decimals="0" unitRef="USD">314,344</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherLiabilitiesCurrent_i02I_maLCzFb4_zi9tEXu4sJh3" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.2in; text-indent: -0.1in">Other liabilities</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2024-03-31" id="Fact000110" format="ixt:numdotdecimal" decimals="0" unitRef="USD">457,653</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000111" format="ixt:numdotdecimal" decimals="0" unitRef="USD">512,520</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--EmployeeRelatedLiabilitiesCurrent_i02I_maLCzFb4_zrWuJvX8hnNi" style="vertical-align: bottom">
    <td style="padding-left: 0.2in; text-indent: -0.1in">Accrued payroll and related taxes</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2024-03-31" id="Fact000113" format="ixt:numdotdecimal" decimals="0" unitRef="USD">519,441</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000114" format="ixt:numdotdecimal" decimals="0" unitRef="USD">462,941</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FinanceLeaseLiabilityCurrent_i02I_maLCzFb4_zvZG7FMAu6rb" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.2in; text-indent: -0.1in">Financing lease liability &#8211; current</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2024-03-31" id="Fact000116" format="ixt:numdotdecimal" decimals="0" unitRef="USD">111,103</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2023-12-31" id="Fact000117" format="ixt:numdotdecimal" decimals="0" unitRef="USD">109,540</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maLCzFb4_ztYXxrrFM7bl" style="vertical-align: bottom">
    <td style="padding-left: 0.2in; text-indent: -0.1in">Operating lease liability &#8211; current</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-03-31" id="Fact000119" format="ixt:numdotdecimal" decimals="0" unitRef="USD">372,109</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-12-31" id="Fact000120" format="ixt:numdotdecimal" decimals="0" unitRef="USD">368,313</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LiabilitiesCurrent_i02TI_mtLCzFb4_maLzvSk_zWs28UEiTqNb" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>TOTAL CURRENT LIABILITIES</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-03-31" id="Fact000122" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,852,927</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000123" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,454,278</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FinanceLeaseLiabilityNoncurrent_i02I_maLzvSk_zwDEC7uDMFUk" style="vertical-align: bottom">
    <td>Financing lease liability, net of current portion</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2024-03-31" id="Fact000125" format="ixt:numdotdecimal" decimals="0" unitRef="USD">288,253</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2023-12-31" id="Fact000126" format="ixt:numdotdecimal" decimals="0" unitRef="USD">316,623</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_maLzvSk_zngWJW5wZVZ2" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 45.5pt; text-indent: -45.5pt">Operating lease liability, net of current portion</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-03-31" id="Fact000128" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,241,837</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-12-31" id="Fact000129" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,336,300</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--Liabilities_i01TI_mtLzvSk_maLASEzytn_zjkjfuhsVefh" style="vertical-align: bottom">
    <td>TOTAL LIABILITIES</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-03-31" id="Fact000131" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,383,017</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-12-31" id="Fact000132" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,107,201</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--StockholdersEquityAbstract_i01B_zYOH98VOHsvi" style="vertical-align: bottom">
    <td>STOCKHOLDERS&#8217; EQUITY</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CommonStockValue_i02I_maSEzqKe_zlBDKgmvh8rd" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.2in; text-indent: -0.1in"><p style="margin-top: 0; margin-bottom: 0">Common stock, $<span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20231231_zWgjtMsLv9Kg"><span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20240331_z3lUjRhCqWV9"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000139" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-03-31" id="Fact000140" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></ix:nonFraction></span>
</span>par value, <span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20231231_zznz9ZgXlNJ8"><span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20240331_z2qH8uDnGOT4"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000141" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-03-31" id="Fact000142" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,000,000</ix:nonFraction></ix:nonFraction></span></span> shares
authorized, <span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_pid_uShares_c20240331_zMIn7cYUE1k8" title="Common stock, shares, issued"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-03-31" id="Fact000144" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">49,143,589</ix:nonFraction></span> and <span id="xdx_903_eus-gaap--CommonStockSharesIssued_iI_pid_uShares_c20231231_zuK0CiX6WeIe"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact000145" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">49,089,864</ix:nonFraction></span>
shares issued <span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_pid_uShares_c20240331_z33gqUN2Cwi1"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-03-31" id="Fact000146" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">45,723,087</ix:nonFraction></span> and <span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_pid_uShares_c20231231_zWryoQXFGazh"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000147" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">45,669,362</ix:nonFraction>
</span>shares outstanding as of March 31, 2024, and December 31, 2023, respectively</p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-03-31" id="Fact000137" format="ixt:numdotdecimal" decimals="0" unitRef="USD">491,436</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31" id="Fact000138" format="ixt:numdotdecimal" decimals="0" unitRef="USD">490,899</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AdditionalPaidInCapitalCommonStock_i02I_maSEzqKe_zVUxef7YA81i" style="vertical-align: bottom">
    <td style="padding-left: 0.2in; text-indent: -0.1in">Additional paid-in capital</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2024-03-31" id="Fact000149" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47,717,888</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2023-12-31" id="Fact000150" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47,018,707</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--TreasuryStockValue_i02NI_di_msSEzqKe_zD0MufXXKDv9" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.2in; text-indent: -0.1in">Treasury stock, <span id="xdx_901_eus-gaap--TreasuryStockPreferredShares_iI_pid_uShares_c20240331_z40p7NZEU1vj" title="Treasury stock, shares"><span id="xdx_906_eus-gaap--TreasuryStockPreferredShares_iI_pid_uShares_c20231231_zEMek3sVtV2k" title="Treasury stock, shares"><ix:nonFraction name="us-gaap:TreasuryStockPreferredShares" contextRef="AsOf2024-03-31" id="Fact000155" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:TreasuryStockPreferredShares" contextRef="AsOf2023-12-31" id="Fact000157" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,420,502</ix:nonFraction></ix:nonFraction></span></span> shares as of March 31, 2024 and December 31, 2023, at cost</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="AsOf2024-03-31" id="Fact000152" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,843,562</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="AsOf2023-12-31" id="Fact000153" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,843,562</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_402_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maSEzqKe_zGfXPxaMm9Lk" style="vertical-align: bottom">
    <td style="padding-left: 0.2in; text-indent: -0.1in">Accumulated deficit</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-03-31" id="Fact000159" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">25,248,231</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31" id="Fact000160" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">23,312,273</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_40E_eus-gaap--StockholdersEquity_i02TI_mtSEzqKe_maLASEzytn_z0gwEYIox6Ua" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>TOTAL STOCKHOLDERS&#8217; EQUITY</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31" id="Fact000162" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,117,531</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000163" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,353,771</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtLASEzytn_z72Gb3MngP12" style="vertical-align: bottom">
    <td>TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-03-31" id="Fact000165" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,500,548</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000166" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,460,972</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying notes are an integral part of these
financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 3 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc"><span style="color: Blue">Table of Contents</span></a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="so"></span><b>KORU MEDICAL SYSTEMS, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>STATEMENTS OF OPERATIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(UNAUDITED)</b></p>

<table cellspacing="0" cellpadding="0" id="xdx_30D_113_z2FsjDzxBhyc" summary="xdx: Statement - STATEMENTS OF OPERATIONS (UNAUDITED)" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 70%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_49E_20240101__20240331_z04FNBPRxJWc" style="width: 12%; text-align: right">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_495_20230101__20230331_zK49mDpjK2q2" style="width: 12%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Three Months Ended</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: Black 1pt solid; text-align: center"><b>March 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--Revenues_maGPzlZh_zG2SRmOvRMaa" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">NET REVENUES</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-01-01to2024-03-31" id="Fact000168" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,197,798</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-01-012023-03-31" id="Fact000169" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,392,605</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CostOfGoodsAndServicesSold_msGPzlZh_zbGFkXac4Wej" style="vertical-align: bottom">
    <td style="padding-left: 0.3in; text-indent: -0.1in">Cost of goods sold</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2024-01-01to2024-03-31" id="Fact000171" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,094,500</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2023-01-012023-03-31" id="Fact000172" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,245,570</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--GrossProfit_iT_mtGPzlZh_maOILzzgr_zQn38oProXa6" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">Gross Profit</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2024-01-01to2024-03-31" id="Fact000174" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,103,298</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2023-01-012023-03-31" id="Fact000175" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,147,035</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingExpensesAbstract_iB_zMoqKzV6Yvj7" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">OPERATING EXPENSES</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--SellingGeneralAndAdministrativeExpense_i01_maOEzn8P_zUSimdcu7rze" style="vertical-align: bottom">
    <td style="padding-left: 0.3in; text-indent: -0.1in">Selling, general and administrative</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2024-01-01to2024-03-31" id="Fact000180" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,357,620</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2023-01-012023-03-31" id="Fact000181" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,425,877</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ResearchAndDevelopmentExpense_i01_maOEzn8P_zlXrrDY67Uhd" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.3in; text-indent: -0.1in">Research and development</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-01to2024-03-31" id="Fact000183" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,475,674</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-03-31" id="Fact000184" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,564,869</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DepreciationDepletionAndAmortization_i01_maOEzn8P_ziKk0aW9xTR7" style="vertical-align: bottom">
    <td style="padding-left: 0.3in; text-indent: -0.1in">Depreciation and amortization</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2024-01-01to2024-03-31" id="Fact000186" format="ixt:numdotdecimal" decimals="0" unitRef="USD">231,370</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2023-01-012023-03-31" id="Fact000187" format="ixt:numdotdecimal" decimals="0" unitRef="USD">213,117</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingExpenses_i01T_mtOEzn8P_msOILzzgr_zUDekhMVnN99" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">Total Operating Expenses</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-01-01to2024-03-31" id="Fact000189" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,064,664</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-01-012023-03-31" id="Fact000190" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,203,863</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingIncomeLoss_iT_mtOILzzgr_maILFCOzgUC_zJo5dJVV9t11" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">Net Operating Loss</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-01to2024-03-31" id="Fact000192" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,961,366</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-012023-03-31" id="Fact000193" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,056,828</ix:nonFraction></td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zbZqI3R3Y1s6" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">Non-Operating Income/(Expense)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_i01_maNIEzQ9q_zwnHRyZcMNge" style="vertical-align: bottom">
    <td style="padding-left: 0.3in; text-indent: -0.1in">Loss on currency exchange </td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2024-01-01to2024-03-31" id="Fact000198" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,479</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2023-01-012023-03-31" id="Fact000199" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">680</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_40A_eus-gaap--GainLossOnSaleOfPropertyPlantEquipment_i01_maNIEzQ9q_zceL2yXeTUn1" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.3in; text-indent: -0.1in">Loss on disposal of fixed assets, net</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="From2024-01-01to2024-03-31" id="Fact000201" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">300</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="From2023-01-012023-03-31" id="Fact000202" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">56,279</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_40D_eus-gaap--OtherNonoperatingIncomeExpense_i01_maNIEzQ9q_zY9OuP2rxea9" style="vertical-align: bottom">
    <td style="padding-left: 0.3in; text-indent: -0.1in">Interest income, net</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2024-01-01to2024-03-31" id="Fact000204" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,187</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2023-01-012023-03-31" id="Fact000205" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,502</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NonoperatingIncomeExpense_i01T_mtNIEzQ9q_maILFCOzgUC_zrCDuTlvIJ25" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">TOTAL OTHER INCOME</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-01-01to2024-03-31" id="Fact000207" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,408</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-01-012023-03-31" id="Fact000208" format="ixt:numdotdecimal" decimals="0" unitRef="USD">68,543</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_iT_mtILFCOzgUC_maNILz45S_zSTZbZnTkGWk" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">LOSS BEFORE INCOME TAXES</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="From2024-01-01to2024-03-31" id="Fact000210" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,935,958</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="From2023-01-012023-03-31" id="Fact000211" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,988,285</ix:nonFraction></td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncomeTaxExpenseBenefit_iN_di_msNILz45S_zdhCJAgFpCll" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.3in; text-indent: -0.1in">Income Tax Benefit</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0213">&#8212;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-012023-03-31" id="Fact000214" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">577,400</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLoss_iT_mtNILz45S_z55nSTZrsXC" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">NET LOSS</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-03-31" id="Fact000216" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,935,958</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31" id="Fact000217" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,410,885</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--EarningsPerShareAbstract_iB_zyAaTDUSOj49" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">NET LOSS PER SHARE</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--EarningsPerShareBasic_i01_zpnyOF6fjZMf" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.2in">Basic</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-01to2024-03-31" id="Fact000222" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.04</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-012023-03-31" id="Fact000223" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.05</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td></tr>
  <tr id="xdx_406_eus-gaap--EarningsPerShareDiluted_i01_zBDtcY6Xe4J8" style="vertical-align: bottom">
    <td style="padding-left: 0.2in">Diluted</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-01to2024-03-31" id="Fact000225" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.04</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-03-31" id="Fact000226" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.05</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--WeightedAverageNumberOfSharesOutstandingAbstract_iB_zp1Q29LVVvCc" style="vertical-align: bottom">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_pid_zEsU72lAYlwa" style="vertical-align: bottom">
    <td style="padding-left: 0.2in">Basic</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-01to2024-03-31" id="Fact000231" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">45,712,224</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-03-31" id="Fact000232" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">45,487,593</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i01_pid_uShares_zT43OveYQZa" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.2in">Diluted</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-01to2024-03-31" id="Fact000234" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">45,712,224</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-03-31" id="Fact000235" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">45,487,593</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying notes are an integral part of these
financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 4 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc"><span style="color: Blue">Table of Contents</span></a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="scf"></span><b>KORU MEDICAL SYSTEMS, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>STATEMENTS OF CASH FLOWS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(UNAUDITED)</b></p>

<table cellspacing="0" cellpadding="0" id="xdx_30E_112_z52C1R2sj1H8" summary="xdx: Statement - STATEMENTS OF CASH FLOWS (UNAUDITED)" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_497_20240101__20240331_zehYZwcBA7K" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_495_20230101__20230331_z1GVCN3bciRb" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>For the<br/>
Three Months Ended</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>March 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 70%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: right">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zZQvFJoPqzF2" style="vertical-align: bottom">
    <td>CASH FLOWS FROM OPERATING ACTIVITIES</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLoss_i01_maCzO1Q_maNCPBUzqPg_z4RedMp95KLl" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.2in">Net Loss</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-03-31" id="Fact000240" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,935,958</ix:nonFraction></td>
    <td>)</td>
    <td>$</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31" id="Fact000241" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,410,885</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zIMKc4DdPO0f" style="vertical-align: bottom">
    <td style="padding-left: 0.3in; text-indent: -0.1in">Adjustments to reconcile net loss to net cash used in operating activities:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ShareBasedCompensation_i02_maCzA0C_maNCPBUzcMq_maNCPBUzqPg_zFesy5nUYmw9" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.4in">Stock-based compensation expense and warrant expense</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-01to2024-03-31" id="Fact000246" format="ixt:numdotdecimal" decimals="0" unitRef="USD">699,718</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-03-31" id="Fact000247" format="ixt:numdotdecimal" decimals="0" unitRef="USD">881,222</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DepreciationDepletionAndAmortization_i02_maCzO1Q_maNCPBUzqPg_zfxN8ad3ZHX5" style="vertical-align: bottom">
    <td style="padding-left: 0.4in">Depreciation and amortization</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2024-01-01to2024-03-31" id="Fact000249" format="ixt:numdotdecimal" decimals="0" unitRef="USD">231,370</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2023-01-012023-03-31" id="Fact000250" format="ixt:numdotdecimal" decimals="0" unitRef="USD">213,117</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredIncomeTaxesAndTaxCredits_i02_maNCPBUzqPg_zUvqEq2q5kr5" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.4in">Deferred income taxes</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0252">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxesAndTaxCredits" contextRef="From2023-01-012023-03-31" id="Fact000253" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">577,400</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_409_eus-gaap--GainLossOnSaleOfOtherAssets_i02N_di_msNCPBUzqPg_zzCMbMHYcNyg" style="vertical-align: bottom">
    <td style="padding-left: 0.4in">Loss on disposal of fixed assets</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:GainLossOnSaleOfOtherAssets" contextRef="From2024-01-01to2024-03-31" id="Fact000255" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">300</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:GainLossOnSaleOfOtherAssets" contextRef="From2023-01-012023-03-31" id="Fact000256" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">56,279</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_ecustom--RouLandlordCredit_i02_maNCPBUzqPg_zxLWK9da5Crj" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.4in">ROU landlord credit</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="krmd:RouLandlordCredit" contextRef="From2024-01-01to2024-03-31" id="Fact000258" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,497</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="krmd:RouLandlordCredit" contextRef="From2023-01-012023-03-31" id="Fact000259" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,497</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i01B_z8FHEKrJLJ7k" style="vertical-align: bottom">
    <td style="padding-left: 0.2in">Changes in operating assets and liabilities:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInAccountsReceivable_i02N_di_msNCPBUzqPg_zbIAuDoXPDOk" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.4in">Increase in Accounts receivable</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2024-01-01to2024-03-31" id="Fact000264" format="ixt:numdotdecimal" decimals="0" unitRef="USD">607,125</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2023-01-012023-03-31" id="Fact000265" format="ixt:numdotdecimal" decimals="0" unitRef="USD">647,994</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncreaseDecreaseInInventories_i02N_di_msNCPBUzqPg_zLSodGPB2Cue" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 0.4in">Decrease / (Increase) in Inventory</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2024-01-01to2024-03-31" id="Fact000267" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">333,989</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2023-01-012023-03-31" id="Fact000268" format="ixt:numdotdecimal" decimals="0" unitRef="USD">233,551</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i02N_di_msNCPBUzqPg_z4m1mMnBLbh6" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.4in">Decrease in Prepaid expenses and other assets</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2024-01-01to2024-03-31" id="Fact000270" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">387,880</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2023-01-012023-03-31" id="Fact000271" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">288,786</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncreaseDecreaseInOtherCurrentLiabilities_i02_maNCPBUzqPg_zSOF7DuP0cM2" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 0.4in">(Decrease) / Increase in Other liabilities</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="From2024-01-01to2024-03-31" id="Fact000273" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">54,867</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="From2023-01-012023-03-31" id="Fact000274" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,207</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncreaseDecreaseInAccountsPayable_i02_maNCPBUzqPg_zTROHrdvVFCl" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.4in">Increase / (Decrease) in Accounts payable</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2024-01-01to2024-03-31" id="Fact000276" format="ixt:numdotdecimal" decimals="0" unitRef="USD">798,992</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2023-01-012023-03-31" id="Fact000277" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">888,679</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncreaseDecreaseInEmployeeRelatedLiabilities_i02_maNCPBUzqPg_zjA3N32ohwE3" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 0.4in">Increase / (Decrease) in Accrued payroll and related taxes</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="From2024-01-01to2024-03-31" id="Fact000279" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,500</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="From2023-01-012023-03-31" id="Fact000280" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">41,984</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_40D_eus-gaap--IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_i02_maNCPBUzqPg_zYD1It6jIuM7" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.4in">Decrease in Accrued expenses</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="From2024-01-01to2024-03-31" id="Fact000282" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">252,022</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="From2023-01-012023-03-31" id="Fact000283" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,298,204</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtNCPBUzqPg_maCCERCzxmM_z934IreeDqjc" style="vertical-align: bottom">
    <td>NET CASH USED IN OPERATING ACTIVITIES</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-01to2024-03-31" id="Fact000285" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">346,720</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-012023-03-31" id="Fact000286" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,660,583</ix:nonFraction></td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zm1RD3rb9Te6" style="vertical-align: bottom">
    <td>CASH FLOWS FROM INVESTING ACTIVITIES</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PaymentsToAcquireProductiveAssets_i01N_di_msNCPBUz9SP_z1SFZjePqvX4" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.2in">Purchases of property and equipment</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="From2024-01-01to2024-03-31" id="Fact000291" format="ixt:numdotdecimal" decimals="0" unitRef="USD">133,083</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="From2023-01-012023-03-31" id="Fact000292" format="ixt:numdotdecimal" decimals="0" unitRef="USD">272,605</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_40C_eus-gaap--PaymentsToAcquireIntangibleAssets_i01N_di_msNCPBUz9SP_zytt7cLaDcB3" style="vertical-align: bottom">
    <td style="padding-left: 0.2in">Purchases of intangible assets</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2024-01-01to2024-03-31" id="Fact000294" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2023-01-012023-03-31" id="Fact000295" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,232</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtNCPBUz9SP_maCCERCzxmM_z05ZTmdiIqv2" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>NET CASH USED IN INVESTING ACTIVITIES</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-01-01to2024-03-31" id="Fact000297" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">133,083</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-01-012023-03-31" id="Fact000298" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">283,837</ix:nonFraction></td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zHus0Db7V7Te" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>CASH FLOWS FROM FINANCING ACTIVITIES</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_ecustom--PaymentsOnIndebtedness_i01N_di_msNCPBUzLOp_zxPY28bDp1hc" style="vertical-align: bottom">
    <td style="padding-left: 0.2in">Payments on indebtedness</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="krmd:PaymentsOnIndebtedness" contextRef="From2024-01-01to2024-03-31" id="Fact000303" format="ixt:numdotdecimal" decimals="0" unitRef="USD">155,313</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="krmd:PaymentsOnIndebtedness" contextRef="From2023-01-012023-03-31" id="Fact000304" format="ixt:numdotdecimal" decimals="0" unitRef="USD">214,892</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_406_eus-gaap--FinanceLeasePrincipalPayments_i01N_di_msNCPBUzLOp_z1DlJQPRSCD4" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 0.2in">Payments on finance lease liability</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: top; text-align: right">(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="From2024-01-01to2024-03-31" id="Fact000306" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,807</ix:nonFraction></td>
    <td style="vertical-align: top">)</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="From2023-01-012023-03-31" id="Fact000307" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,080</ix:nonFraction></td>
    <td style="vertical-align: bottom">)</td></tr>
  <tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInFinancingActivities_mtNCPBUzLOp_maCCERCzxmM_za4FSk5qd1D5" style="vertical-align: bottom">
    <td>NET CASH USED IN FINANCING ACTIVITIES</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-01-01to2024-03-31" id="Fact000309" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">182,120</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-012023-03-31" id="Fact000310" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">238,972</ix:nonFraction></td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCCERCzxmM_zZBfoekoli6l" style="vertical-align: bottom">
    <td>NET DECREASE IN CASH AND CASH EQUIVALENTS</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2024-01-01to2024-03-31" id="Fact000312" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">661,923</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-01-012023-03-31" id="Fact000313" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,183,392</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_404_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_zTi6T1JWbine" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact000315" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,482,240</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" id="Fact000316" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,408,257</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_zAJyeg29Zrmk" style="vertical-align: bottom">
    <td>CASH AND CASH EQUIVALENTS, END OF PERIOD</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2024-03-31" id="Fact000318" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,820,317</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-03-31" id="Fact000319" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,224,865</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zCGjXotqWBIe" style="vertical-align: bottom">
    <td>Supplemental Information</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_ecustom--CashPaidDuringPeriodsForAbstract_iB_zoOVphCIZYc6" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Cash paid during the periods for:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--InterestPaidNet_i01_zeQU9vwYcGAd" style="vertical-align: bottom">
    <td style="padding-left: 0.2in">Interest</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2024-01-01to2024-03-31" id="Fact000327" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,296</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2023-01-012023-03-31" id="Fact000328" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,326</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeTaxesPaidNet_i01_zo27PEUiy7j3" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.2in">Income taxes</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0330">&#8212;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0331">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB_zUMs4TOUJfj4" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Schedule of Non-Cash Operating, Investing and Financing Activities:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_ecustom--IssuanceOfCommonStockCompensation_i01_zCxQLpEGK4Jf" style="vertical-align: bottom">
    <td style="padding-left: 0.2in">Issuance of common stock as compensation</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="krmd:IssuanceOfCommonStockCompensation" contextRef="From2024-01-01to2024-03-31" id="Fact000336" format="ixt:numdotdecimal" decimals="0" unitRef="USD">123,804</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="krmd:IssuanceOfCommonStockCompensation" contextRef="From2023-01-012023-03-31" id="Fact000337" format="ixt:numdotdecimal" decimals="0" unitRef="USD">175,776</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying notes are an integral part of these
financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 5 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc"><span style="color: Blue">Table of Contents</span></a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="se"></span><b>KORU MEDICAL SYSTEMS, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(UNAUDITED)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Three Months Ended March 31, 2024</b></p>

<table cellspacing="0" cellpadding="0" id="xdx_305_114_z5l1okOxCp3a" summary="xdx: Statement - STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 28%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zGFFCrZFNGE" style="width: 7%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_z7pz95bFCzM1" style="width: 9%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zAgiM4vIk7Oa" style="width: 10%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_4B9_us-gaap--StatementEquityComponentsAxis_us-gaap--TreasuryStockCommonMember_zdPabM4U3srk" style="width: 9%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_4B2_zCEKbDEV30El" style="width: 11%">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="4">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>Additional</b></td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>Total</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>Common Stock</b></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>Paid-in</b></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>Retained</b></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>Treasury</b></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>Stockholders&#8217;</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Amount</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Capital</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Deficit</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Stock</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Equity</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_43E_c20240101__20240331_eus-gaap--StockholdersEquity_iS_zffaVHubJ6L" style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="padding-left: 8.25pt; text-indent: -8.25pt">BALANCE, DECEMBER 31, 2023</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--SharesOutstanding_iS_pid_uShares_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKK8Oe6k7NX" title="Beginning balance (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000345" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">49,089,864</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000339" format="ixt:numdotdecimal" decimals="0" unitRef="USD">490,899</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000340" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47,018,707</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000341" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">23,312,273</ix:nonFraction></td>
    <td>)</td>
    <td>$</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember" id="Fact000342" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,843,562</ix:nonFraction></td>
    <td>)</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000343" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,353,771</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_438_c20240101__20240331_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_zsVAA6EAIaDd" style="vertical-align: bottom">
    <td style="padding-left: 8.25pt; text-indent: -8.25pt">Issuance of stock-based compensation</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pid_uShares_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_za4CLNMXm38c" title="Issuance of stock-based compensation (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000353" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">53,725</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000347" format="ixt:numdotdecimal" decimals="0" unitRef="USD">537</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000348" format="ixt:numdotdecimal" decimals="0" unitRef="USD">123,267</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0349">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0350">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-01-01to2024-03-31" id="Fact000351" format="ixt:numdotdecimal" decimals="0" unitRef="USD">123,804</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_439_c20240101__20240331_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_zzvzwxZf9XBf" style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="padding-left: 8.25pt; text-indent: -8.25pt">Compensation expense related to stock options </td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0355">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000356" format="ixt:numdotdecimal" decimals="0" unitRef="USD">393,113</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0357">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0358">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-01to2024-03-31" id="Fact000359" format="ixt:numdotdecimal" decimals="0" unitRef="USD">393,113</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_432_c20240101__20240331_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_z8glhsvZOYTh" style="vertical-align: bottom">
    <td style="padding-left: 8.25pt; text-indent: -8.25pt">Compensation related to Restricted Stock</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0361">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000362" format="ixt:numdotdecimal" decimals="0" unitRef="USD">130,676</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0363">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0364">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2024-01-01to2024-03-31" id="Fact000365" format="ixt:numdotdecimal" decimals="0" unitRef="USD">130,676</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_431_c20240101__20240331_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_zPQxSf5N9Arb" style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="padding-left: 8.25pt; text-indent: -8.25pt">Issuance of warrants</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0367">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000368" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,125</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0369">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0370">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2024-01-01to2024-03-31" id="Fact000371" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,125</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_433_c20240101__20240331_eus-gaap--NetIncomeLoss_zdmYfzKJT6Wb" style="vertical-align: bottom">
    <td style="padding-left: 8.25pt; text-indent: -8.25pt">Net loss</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0373">&#8212;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0374">&#8212;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="Fact000375" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,935,958</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0376">&#8212;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-03-31" id="Fact000377" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,935,958</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_438_c20240101__20240331_eus-gaap--StockholdersEquity_iE_zYLIKqrSVoVb" style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="padding-left: 8.25pt; text-indent: -8.25pt">BALANCE, MARCH 31, 2024</td>
    <td>&#160;</td>
    <td id="xdx_98B_eus-gaap--SharesOutstanding_iE_pid_uShares_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAaJMduqvhOd" title="Ending balance (in shares)" style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" id="Fact000385" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">49,143,589</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" id="Fact000379" format="ixt:numdotdecimal" decimals="0" unitRef="USD">491,436</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000380" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47,717,888</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember" id="Fact000381" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">25,248,231</ix:nonFraction></td>
    <td style="border-bottom: white 1.5pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_TreasuryStockCommonMember" id="Fact000382" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,843,562</ix:nonFraction></td>
    <td style="border-bottom: white 1.5pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31" id="Fact000383" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,117,531</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Three Months Ended March 31, 2023</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 28%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zvqI34O8Bjb2" style="width: 7%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zLxwpBZIngEg" style="width: 9%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zX7ZTAc15KKd" style="width: 10%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_4B9_us-gaap--StatementEquityComponentsAxis_us-gaap--TreasuryStockCommonMember_zmoR3NU2sbCa" style="width: 9%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_4B2_z3Mml6iPO7nk" style="width: 11%">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="4" style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center"><b>Additional</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center"><b>Total</b></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>Common Stock</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center"><b>Paid-in</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center"><b>Retained</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center"><b>Treasury</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center"><b>Stockholders&#8217;</b></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>Shares</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>Amount</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>Capital</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>Deficit</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>Stock</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>Equity</b></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_43F_c20230101__20230331_eus-gaap--StockholdersEquity_iS_zYUm4288U2J5" style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="padding-left: 8.25pt; text-indent: -8.25pt">BALANCE, DECEMBER 31, 2022</td>
    <td>&#160;</td>
    <td id="xdx_98E_eus-gaap--SharesOutstanding_iS_pid_uShares_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zb3ACB5zcIj7" title="Beginning balance (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000393" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48,861,891</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000387" format="ixt:numdotdecimal" decimals="0" unitRef="USD">488,619</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000388" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,252,117</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact000389" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,571,211</ix:nonFraction></td>
    <td>)</td>
    <td>$</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_TreasuryStockCommonMember" id="Fact000390" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,843,562</ix:nonFraction></td>
    <td>)</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000391" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,325,963</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_43C_c20230101__20230331_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_z0SoSMio2dqf" style="vertical-align: bottom">
    <td style="padding-left: 8.25pt; text-indent: -8.25pt">Issuance of stock-based compensation</td>
    <td>&#160;</td>
    <td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pid_uShares_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zD3ksiDTMs6l" title="Issuance of stock-based compensation (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="Fact000401" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48,875</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="Fact000395" format="ixt:numdotdecimal" decimals="0" unitRef="USD">489</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000396" format="ixt:numdotdecimal" decimals="0" unitRef="USD">175,287</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0397">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0398">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-03-31" id="Fact000399" format="ixt:numdotdecimal" decimals="0" unitRef="USD">175,776</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_43C_c20230101__20230331_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_zA6NkyoFp3Gk" style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="padding-left: 8.25pt; text-indent: -8.25pt">Compensation expense related to stock options</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0403">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000404" format="ixt:numdotdecimal" decimals="0" unitRef="USD">535,059</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0405">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0406">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-03-31" id="Fact000407" format="ixt:numdotdecimal" decimals="0" unitRef="USD">535,059</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_436_c20230101__20230331_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_zpsvkLYcGSVd" style="vertical-align: bottom">
    <td style="padding-left: 8.25pt; text-indent: -8.25pt">Compensation related to Restricted Stock</td>
    <td>&#160;</td>
    <td id="xdx_98D_ecustom--CompensationeExpenseRelatedToRestrictedStockAwards_iP3us-gaap--AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_pid_uShares_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_za7REB1Gkri" title="Compensation expense related to restricted stock (in shares)" style="text-align: right"><ix:nonFraction name="krmd:CompensationeExpenseRelatedToRestrictedStockAwards" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="Fact000415" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="Fact000409" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000410" format="ixt:numdotdecimal" decimals="0" unitRef="USD">169,887</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-012023-03-31" id="Fact000413" format="ixt:numdotdecimal" decimals="0" unitRef="USD">170,387</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_43E_c20230101__20230331_eus-gaap--NetIncomeLoss_zLpVGpwr77Ze" style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="padding-left: 8.25pt; text-indent: -8.25pt">Net loss</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0417">&#8212;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0418">&#8212;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="Fact000419" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,410,885</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0420">&#8212;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31" id="Fact000421" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,410,885</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_430_c20230101__20230331_eus-gaap--StockholdersEquity_iE_zVQnjBFNv1Y" style="vertical-align: bottom">
    <td style="padding-left: 8.25pt; text-indent: -8.25pt">BALANCE, MARCH 31, 2023</td>
    <td>&#160;</td>
    <td id="xdx_982_eus-gaap--SharesOutstanding_iE_pid_uShares_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRSwYk5MrbEf" title="Ending balance (in shares)" style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" id="Fact000429" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48,960,766</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" id="Fact000423" format="ixt:numdotdecimal" decimals="0" unitRef="USD">489,608</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000424" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,132,350</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember" id="Fact000425" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,982,096</ix:nonFraction></td>
    <td style="border-bottom: white 1.5pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_TreasuryStockCommonMember" id="Fact000426" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,843,562</ix:nonFraction></td>
    <td style="border-bottom: white 1.5pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31" id="Fact000427" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,796,300</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 6 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc"><span style="color: Blue">Table of Contents</span></a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="notes"></span><b>KORU MEDICAL SYSTEMS, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO THE UNAUDITED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000431" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"><p id="xdx_808_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zHbZTY15EU52" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 1 &#8212; <span id="xdx_825_zps1R66qG5Q4">NATURE OF OPERATIONS AND SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000433" name="us-gaap:NatureOfOperations"><p id="xdx_84C_eus-gaap--NatureOfOperations_zuNRR9X8WuT5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_860_zL58AmV7DqSg">NATURE OF OPERATIONS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">KORU MEDICAL SYSTEMS, INC. (the &#8220;Company,&#8221;
&#8220;KORU Medical,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;) designs, manufactures and markets proprietary portable
and innovative medical devices primarily for the subcutaneous drug delivery market as governed by the United States Food and Drug Administration
(the &#8220;FDA&#8221;) quality and regulatory system and international regulations and standards for quality system management. The Company
operates as <span id="xdx_903_eus-gaap--NumberOfReportableSegments_dxH_uN_c20240101__20240331_zHYjAdyxPnMa" title="Number of segment::XDX::1">one</span> segment.</p>

</ix:nonNumeric><p id="xdx_85A_zlKzyNhotq45" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000437" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zxTa5f2NTFU5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_863_z3u1ztSDWWPc">BASIS OF PRESENTATION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying financial statements should be read
in conjunction with the Company&#8217;s annual report on Form 10-K for the year ended December 31, 2023 (&#8220;Annual Report&#8221;).
&#160;In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;), the Company has
omitted footnote disclosures that would substantially duplicate the disclosures contained in the audited financial statements of the Company.
The accompanying interim financial statements are unaudited and reflect all adjustments which are in the opinion of management necessary
for a fair statement of the Company&#8217;s financial position, results of operations, and cash flows for the periods presented. &#160;All
such adjustments are of a normal, recurring nature. &#160;The Company&#8217;s results of operations and cash flows for the interim periods
are not necessarily indicative of the results of operations and cash flows that it may achieve in future periods.</p>

</ix:nonNumeric><p id="xdx_858_zjxYcOOJfiPk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000439" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zZ86aZl4CBLi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_86B_zxJfOor2QNue">CASH AND CASH EQUIVALENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For purposes of the statements of cash flows, the
Company considers all short-term investments with an original maturity of three months or less to be cash equivalents. &#160;The Company
has historically held cash balances in excess of $<span id="xdx_90E_eus-gaap--CashUninsuredAmount_iI_c20240331_znGjeFWwJNr7" title="FDIC cash uninsured amount"><ix:nonFraction name="us-gaap:CashUninsuredAmount" contextRef="AsOf2024-03-31" id="Fact000441" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span> at its primary commercial bank, which exceeds FDIC insurance limits. To reduce
the risk of uninsured deposits, the Company entered an insured cash sweep program with KeyBank during the second quarter of 2023 to automatically
invest its uninsured bank cash balances over $250,000 into FDIC insured banks so there is no more than $250,000 maintained at any one
bank. As of March 31, 2024 the Company has an investment balance of $<span id="xdx_907_eus-gaap--InterestIncomeSecuritiesUSTreasury_dm_c20240101__20240331_zAroHWx5QOCk" title="Investment securities treasury bill"><ix:nonFraction name="us-gaap:InterestIncomeSecuritiesUSTreasury" contextRef="From2024-01-01to2024-03-31" id="Fact000443" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">10.2</ix:nonFraction> million</span> in a US Treasury bill that matures every 90 days.</p>

</ix:nonNumeric><p id="xdx_853_zwcCH9ltGUkf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000445" name="us-gaap:IntangibleAssetsFiniteLivedPolicy"><p id="xdx_842_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zpHXUHJP89Z8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_868_zfJNXKfqZn1b">PATENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Costs incurred in obtaining patents have been capitalized
and are being amortized over the legal life of the patents.</p>

</ix:nonNumeric><p id="xdx_852_zT8HRlDMNaOc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000447" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_84B_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zqiFo0vrTd6d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_864_zLIdpY0GWn3i">STOCK-BASED COMPENSATION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company maintains a stock option plan and an omnibus
equity incentive plan under which it grants stock options to certain executives, key employees and consultants. The fair value of each
option grant is estimated on the date of the grant using the Black-Scholes option-pricing model. &#160;All options are charged against
income at their fair value. &#160;The entire compensation expense of the award is recognized over the vesting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company also maintains a non-employee director
compensation plan. Shares of stock granted for director fees are recorded at the fair value of the shares at the grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company issues restricted stock awards. Restricted
stock awards are equity classified and measured at the fair market value of the underlying stock at the grant date. The fair value of
restricted stock awards vesting at certain market capitalization thresholds were estimated on the date of grant using the Brownian Motion
Monte Carlo lattice model. The fair value of restricted stock awards with time-based vesting were estimated on the date of grant at the
current stock price. The fair value of restricted stock awards vesting at certain annual sales growth thresholds were estimated as of
the date of Board acknowledgement of the achievement, at the current stock price. We recognize restricted stock expense using the straight-line
attribution method over the requisite service period and account for forfeitures as they occur.</p>

</ix:nonNumeric><p id="xdx_858_zPuK4iHPQXOj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><div id="xdx_230_zhmmPnEyVeW1">
<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 7 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc"><span style="color: Blue">Table of Contents</span></a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></div></ix:exclude>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000450" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zEjvUKTCnSuj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_86B_zzX85zWjkZU3">NET LOSS PER COMMON SHARE</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic net loss per common share is calculated by dividing
net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed
by dividing net loss by the weighted average number of common and common equivalent shares outstanding during the period. The Company&#8217;s
potentially dilutive common shares are those that result from diluted common stock options and unvested restricted stock awards. The calculation
of diluted net loss per share excluded stock options of <span id="xdx_90A_ecustom--AntiDilutiveStockOptions_pid_dxL_uShares_c20240101__20240331_zAyKVLY6I0Kb" title="Anti-dilutive stock options::XDX::0"><span style="-sec-ix-hidden: xdx2ixbrl0452">zero</span></span> and <span id="xdx_906_ecustom--AntiDilutiveStockOptions_pid_uShares_c20230101__20230331_z2JVos5KlZMg" title="Anti-dilutive stock options"><ix:nonFraction name="krmd:AntiDilutiveStockOptions" contextRef="From2023-01-012023-03-31" id="Fact000454" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,626</ix:nonFraction></span>, respectively, in weighted-average shares for each of the three
months ended March 31, 2024 and 2023, as their effect was anti-dilutive as a result of the net loss incurred for those periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The calculation of diluted net loss per share excluded
stock options, performance-based restricted stock and performance-based restricted stock units (PSUs) of <span id="xdx_90C_ecustom--AntiDilutiveSecurities_pid_uShares_c20240101__20240331_zLD40VIT7Xpi" title="Anti-dilutive securities"><ix:nonFraction name="krmd:AntiDilutiveSecurities" contextRef="From2024-01-01to2024-03-31" id="Fact000456" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">904,496</ix:nonFraction></span> and <span id="xdx_904_ecustom--AntiDilutiveSecurities_pid_uShares_c20230101__20230331_zYK7EYycKdx4" title="Anti-dilutive Securities"><ix:nonFraction name="krmd:AntiDilutiveSecurities" contextRef="From2023-01-012023-03-31" id="Fact000458" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">914,626</ix:nonFraction></span> respectively,
in weighted-average shares for each of the three months ended March 31, 2024 and 2023, as their effect was anti-dilutive as a result of
the net loss incurred for those periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000460" name="krmd:ScheduleOfSecuritiesTextBlock"><p id="xdx_89F_ecustom--ScheduleOfSecuritiesTextBlock_zzpQsQwqywxl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B1_zFRbRMeqbCI6">The following securities were not included in the
computation of diluted shares outstanding for the three months ended March 31, 2024, and 2023 because the effect would be anti-dilutive:</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.25in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 64%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_491_20240101__20240331_z5gHa56Js7j9" style="width: 15%; text-align: right">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_495_20230101__20230331_znrL5Y2snEGd" style="width: 15%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Three Months Ended</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>March 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_ecustom--CommonStockOptions_pid_uShares_zXCYQ9M0n2Ak" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Common stock options</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0462">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:CommonStockOptions" contextRef="From2023-01-012023-03-31" id="Fact000463" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,626</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_ecustom--PerformanceStockUnits_pid_uShares_zTxSUpVHYgl1" style="vertical-align: bottom">
    <td>PSUs</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:PerformanceStockUnits" contextRef="From2024-01-01to2024-03-31" id="Fact000465" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">54,496</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0466">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_ecustom--RestrictedStockUnits_pid_zd0Ut9uoSEBj" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Restricted stock </td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="krmd:RestrictedStockUnits" contextRef="From2024-01-01to2024-03-31" id="Fact000468" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">850,000</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="krmd:RestrictedStockUnits" contextRef="From2023-01-012023-03-31" id="Fact000469" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">900,000</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_ecustom--AntiDilutedSecurities_pid_zwi8ws9Cj7l8" style="vertical-align: bottom">
    <td><b>Total</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="krmd:AntiDilutedSecurities" contextRef="From2024-01-01to2024-03-31" id="Fact000471" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">904,496</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="krmd:AntiDilutedSecurities" contextRef="From2023-01-012023-03-31" id="Fact000472" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">914,626</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A9_znhncoWTWmPj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000474" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zBaLzXTzUa93" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B6_z7l4QIjCFLal">Therefore, diluted weighted average number of shares
outstanding and diluted net loss per share were the same as basic weighted average number of shares outstanding and net loss per share
for the three months ended March 31, 2024 and 2023.</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.25in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_49E_20240101__20240331_zKWPQDLuseWi" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49C_20230101__20230331_zwiXwTi9WQqb" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Three Months Ended</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>March 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 64%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: right">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_zRGQTXHoMhT9" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Net loss</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">$</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-03-31" id="Fact000476" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,935,958</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">$</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31" id="Fact000477" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,410,885</ix:nonFraction></td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasicAbstract_iB_zgy58JSQ1or" style="vertical-align: bottom">
    <td>Weighted Average Outstanding Shares:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_uShares_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJkv6CGHEuqk" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.2in">Basic weighted average shares outstanding</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000482" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">45,712,224</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="Fact000483" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">45,487,593</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock_pid_uShares_zU067aM1fsOl" style="vertical-align: bottom">
    <td style="padding-left: 0.2in">Dilutive effect of outstanding stock options and unvested restricted stock</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0485">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0486">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_uShares_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zd27J1f9JnPk" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.2in">Diluted weighted average shares outstanding</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000488" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">45,712,224</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="Fact000489" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">45,487,593</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--EarningsPerShareAbstract_iB_zOB9mDzjNIdh" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Net loss per share</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--EarningsPerShareBasic_pid_uUSDPShares_zcSlm2QFwCO3" style="vertical-align: bottom">
    <td style="padding-left: 0.2in">Basic</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-01to2024-03-31" id="Fact000494" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.04</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-012023-03-31" id="Fact000495" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.05</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td></tr>
  <tr id="xdx_404_eus-gaap--EarningsPerShareDiluted_pid_uUSDPShares_zpl67c48EQjj" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.2in">Diluted</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-01to2024-03-31" id="Fact000497" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.04</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-03-31" id="Fact000498" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.05</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zOZuMH9KPgh" style="margin-top: 0; margin-bottom: 0">&#160;</p>
</ix:nonNumeric><p id="xdx_850_zWUC8JD5Vj4h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000500" name="us-gaap:UseOfEstimates"><p id="xdx_848_eus-gaap--UseOfEstimates_zwBJwuyIaRwk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_867_zXdhu3aGikK9">USE OF ESTIMATES IN THE FINANCIAL STATEMENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity
with United States generally accepted accounting principles (&#8220;GAAP&#8221;) requires management to make estimates and assumptions
that affect the amounts reported in the financial statements and accompanying notes. &#160;Actual results could differ from those estimates.
Important estimates include but are not limited to asset lives, deferred tax valuation allowances, inventory valuation, and customer rebate
and incentive accruals. The results of operations for the three months ended March 31, 2024 are not necessarily indicative of the results
that may be expected for the entire 2024 fiscal year.</p>

</ix:nonNumeric><p id="xdx_853_zDMfURqrRNTe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><div id="xdx_23E_ztXGkI6Udi27">
<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 8 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc"><span style="color: Blue">Table of Contents</span></a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></div></ix:exclude>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000503" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock"><p id="xdx_848_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zBnku6HMugG2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_861_zAVc8rBfNITh">REVENUE RECOGNITION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our revenues are derived from three business sources:
(i) domestic core (which consists of US and Canada), (ii) international core, and (iii) novel therapies. &#160;Our core domestic and international
revenues consist of sales of our syringe drivers, tubing and needles (&#8220;Product Revenue&#8221;) for the delivery of subcutaneous
drugs that are FDA cleared for use with the KORU Medical infusion system, with the primary delivery for immunoglobulin to treat Primary
Immunodeficiency Diseases (&#8220;PIDD&#8221;) and Chronic Inflammatory Demyelinating Polyneuropathy (&#8220;CIDP&#8221;). Novel therapies
consist of Product Revenue for feasibility/clinical trials (pre-clinical studies, Phase I, Phase II, Phase III) of biopharmaceutical companies
in the drug development process as well as non-recurring engineering services (&#8220;NRE&#8221;) revenues (including testing and registration
services) received from biopharmaceutical companies to ready or customize the FREEDOM System for clinical and commercial use across multiple
drug categories.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For Product Revenue, we recognize revenues when shipment
occurs, and at which point the customer obtains control and ownership of the goods. &#160;Shipping costs generally are billed to customers
and are included in Product Revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company generally does not accept return of goods
shipped unless it is a Company error. &#160;The only credits provided to customers are for defective merchandise. &#160;The Company warrants
the syringe driver from defects in materials and workmanship under normal use and the warranty does not include a performance obligation.
&#160;The costs under the warranty are expensed as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Rebates are provided to distributors for the difference
in selling price to distributor and pricing specified to select customers. &#160;In addition, rebates are provided to customers for meeting
growth targets. &#160;Provisions for both distributor pricing and customer growth rebates are variable consideration and are recorded
as a reduction of revenue in the same period the related sales are recorded or when it is probable the growth target will be achieved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We recognize NRE revenue under an input method, which
recognizes revenue on the basis of our efforts or inputs (for example, resources consumed, labor hours expended, costs incurred, or time
elapsed) to the satisfaction of a performance obligation relative to the total expected inputs to the satisfaction of that performance
obligation (i.e. completion milestone). The input method that we use is based on costs incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Contracts are often modified to account for changes
in contract specifications and requirements. Contract modifications exist when the modification either creates new, or changes existing,
enforceable rights and obligations. Generally, when contract modifications create new performance obligations, the modification is considered
to be a separate contract and revenue is recognized prospectively. When contract modifications change existing performance obligations,
the impact on the existing transaction price and measure of progress for the performance obligation to which it relates is generally recognized
as an adjustment to revenue (either as an increase in or a reduction of revenue) on a cumulative catch-up basis. Contract assets primarily
represent revenue earnings over time that are not yet billable based on the terms of the contracts. Contract liabilities (i.e., deferred
revenue) consist of fees invoiced or paid by the Company&#8217;s customers for which the associated performance obligations have not been
satisfied and revenue has not been recognized based on the Company&#8217;s revenue recognition criteria described above. As of March 31,
2024, the Company has recognized a contract asset of zero.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000505" name="krmd:ScheduleOfNetSalesByGeography"><p id="xdx_89B_ecustom--ScheduleOfNetSalesByGeography_zDNyTfMVxHZc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8BB_zofRxwMyRalc">The following table summarizes net revenues by geography
for the three months ended March 31, 2024, and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>Three Months Ended March 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 46%"><b>Revenues</b></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 22%; text-align: right">&#160;</td>
    <td style="width: 6%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 22%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.2in">Domestic</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_984_eus-gaap--Revenues_c20240101__20240331__srt--StatementGeographicalAxis__country--US_zfekj6YiphU1" title="Net Revenue" style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-01-012024-03-31_country_US" id="Fact000507" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,384,083</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_989_eus-gaap--Revenues_c20230101__20230331__srt--StatementGeographicalAxis__country--US_zU239wHzX3td" title="Net Revenue" style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-01-012023-03-31_country_US" id="Fact000509" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,283,965</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.2in">International</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_989_eus-gaap--Revenues_c20240101__20240331__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zszLQcyBXTo6" title="Net Revenues" style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-01-012024-03-31_us-gaap_NonUsMember" id="Fact000511" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,813,715</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_989_eus-gaap--Revenues_c20230101__20230331__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zligqYQgmNRk" title="Net Revenues" style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-01-012023-03-31_us-gaap_NonUsMember" id="Fact000513" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,108,640</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td><b>Total</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_98C_eus-gaap--Revenues_c20240101__20240331_zBlWjzy5lZTl" title="Revenues" style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-01-01to2024-03-31" id="Fact000515" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,197,798</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_98F_eus-gaap--Revenues_c20230101__20230331_zgjEkojcqhJ3" title="Revenues" style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-01-012023-03-31" id="Fact000517" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,392,605</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_z4HPq9rP1jhi" style="margin-top: 0; margin-bottom: 0">&#160;</p>
</ix:nonNumeric><p id="xdx_857_z8UF6jlgSFE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:exclude><div id="xdx_23B_zNiBCwK4RZig">
<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 9 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc"><span style="color: Blue">Table of Contents</span></a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></div></ix:exclude>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000520" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zJbmPfiRquv2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_86F_zQB5mnbGtWH1">ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers the applicability and
impact of all recently issued accounting pronouncements. &#160;Recent accounting pronouncements not specifically identified in our disclosures
are either not applicable to the Company or are not expected to have a material effect on our financial condition or results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2016, the FASB issued ASU No. 2016-13, <i>Financial
Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i>, which amends guidance on reporting
credit losses for assets held at amortized cost basis and available for sale debt securities. &#160;For assets held at amortized cost
basis, Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its
current estimate of all expected credit losses. &#160;The allowance for credit losses is a valuation account that is deducted from the
amortized cost basis of the financial assets to present the net amount expected to be collected. &#160;For available for sale debt securities,
credit losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as
an allowance rather than as a write-down. &#160;This ASU affects entities holding financial assets and net investment in leases that are
not accounted for at fair value through net income. &#160;The amendments affect loans, debt securities, trade receivables, net investments
in leases, off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that
have the contractual right to receive cash. &#160;The Company adopted the pronouncement on January 1, 2023, and there was no impact on
its financial statements.</p>

</ix:nonNumeric><p id="xdx_853_zVK9dDlVTpoc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000522" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_848_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zjylkD9Qp3Wb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_864_zsUqUv4pUBy">FAIR VALUE MEASUREMENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fair value is the exit price that would be received
to sell an asset or paid to transfer a liability. &#160;Fair value is a market-based measurement that should be determined using assumptions
that market participants would use in pricing an asset or liability. Valuation techniques used to measure fair value should maximize the
use of observable inputs and minimize the use of unobservable inputs. &#160;To measure fair value, the Company uses the following fair
value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: center">&#8226;</td>
    <td style="width: 7in; text-align: justify">Level 1 &#8211; Quoted prices in active markets for identical assets or liabilities.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td style="text-align: justify">Level 2 &#8211; Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data by correlation or other means.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td style="text-align: justify">Level 3 &#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. &#160;Value is determined using pricing models, discounted cash flow methodologies, or similar techniques and includes instruments for which the determination of fair value requires significant judgment or estimation.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The carrying amounts of cash and cash equivalents,
including investments in short-term U.S. Treasury bills, accounts receivable, prepaid expenses, accounts payable and accrued expenses
are considered to be representative of their fair values because of the short-term nature of those instruments. &#160;There were no transfers
between levels in the fair value hierarchy during the three months ended March 31, 2024 and 2023.</p>

</ix:nonNumeric><p id="xdx_85A_z4NSgm49D4Wd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000524" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_84B_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z50C5i0C6KEg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_86B_zEgjNVcrMTh8">IMPAIRMENT OF LONG-LIVED ASSETS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company reviews long-lived assets for impairment
whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. &#160;An impairment
loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition
are less than the carrying amount. &#160;The impairment loss, if recognized, would be based on the excess of the carrying value of the
impaired asset over its respective fair value. &#160;The Company did not record any impairment losses through March 31, 2024.</p>

</ix:nonNumeric><p id="xdx_85F_z5G37SYemi95" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

</ix:nonNumeric><p id="xdx_810_zIl8krWJa3U2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 10 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc"><span style="color: Blue">Table of Contents</span></a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000526" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_80F_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zJchNRUsOyHk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 2 &#8212; <span id="xdx_82F_zmPySt8BEpfh">PROPERTY AND EQUIPMENT</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000528" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_891_eus-gaap--PropertyPlantAndEquipmentTextBlock_zYohctDB84N3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8BC_zZFzrzgyaOqi">Property and equipment consists of the following at:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 6in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>March 31, 2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 55%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 19%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 19%">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Furniture and office equipment</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20240331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zxn6LKV20sN3" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-03-31_custom_FurnitureAndOfficeEquipmentMember" id="Fact000529" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,423,093</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zWUXpZxHSpy7" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_custom_FurnitureAndOfficeEquipmentMember" id="Fact000530" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,412,164</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Leasehold improvements</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20240331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z6zGUIqg1786" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-03-31_us-gaap_LeaseholdImprovementsMember" id="Fact000531" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,953,653</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zO7mQR53vrZ" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember" id="Fact000532" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,953,653</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Manufacturing equipment and tooling</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20240331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentAndToolingMember_zqNOXgZ6cnze" style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-03-31_custom_ManufacturingEquipmentAndToolingMember" id="Fact000533" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,311,833</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentAndToolingMember_zUgaSnHXixM9" style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_custom_ManufacturingEquipmentAndToolingMember" id="Fact000534" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,193,113</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 0.2in">Total property and equipment</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20240331_zSlcSOC85Vi9" title="Total property and equipment" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-03-31" id="Fact000536" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,688,579</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231_zsEKGEvpY8Zi" title="Total property and equipment" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31" id="Fact000538" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,558,930</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Less: accumulated depreciation and amortization</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_984_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20240331_zOTht4UYY9Ec" title="Less: accumulated depreciation and amortization" style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2024-03-31" id="Fact000540" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,933,049</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_988_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20231231_zJITZYSBPNy5" title="Less: accumulated depreciation and amortization" style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2023-12-31" id="Fact000542" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,721,273</ix:nonFraction></td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Property and equipment, net</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20240331_z4cl2qc71P59" title="Property and equipment, net" style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-03-31" id="Fact000544" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,755,530</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20231231_zlbjEsW8Rbb3" title="Property and equipment, net" style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact000546" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,837,657</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AB_zo8Dra3pFcp1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Depreciation and amortization expense was $<span id="xdx_904_eus-gaap--Depreciation_c20240101__20240331_zIsc01H3fYM2" title="Depreciation and amortization expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-01-01to2024-03-31" id="Fact000548" format="ixt:numdotdecimal" decimals="0" unitRef="USD">214,910</ix:nonFraction></span>
and $<span id="xdx_900_eus-gaap--Depreciation_c20230101__20230331_zq4sM5F5JsF8" title="Depreciation and amortization expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-01-012023-03-31" id="Fact000550" format="ixt:numdotdecimal" decimals="0" unitRef="USD">197,233</ix:nonFraction></span> for the three months ended March 31, 2024 and 2023, respectively.</p>

</ix:nonNumeric><p id="xdx_819_zkctCoz9Y5ui" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000552" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_805_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zo3NqYgGZ74e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 3 &#8212; <span id="xdx_82F_z2ZimLmWL1qg">STOCK-BASED COMPENSATION</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company maintains a stock option plan and omnibus
equity incentive plan under which it grants stock options to certain executives, key employees and consultants. It also has granted stock
options outside of the plans as inducement awards. The fair value of each option grant is estimated on the date of the grant using the
Black-Scholes option-pricing model. &#160;All options are charged against income at their fair value. &#160;The entire compensation expense
of the award is recognized over the vesting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company issues performance share units (PSUs) under its omnibus equity
incentive plan. Performance share units are equity classified and measured at the fair market value of the underlying stock at the grant
date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Shares of stock granted for director fees under the
non-employee director compensation plan and under its omnibus equity incentive plan are recorded at the fair value of the shares at the
grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company issues restricted stock awards under its
omnibus equity incentive plan and outside the plan as incentive awards. Restricted stock awards are equity classified and measured at
the fair market value of the underlying stock at the grant date. The fair value of restricted stock awards vesting at certain market capitalization
thresholds were estimated on the date of grant using the Brownian Motion Monte Carlo lattice model. The fair value of other restricted
stock awards were estimated on the date of grant at the current stock price. We recognize restricted stock expense using the straight-line
attribution method over the requisite service period and account for forfeitures as they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has three equity incentive plans: the
2015 Stock Option Plan, as amended (the &#8220;2015 Plan&#8221;), the 2021 Omnibus Equity Incentive Plan (the &#8220;2021 Plan&#8221;),
and the Non-Employee Director Compensation Plan. The Company has also issued restricted stock and stock options as employment inducement
awards to its Chief Executive Officer and Chief Commercial Officer, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2015 plan provides for the grant of incentive
stock options and nonqualified stock options. As of March 31, 2024, there were <span id="xdx_90D_ecustom--SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan_pid_uShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z8JkAgpVAmZh" title="Shares issued under plan"><ix:nonFraction name="krmd:SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan" contextRef="From2024-01-012024-03-31_custom_StockOptionPlan2015Member" id="Fact000554" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,120,000</ix:nonFraction></span> shares reserved for outstanding awards and <span id="xdx_90F_ecustom--SharesAvailableForIssuanceShareBasedCompensation_iI_pid_uShares_c20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zCq5W8k1PF11" title="Shares available for issuance"><ix:nonFraction name="krmd:SharesAvailableForIssuanceShareBasedCompensation" contextRef="AsOf2024-03-31_custom_StockOptionPlan2015Member" id="Fact000556" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">604,250</ix:nonFraction></span>
shares available for issuance under the 2015 Plan. Additional options may be issued under the 2015 Plan as outstanding options are forfeited.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2021 Plan provides for the grant of incentive
stock options, nonqualified stock options, stock awards, restricted stock awards, restricted stock units and/or stock appreciation rights
to employees, consultants and directors. As of March 31, 2024, there were <span id="xdx_90D_ecustom--SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan_pid_uShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zAaNyZXEewM" title="Shares issued under plan"><ix:nonFraction name="krmd:SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan" contextRef="From2024-01-012024-03-31_custom_StockOptionPlan2021Member" id="Fact000558" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">656,744</ix:nonFraction></span> shares reserved for outstanding awards and <span id="xdx_909_ecustom--SharesAvailableForIssuanceShareBasedCompensation_iI_pid_uShares_c20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zibuOTaz1fv2" title="Shares available for issuance"><ix:nonFraction name="krmd:SharesAvailableForIssuanceShareBasedCompensation" contextRef="AsOf2024-03-31_custom_StockOptionPlan2021Member" id="Fact000560" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">152,811</ix:nonFraction></span> shares
available for issuance under the 2021 Plan. Additional awards may be issued under the 2021 Plan as outstanding awards are forfeited.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each non-employee director of the Company (other than
the Chairman of the Board) is eligible to receive $<span id="xdx_909_ecustom--NonemployeeServicesTransactionCost_pid_uShares_c20240101__20240331__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorAndBoardAdvisorMember_zc2412wPPQ9" title="Nonemployee services transaction cost"><ix:nonFraction name="krmd:NonemployeeServicesTransactionCost" contextRef="From2024-01-012024-03-31_custom_NonEmployeeDirectorAndBoardAdvisorMember" id="Fact000562" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">110,000</ix:nonFraction></span> annually, <span id="xdx_900_eus-gaap--DeferredCompensationArrangementsOverallDescription_c20240101__20240331__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorAndBoardAdvisorMember_zPH2ZzmWWyi3" title="Share-based goods and non-employee services transaction"><ix:nonNumeric contextRef="From2024-01-012024-03-31_custom_NonEmployeeDirectorAndBoardAdvisorMember" id="Fact000564" name="us-gaap:DeferredCompensationArrangementsOverallDescription">to be paid quarterly $12,500 in cash and $15,000 in common stock.</ix:nonNumeric></span>
&#160;The Chairman of the Board is eligible to receive $<span id="xdx_902_ecustom--NonemployeeServicesTransactionCost_pid_uShares_c20240101__20240331__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zd3co86c6aQc" title="Nonemployee services transaction cost"><ix:nonFraction name="krmd:NonemployeeServicesTransactionCost" contextRef="From2024-01-012024-03-31_srt_BoardOfDirectorsChairmanMember" id="Fact000566" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">140,000</ix:nonFraction></span> annually, <span id="xdx_90E_eus-gaap--DeferredCompensationArrangementsOverallDescription_c20240101__20240331__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zGmDiHNjbIV" title="Share-based goods and non-employee services transaction"><ix:nonNumeric contextRef="From2024-01-012024-03-31_srt_BoardOfDirectorsChairmanMember" id="Fact000568" name="us-gaap:DeferredCompensationArrangementsOverallDescription">to be paid quarterly $12,500 in cash and $22,500 in common stock.</ix:nonNumeric>
</span>Non-employee director compensation is paid pursuant to the Non-Employee Director Compensation Plan. All payments were and are pro-rated
for partial service.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><div id="xdx_234_zTcBoaBqxsk3">
<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 11 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc"><span style="color: Blue">Table of Contents</span></a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></div></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Time Based Stock Options</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000571" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_898_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zlWrq3Mfyb6b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8BD_zvPKrWKfE2Hk">The following table summarizes the activities for
our stock options with time based vesting for the three months ended March 31, 2024, and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 4.5in; border-collapse: collapse">
  <tr style="background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>March 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 44%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 22%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 22%">&#160;</td>
    <td style="width: 2%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Dividend yield</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zZSuCsvVBIS8" title="Dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2024-01-012024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" id="Fact000573" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zfjBMFk5KbQ" title="Dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2023-01-012023-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" id="Fact000575" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></span>%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Expected Volatility</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zDaUabp6Fyul" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-01-012024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MinimumMember" id="Fact000577" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">46.18</ix:nonFraction></span> - <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zg0C9AWaVRP4" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-01-012024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MaximumMember" id="Fact000579" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">46.21</ix:nonFraction></span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zuoZ3Pq4ySTa" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-01-012023-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" id="Fact000581" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">61.3</ix:nonFraction></span>%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Weighted-average volatility</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp0_uPure_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zV5OjUQjvGC6" title="Weighted-average volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="From2024-01-012024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" id="Fact000583" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure">&#8212;</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp0_uPure_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zVyys5zzYZ89" title="Weighted-average volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="From2023-01-012023-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" id="Fact000585" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure">&#8212;</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Expected dividends</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_d0_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zB6E6iySGl1c" title="Expected dividends"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" contextRef="From2024-01-012024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" id="Fact000587" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_d0_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z4DBuV6Vbh0e" title="Expected dividends"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" contextRef="From2023-01-012023-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" id="Fact000589" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Expected term (in years)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zZeIzhdCHAfb" title="Expected term (in years)::XDX::P10Y"><span style="-sec-ix-hidden: xdx2ixbrl0591">10</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z1byDkyDfC2i" title="Expected term (in years)::XDX::P10Y"><span style="-sec-ix-hidden: xdx2ixbrl0593">10</span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Risk-free rate</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zcSsb2JN5pRg" title="Risk-free rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-01-012024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MinimumMember" id="Fact000595" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.2</ix:nonFraction></span>% - <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zPRdMSdg4Jm6" title="Risk-free rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-01-012024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MaximumMember" id="Fact000597" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.3</ix:nonFraction></span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zMcAlCg3jvX7" title="Risk-free rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-01-012023-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" id="Fact000599" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.53</ix:nonFraction></span>%</td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A0_z2l7PKyaBFtk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000601" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z9u1GmXy9bRd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B2_zJ8DmKTKjUPd">The following table summarizes the status of the stock
options:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="9" style="border-bottom: black 1pt solid; text-align: center"><b>Three Months Ended March 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 54%">Outstanding at January 1</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zYoiTVrmYcPf" title="Outstanding at beginning" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" id="Fact000603" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,256,250</ix:nonFraction></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zxKkDVi3IAXf" title="Outstanding at beginning" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" id="Fact000605" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.66</ix:nonFraction></td>
    <td style="width: 2%">&#160;</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zAAYvVJlyYVa" title="Outstanding at beginning" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" id="Fact000607" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,035,000</ix:nonFraction></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zhNzoga14ma6" title="Outstanding at beginning" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" id="Fact000609" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.93</ix:nonFraction></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Granted</td>
    <td>&#160;</td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_ziK7kuxQgc29" title="Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-01-012024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" id="Fact000611" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">65,000</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zwe0tBog49Ag" title="Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" id="Fact000613" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.21</ix:nonFraction></td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z2neB2rU5jE2" title="Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-01-012023-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" id="Fact000615" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,000</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zrO57WfTOI1a" title="Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" id="Fact000617" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.91</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Exercised</td>
    <td>&#160;</td>
    <td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zNFGcmXnfZei" title="Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0619">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zdOs5FzRoU5i" title="Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0621">&#8212;</span></td>
    <td>&#160;</td>
    <td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zrmoyx70kaA9" title="Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0623">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zDYgCzgwe9oe" title="Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0625">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Forfeited</td>
    <td>&#160;</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zuML3OHLNHic" title="Forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2024-01-012024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" id="Fact000627" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">381,250</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zAQujz4UAVL9" title="Forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" id="Fact000629" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.0</ix:nonFraction></td>
    <td>&#160;</td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zcdYDgDNjF92" title="Forfeited" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0631">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z2FoRJB8U7gj" title="Forfeited" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0633">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Outstanding at March 31</td>
    <td>&#160;</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zSkdBzXYYMvk" title="Outstanding at ending" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" id="Fact000635" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,940,000</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zUMNnfyoqoXg" title="Outstanding at ending" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" id="Fact000637" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.19</ix:nonFraction></td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zmLssqaTjuyl" title="Outstanding at ending" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" id="Fact000639" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,075,000</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zJz1aNHxEbHe" title="Outstanding at ending" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" id="Fact000641" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.92</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Options exercisable at March 31</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zwxrpXUOKwrc" title="Options exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" id="Fact000643" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,393,750</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zOKzHkx1nZw6" title="Options exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" id="Fact000645" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.59</ix:nonFraction></td>
    <td>&#160;</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zQkyiePyAbxj" title="Options exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2023-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" id="Fact000647" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,010,000</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zrDnZxmsiV75" title="Options exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" id="Fact000649" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.63</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Weighted average fair value of options granted during the period</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zZmrFPqZ2UWa" title="Weighted average fair value of options granted during the period" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" id="Fact000651" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.39</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zY8ko5SEmoPj" title="Weighted average fair value of options granted during the period" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" id="Fact000653" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.83</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Stock-based compensation expense</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zQAFevKilFAh" title="Stock-based compensation expense" style="text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" id="Fact000655" format="ixt:numdotdecimal" decimals="0" unitRef="USD">393,113</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zvRaPBX5SuA3" title="Stock-based compensation expense" style="text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" id="Fact000657" format="ixt:numdotdecimal" decimals="0" unitRef="USD">535,059</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AF_zRbcbz427Ulg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Total stock-based compensation expense was $<span id="xdx_906_ecustom--StockBasedCompensationStockOptions_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zTiGHoCLI8r7" title="Stock-based compensation expense"><ix:nonFraction name="krmd:StockBasedCompensationStockOptions" contextRef="From2024-01-012024-03-31_custom_StockOptionPlans2015And2021CombinedMember_custom_TimeBasedSharesOptionsMember" id="Fact000659" format="ixt:numdotdecimal" decimals="0" unitRef="USD">393,113</ix:nonFraction></span>
and $<span id="xdx_906_ecustom--StockBasedCompensationStockOptions_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zwgMAJ6yWV0d" title="Stock-based compensation expense"><ix:nonFraction name="krmd:StockBasedCompensationStockOptions" contextRef="From2023-01-012023-03-31_custom_StockOptionPlans2015And2021CombinedMember_custom_TimeBasedSharesOptionsMember" id="Fact000661" format="ixt:numdotdecimal" decimals="0" unitRef="USD">535,059</ix:nonFraction></span> for the three months ended March 31, 2024, and 2023, respectively. No cash was received from option exercises for the three
months ended March 31, 2024, and 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000663" name="krmd:ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock"><p id="xdx_89E_ecustom--ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock_zPvoFlRomfAk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table presents information pertaining
to options outstanding at March 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid"><b>Range of Exercise Price</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Number<br/>
Outstanding</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Remaining<br/>
Contractual<br/>
Life</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Number<br/>
Exercisable</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 29%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>$2.18 - $4.37</td>
    <td>&#160;</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_uShares_c20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zsp8OekKpoVc" title="Number outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member" id="Fact000665" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,940,000</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dxL_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zrPHLUL09Mje" title="Weighted average remaining contractual life::XDX::P6Y10M25D"><span style="-sec-ix-hidden: xdx2ixbrl0667">6.9</span></span> years</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_uUSDPShares_c20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zaUD8pR3q3Sa" title="Weighted average exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member" id="Fact000669" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.19</ix:nonFraction></td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_uShares_c20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_z0inQJXrmbri" title="Number exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member" id="Fact000671" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,393,750</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_uUSDPShares_c20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zcgmIrpLA4ic" title="Weighted average exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="AsOf2024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member" id="Fact000673" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.59</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A3_z7lVE1Cfr7Xh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2024, there was $<span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20240331__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z0n9toIWnu0i" title="Total unrecognized compensation cost"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2024-03-31_custom_StockOptionPlans2015And2021CombinedMember_custom_TimeBasedSharesOptionsMember" id="Fact000675" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,719,478</ix:nonFraction></span> of total
unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the Plans. &#160;That cost is
expected to be recognized over a weighted-average period of 46 months. &#160;The total fair value of shares vested as of March 31, 2024,
and March 31, 2023, was $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_c20240331__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember_zjVbUYwyoaZ1" title="Fair value of shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" contextRef="AsOf2024-03-31_custom_StockOptionPlans2015And2021CombinedMember" id="Fact000677" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,884,426</ix:nonFraction></span> and $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_c20230331__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember_zneaG83Fw18k" title="Fair value of shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" contextRef="AsOf2023-03-31_custom_StockOptionPlans2015And2021CombinedMember" id="Fact000679" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,511,874</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<div id="xdx_235_zrZVBeJ1vi28">
<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 12 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc"><span style="color: Blue">Table of Contents</span></a></i></p>

<p id="xdx_234_zIIQrbiZSOd2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Performance Based Stock Options</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000683" name="us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock"><p id="xdx_89D_eus-gaap--ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_zfdU1nleHWD3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;<span id="xdx_8B8_zXaeFjqp7yzf">The following table summarizes the activities
for our unvested performance based stock option awards for the three months ended March 31, 2024, and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="9" style="border-bottom: black 1pt solid; text-align: center"><b>Three Months Ended March 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Grant-Date<br/>
Fair Value</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Grant-Date<br/>
Fair Value</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 41%">Unvested at January 1</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByUnvestedAwardOptions_iS_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zotXsiT7eLUi" title="Unvested at beginning" style="width: 12%; text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByUnvestedAwardOptions" contextRef="AsOf2023-12-31_custom_PerformanceBasedSharesOptionsMember" id="Fact000685" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000</ix:nonFraction></td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zJQQjo9OzeD5" title="Unvested at beginning" style="width: 11%; text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_custom_PerformanceBasedSharesOptionsMember" id="Fact000687" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.48</ix:nonFraction></td>
    <td style="width: 3%">&#160;</td>
    <td id="xdx_984_ecustom--ShareBasedCompensationArrangementByUnvestedAwardOptions_iS_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zR9hL9pdviS8" title="Outstanding at beginning" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0689">&#8212;</span></td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zprybgccS3Z" style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0690">&#8212;</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Granted</td>
    <td>&#160;</td>
    <td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_pid_d0_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zTEEWu3cIbFi" title="Granted" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" contextRef="From2024-01-012024-03-31_custom_PerformanceBasedSharesOptionsMember" id="Fact000692" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8212;</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zeya2LFwdaRd" title="Granted" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" contextRef="From2024-01-012024-03-31_custom_PerformanceBasedSharesOptionsMember" id="Fact000694" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8212;</ix:nonFraction></td>
    <td>&#160;</td>
    <td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_pid_d0_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zXWOaTaNmEe1" title="Granted" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" contextRef="From2023-01-012023-03-31_custom_PerformanceBasedSharesOptionsMember" id="Fact000696" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8212;</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zsi3lmH5hgo2" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" contextRef="From2023-01-012023-03-31_custom_PerformanceBasedSharesOptionsMember" id="Fact000697" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8212;</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Vested</td>
    <td>&#160;</td>
    <td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested_pid_d0_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zUsOlgAh1JPh" title="Vested" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested" contextRef="From2024-01-012024-03-31_custom_PerformanceBasedSharesOptionsMember" id="Fact000699" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8212;</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zpuvY05Z4xj5" title="Vested" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1" contextRef="From2024-01-012024-03-31_custom_PerformanceBasedSharesOptionsMember" id="Fact000701" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8212;</ix:nonFraction></td>
    <td>&#160;</td>
    <td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested_pid_d0_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zK59qA2YlLx3" title="Forfeited" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested" contextRef="From2023-01-012023-03-31_custom_PerformanceBasedSharesOptionsMember" id="Fact000703" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8212;</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zWxMuPh3Rqcj" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1" contextRef="From2023-01-012023-03-31_custom_PerformanceBasedSharesOptionsMember" id="Fact000704" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8212;</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Forfeited/canceled</td>
    <td>&#160;</td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures_pid_d0_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zpZ0uITitbJl" title="Forfeited/canceled" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures" contextRef="From2024-01-012024-03-31_custom_PerformanceBasedSharesOptionsMember" id="Fact000706" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8212;</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zk41Ro850OGl" title="Forfeited/canceled" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" contextRef="From2024-01-012024-03-31_custom_PerformanceBasedSharesOptionsMember" id="Fact000708" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8212;</ix:nonFraction></td>
    <td>&#160;</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures_pid_d0_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zFpVkK1Ao6x6" title="Forfeited" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures" contextRef="From2023-01-012023-03-31_custom_PerformanceBasedSharesOptionsMember" id="Fact000710" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8212;</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zbsX2bw9yNdd" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" contextRef="From2023-01-012023-03-31_custom_PerformanceBasedSharesOptionsMember" id="Fact000711" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8212;</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Unvested at March 31</td>
    <td>&#160;</td>
    <td id="xdx_981_ecustom--ShareBasedCompensationArrangementByUnvestedAwardOptions_iE_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zA0woV7FpRF1" title="Unvested at ending" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByUnvestedAwardOptions" contextRef="AsOf2024-03-31_custom_PerformanceBasedSharesOptionsMember" id="Fact000713" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_z11bZTkeKju3" title="Unvested at ending" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice" contextRef="AsOf2024-03-31_custom_PerformanceBasedSharesOptionsMember" id="Fact000715" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.48</ix:nonFraction></td>
    <td>&#160;</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByUnvestedAwardOptions_iE_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zL8NJNwlP4Oc" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0716">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zy5RGvR7rdu5" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0717">&#8212;</span></td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A6_zfCIxTX6T4ci" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Total stock-based compensation expense was $<span id="xdx_903_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zS1xOOjuCjil" title="Total stock-based compensation expense"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2024-01-012024-03-31_us-gaap_PerformanceSharesMember" id="Fact000719" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,121</ix:nonFraction></span>
and <span id="xdx_90A_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_dxL_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zkkRoYDuQnf4" title="Total stock-based compensation expense::XDX::0"><span style="-sec-ix-hidden: xdx2ixbrl0721">zero</span></span> for the three months ended March 31, 2024, and 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2024, there was $<span id="xdx_905_ecustom--UnrecognizedCompensationCost_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zDZFp88xtrTf" title="Unrecognized compensation cost"><ix:nonFraction name="krmd:UnrecognizedCompensationCost" contextRef="From2024-01-012024-03-31_us-gaap_PerformanceSharesMember" id="Fact000723" format="ixt:numdotdecimal" decimals="0" unitRef="USD">168,223</ix:nonFraction></span> of unrecognized
compensation cost related to unvested employee performance based options. This amount is expected to be recognized over a weighted-average
period of 36 months.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Restricted Stock Awards and PSUs</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000725" name="us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_z9ygRDHDD4y4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B1_zutCAf93qVe5">The following table summarizes the activities for
our restricted stock awards and PSUs for the three months ended March 31, 2024, and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="9" style="border-bottom: black 1pt solid; text-align: center"><b>Three Months Ended March 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Grant-Date Fair Value</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Grant-Date Fair Value</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 41%">Unvested at January 1</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zKYWgn2mgeg7" title="Outstanding at beginning" style="width: 12%; text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" contextRef="AsOf2023-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" id="Fact000727" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">904,496</ix:nonFraction></td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_znguJnC4jSch" title="Outstanding at beginning" style="width: 11%; text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" contextRef="AsOf2023-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" id="Fact000729" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.80</ix:nonFraction></td>
    <td style="width: 3%">&#160;</td>
    <td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_ziNpjHxQAwWe" title="Outstanding at beginning" style="width: 12%; text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" contextRef="AsOf2022-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" id="Fact000731" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">950,000</ix:nonFraction></td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_pid_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zCIwRk1DycGk" title="Outstanding at beginning" style="width: 11%; text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" contextRef="AsOf2022-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" id="Fact000733" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.04</ix:nonFraction></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Granted</td>
    <td>&#160;</td>
    <td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zR0yXwCX9oBb" title="Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0735">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zzILKzaYeEi6" title="Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0737">&#8212;</span></td>
    <td>&#160;</td>
    <td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zKrUnVs8DfHf" title="Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0739">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z9q5qkqj6DKj" title="Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0741">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Vested</td>
    <td>&#160;</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z2bO08kSVx91" title="Vested" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0743">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_ze8tsIucLVlg" title="Vested" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0745">&#8212;</span></td>
    <td>&#160;</td>
    <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zgTceYgH9i3g" title="Vested" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" contextRef="From2023-01-012023-03-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" id="Fact000747" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zZVhFi4utnhl" title="Vested" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-03-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" id="Fact000749" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.31</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Forfeited/canceled</td>
    <td>&#160;</td>
    <td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z8APshZWAndi" title="Forfeited/canceled" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0751">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z1FZxq0fktp9" title="Forfeited/canceled" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0753">&#8212;</span></td>
    <td>&#160;</td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zHJ4BQvdTDKd" title="Forfeited/canceled" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0755">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zxVVVZJpYx27" title="Forfeited/canceled" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0757">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Unvested at March 31</td>
    <td>&#160;</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zLmPv1DufjFf" title="Outstanding at ending" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" contextRef="AsOf2024-03-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" id="Fact000759" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">904,496</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zIuBm8uUqbT5" title="Outstanding at ending" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" contextRef="AsOf2024-03-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" id="Fact000761" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.80</ix:nonFraction></td>
    <td>&#160;</td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zkPMoHvDvW7a" title="Outstanding at ending" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" contextRef="AsOf2023-03-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" id="Fact000763" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">900,000</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_pid_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zuylbHtfoaT3" title="Outstanding at ending" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" contextRef="AsOf2023-03-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" id="Fact000765" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.93</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A1_zKkyMje4eMt8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Total stock-based compensation expense was $<span id="xdx_905_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zDGx7mNi5eIg" title="Total stock-based compensation expense"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2024-01-012024-03-31_us-gaap_RestrictedStockMember" id="Fact000767" format="ixt:numdotdecimal" decimals="0" unitRef="USD">122,551</ix:nonFraction></span>
and $<span id="xdx_901_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zlfXfy1yf1Fb" title="Total stock-based compensation expense"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2023-01-012023-03-31_us-gaap_RestrictedStockMember" id="Fact000769" format="ixt:numdotdecimal" decimals="0" unitRef="USD">170,387</ix:nonFraction></span> for the three months ended March 31, 2024, and 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2024, and 2023, there was $<span id="xdx_906_ecustom--UnrecognizedCompensationCost_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zVLYduJ3g3u2" title="Unrecognized compensation cost"><ix:nonFraction name="krmd:UnrecognizedCompensationCost" contextRef="From2024-01-012024-03-31_us-gaap_RestrictedStockMember" id="Fact000771" format="ixt:numdotdecimal" decimals="0" unitRef="USD">755,513</ix:nonFraction></span>
and $<span id="xdx_90D_ecustom--UnrecognizedCompensationCost_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zpR1pnKUb0G" title="Unrecognized compensation cost"><ix:nonFraction name="krmd:UnrecognizedCompensationCost" contextRef="From2023-01-012023-03-31_us-gaap_RestrictedStockMember" id="Fact000773" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,447,790</ix:nonFraction></span> of unrecognized compensation cost related to unvested employee restricted stock awards and PSUs. This amount is expected
to be recognized over a weighted-average period of 21 months.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><div id="xdx_239_zVDsfHt93191">
<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 13 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc"><span style="color: Blue">Table of Contents</span></a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></div></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Common Stock Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000776" name="us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock"><p id="xdx_898_eus-gaap--ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_zIKqcXIf9dk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B4_zELoc4sie5I8">The following table summarizes the activities for
our common stock warrants issued in connection with our loan financing agreement with HSBC for the three months ended March 31, 2024,
and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="9" style="border-bottom: black 1pt solid; text-align: center"><b>Three Months Ended March 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Grant-Date Fair Value</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Grant-Date Fair Value</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 41%">Unvested at January 1</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z32p3x7EvNAi" title="Outstanding at beginning" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0778">&#8212;</span></td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z6WNsuByy9Hb" title="Outstanding at beginning" style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0780">&#8212;</span></td>
    <td style="width: 3%">&#160;</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zAxpnMBih8G7" title="Outstanding at beginning" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0782">&#8212;</span></td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_pid_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zfk2gwBzJGb9" title="Outstanding at beginning" style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0784">&#8212;</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Granted</td>
    <td>&#160;</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zSA31aYSHUY8" title="Granted" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" contextRef="From2024-01-012024-03-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member" id="Fact000786" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">76,104</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zc5SR8rOvrJf" title="Granted" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" contextRef="From2024-01-012024-03-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member" id="Fact000788" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.37</ix:nonFraction></td>
    <td>&#160;</td>
    <td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zzCkLpkxkpX2" title="Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0790">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z8GphMB98u8h" title="Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0792">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Vested</td>
    <td>&#160;</td>
    <td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_ziSVH8pmo6B6" title="Vested" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" contextRef="From2024-01-012024-03-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member" id="Fact000794" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">38,052</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zjFtWrc3Q9D6" title="Vested" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-03-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member" id="Fact000796" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.37</ix:nonFraction></td>
    <td>&#160;</td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zFmp0xx4pNtk" title="Vested" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0798">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zxbtd3qnDml7" title="Vested" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0800">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Forfeited/canceled</td>
    <td>&#160;</td>
    <td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zLxCz4v7LCIk" title="Forfeited/canceled" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0802">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z2l0CNeiBtLb" title="Forfeited/canceled" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0804">&#8212;</span></td>
    <td>&#160;</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z0tyiOTYMoB1" title="Forfeited/canceled" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0806">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zoF53Nge4OY3" title="Forfeited/canceled" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0808">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Unvested at March 31</td>
    <td>&#160;</td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zdQalfv0smS7" title="Outstanding at ending" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" contextRef="AsOf2024-03-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member" id="Fact000810" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">38,052</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z0AnyDlHUsy4" title="Outstanding at ending" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" contextRef="AsOf2024-03-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member" id="Fact000812" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.37</ix:nonFraction></td>
    <td>&#160;</td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z3qLHiDO5Hm8" title="Outstanding at ending" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0814">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_pid_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zXGxwUbpLKxa" title="Outstanding at ending" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0816">&#8212;</span></td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AF_zVLUdOWcsDWh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2024, and 2023, there was $<span id="xdx_904_ecustom--UnrecognizedCompensationCost_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember_z7HXh3eYmTX7" title="Unrecognized cost"><ix:nonFraction name="krmd:UnrecognizedCompensationCost" contextRef="From2024-01-012024-03-31_custom_CommonStockWarrantsMember" id="Fact000818" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,125</ix:nonFraction></span>
and <span id="xdx_901_ecustom--UnrecognizedCompensationCost_dxL_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember_zb5XL6m2x191" title="Unrecognized cost::XDX::0"><span style="-sec-ix-hidden: xdx2ixbrl0820">zero</span></span> of unrecognized cost related to unvested warrants.</p>

</ix:nonNumeric><p id="xdx_810_zrWojanbFFe9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000822" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_807_eus-gaap--DebtDisclosureTextBlock_z3cf6wwfzpNb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 4 &#8212; <span id="xdx_824_zkyWV8c7dytc">DEBT OBLIGATIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 28, 2023, the Company entered into a
commercial insurance premium finance and security agreement with AON Premium Finance, LLC in the aggregate principal amount of
$<span id="xdx_906_eus-gaap--NotesPayable_iI_dm_c20230728__dei--LegalEntityAxis__custom--AONPremiumFinanceLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_z27QFGKX2xac" title="Notes payable"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2023-07-28_custom_AONPremiumFinanceLLCMember_custom_PromissoryNoteMember" id="Fact000824" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">0.57</ix:nonFraction>
million</span> bearing an annual percentage rate of <span id="xdx_901_ecustom--NotePayableTerms_pid_dp_uPure_c20230726__20230728__dei--LegalEntityAxis__custom--AONPremiumFinanceLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zEt4adGtrBvk" title="Note payable terms"><ix:nonFraction name="krmd:NotePayableTerms" contextRef="From2023-07-262023-07-28_custom_AONPremiumFinanceLLCMember_custom_PromissoryNoteMember" id="Fact000826" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9.5</ix:nonFraction></span>%,
to finance its insurance premiums. <span id="xdx_908_eus-gaap--DebtInstrumentFrequencyOfPeriodicPayment_c20230726__20230728__dei--LegalEntityAxis__custom--AONPremiumFinanceLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zrZ35925XQj8" title="Description of the frequency of periodic payments"><ix:nonNumeric contextRef="From2023-07-262023-07-28_custom_AONPremiumFinanceLLCMember_custom_PromissoryNoteMember" id="Fact000828" name="us-gaap:DebtInstrumentFrequencyOfPeriodicPayment">Monthly
payments are due on the first of each month beginning August 1, 2023 through June 1, 2024.</ix:nonNumeric></span> The balance of the AON note was
$<span id="xdx_906_eus-gaap--OtherLongTermDebtNoncurrent_iI_c20231231__dei--LegalEntityAxis__custom--AONPremiumFinanceLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zaQRudaPpskk" title="Balance of AON note"><ix:nonFraction name="us-gaap:OtherLongTermDebtNoncurrent" contextRef="AsOf2023-12-31_custom_AONPremiumFinanceLLCMember_custom_PromissoryNoteMember" id="Fact000830" format="ixt:numdotdecimal" decimals="0" unitRef="USD">314,344</ix:nonFraction></span>
as of December 31, 2023 and $<span id="xdx_903_eus-gaap--OtherLongTermDebtNoncurrent_iI_c20240331__dei--LegalEntityAxis__custom--AONPremiumFinanceLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zg1HcVxIsuOe" title="Balance of AON note"><ix:nonFraction name="us-gaap:OtherLongTermDebtNoncurrent" contextRef="AsOf2024-03-31_custom_AONPremiumFinanceLLCMember_custom_PromissoryNoteMember" id="Fact000832" format="ixt:numdotdecimal" decimals="0" unitRef="USD">159,031</ix:nonFraction></span>
as of March 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 8, 2024, the Company entered into a loan
and security agreement with HSBC Ventures USA Inc., as lender, providing for a $<span id="xdx_90A_eus-gaap--LinesOfCreditCurrent_iI_c20240308__dei--LegalEntityAxis__custom--HSBCVenturesUSAIncMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zDHRn3zBUwmk" title="Revolving credit facility"><ix:nonFraction name="us-gaap:LinesOfCreditCurrent" contextRef="AsOf2024-03-08_custom_HSBCVenturesUSAIncMember_us-gaap_RevolvingCreditFacilityMember" id="Fact000834" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000,000</ix:nonFraction></span> revolving credit facility and a $<span id="xdx_905_ecustom--LinesOfCreditCurrent1_iI_c20240308__dei--LegalEntityAxis__custom--HSBCVenturesUSAIncMember__us-gaap--CreditFacilityAxis__custom--TermLoanFacilityMember_zKis0mgO2FS9" title="Term loan facility"><ix:nonFraction name="krmd:LinesOfCreditCurrent1" contextRef="AsOf2024-03-08_custom_HSBCVenturesUSAIncMember_custom_TermLoanFacilityMember" id="Fact000836" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000,000</ix:nonFraction></span> term
loan facility. Borrowings are secured by a first-priority lien on substantially all of the assets of the Company, subject to customary
exceptions. The revolving credit facility matures on December 31, 2025 and the term loan matures on December 1, 2028. Our former revolving
credit facility with Key Bank expired during the quarter ended September 30, 2023. As of March 31, 2024, there were no outstanding borrowings
under the term loan nor the revolving credit facility.</p>

</ix:nonNumeric><p id="xdx_811_zDp2G4skj2h3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000838" name="us-gaap:LeasesOfLesseeDisclosureTextBlock"><p id="xdx_801_eus-gaap--LeasesOfLesseeDisclosureTextBlock_zk5BZxcXN6ff" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 5 &#8212; <span id="xdx_82B_zpMVH4UhthY9">LEASES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have finance and operating leases for our corporate
office and certain office and computer equipment. &#160;Our two operating leases have remaining lease terms of <span id="xdx_90A_ecustom--LesseeOperatingLeaseRemainingTerm_dxL_c20240101__20240331__us-gaap--LeaseContractualTermAxis__custom--LeaseOneMember_zS39fX1ATpHh" title="Operating lease remaining term::XDX::P8Y4M24D"><span style="-sec-ix-hidden: xdx2ixbrl0840">8.4</span></span> years and <span id="xdx_908_ecustom--LesseeOperatingLeaseRemainingTerm_dxL_c20240101__20240331__us-gaap--LeaseContractualTermAxis__custom--LeaseTwoMember_zuxS5Y2FwZri" title="Operating lease remaining term::XDX::P4Y9M18D"><span style="-sec-ix-hidden: xdx2ixbrl0842">4.8</span></span> years,
respectively. Our three finance leases have remaining lease terms of <span id="xdx_902_ecustom--LesseeFinanceLeaseRemainingTerm_dxL_c20240101__20240331__us-gaap--LeaseContractualTermAxis__custom--LeaseOneMember_zTn177XUF3r6" title="Finance lease remaining term::XDX::P3Y2M12D"><span style="-sec-ix-hidden: xdx2ixbrl0844">3.2</span></span> years, <span id="xdx_905_ecustom--LesseeFinanceLeaseRemainingTerm_dxL_c20240101__20240331__us-gaap--LeaseContractualTermAxis__custom--LeaseTwoMember_zPLpD3ncnP1c" title="Finance lease remaining term::XDX::P2Y9M0D"><span style="-sec-ix-hidden: xdx2ixbrl0846">2.75</span></span> years, and <span id="xdx_900_ecustom--LesseeFinanceLeaseRemainingTerm_dxL_c20240101__20240331__us-gaap--LeaseContractualTermAxis__custom--LeaseThreeMember_zpkUK7LeVvpe" title="Finance lease remaining term::XDX::P4Y6M0D"><span style="-sec-ix-hidden: xdx2ixbrl0848">4.5</span></span> years, respectively, as of March 31,
2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000850" name="us-gaap:LeaseCostTableTextBlock"><p id="xdx_89E_eus-gaap--LeaseCostTableTextBlock_zauTH8fo6kWa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8BE_z1UUuMP6ctD5">The components of lease expense were as follows:</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 4.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_496_20240101__20240331_zPZhZXkiyey3" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_490_20230101__20230331_zB4RJACsSBi2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Three Months Ended</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>March 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 62%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: right">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseCost_maLCzGTc_zFrhS2aSiqqb" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Operating lease cost</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2024-01-01to2024-03-31" id="Fact000852" format="ixt:numdotdecimal" decimals="0" unitRef="USD">111,548</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2023-01-012023-03-31" id="Fact000853" format="ixt:numdotdecimal" decimals="0" unitRef="USD">112,522</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ShortTermLeaseCost_maLCzGTc_zSXcYUba4MP6" style="vertical-align: bottom">
    <td>Short-term lease cost</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="From2024-01-01to2024-03-31" id="Fact000855" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,460</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="From2023-01-012023-03-31" id="Fact000856" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,894</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LeaseCost_zKRTYi0GRENg" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Total lease cost</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2024-01-01to2024-03-31" id="Fact000858" format="ixt:numdotdecimal" decimals="0" unitRef="USD">115,008</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2023-01-012023-03-31" id="Fact000859" format="ixt:numdotdecimal" decimals="0" unitRef="USD">165,416</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_ecustom--FinanceLeaseCost1Abstract_iB_zZm9UtAhC4va" style="vertical-align: bottom">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">Finance lease cost:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_i01_maFLCzAT2_z6I3gfDgKNQ5" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.2in">Amortization of right-of-use assets</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="From2024-01-01to2024-03-31" id="Fact000864" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,896</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="From2023-01-012023-03-31" id="Fact000865" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,223</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--FinanceLeaseInterestExpense_i01_maFLCzAT2_zMns9RB1ItPk" style="vertical-align: bottom">
    <td style="padding-left: 0.2in">Interest on lease liabilities</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseInterestExpense" contextRef="From2024-01-01to2024-03-31" id="Fact000867" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,053</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseInterestExpense" contextRef="From2023-01-012023-03-31" id="Fact000868" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,720</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_ecustom--FinanceLeaseCost_i01_zqGwjQy9Sim2" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Total finance lease cost</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="krmd:FinanceLeaseCost" contextRef="From2024-01-01to2024-03-31" id="Fact000870" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,949</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="krmd:FinanceLeaseCost" contextRef="From2023-01-012023-03-31" id="Fact000871" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,943</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A3_zfUOYrNp5RPd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><div id="xdx_232_zPU6a2GdD9Wc">
<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 14 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc"><span style="color: Blue">Table of Contents</span></a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></div></ix:exclude>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000874" name="us-gaap:OperatingLeaseLeaseIncomeTableTextBlock"><p id="xdx_89F_eus-gaap--OperatingLeaseLeaseIncomeTableTextBlock_zKNpO7m0QyU3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B8_zC6gKwzRWUK5">Supplemental cash flow information related to leases
was as follows:</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 6.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_495_20240101__20240331_zVppJ63WtQ94" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_490_20230101__20230331_zpl9Na4lfwZ6" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Three Months Ended</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>March 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashFlowOperatingActivitiesLesseeAbstract_iB" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 70%; padding-left: 8.25pt; text-indent: -8.25pt">Cash paid for amounts included in the measurement of lease liabilities:</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeasePayments_i01_zsEqvrMPSCH6" style="vertical-align: bottom">
    <td>Operating cash flows from operating leases</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2024-01-01to2024-03-31" id="Fact000879" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,365</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2023-01-012023-03-31" id="Fact000880" format="ixt:numdotdecimal" decimals="0" unitRef="USD">113,813</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FinanceLeaseInterestPaymentOnLiability_i01_zc6FMQiffytl" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Financing cash flows from finance leases</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseInterestPaymentOnLiability" contextRef="From2024-01-01to2024-03-31" id="Fact000882" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,859</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseInterestPaymentOnLiability" contextRef="From2023-01-012023-03-31" id="Fact000883" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,800</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A2_znLkcIgBIoLb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000885" name="us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock"><p id="xdx_899_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_zvPao6Y57qB7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B2_zHobzA7gJrza">Supplemental balance sheet information related to
leases was as follows:</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49E_20240331_zd6RSgwy3vY7" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_492_20231231_zfj7QKjQoz3f" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>March 31,<br/>
2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,<br/>
2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 55%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 17%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 17%">&#160;</td>
    <td style="width: 2%">&#160;</td></tr>
  <tr id="xdx_402_ecustom--AssetsAndLiabilitiesOperatingLesseeAbstract_iB_zUKGoupTq6x7" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt"><b>Operating Leases</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_z7iI4XVnolG1" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Operating lease right-of-use assets</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-03-31" id="Fact000890" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,428,885</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-12-31" id="Fact000891" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,514,055</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityCurrent_i01I_z2Bc90rfh79b" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Operating lease current liabilities</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-03-31" id="Fact000893" format="ixt:numdotdecimal" decimals="0" unitRef="USD">372,109</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-12-31" id="Fact000894" format="ixt:numdotdecimal" decimals="0" unitRef="USD">368,313</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_zpCmZ4XeYpzd" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Operating lease long term liabilities</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-03-31" id="Fact000896" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,241,837</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-12-31" id="Fact000897" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,336,300</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiability_i01I_zloCrfDY96a4" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">Total operating lease liabilities</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2024-03-31" id="Fact000899" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,613,946</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2023-12-31" id="Fact000900" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,704,613</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_ecustom--AssetsAndLiabilitiesLesseeFinanceAbstract_iB_zYpNM6sUPA98" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt"><b>Finance Leases</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentOther_i01I_z2bIO0JnclQ6" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Property and equipment, at cost</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentOther" contextRef="AsOf2024-03-31" id="Fact000905" format="ixt:numdotdecimal" decimals="0" unitRef="USD">577,929</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentOther" contextRef="AsOf2023-12-31" id="Fact000906" format="ixt:numdotdecimal" decimals="0" unitRef="USD">577,929</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentOtherAccumulatedDepreciation_i01NI_di_z1PbQqb7pPHk" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Accumulated depreciation</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation" contextRef="AsOf2024-03-31" id="Fact000908" format="ixt:numdotdecimal" decimals="0" unitRef="USD">190,358</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation" contextRef="AsOf2023-12-31" id="Fact000909" format="ixt:numdotdecimal" decimals="0" unitRef="USD">161,461</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentOtherNet_i01I_zohKRMyBndKd" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Property and equipment, net</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentOtherNet" contextRef="AsOf2024-03-31" id="Fact000911" format="ixt:numdotdecimal" decimals="0" unitRef="USD">387,571</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentOtherNet" contextRef="AsOf2023-12-31" id="Fact000912" format="ixt:numdotdecimal" decimals="0" unitRef="USD">416,468</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FinanceLeaseLiabilityCurrent_iI_zQQS7vFSwB8i" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Finance lease current liabilities</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2024-03-31" id="Fact000914" format="ixt:numdotdecimal" decimals="0" unitRef="USD">111,103</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2023-12-31" id="Fact000915" format="ixt:numdotdecimal" decimals="0" unitRef="USD">109,540</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_zumSjJzwUjP6" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Finance lease long term liabilities</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2024-03-31" id="Fact000917" format="ixt:numdotdecimal" decimals="0" unitRef="USD">288,253</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2023-12-31" id="Fact000918" format="ixt:numdotdecimal" decimals="0" unitRef="USD">316,623</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--FinanceLeaseLiability_iI_zYz94yTFuF22" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">Total finance lease liabilities</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiability" contextRef="AsOf2024-03-31" id="Fact000920" format="ixt:numdotdecimal" decimals="0" unitRef="USD">399,356</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiability" contextRef="AsOf2023-12-31" id="Fact000921" format="ixt:numdotdecimal" decimals="0" unitRef="USD">426,163</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 5in; border-collapse: collapse">
  <tr>
    <td style="vertical-align: bottom; width: 55%">&#160;</td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 19%; text-align: center"><b>March 31,<br/>
2024</b></td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: top; width: 19%; text-align: center"><b>December 31,<br/>
2023</b></td>
    <td style="vertical-align: top; width: 2%">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom"><b>Weighted Average Remaining Lease Term</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-left: 0.2in">Operating leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span id="xdx_90D_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dxL_c20240331_z8uD2GUNGQ71" title="Operating leases term::XDX::P6Y7M6D"><span style="-sec-ix-hidden: xdx2ixbrl0923">6.6</span></span> Years</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span id="xdx_907_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dxL_c20231231_z8y6Zc5zuA8f" title="::XDX::P6Y10M25D"><span style="-sec-ix-hidden: xdx2ixbrl0924">6.9</span></span> Years</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 0.2in">Finance leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span id="xdx_90B_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dxL_c20240331_zjyamX7bpi3a" title="Finance leases  term::XDX::P3Y7M6D"><span style="-sec-ix-hidden: xdx2ixbrl0926">3.6</span></span> Years</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span id="xdx_90F_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dxL_c20231231_ziSWWq7j83ck" title="::XDX::P6Y8M12D"><span style="-sec-ix-hidden: xdx2ixbrl0927">3.7</span></span> Years</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom"><b>Weighted Average Discount Rate</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-left: 0.2in">Operating leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span id="xdx_904_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20240331_zSIydO3clCqg" title="Operating leases discount rate"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseDiscountRate" contextRef="AsOf2024-03-31" id="Fact000929" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.73</ix:nonFraction></span>%</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span id="xdx_907_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20231231_zWAR3Jqmunb1"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseDiscountRate" contextRef="AsOf2023-12-31" id="Fact000930" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.76</ix:nonFraction></span>%</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 0.2in">Finance leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span id="xdx_900_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_pid_dp_uPure_c20240331_z6TiDvQXNJu3" title="Finance leases discount rate"><ix:nonFraction name="us-gaap:LesseeFinanceLeaseDiscountRate" contextRef="AsOf2024-03-31" id="Fact000932" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6.17</ix:nonFraction></span>%</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span id="xdx_90A_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_pid_dp_uPure_c20231231_z9i6Vxe0410h"><ix:nonFraction name="us-gaap:LesseeFinanceLeaseDiscountRate" contextRef="AsOf2023-12-31" id="Fact000933" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6.19</ix:nonFraction></span>%</td>
    <td style="vertical-align: top">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AD_zvGn0RGtdUqh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000935" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_892_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zZh9W77sRRAa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B6_zQqUwkv5Smyl">Maturities of lease liabilities are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom"><b>Year Ending December 31,</b></td>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>Operating Leases</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>Finance Leases</b></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; width: 52%">Remainder of 2024</td>
    <td style="vertical-align: top; width: 3%">&#160;</td>
    <td style="vertical-align: bottom; width: 2%">$</td>
    <td id="xdx_98B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20240331_zanzfq8GuNhb" title="2024 - Operating Leases" style="vertical-align: bottom; width: 18%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2024-03-31" id="Fact000937" format="ixt:numdotdecimal" decimals="0" unitRef="USD">384,041</ix:nonFraction></td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td id="xdx_98E_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20240331_zN3jqj0wcU1i" title="2024 - Finance Leases" style="vertical-align: bottom; width: 18%; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2024-03-31" id="Fact000939" format="ixt:numdotdecimal" decimals="0" unitRef="USD">98,578</ix:nonFraction></td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>2025</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_c20240331_z7s6l8TSl4Wg" title="2025 - Operating Leases" style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2024-03-31" id="Fact000941" format="ixt:numdotdecimal" decimals="0" unitRef="USD">512,055</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_c20240331_zRUoU2hVhPb2" title="2025 - Finance Leases" style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2024-03-31" id="Fact000943" format="ixt:numdotdecimal" decimals="0" unitRef="USD">131,437</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2026</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_c20240331_zg5vTq2XkmZg" title="2026 - Operating Leases" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2024-03-31" id="Fact000945" format="ixt:numdotdecimal" decimals="0" unitRef="USD">512,055</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_986_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_c20240331_zoX17dI2XQ79" title="2026 - Finance Leases" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2024-03-31" id="Fact000947" format="ixt:numdotdecimal" decimals="0" unitRef="USD">131,437</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">2027</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_c20240331_z2KRKq1vCqLj" title="2027 - Operating Leases" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2024-03-31" id="Fact000949" format="ixt:numdotdecimal" decimals="0" unitRef="USD">512,055</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_c20240331_zounU9bLy9Pl" title="2027 - Finance Leases" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2024-03-31" id="Fact000951" format="ixt:numdotdecimal" decimals="0" unitRef="USD">74,194</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2028</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_c20240331_zpTHKbaDDgVb" title="2028 - Operating Leases" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="AsOf2024-03-31" id="Fact000953" format="ixt:numdotdecimal" decimals="0" unitRef="USD">511,009</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98C_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_iI_c20240331_zweTlmwMVuXk" title="2028 - Finance Leases" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" contextRef="AsOf2024-03-31" id="Fact000955" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,179</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">Thereafter</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_989_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_c20240331_zsGbBJNckw15" title="Thereafter - Operating Leases" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="AsOf2024-03-31" id="Fact000957" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,833,604</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_98E_eus-gaap--FinanceLeaseLiabilityPaymentsDueAfterYearFive_iI_c20240331_zHAmz4lUIWrk" title="Thereafter - Finance Leases" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0959">&#8212;</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">Total undiscounted lease payments</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_980_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueTotal_iI_c20240331_zxoLT9s7r5pi" title="Total undiscounted lease payments - Operating Leases" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="krmd:LesseeOperatingLeaseLiabilityPaymentsDueTotal" contextRef="AsOf2024-03-31" id="Fact000961" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,264,819</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_982_ecustom--LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal_iI_c20240331_zWaFrJrbLQSk" title="Total undiscounted lease payments - Finance Leases" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="krmd:LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal" contextRef="AsOf2024-03-31" id="Fact000963" format="ixt:numdotdecimal" decimals="0" unitRef="USD">441,825</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-left: 16.45pt">Less: imputed interest</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_985_ecustom--LesseeOperatingLeaseImputedInterest_iNI_di_c20240331_zydmttaezh5g" title="Less: imputed interest - Operating Leases" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">(<ix:nonFraction name="krmd:LesseeOperatingLeaseImputedInterest" contextRef="AsOf2024-03-31" id="Fact000965" format="ixt:numdotdecimal" decimals="0" unitRef="USD">650,873</ix:nonFraction></td>
    <td style="vertical-align: bottom">)</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_983_ecustom--LesseeFinancingLeaseImputedInterest_iNI_di_c20240331_zmxAZ4l6Q9g2" title="Less: imputed interest - Finance Leases" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">(<ix:nonFraction name="krmd:LesseeFinancingLeaseImputedInterest" contextRef="AsOf2024-03-31" id="Fact000967" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,469</ix:nonFraction></td>
    <td style="vertical-align: bottom">)</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">Total lease liabilities</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">$</td>
    <td id="xdx_983_eus-gaap--OperatingLeaseLiability_iI_c20240331_z5NJJfYHuG68" title="Total lease liabilities - Operating Leases" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2024-03-31" id="Fact000969" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,613,946</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">$</td>
    <td id="xdx_98B_eus-gaap--FinanceLeaseLiability_iI_c20240331_zuHy3SmrjCza" title="Total lease liabilities - Finance Leases" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiability" contextRef="AsOf2024-03-31" id="Fact000971" format="ixt:numdotdecimal" decimals="0" unitRef="USD">399,356</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zuNGCSXdVu49" style="margin-top: 0; margin-bottom: 0">&#160;</p>
</ix:nonNumeric><p id="xdx_819_z1Di6Ez70RA8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 15 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc"><span style="color: Blue">Table of Contents</span></a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000973" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_803_eus-gaap--IncomeTaxDisclosureTextBlock_z0BD5KGS1Mw2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 6 &#8212; <span id="xdx_822_zJwD9oNZlMie">INCOME TAXES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For interim income tax reporting, the Company estimates
its annual effective tax rate and applies it to fiscal year-to-date pretax loss, excluding unusual or infrequently occurring discrete
items. Tax jurisdictions with losses for which tax benefits cannot be realized are excluded. The Company reported an income tax expense
of <span id="xdx_902_eus-gaap--DeferredIncomeTaxExpenseBenefit_dmxL_c20240101__20240331_zJQ3QkPBTldk" title="Income tax expense::XDX::0"><span style="-sec-ix-hidden: xdx2ixbrl0975">zero</span></span> and income tax benefit of $<span id="xdx_906_eus-gaap--DeferredIncomeTaxExpenseBenefit_dm_c20230101__20230331_zd6i30huUq2f" title="Income tax benefit"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2023-01-012023-03-31" id="Fact000977" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">0.6</ix:nonFraction> million</span> for the periods ended March 31, 2024 and 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We evaluate our deferred tax assets to determine if
they are more likely than not to be realized by assessing both positive and negative evidence in accordance with ASC Topic 740, Income
Taxes.&#160; After considering our cumulative pretax loss (the three-year period ending with the current year), as well as analyzing all
available evidence,&#160;we have recorded a valuation allowance of $<span id="xdx_902_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_dm_c20231231_zpyTEC5j3tVi" title="Valuation Allowance"><ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-12-31" id="Fact000979" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">6.0</ix:nonFraction> million</span> against our net deferred tax assets during the year ended
December 31, 2023.&#160; As of March 31, 2024, the valuation allowance is $<span id="xdx_90A_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_dm_c20240331_zXoUjDjdRf8g" title="Valuation Allowance"><ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2024-03-31" id="Fact000981" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">6.4</ix:nonFraction> million</span> As we continue to assess the realizability of our
deferred tax assets, reported pretax income and new evidence may result in a partial or full reduction of the valuation allowance in future
periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Recurring items cause our effective tax rate to differ
from the U.S. federal statutory rate of <span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20240101__20240331_zH6tqN3GBnFi" title="Statutory rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2024-01-01to2024-03-31" id="Fact000983" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21</ix:nonFraction></span>%, including U.S. federal R&amp;D credits, U.S. state tax rates, and stock-based compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Beginning in 2022, certain research and development
costs are required to be capitalized and amortized over a five-year period under the Tax Cuts and Jobs Act enacted in December 2017. This
change will impact the expected U.S. federal and state income tax expense and cash taxes to be paid for our fiscal 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company files income tax returns in the U.S. federal
jurisdiction and in various state jurisdictions. Income tax returns for years prior to fiscal 2020 are no longer subject to examination
by tax authorities.</p>

</ix:nonNumeric><p id="xdx_816_zPCFa6l1PEsf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000985" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_80B_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zLsfjh654rbc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 7 &#8212; <span id="xdx_823_z9rHQQEUoJdf">COMMITMENTS AND CONTINGENCIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>LEGAL PROCEEDINGS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has been and may again become involved
in legal proceedings, claims and litigation arising in the ordinary course of business. &#160;KORU Medical Systems Inc. is not presently a party to
any litigation or other legal proceeding that is believed to be material to its financial condition.</p>

</ix:nonNumeric><p id="xdx_810_zvpjvdXXHtd1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000987" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_809_eus-gaap--SubsequentEventsTextBlock_zN7pEo3Y175" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 8 &#8212; <span id="xdx_828_zHS0OdBt4v4k">SUBSEQUENT EVENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 8, 2024, the Company&#8217;s appeal to BSI
in connection with a prior audit matter was upheld resulting in no disruption of sales of the Company to the market and patients. Our
products remain certified, marketed and sold in the EU. The Company intends to address the identified nonconformance through the routine
BSI assessment process.</p>

</ix:nonNumeric><p id="xdx_811_zbKi6z3Qc3zh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 16 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc"><span style="color: Blue">Table of Contents</span></a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="Part_I_Item_2"></span><b>PART I &#8212; ITEM 2. &#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This Quarterly Report on Form 10-Q contains, and our
officers and representatives may from time to time make, certain &#8220;forward-looking&#8221; statements (as such term is defined in
the Private Securities Litigation Reform Act of 1995) and information relating to us that are based on the beliefs of the management,
as well as assumptions made and information currently available. Forward-looking statements are neither historical facts nor assurances
of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business,
future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking
statements relate to the future, they are subject to uncertainties, risks and changes in circumstances that are difficult to predict and
many of which are outside of our control.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our actual results may vary materially from the forward-looking
statements made in this report due to important factors such as uncertainties associated with global health crises, inflation, war and
other geopolitical conflicts, customer ordering patterns, availability and costs of raw materials and labor and our ability to recover
such costs, our ability to convert inventory to a source of cash, future operating results, growth of new patient starts and the SCIg
market, our ability to partner with biopharmaceutical companies in our novel therapies business, Food and Drug Administration and foreign
authority regulations and the outcome of regulatory audits, introduction of competitive products, acceptance of and demand for new and
existing products, ability to penetrate new markets, success in enforcing and obtaining patents, reimbursement related risks, government
regulation of the home health care industry, success of our research and development effort, expanding the market of FREEDOM system demand
in the SCIg market, availability of sufficient capital if or when needed, dependence on key personnel, and the impact of recent accounting
pronouncements, as well as those risks and uncertainties described in Part II.&#8212; Item IA. &#8220;Risk Factors&#8221; in this report
and from time to time in our past and future reports filed with the Securities and Exchange Commission, including in our Annual Report
on Form 10-K for the year ended December 31, 2023 in addition to others. When used in this report, the words &#8220;estimate,&#8221; &#8220;project,&#8221;
&#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;expect&#8221; and
similar expressions are intended to identify forward-looking statements, which include, without limitation, statements regarding reduction
of inventory, and need for additional financing. &#160;Such statements reflect current views with respect to future events based on currently
available information and are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated
in such forward-looking statements. &#160;Readers are cautioned not to place undue reliance on these forward-looking statements, which
speak only as of the date hereof. &#160;The Company does not undertake any obligation to release publicly any revision to these forward-looking
statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Throughout this report, the &#8220;Company,&#8221;
&#8220;KORU Medical,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; refers to KORU Medical Systems, Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>OVERVIEW</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company develops, manufactures and markets proprietary
portable and innovative medical devices primarily for the subcutaneous drug delivery market as governed by the United States Food and
Drug Administration (the &#8220;FDA&#8221;) quality and regulatory system and international regulations and standards for quality system
management.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our revenues derive from three business sources: (i)
domestic core (which consists of US and Canada), (ii) international core, and (iii) novel therapies.&#160; Our domestic core and international
core revenues consist of sales of our products for the delivery of subcutaneous drugs that are FDA cleared for use with the FREEDOM Infusion
System, with the primary delivery for immunoglobulin to treat Primary Immunodeficiency Diseases (&#8220;PIDD&#8221;) and Chronic Inflammatory
Demyelinating Polyneuropathy (&#8220;CIDP&#8221;). Novel therapies revenues consist of product revenues from our infusion system (syringe
drivers, tubing and needles) for feasibility/clinical trials (pre-clinical studies, Phase I, Phase II, Phase III) of biopharmaceutical
companies in the drug development process as well as non-recurring engineering services revenues (&#8220;NRE&#8221;) received from biopharmaceutical
companies to ready or customize the FREEDOM System for clinical and commercial use.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company ended the first quarter of 2024 with $8.2
million in net revenues, a 10.9% increase compared with $7.4 million in the same period last year. Revenues were driven by volume growth
in our core domestic and international business of 4.1% and 63.1% respectively, slightly offset by a 21.3% decline in our novel therapies
business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Gross profit for the three months ended March 31,
2024, was $5.1 million, an increase of $1 million, or 23.1%, from $4.1 million for the same period last year, driven primarily by additional
revenue from volume in our core businesses and manufacturing efficiencies from our outsourced manufacturing compared to the same period
last year. Gross margin was 62.3%, an increase from 56.1% in the prior year period. We define gross margin as gross profit stated as a
percentage of net revenues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Operating expenses for the three months ended March
31, 2024, were $7.1 million, compared to $7.2 million for the same period last year, driven primarily by a decrease of $0.1 million
in research and development expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 17 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc"><span style="color: Blue">Table of Contents</span></a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>RESULTS OF OPERATIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Three months ended March 31, 2024, compared to
March 31, 2023</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Net Revenues</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes our net revenues for
the three months ended March 31, 2024, and 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>Three Months Ended March 31,</b></td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>Change from Prior Year</b></td>
    <td>&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><b>% of Net Revenues</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>$</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>%</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 24%"><b>Net Revenues</b></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: right">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: right">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 7%; text-align: right">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 7%; text-align: right">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 7%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in">Domestic Core</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">5,953,865</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">5,719,135</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">234,730</td>
    <td>&#160;</td>
    <td style="text-align: right">4.1%</td>
    <td>&#160;</td>
    <td style="text-align: right">72.7%</td>
    <td>&#160;</td>
    <td style="text-align: right">77.4%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 0.1in">International Core</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">1,790,483</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">1,097,490</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">692,993</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">63.1%</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">21.8%</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">14.8%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in">Total Core</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">7,744,348</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">6,816,625</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">927,723</td>
    <td>&#160;</td>
    <td style="text-align: right">13.6%</td>
    <td>&#160;</td>
    <td style="text-align: right">94.5%</td>
    <td>&#160;</td>
    <td style="text-align: right">92.2%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.1in">Novel Therapies</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">453,450</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">575,980</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(122,530</td>
    <td>)</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(21.3%</td>
    <td>)</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">5.5%</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">7.8%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E8E8E8">
    <td><b>Total</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">8,197,798</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">7,392,605</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">805,193</td>
    <td style="border-bottom: white 2.25pt double">&#160;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: right">10.9%</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: right">100%</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: right">100%</td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Total net revenues increased $0.8 million, or 10.9%, to $8.2 million for
the three months ended March 31, 2024, as compared with the same period in 2023. Domestic Core revenues increased by 4.1% from higher
consumable volumes driven by new patients starts and share gains. International Core revenues increased by 63.1%, from higher consumable
and pump volumes driven largely by increased Ig supply, increased penetration within approved indications, and geographic expansion.
International orders were expedited for certain distribution partners of $0.26 million in March 2024 to ensure adequate inventory to fulfill
patient needs in the event of a supply disruption related to the BSI regulatory review process. Novel therapies net revenues declined
by 21.3% primarily driven by a milestone completion for a collaboration agreement in the prior year period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Gross Profit</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our gross profit for the three months ended March
31, 2024 and 2023 is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>Three Months Ended March 31,</b></td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>Change from Prior Year</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>$</b></td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><b>%</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 42%">Gross Profit </td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 12%; text-align: right">5,103,298</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 12%; text-align: right">4,147,035</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 10%; text-align: right">956,263</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 7%; text-align: right">23.1%</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 0.1in">Gross Margin</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">62.3%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">56.1%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Gross profit increased $1.0 million to $5.1 million
in the three months ended March 31, 2024, compared to $4.1 million in the same period in 2023. Gross margin increased to 62.3% compared
to 56.1% in the first quarter of 2023. &#160;The increase in gross margin was primarily driven by production efficiencies from outsourced
manufacturing and consolidation of US manufacturing sites when compared to the prior year period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Operating Expenses</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our selling, general and administrative, research
and development and depreciation and amortization expenses for the three months ended March 31, 2024 and 2023 are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>Three Months Ended March 31,</b></td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>Change from Prior Year</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>$</b></td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><b>%</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 42%">Selling, general and administrative</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 12%; text-align: right">5,357,620</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 12%; text-align: right">5,425,877</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 10%; text-align: right">(68,257</td>
    <td style="width: 4%">)</td>
    <td style="width: 7%; text-align: right">(1.3%</td>
    <td style="width: 1%">)</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Research and development</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">1,475,674</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">1,564,869</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(89,195</td>
    <td>)</td>
    <td style="text-align: right">(5.7%</td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Depreciation and amortization</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">231,370</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">213,117</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">18,253</td>
    <td>&#160;</td>
    <td style="text-align: right">8.6%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">7,064,664</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">7,203,863</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(139,199</td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="text-align: right">(1.9%</td>
    <td style="border-bottom: white 1.5pt double">)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Selling, general and administrative expenses decreased
$0.1 million, or 1.3%, during the three months ended March 31, 2024 compared with the same period last year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development expenses decreased $0.1 million,
or 5.7% during the three months ended March 31, 2024 compared with the same period last year, primarily due to timing of project spend
in support of our innovation efforts for both core and novel therapies businesses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 18 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc"><span style="color: Blue">Table of Contents</span></a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Depreciation and amortization expense increased by 8.6% to $231,370 in
the three months ended March 31, 2024 compared with $213,117 in the three months ended March 31, 2023. The increase was driven by research
and development tooling and equipment commissioned during 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Net Loss</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>Three Months Ended March 31,</b></td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>Change from Prior Year</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>$</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>%</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 42%">Net Loss</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 12%; text-align: right">(1,935,958</td>
    <td style="width: 4%">)</td>
    <td style="width: 1%">$</td>
    <td style="width: 12%; text-align: right">(2,410,885</td>
    <td style="width: 4%">)</td>
    <td style="width: 1%">$</td>
    <td style="width: 10%; text-align: right">474,927</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 7%; text-align: right">19.7%</td>
    <td style="width: 1%">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our net loss decreased $0.5 million in the three months ended March 31,
2024 compared with the same period last year, mostly driven by an increase in gross profit of $1.0 million and a decrease in operating
expenses of $0.1 million partially offset by a decrease in tax benefit of $0.6 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>LIQUIDITY AND CAPITAL RESOURCES.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our principal source of liquidity is our cash on hand
of $10.8 million as of March 31, 2024. &#160;Our principal source of operating cash inflows is from sales of our products and NRE. Our
principal cash outflows relate to the purchase and production of inventory, funding of research and development, and selling, general
and administrative expenses. To develop new products, support future growth, achieve operating efficiencies, and maintain product quality,
we are continuing to invest in research and development, and equipment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our inventory position was $3.1 million at March 31,
2024, which reflects a decrease of $0.3 million from December 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We expect that our cash on hand and cash flows from
operations will be sufficient to meet our requirements at least through the next twelve months. Continued execution on our longer-term
strategic plan may require the Company to draw on our new credit facility, take on additional debt, raise capital through issuance of
equity, or a combination of both. Our future capital requirements may vary from those currently planned and will depend on many factors,
including our rate of sales growth, the timing and extent of spending on various strategic initiatives including research and development,
our international expansion, the timing of new product introductions, market acceptance of our solutions, and overall economic conditions
including inflation and the potential impact of global supply imbalances on the global financial markets. To the extent that current and
anticipated future sources of liquidity are or are expected to be insufficient to fund our future business activities and requirements,
we may be required to draw on our new credit facility or seek additional equity or debt financing sooner. There can be no assurance the
Company will be able to obtain the financing or raise the capital required to fund its operations or planned expansion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Cash Flows</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes our cash flows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 6.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Three Months Ended<br/>
March 31, 2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Three Months Ended<br/>
March 31, 2023</b></td>
    <td>&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: top; width: 53%">Net cash used in operating activities</td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="vertical-align: bottom; width: 2%">$</td>
    <td style="vertical-align: top; width: 17%; text-align: right">(346,720</td>
    <td style="vertical-align: top; width: 4%">)</td>
    <td style="vertical-align: bottom; width: 2%">$</td>
    <td style="vertical-align: top; width: 18%; text-align: right">(4,660,583</td>
    <td style="vertical-align: bottom; width: 2%">)</td></tr>
  <tr>
    <td style="vertical-align: top">Net cash used in investing activities</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">$</td>
    <td style="vertical-align: top; text-align: right">(133,083</td>
    <td style="vertical-align: top">)</td>
    <td style="vertical-align: bottom">$</td>
    <td style="vertical-align: top; text-align: right">(283,837</td>
    <td style="vertical-align: bottom">)</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: top">Net cash used in financing activities</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">$</td>
    <td style="vertical-align: top; text-align: right">(182,120</td>
    <td style="vertical-align: top">)</td>
    <td style="vertical-align: bottom">$</td>
    <td style="vertical-align: top; text-align: right">(238,972</td>
    <td style="vertical-align: bottom">)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Operating Activities</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net cash used in operating activities was $0.3 million
for the three months ended March 31, 2024 vs $4.7 million in the prior year. This net cash usage of $0.3 million was primarily due to
the net loss of $1.9 million, an increase in accounts receivable of $0.3 million, a reduction of accrued expenses of $0.2 million driven
by payment of 2023 bonuses, offset by an increase in accounts payable of $0.8 million, a decrease in inventory of $0.3 million, and non-cash
items including stock-based compensation expense of $0.7 million, and depreciation and amortization expense of $0.2 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 19 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc"><span style="color: Blue">Table of Contents</span></a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net cash used in operating activities of $4.7 million
for the three months ended March 31, 2023 was primarily due to the net loss of $2.4 million, working capital changes which included an
increase in accounts receivable of $0.6 million, an increase in inventory of $0.2 million, a decrease in accrued expenses of $1.3 million,
a decrease in accounts payable of $0.9 million, and a decrease in prepaid expense of $0.3 million. &#160;Further contributing was an increase
in deferred tax assets of $0.6 million. &#160;Offsetting these were primarily non-cash charges for stock-based compensation of $0.9 million,
depreciation and amortization of $0.2 million, and a loss on disposal of fixed assets of $0.1 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Investing Activities</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net cash used in investing activities of $0.1 million
for the three months ending March 31, 2024, was for capital expenditures for research and development and manufacturing equipment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net cash used in investing activities of $0.3 million
for the three months ending March 31, 2023, was for capital expenditures for research and development and office equipment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Financing Activities</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net cash used in financing activities for the three months ended March
31, 2024 was $0.2 million, due to payments on our note payable for insurance premium financing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net cash used in financing activities for the three months ended March
31, 2023, was $0.2 million, due to payments on our note payable for insurance premium financing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>ACCOUNTING PRONOUNCEMENTS NOT YET ADOPTED</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Refer to &#8220;NOTE 1 &#8212; NATURE OF OPERATIONS
AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&#8221; in the accompanying financial statements, which is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="Part_I_Item_3"></span><b>ITEM 3. &#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET
RISK</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="Part_I_Item_4"></span><b>ITEM 4. &#160;CONTROLS AND PROCEDURES</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s management, including the Company&#8217;s
Principal Executive Officer and Principal Financial Officer, has evaluated the effectiveness of the Company&#8217;s disclosure controls
and procedures as such is defined in Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange
Act&#8221;). &#160;Based upon their evaluations, the Principal Executive Officer and Principal Financial Officer concluded that, as of
the end of the period covered by this report, the Company&#8217;s disclosure controls and procedures were effective for the purpose of
ensuring that the information required to be disclosed in the reports that the Company files or submits under the Exchange Act with the
Securities and Exchange Commission (the &#8220;SEC&#8221;) (1) is recorded, processed, summarized and reported within the time periods
specified in the SEC&#8217;s rules and forms and (2) is accumulated and communicated to the Company&#8217;s management, including its
Principal Executive Officer and Principal Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There have been no changes in the Company&#8217;s
internal control over financial reporting during the three months ended March 31, 2024, that have materially affected, or are reasonably
likely to materially affect, the Company&#8217;s internal control over financial reporting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>PART II &#8211; OTHER INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="Part_II_Item_1A"></span><b>ITEM 1A. &#160;RISK FACTORS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our operations and financial results are subject to
various risks and uncertainties, including those described in &#8220;PART 1, ITEM 1A. RISK FACTORS&#8221; in our Annual Report on Form
10-K for the year ended December 31, 2023, which could adversely affect our business, financial condition, results of operations, cash
flows, and the trading price of our common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 20 -</p>

<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc"><span style="color: Blue">Table of Contents</span></a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="Part_II_Item_6"></span><b>PART II &#8211; ITEM 6. &#160;EXHIBITS.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 0.75in"><b>Exhibit No.</b></td>
    <td style="border-bottom: black 1pt solid; text-align: justify; width: 6.75in"><b>Description</b></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>31.1</td>
    <td style="text-align: justify"><a href="ex_31-1.htm">Certification of Principal Executive Officer Pursuant to Section 302 of Sarbanes-Oxley Act 2002</a></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>31.2</td>
    <td style="text-align: justify"><a href="ex_31-2.htm">Certification of Principal Financial Officer Pursuant to Section 302 of Sarbanes-Oxley Act 2002</a></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>32.1</td>
    <td style="text-align: justify"><a href="ex_32-1.htm">Certification of Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act 2002</a></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>32.2</td>
    <td style="text-align: justify"><a href="ex_32-2.htm">Certification of Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act 2002</a></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>101.INS</td>
    <td style="text-align: justify">Inline XBRL Instance Document - the XBRL Instance Document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>101.SCH</td>
    <td style="text-align: justify">Inline XBRL Taxonomy Extension Schema Document</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>101.CAL</td>
    <td style="text-align: justify">Inline XBRL Taxonomy Extension Calculation Linkbase Document</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>101.DEF</td>
    <td style="text-align: justify">Inline XBRL Taxonomy Definition Linkbase Document</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>101.LAB</td>
    <td style="text-align: justify">Inline XBRL Taxonomy Extension Label Linkbase Document</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>101.PRE</td>
    <td style="text-align: justify">Inline XBRL Taxonomy Extension Presentation Linkbase Document</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>104</td>
    <td style="text-align: justify">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 21 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc"><span style="color: Blue">Table of Contents</span></a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="signatures"></span><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3.75in">&#160;</td>
    <td style="width: 3.75in">KORU MEDICAL SYSTEMS, INC.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>May 1, 2024</td>
    <td><span style="text-decoration: underline">/s/ Linda Tharby</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>Linda Tharby, President and Chief Executive Officer<br/>
(Principal Executive Officer)</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>May 1, 2024</td>
    <td><span style="text-decoration: underline">/s/ Thomas Adams</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>Thomas Adams, Chief Financial Officer and Treasurer<br/>
(Principal Financial Officer)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 22 -</p>

<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/>

</div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>2
<FILENAME>ex_31-1.htm
<DESCRIPTION>CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<DIV STYLE="width: 7.5in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXHIBIT 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">RULE 13A-14(A) / 15D-14(A) CERTIFICATION OF</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">PRINCIPAL EXECUTIVE OFFICER</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">I, Linda Tharby, Principal Executive Officer, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 7.5in; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>1)</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">I have reviewed this Quarterly Report on Form 10-Q of KORU Medical Systems, Inc. (the &ldquo;Report&rdquo;);</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>2)</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>3)</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>4)</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 7in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(a)</TD>
    <TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(b)</TD>
    <TD STYLE="text-align: justify">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(c)</TD>
    <TD STYLE="text-align: justify">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(d)</TD>
    <TD STYLE="text-align: justify">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>5)</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing this equivalent function):</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(a)</TD>
    <TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect registrant&rsquo;s ability to record, process, summarize and report financial information; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(b)</TD>
    <TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">Date: May 1, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><U>/s/ Linda Tharby</U></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">Linda Tharby, President and Chief Executive Officer</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">(Principal Executive Officer)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>3
<FILENAME>ex_31-2.htm
<DESCRIPTION>CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<DIV STYLE="width: 7.5in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXHIBIT 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">RULE 13A-14(A) / 15D-14(A) CERTIFICATION OF</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">PRINCIPAL FINANCIAL OFFICER</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">I, Thomas Adams, Principal Financial Officer, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>1)</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">I have reviewed this Quarterly Report on Form 10-Q of KORU Medical Systems, Inc. (the &ldquo;Report&rdquo;);</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>2)</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>3)</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>4)</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 7in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(a)</TD>
    <TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(b)</TD>
    <TD STYLE="text-align: justify">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(c)</TD>
    <TD STYLE="text-align: justify">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(d)</TD>
    <TD STYLE="text-align: justify">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>5)</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing this equivalent function):</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(a)</TD>
    <TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect registrant&rsquo;s ability to record, process, summarize and report financial information; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(b)</TD>
    <TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">Date: May 1, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><U>/s/ Thomas Adams</U></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">Thomas Adams, Chief Financial Officer and Treasurer</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">(Principal Financial Officer)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>4
<FILENAME>ex_32-1.htm
<DESCRIPTION>CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<DIV STYLE="width: 7.5in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXHIBIT 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">AS ADDED BY SECTION 906 OF THE SARBANES-OXLEY ACT OF
2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">In connection with the Quarterly Report of KORU Medical Systems, Inc. (the
&ldquo;Company&rdquo;) on Form 10-Q (the &ldquo;Report&rdquo;) for the quarter ended March 31, 2024 as filed with the Securities and
Exchange Commission, I, Linda Tharby, Principal Executive Officer, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">(1)</TD>
    <TD STYLE="text-align: justify; width: 7in">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(2)</TD>
    <TD STYLE="text-align: justify">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">Date: May 1, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><U>/s/ Linda Tharby</U></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">Linda Tharby, President and Chief Executive Officer</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">(Principal Executive Officer)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>5
<FILENAME>ex_32-2.htm
<DESCRIPTION>CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<DIV STYLE="width: 7.5in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXHIBIT 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">AS ADDED BY SECTION 906 OF THE SARBANES-OXLEY ACT OF
2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">In connection with the Quarterly Report of KORU Medical Systems, Inc. (the
&ldquo;Company&rdquo;) on Form 10-Q (the &ldquo;Report&rdquo;) for the quarter ended March 31, 2024 as filed with the Securities and Exchange
Commission, I, Thomas Adams, Principal Financial Officer, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
906 of the Sarbanes-Oxley Act of 2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">(1)</TD>
    <TD STYLE="text-align: justify; width: 7in">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(2)</TD>
    <TD STYLE="text-align: justify">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">Date: May 1, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><U>/s/ Thomas Adams</U></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">Thomas Adams, Chief Financial Officer and Treasurer</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">(Principal Financial Officer)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>krmd-20240331.xsd
<DESCRIPTION>INLINE XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /6I5w7xRiXgen8uPa3csWa2MqaPtzJZySekxvmx1HQlq/ycmcJyRwyZkHeYmoQ8H -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:krmd="http://korumedical.com/20240331" elementFormDefault="qualified" targetNamespace="http://korumedical.com/20240331">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://korumedical.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - BALANCE SHEETS (UNAUDITED)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - BALANCE SHEETS (UNAUDITED) (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/StatementsOfOperations" id="StatementsOfOperations">
          <link:definition>00000004 - Statement - STATEMENTS OF OPERATIONS (UNAUDITED)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000005 - Statement - STATEMENTS OF CASH FLOWS (UNAUDITED)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/StatementsOfStockholdersEquity" id="StatementsOfStockholdersEquity">
          <link:definition>00000006 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" id="NatureOfOperationsAndSummaryOfSignificantAccountingPolicies">
          <link:definition>00000007 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
          <link:definition>00000008 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/Stock-basedCompensation" id="Stock-basedCompensation">
          <link:definition>00000009 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/DebtObligations" id="DebtObligations">
          <link:definition>00000010 - Disclosure - DEBT OBLIGATIONS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/Leases" id="Leases">
          <link:definition>00000011 - Disclosure - LEASES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>00000012 - Disclosure - INCOME TAXES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>00000013 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>00000014 - Disclosure - SUBSEQUENT EVENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" id="NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>00000015 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" id="NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables">
          <link:definition>00000016 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
          <link:definition>00000017 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/Stock-basedCompensationTables" id="Stock-basedCompensationTables">
          <link:definition>00000018 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/LeasesTables" id="LeasesTables">
          <link:definition>00000019 - Disclosure - LEASES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/FollowingSecuritiesWereNotIncludedInComputationOfDilutedSharesOutstandingForThreeMonthsEndedMarch312024And2023BecauseEffectWouldBeAnti-dilutiveDetails" id="FollowingSecuritiesWereNotIncludedInComputationOfDilutedSharesOutstandingForThreeMonthsEndedMarch312024And2023BecauseEffectWouldBeAnti-dilutiveDetails">
          <link:definition>00000020 - Disclosure - The following securities were not included in the computation of diluted shares outstanding for the three months ended March 31, 2024, and 2023 because the effect would be anti-dilutive: (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/ThereforeDilutedWeightedAverageNumberOfSharesOutstandingAndDilutedNetLossPerShareWereSameAsBasicWeightedAverageNumberOfSharesOutstandingAndNetLossPerShareForThreeMonthsEndedMarch312024And2023.Details" id="ThereforeDilutedWeightedAverageNumberOfSharesOutstandingAndDilutedNetLossPerShareWereSameAsBasicWeightedAverageNumberOfSharesOutstandingAndNetLossPerShareForThreeMonthsEndedMarch312024And2023.Details">
          <link:definition>00000021 - Disclosure - Therefore, diluted weighted average number of shares outstanding and diluted net loss per share were the same as basic weighted average number of shares outstanding and net loss per share for the three months ended March 31, 2024 and 2023. (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/FollowingTableSummarizesNetRevenuesByGeographyForThreeMonthsEndedMarch312024And2023Details" id="FollowingTableSummarizesNetRevenuesByGeographyForThreeMonthsEndedMarch312024And2023Details">
          <link:definition>00000022 - Disclosure - The following table summarizes net revenues by geography for the three months ended March 31, 2024, and 2023: (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" id="NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>00000023 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails" id="PropertyAndEquipmentConsistsOfFollowingAtDetails">
          <link:definition>00000024 - Disclosure - Property and equipment consists of the following at: (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/PropertyAndEquipmentDetailsNarrative" id="PropertyAndEquipmentDetailsNarrative">
          <link:definition>00000025 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurStockOptionsWithTimeBasedVestingForThreeMonthsEndedMarch312024And2023.Details" id="FollowingTableSummarizesActivitiesForOurStockOptionsWithTimeBasedVestingForThreeMonthsEndedMarch312024And2023.Details">
          <link:definition>00000026 - Disclosure - The following table summarizes the activities for our stock options with time based vesting for the three months ended March 31, 2024, and 2023. (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/FollowingTableSummarizesStatusOfStockOptionsDetails" id="FollowingTableSummarizesStatusOfStockOptionsDetails">
          <link:definition>00000027 - Disclosure - The following table summarizes the status of the stock options: (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/FollowingTablePresentsInformationPertainingToOptionsOutstandingAtMarch312024Details" id="FollowingTablePresentsInformationPertainingToOptionsOutstandingAtMarch312024Details">
          <link:definition>00000028 - Disclosure - The following table presents information pertaining to options outstanding at March 31, 2024: (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformanceBasedStockOptionAwardsForThreeMonthsEndedMarch312024And2023.Details" id="FollowingTableSummarizesActivitiesForOurUnvestedPerformanceBasedStockOptionAwardsForThreeMonthsEndedMarch312024And2023.Details">
          <link:definition>00000029 - Disclosure - The following table summarizes the activities for our unvested performance based stock option awards for the three months ended March 31, 2024, and 2023. (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurRestrictedStockAwardsAndPsusForThreeMonthsEndedMarch312024And2023.Details" id="FollowingTableSummarizesActivitiesForOurRestrictedStockAwardsAndPsusForThreeMonthsEndedMarch312024And2023.Details">
          <link:definition>00000030 - Disclosure - The following table summarizes the activities for our restricted stock awards and PSUs for the three months ended March 31, 2024, and 2023. (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurCommonStockWarrantsIssuedInConnectionWithOurLoanFinancingAgreementWithHsbcForThreeMonthsEndedMarch312024And2023.Details" id="FollowingTableSummarizesActivitiesForOurCommonStockWarrantsIssuedInConnectionWithOurLoanFinancingAgreementWithHsbcForThreeMonthsEndedMarch312024And2023.Details">
          <link:definition>00000031 - Disclosure - The following table summarizes the activities for our common stock warrants issued in connection with our loan financing agreement with HSBC for the three months ended March 31, 2024, and 2023. (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/Stock-basedCompensationDetailsNarrative" id="Stock-basedCompensationDetailsNarrative">
          <link:definition>00000032 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/DebtObligationsDetailsNarrative" id="DebtObligationsDetailsNarrative">
          <link:definition>00000033 - Disclosure - DEBT OBLIGATIONS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/ComponentsOfLeaseExpenseWereAsFollowsDetails" id="ComponentsOfLeaseExpenseWereAsFollowsDetails">
          <link:definition>00000034 - Disclosure - The components of lease expense were as follows: (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/SupplementalCashFlowInformationRelatedToLeasesWasAsFollowsDetails" id="SupplementalCashFlowInformationRelatedToLeasesWasAsFollowsDetails">
          <link:definition>00000035 - Disclosure - Supplemental cash flow information related to leases was as follows: (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails" id="SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails">
          <link:definition>00000036 - Disclosure - Supplemental balance sheet information related to leases was as follows: (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails" id="MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails">
          <link:definition>00000037 - Disclosure - Maturities of lease liabilities are as follows: (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
          <link:definition>00000038 - Disclosure - LEASES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>00000039 - Disclosure - INCOME TAXES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="krmd-20240331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="krmd-20240331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="krmd-20240331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="krmd-20240331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
    <element id="krmd_FurnitureAndOfficeEquipmentMember" name="FurnitureAndOfficeEquipmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ManufacturingEquipmentAndToolingMember" name="ManufacturingEquipmentAndToolingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_StockOptionPlan2015Member" name="StockOptionPlan2015Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_StockOptionPlan2021Member" name="StockOptionPlan2021Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_NonEmployeeDirectorAndBoardAdvisorMember" name="NonEmployeeDirectorAndBoardAdvisorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_StockOptionPlans2015And2021CombinedMember" name="StockOptionPlans2015And2021CombinedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_TimeBasedSharesOptionsMember" name="TimeBasedSharesOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_CommonStockWarrantsMember" name="CommonStockWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ExercisePrice1Member" name="ExercisePrice1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_PerformanceBasedSharesOptionsMember" name="PerformanceBasedSharesOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_RestrictedStockAwardsMember" name="RestrictedStockAwardsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_AONPremiumFinanceLLCMember" name="AONPremiumFinanceLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_PromissoryNoteMember" name="PromissoryNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_HSBCVenturesUSAIncMember" name="HSBCVenturesUSAIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_TermLoanFacilityMember" name="TermLoanFacilityMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_LeaseOneMember" name="LeaseOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_LeaseTwoMember" name="LeaseTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_LeaseThreeMember" name="LeaseThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_RouLandlordCredit" name="RouLandlordCredit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_PaymentsOnIndebtedness" name="PaymentsOnIndebtedness" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_CashPaidDuringPeriodsForAbstract" name="CashPaidDuringPeriodsForAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_IssuanceOfCommonStockCompensation" name="IssuanceOfCommonStockCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_CompensationeExpenseRelatedToRestrictedStockAwards" name="CompensationeExpenseRelatedToRestrictedStockAwards" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_DisclosureSubsequentEventsAbstract" name="DisclosureSubsequentEventsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ScheduleOfSecuritiesTextBlock" name="ScheduleOfSecuritiesTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ScheduleOfNetSalesByGeography" name="ScheduleOfNetSalesByGeography" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock" name="ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_CommonStockOptions" name="CommonStockOptions" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_PerformanceStockUnits" name="PerformanceStockUnits" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_RestrictedStockUnits" name="RestrictedStockUnits" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_AntiDilutedSecurities" name="AntiDilutedSecurities" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock" name="DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_AntiDilutiveStockOptions" name="AntiDilutiveStockOptions" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_AntiDilutiveSecurities" name="AntiDilutiveSecurities" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions" name="ShareBasedCompensationArrangementByUnvestedAwardOptions" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan" name="SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_SharesAvailableForIssuanceShareBasedCompensation" name="SharesAvailableForIssuanceShareBasedCompensation" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_NonemployeeServicesTransactionCost" name="NonemployeeServicesTransactionCost" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_StockBasedCompensationStockOptions" name="StockBasedCompensationStockOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_UnrecognizedCompensationCost" name="UnrecognizedCompensationCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_NotePayableTerms" name="NotePayableTerms" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_LinesOfCreditCurrent1" name="LinesOfCreditCurrent1" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_FinanceLeaseCost1Abstract" name="FinanceLeaseCost1Abstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_FinanceLeaseCost" name="FinanceLeaseCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_AssetsAndLiabilitiesOperatingLesseeAbstract" name="AssetsAndLiabilitiesOperatingLesseeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_AssetsAndLiabilitiesLesseeFinanceAbstract" name="AssetsAndLiabilitiesLesseeFinanceAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal" name="LesseeOperatingLeaseLiabilityPaymentsDueTotal" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal" name="LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_LesseeOperatingLeaseImputedInterest" name="LesseeOperatingLeaseImputedInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_LesseeFinancingLeaseImputedInterest" name="LesseeFinancingLeaseImputedInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_LesseeOperatingLeaseRemainingTerm" name="LesseeOperatingLeaseRemainingTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_LesseeFinanceLeaseRemainingTerm" name="LesseeFinanceLeaseRemainingTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1" name="StockIssuedDuringPeriodSharesStockOptionsExercised1" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDue" name="LesseeFinancingLeaseLeaseLiabilityPaymentsDue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_LessorOperatingLeaseOptionToTerminate1" name="LessorOperatingLeaseOptionToTerminate1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_BorrowingsFromIndebtedness" name="BorrowingsFromIndebtedness" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_AmortizationOfIntangibleAssets1" name="AmortizationOfIntangibleAssets1" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_DepreciationDepletionAndAmortization1" name="DepreciationDepletionAndAmortization1" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_RdCredit" name="RdCredit" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_Nol" name="Nol" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_AllowanceForDoubtfulOtherReceivables1Current" name="AllowanceForDoubtfulOtherReceivables1Current" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_DescriptionOfMatchingContribution" name="DescriptionOfMatchingContribution" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_DescriptionOfLessorOperatingLeaseTerm" name="DescriptionOfLessorOperatingLeaseTerm" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_EquipmentAndToolingMember" name="EquipmentAndToolingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ScheduleOfNetRevenuesByGeography" name="ScheduleOfNetRevenuesByGeography" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_TaxBenefitFromStockBasedCompensation" name="TaxBenefitFromStockBasedCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_TaxBenefitFromRestrictedStockCompensation" name="TaxBenefitFromRestrictedStockCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_StockBasedCompensationSharesIssuable" name="StockBasedCompensationSharesIssuable" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_FDICBankMember" name="FDICBankMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_CashReceivedFromOptionExercise" name="CashReceivedFromOptionExercise" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBloc" name="ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBloc" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_PatentsAndTrademarksMember" name="PatentsAndTrademarksMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_AntiDilutedSecuritiesPerformancBased" name="AntiDilutedSecuritiesPerformancBased" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_AntiDilutedSecuritiesTimeBased" name="AntiDilutedSecuritiesTimeBased" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_StockOptions" name="StockOptions" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_WriteoffOfDeferredTaxAsset" name="WriteoffOfDeferredTaxAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_AllowanceForNonRealizationOfDeferredTaxAsset" name="AllowanceForNonRealizationOfDeferredTaxAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_CustomerOneMember" name="CustomerOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_FinanceLeaseROUAsset" name="FinanceLeaseROUAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ExecutivesEmployeesConsultantsMember" name="ExecutivesEmployeesConsultantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_AntiDilutiveCommonStockOptions" name="AntiDilutiveCommonStockOptions" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_AntiDilutivePerformanceBasedStock" name="AntiDilutivePerformanceBasedStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_AntiDilutiveTimeBasedStock" name="AntiDilutiveTimeBasedStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_DepreciationAndAmortizationPropertyAndEquipment" name="DepreciationAndAmortizationPropertyAndEquipment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_AntiDilutiveRestrictedStock" name="AntiDilutiveRestrictedStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>krmd-20240331_cal.xml
<DESCRIPTION>INLINE XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://korumedical.com/role/Cover" xlink:href="krmd-20240331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/BalanceSheets" xlink:href="krmd-20240331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/BalanceSheetsParenthetical" xlink:href="krmd-20240331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/StatementsOfOperations" xlink:href="krmd-20240331.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/StatementsOfCashFlows" xlink:href="krmd-20240331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/StatementsOfStockholdersEquity" xlink:href="krmd-20240331.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:href="krmd-20240331.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/PropertyAndEquipment" xlink:href="krmd-20240331.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Stock-basedCompensation" xlink:href="krmd-20240331.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/DebtObligations" xlink:href="krmd-20240331.xsd#DebtObligations" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Leases" xlink:href="krmd-20240331.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/IncomeTaxes" xlink:href="krmd-20240331.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/CommitmentsAndContingencies" xlink:href="krmd-20240331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/SubsequentEvents" xlink:href="krmd-20240331.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="krmd-20240331.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="krmd-20240331.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/PropertyAndEquipmentTables" xlink:href="krmd-20240331.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Stock-basedCompensationTables" xlink:href="krmd-20240331.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/LeasesTables" xlink:href="krmd-20240331.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FollowingSecuritiesWereNotIncludedInComputationOfDilutedSharesOutstandingForThreeMonthsEndedMarch312024And2023BecauseEffectWouldBeAnti-dilutiveDetails" xlink:href="krmd-20240331.xsd#FollowingSecuritiesWereNotIncludedInComputationOfDilutedSharesOutstandingForThreeMonthsEndedMarch312024And2023BecauseEffectWouldBeAnti-dilutiveDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ThereforeDilutedWeightedAverageNumberOfSharesOutstandingAndDilutedNetLossPerShareWereSameAsBasicWeightedAverageNumberOfSharesOutstandingAndNetLossPerShareForThreeMonthsEndedMarch312024And2023.Details" xlink:href="krmd-20240331.xsd#ThereforeDilutedWeightedAverageNumberOfSharesOutstandingAndDilutedNetLossPerShareWereSameAsBasicWeightedAverageNumberOfSharesOutstandingAndNetLossPerShareForThreeMonthsEndedMarch312024And2023.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FollowingTableSummarizesNetRevenuesByGeographyForThreeMonthsEndedMarch312024And2023Details" xlink:href="krmd-20240331.xsd#FollowingTableSummarizesNetRevenuesByGeographyForThreeMonthsEndedMarch312024And2023Details" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="krmd-20240331.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails" xlink:href="krmd-20240331.xsd#PropertyAndEquipmentConsistsOfFollowingAtDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="krmd-20240331.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurStockOptionsWithTimeBasedVestingForThreeMonthsEndedMarch312024And2023.Details" xlink:href="krmd-20240331.xsd#FollowingTableSummarizesActivitiesForOurStockOptionsWithTimeBasedVestingForThreeMonthsEndedMarch312024And2023.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FollowingTableSummarizesStatusOfStockOptionsDetails" xlink:href="krmd-20240331.xsd#FollowingTableSummarizesStatusOfStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FollowingTablePresentsInformationPertainingToOptionsOutstandingAtMarch312024Details" xlink:href="krmd-20240331.xsd#FollowingTablePresentsInformationPertainingToOptionsOutstandingAtMarch312024Details" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformanceBasedStockOptionAwardsForThreeMonthsEndedMarch312024And2023.Details" xlink:href="krmd-20240331.xsd#FollowingTableSummarizesActivitiesForOurUnvestedPerformanceBasedStockOptionAwardsForThreeMonthsEndedMarch312024And2023.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurRestrictedStockAwardsAndPsusForThreeMonthsEndedMarch312024And2023.Details" xlink:href="krmd-20240331.xsd#FollowingTableSummarizesActivitiesForOurRestrictedStockAwardsAndPsusForThreeMonthsEndedMarch312024And2023.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurCommonStockWarrantsIssuedInConnectionWithOurLoanFinancingAgreementWithHsbcForThreeMonthsEndedMarch312024And2023.Details" xlink:href="krmd-20240331.xsd#FollowingTableSummarizesActivitiesForOurCommonStockWarrantsIssuedInConnectionWithOurLoanFinancingAgreementWithHsbcForThreeMonthsEndedMarch312024And2023.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="krmd-20240331.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/DebtObligationsDetailsNarrative" xlink:href="krmd-20240331.xsd#DebtObligationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ComponentsOfLeaseExpenseWereAsFollowsDetails" xlink:href="krmd-20240331.xsd#ComponentsOfLeaseExpenseWereAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/SupplementalCashFlowInformationRelatedToLeasesWasAsFollowsDetails" xlink:href="krmd-20240331.xsd#SupplementalCashFlowInformationRelatedToLeasesWasAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails" xlink:href="krmd-20240331.xsd#SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails" xlink:href="krmd-20240331.xsd#MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/LeasesDetailsNarrative" xlink:href="krmd-20240331.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/IncomeTaxesDetailsNarrative" xlink:href="krmd-20240331.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/BalanceSheets" xlink:title="00000002 - Statement - BALANCE SHEETS (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaapOtherReceivables" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapOtherReceivables" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaapDeferredIncomeTaxAssetsNet" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapDeferredIncomeTaxAssetsNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaapTreasuryStockValue" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapTreasuryStockValue" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - BALANCE SHEETS (UNAUDITED) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - STATEMENTS OF OPERATIONS (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/StatementsOfCashFlows" xlink:title="00000005 - Statement - STATEMENTS OF CASH FLOWS (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="loc_us-gaapDeferredIncomeTaxesAndTaxCredits" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDeferredIncomeTaxesAndTaxCredits" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="loc_us-gaapGainLossOnSaleOfOtherAssets" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainLossOnSaleOfOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_RouLandlordCredit" xlink:label="loc_krmdRouLandlordCredit" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_krmdRouLandlordCredit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaapPaymentsToAcquireProductiveAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireProductiveAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_PaymentsOnIndebtedness" xlink:label="loc_krmdPaymentsOnIndebtedness" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_krmdPaymentsOnIndebtedness" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/StatementsOfStockholdersEquity" xlink:title="00000006 - Statement - STATEMENTS OF STOCKHOLDERS&apos; EQUITY (UNAUDITED)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/PropertyAndEquipment" xlink:title="00000008 - Disclosure - PROPERTY AND EQUIPMENT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/Stock-basedCompensation" xlink:title="00000009 - Disclosure - STOCK-BASED COMPENSATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/DebtObligations" xlink:title="00000010 - Disclosure - DEBT OBLIGATIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/Leases" xlink:title="00000011 - Disclosure - LEASES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/IncomeTaxes" xlink:title="00000012 - Disclosure - INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/CommitmentsAndContingencies" xlink:title="00000013 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/SubsequentEvents" xlink:title="00000014 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000015 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="00000016 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/PropertyAndEquipmentTables" xlink:title="00000017 - Disclosure - PROPERTY AND EQUIPMENT (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/Stock-basedCompensationTables" xlink:title="00000018 - Disclosure - STOCK-BASED COMPENSATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/LeasesTables" xlink:title="00000019 - Disclosure - LEASES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/FollowingSecuritiesWereNotIncludedInComputationOfDilutedSharesOutstandingForThreeMonthsEndedMarch312024And2023BecauseEffectWouldBeAnti-dilutiveDetails" xlink:title="00000020 - Disclosure - The following securities were not included in the computation of diluted shares outstanding for the three months ended March 31, 2024, and 2023 because the effect would be anti-dilutive: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ThereforeDilutedWeightedAverageNumberOfSharesOutstandingAndDilutedNetLossPerShareWereSameAsBasicWeightedAverageNumberOfSharesOutstandingAndNetLossPerShareForThreeMonthsEndedMarch312024And2023.Details" xlink:title="00000021 - Disclosure - Therefore, diluted weighted average number of shares outstanding and diluted net loss per share were the same as basic weighted average number of shares outstanding and net loss per share for the three months ended March 31, 2024 and 2023. (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/FollowingTableSummarizesNetRevenuesByGeographyForThreeMonthsEndedMarch312024And2023Details" xlink:title="00000022 - Disclosure - The following table summarizes net revenues by geography for the three months ended March 31, 2024, and 2023: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000023 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails" xlink:title="00000024 - Disclosure - Property and equipment consists of the following at: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="00000025 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurStockOptionsWithTimeBasedVestingForThreeMonthsEndedMarch312024And2023.Details" xlink:title="00000026 - Disclosure - The following table summarizes the activities for our stock options with time based vesting for the three months ended March 31, 2024, and 2023. (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/FollowingTableSummarizesStatusOfStockOptionsDetails" xlink:title="00000027 - Disclosure - The following table summarizes the status of the stock options: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/FollowingTablePresentsInformationPertainingToOptionsOutstandingAtMarch312024Details" xlink:title="00000028 - Disclosure - The following table presents information pertaining to options outstanding at March 31, 2024: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformanceBasedStockOptionAwardsForThreeMonthsEndedMarch312024And2023.Details" xlink:title="00000029 - Disclosure - The following table summarizes the activities for our unvested performance based stock option awards for the three months ended March 31, 2024, and 2023. (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurRestrictedStockAwardsAndPsusForThreeMonthsEndedMarch312024And2023.Details" xlink:title="00000030 - Disclosure - The following table summarizes the activities for our restricted stock awards and PSUs for the three months ended March 31, 2024, and 2023. (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurCommonStockWarrantsIssuedInConnectionWithOurLoanFinancingAgreementWithHsbcForThreeMonthsEndedMarch312024And2023.Details" xlink:title="00000031 - Disclosure - The following table summarizes the activities for our common stock warrants issued in connection with our loan financing agreement with HSBC for the three months ended March 31, 2024, and 2023. (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000032 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/DebtObligationsDetailsNarrative" xlink:title="00000033 - Disclosure - DEBT OBLIGATIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ComponentsOfLeaseExpenseWereAsFollowsDetails" xlink:title="00000034 - Disclosure - The components of lease expense were as follows: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/SupplementalCashFlowInformationRelatedToLeasesWasAsFollowsDetails" xlink:title="00000035 - Disclosure - Supplemental cash flow information related to leases was as follows: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails" xlink:title="00000036 - Disclosure - Supplemental balance sheet information related to leases was as follows: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails" xlink:title="00000037 - Disclosure - Maturities of lease liabilities are as follows: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/LeasesDetailsNarrative" xlink:title="00000038 - Disclosure - LEASES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000039 - Disclosure - INCOME TAXES (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>krmd-20240331_def.xml
<DESCRIPTION>INLINE XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://korumedical.com/role/Cover" xlink:href="krmd-20240331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/BalanceSheets" xlink:href="krmd-20240331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/BalanceSheetsParenthetical" xlink:href="krmd-20240331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/StatementsOfOperations" xlink:href="krmd-20240331.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/StatementsOfCashFlows" xlink:href="krmd-20240331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/StatementsOfStockholdersEquity" xlink:href="krmd-20240331.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:href="krmd-20240331.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/PropertyAndEquipment" xlink:href="krmd-20240331.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Stock-basedCompensation" xlink:href="krmd-20240331.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/DebtObligations" xlink:href="krmd-20240331.xsd#DebtObligations" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Leases" xlink:href="krmd-20240331.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/IncomeTaxes" xlink:href="krmd-20240331.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/CommitmentsAndContingencies" xlink:href="krmd-20240331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/SubsequentEvents" xlink:href="krmd-20240331.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="krmd-20240331.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="krmd-20240331.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/PropertyAndEquipmentTables" xlink:href="krmd-20240331.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Stock-basedCompensationTables" xlink:href="krmd-20240331.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/LeasesTables" xlink:href="krmd-20240331.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FollowingSecuritiesWereNotIncludedInComputationOfDilutedSharesOutstandingForThreeMonthsEndedMarch312024And2023BecauseEffectWouldBeAnti-dilutiveDetails" xlink:href="krmd-20240331.xsd#FollowingSecuritiesWereNotIncludedInComputationOfDilutedSharesOutstandingForThreeMonthsEndedMarch312024And2023BecauseEffectWouldBeAnti-dilutiveDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ThereforeDilutedWeightedAverageNumberOfSharesOutstandingAndDilutedNetLossPerShareWereSameAsBasicWeightedAverageNumberOfSharesOutstandingAndNetLossPerShareForThreeMonthsEndedMarch312024And2023.Details" xlink:href="krmd-20240331.xsd#ThereforeDilutedWeightedAverageNumberOfSharesOutstandingAndDilutedNetLossPerShareWereSameAsBasicWeightedAverageNumberOfSharesOutstandingAndNetLossPerShareForThreeMonthsEndedMarch312024And2023.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FollowingTableSummarizesNetRevenuesByGeographyForThreeMonthsEndedMarch312024And2023Details" xlink:href="krmd-20240331.xsd#FollowingTableSummarizesNetRevenuesByGeographyForThreeMonthsEndedMarch312024And2023Details" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="krmd-20240331.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails" xlink:href="krmd-20240331.xsd#PropertyAndEquipmentConsistsOfFollowingAtDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="krmd-20240331.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurStockOptionsWithTimeBasedVestingForThreeMonthsEndedMarch312024And2023.Details" xlink:href="krmd-20240331.xsd#FollowingTableSummarizesActivitiesForOurStockOptionsWithTimeBasedVestingForThreeMonthsEndedMarch312024And2023.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FollowingTableSummarizesStatusOfStockOptionsDetails" xlink:href="krmd-20240331.xsd#FollowingTableSummarizesStatusOfStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FollowingTablePresentsInformationPertainingToOptionsOutstandingAtMarch312024Details" xlink:href="krmd-20240331.xsd#FollowingTablePresentsInformationPertainingToOptionsOutstandingAtMarch312024Details" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformanceBasedStockOptionAwardsForThreeMonthsEndedMarch312024And2023.Details" xlink:href="krmd-20240331.xsd#FollowingTableSummarizesActivitiesForOurUnvestedPerformanceBasedStockOptionAwardsForThreeMonthsEndedMarch312024And2023.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurRestrictedStockAwardsAndPsusForThreeMonthsEndedMarch312024And2023.Details" xlink:href="krmd-20240331.xsd#FollowingTableSummarizesActivitiesForOurRestrictedStockAwardsAndPsusForThreeMonthsEndedMarch312024And2023.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurCommonStockWarrantsIssuedInConnectionWithOurLoanFinancingAgreementWithHsbcForThreeMonthsEndedMarch312024And2023.Details" xlink:href="krmd-20240331.xsd#FollowingTableSummarizesActivitiesForOurCommonStockWarrantsIssuedInConnectionWithOurLoanFinancingAgreementWithHsbcForThreeMonthsEndedMarch312024And2023.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="krmd-20240331.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/DebtObligationsDetailsNarrative" xlink:href="krmd-20240331.xsd#DebtObligationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ComponentsOfLeaseExpenseWereAsFollowsDetails" xlink:href="krmd-20240331.xsd#ComponentsOfLeaseExpenseWereAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/SupplementalCashFlowInformationRelatedToLeasesWasAsFollowsDetails" xlink:href="krmd-20240331.xsd#SupplementalCashFlowInformationRelatedToLeasesWasAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails" xlink:href="krmd-20240331.xsd#SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails" xlink:href="krmd-20240331.xsd#MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/LeasesDetailsNarrative" xlink:href="krmd-20240331.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/IncomeTaxesDetailsNarrative" xlink:href="krmd-20240331.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/BalanceSheets" xlink:title="00000002 - Statement - BALANCE SHEETS (UNAUDITED)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - BALANCE SHEETS (UNAUDITED) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - STATEMENTS OF OPERATIONS (UNAUDITED)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/StatementsOfCashFlows" xlink:title="00000005 - Statement - STATEMENTS OF CASH FLOWS (UNAUDITED)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/StatementsOfStockholdersEquity" xlink:title="00000006 - Statement - STATEMENTS OF STOCKHOLDERS&apos; EQUITY (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="loc_us-gaapTreasuryStockCommonMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapTreasuryStockCommonMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_CompensationeExpenseRelatedToRestrictedStockAwards" xlink:label="loc_krmdCompensationeExpenseRelatedToRestrictedStockAwards_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_krmdCompensationeExpenseRelatedToRestrictedStockAwards_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/PropertyAndEquipment" xlink:title="00000008 - Disclosure - PROPERTY AND EQUIPMENT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/Stock-basedCompensation" xlink:title="00000009 - Disclosure - STOCK-BASED COMPENSATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/DebtObligations" xlink:title="00000010 - Disclosure - DEBT OBLIGATIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/Leases" xlink:title="00000011 - Disclosure - LEASES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/IncomeTaxes" xlink:title="00000012 - Disclosure - INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/CommitmentsAndContingencies" xlink:title="00000013 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/SubsequentEvents" xlink:title="00000014 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000015 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="00000016 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/PropertyAndEquipmentTables" xlink:title="00000017 - Disclosure - PROPERTY AND EQUIPMENT (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/Stock-basedCompensationTables" xlink:title="00000018 - Disclosure - STOCK-BASED COMPENSATION (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/LeasesTables" xlink:title="00000019 - Disclosure - LEASES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/FollowingSecuritiesWereNotIncludedInComputationOfDilutedSharesOutstandingForThreeMonthsEndedMarch312024And2023BecauseEffectWouldBeAnti-dilutiveDetails" xlink:title="00000020 - Disclosure - The following securities were not included in the computation of diluted shares outstanding for the three months ended March 31, 2024, and 2023 because the effect would be anti-dilutive: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/ThereforeDilutedWeightedAverageNumberOfSharesOutstandingAndDilutedNetLossPerShareWereSameAsBasicWeightedAverageNumberOfSharesOutstandingAndNetLossPerShareForThreeMonthsEndedMarch312024And2023.Details" xlink:title="00000021 - Disclosure - Therefore, diluted weighted average number of shares outstanding and diluted net loss per share were the same as basic weighted average number of shares outstanding and net loss per share for the three months ended March 31, 2024 and 2023. (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasicAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasicAbstract_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock" xlink:label="loc_krmdDilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_krmdDilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareAbstract_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted_50" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/FollowingTableSummarizesNetRevenuesByGeographyForThreeMonthsEndedMarch312024And2023Details" xlink:title="00000022 - Disclosure - The following table summarizes net revenues by geography for the three months ended March 31, 2024, and 2023: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="loc_countryUS_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaapNonUsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_us-gaapNonUsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenues_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000023 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails" xlink:title="00000024 - Disclosure - Property and equipment consists of the following at: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_FurnitureAndOfficeEquipmentMember" xlink:label="loc_krmdFurnitureAndOfficeEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_krmdFurnitureAndOfficeEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ManufacturingEquipmentAndToolingMember" xlink:label="loc_krmdManufacturingEquipmentAndToolingMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_krmdManufacturingEquipmentAndToolingMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_90" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="00000025 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurStockOptionsWithTimeBasedVestingForThreeMonthsEndedMarch312024And2023.Details" xlink:title="00000026 - Disclosure - The following table summarizes the activities for our stock options with time based vesting for the three months ended March 31, 2024, and 2023. (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_StockOptionPlan2015Member" xlink:label="loc_krmdStockOptionPlan2015Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2015Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_TimeBasedSharesOptionsMember" xlink:label="loc_krmdTimeBasedSharesOptionsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdTimeBasedSharesOptionsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_50" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/FollowingTableSummarizesStatusOfStockOptionsDetails" xlink:title="00000027 - Disclosure - The following table summarizes the status of the stock options: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_StockOptionPlan2015Member" xlink:label="loc_krmdStockOptionPlan2015Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2015Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_TimeBasedSharesOptionsMember" xlink:label="loc_krmdTimeBasedSharesOptionsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdTimeBasedSharesOptionsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_70" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/FollowingTablePresentsInformationPertainingToOptionsOutstandingAtMarch312024Details" xlink:title="00000028 - Disclosure - The following table presents information pertaining to options outstanding at March 31, 2024: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_StockOptionPlan2015Member" xlink:label="loc_krmdStockOptionPlan2015Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2015Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_TimeBasedSharesOptionsMember" xlink:label="loc_krmdTimeBasedSharesOptionsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdTimeBasedSharesOptionsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ExercisePrice1Member" xlink:label="loc_krmdExercisePrice1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_krmdExercisePrice1Member_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_30" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformanceBasedStockOptionAwardsForThreeMonthsEndedMarch312024And2023.Details" xlink:title="00000029 - Disclosure - The following table summarizes the activities for our unvested performance based stock option awards for the three months ended March 31, 2024, and 2023. (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_PerformanceBasedSharesOptionsMember" xlink:label="loc_krmdPerformanceBasedSharesOptionsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdPerformanceBasedSharesOptionsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions" xlink:label="loc_krmdShareBasedCompensationArrangementByUnvestedAwardOptions_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByUnvestedAwardOptions_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_70" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurRestrictedStockAwardsAndPsusForThreeMonthsEndedMarch312024And2023.Details" xlink:title="00000030 - Disclosure - The following table summarizes the activities for our restricted stock awards and PSUs for the three months ended March 31, 2024, and 2023. (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_RestrictedStockAwardsMember" xlink:label="loc_krmdRestrictedStockAwardsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdRestrictedStockAwardsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_StockOptionPlan2021Member" xlink:label="loc_krmdStockOptionPlan2021Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2021Member_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_70" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurCommonStockWarrantsIssuedInConnectionWithOurLoanFinancingAgreementWithHsbcForThreeMonthsEndedMarch312024And2023.Details" xlink:title="00000031 - Disclosure - The following table summarizes the activities for our common stock warrants issued in connection with our loan financing agreement with HSBC for the three months ended March 31, 2024, and 2023. (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_CommonStockWarrantsMember" xlink:label="loc_krmdCommonStockWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdCommonStockWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_StockOptionPlan2021Member" xlink:label="loc_krmdStockOptionPlan2021Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2021Member_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_70" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000032 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_StockOptionPlan2015Member" xlink:label="loc_krmdStockOptionPlan2015Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2015Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_StockOptionPlan2021Member" xlink:label="loc_krmdStockOptionPlan2021Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2021Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_StockOptionPlans2015And2021CombinedMember" xlink:label="loc_krmdStockOptionPlans2015And2021CombinedMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlans2015And2021CombinedMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_NonEmployeeDirectorAndBoardAdvisorMember" xlink:label="loc_krmdNonEmployeeDirectorAndBoardAdvisorMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_krmdNonEmployeeDirectorAndBoardAdvisorMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="loc_srtBoardOfDirectorsChairmanMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtBoardOfDirectorsChairmanMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_TimeBasedSharesOptionsMember" xlink:label="loc_krmdTimeBasedSharesOptionsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdTimeBasedSharesOptionsMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaapPerformanceSharesMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapPerformanceSharesMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_CommonStockWarrantsMember" xlink:label="loc_krmdCommonStockWarrantsMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdCommonStockWarrantsMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan" xlink:label="loc_krmdSharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdSharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan_180" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_SharesAvailableForIssuanceShareBasedCompensation" xlink:label="loc_krmdSharesAvailableForIssuanceShareBasedCompensation_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdSharesAvailableForIssuanceShareBasedCompensation_180" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_NonemployeeServicesTransactionCost" xlink:label="loc_krmdNonemployeeServicesTransactionCost_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdNonemployeeServicesTransactionCost_180" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementsOverallDescription" xlink:label="loc_us-gaapDeferredCompensationArrangementsOverallDescription_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapDeferredCompensationArrangementsOverallDescription_180" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_StockBasedCompensationStockOptions" xlink:label="loc_krmdStockBasedCompensationStockOptions_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdStockBasedCompensationStockOptions_180" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_180" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_180" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation_180" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_UnrecognizedCompensationCost" xlink:label="loc_krmdUnrecognizedCompensationCost_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdUnrecognizedCompensationCost_180" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/DebtObligationsDetailsNarrative" xlink:title="00000033 - Disclosure - DEBT OBLIGATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_AONPremiumFinanceLLCMember" xlink:label="loc_krmdAONPremiumFinanceLLCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_krmdAONPremiumFinanceLLCMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_HSBCVenturesUSAIncMember" xlink:label="loc_krmdHSBCVenturesUSAIncMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_krmdHSBCVenturesUSAIncMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_PromissoryNoteMember" xlink:label="loc_krmdPromissoryNoteMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_krmdPromissoryNoteMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaapCreditFacilityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapCreditFacilityAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaapRevolvingCreditFacilityMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_us-gaapRevolvingCreditFacilityMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_TermLoanFacilityMember" xlink:label="loc_krmdTermLoanFacilityMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_krmdTermLoanFacilityMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapNotesPayable_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_NotePayableTerms" xlink:label="loc_krmdNotePayableTerms_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_krmdNotePayableTerms_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="loc_us-gaapDebtInstrumentFrequencyOfPeriodicPayment_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFrequencyOfPeriodicPayment_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLongTermDebtNoncurrent" xlink:label="loc_us-gaapOtherLongTermDebtNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapOtherLongTermDebtNoncurrent_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="loc_us-gaapLinesOfCreditCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapLinesOfCreditCurrent_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_LinesOfCreditCurrent1" xlink:label="loc_krmdLinesOfCreditCurrent1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_krmdLinesOfCreditCurrent1_70" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/ComponentsOfLeaseExpenseWereAsFollowsDetails" xlink:title="00000034 - Disclosure - The components of lease expense were as follows: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/SupplementalCashFlowInformationRelatedToLeasesWasAsFollowsDetails" xlink:title="00000035 - Disclosure - Supplemental cash flow information related to leases was as follows: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails" xlink:title="00000036 - Disclosure - Supplemental balance sheet information related to leases was as follows: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails" xlink:title="00000037 - Disclosure - Maturities of lease liabilities are as follows: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/LeasesDetailsNarrative" xlink:title="00000038 - Disclosure - LEASES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaapLeaseContractualTermAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapLeaseContractualTermAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaapLeaseContractualTermDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLeaseContractualTermAxis" xlink:to="loc_us-gaapLeaseContractualTermDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaapLeaseContractualTermDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLeaseContractualTermAxis" xlink:to="loc_us-gaapLeaseContractualTermDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_LeaseOneMember" xlink:label="loc_krmdLeaseOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLeaseContractualTermDomain" xlink:to="loc_krmdLeaseOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_LeaseTwoMember" xlink:label="loc_krmdLeaseTwoMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLeaseContractualTermDomain" xlink:to="loc_krmdLeaseTwoMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_LeaseThreeMember" xlink:label="loc_krmdLeaseThreeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLeaseContractualTermDomain" xlink:to="loc_krmdLeaseThreeMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_LesseeOperatingLeaseRemainingTerm" xlink:label="loc_krmdLesseeOperatingLeaseRemainingTerm_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_krmdLesseeOperatingLeaseRemainingTerm_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_LesseeFinanceLeaseRemainingTerm" xlink:label="loc_krmdLesseeFinanceLeaseRemainingTerm_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_krmdLesseeFinanceLeaseRemainingTerm_40" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000039 - Disclosure - INCOME TAXES (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>krmd-20240331_lab.xml
<DESCRIPTION>INLINE XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="us-gaap_TreasuryStockCommonMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonMember" xlink:to="us-gaap_TreasuryStockCommonMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockCommonMember_lbl" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="country_US" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US">UNITED STATES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonUsMember" xlink:to="us-gaap_NonUsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonUsMember_lbl" xml:lang="en-US">Non-US [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_FurnitureAndOfficeEquipmentMember" xlink:label="krmd_FurnitureAndOfficeEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_FurnitureAndOfficeEquipmentMember" xlink:to="krmd_FurnitureAndOfficeEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_FurnitureAndOfficeEquipmentMember_lbl" xml:lang="en-US">Furniture and Office Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ManufacturingEquipmentAndToolingMember" xlink:label="krmd_ManufacturingEquipmentAndToolingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ManufacturingEquipmentAndToolingMember" xlink:to="krmd_ManufacturingEquipmentAndToolingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ManufacturingEquipmentAndToolingMember_lbl" xml:lang="en-US">Manufacturing Equipment and Tooling [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_StockOptionPlan2015Member" xlink:label="krmd_StockOptionPlan2015Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockOptionPlan2015Member" xlink:to="krmd_StockOptionPlan2015Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_StockOptionPlan2015Member_lbl" xml:lang="en-US">Stock Option Plan 2015 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_StockOptionPlan2021Member" xlink:label="krmd_StockOptionPlan2021Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockOptionPlan2021Member" xlink:to="krmd_StockOptionPlan2021Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_StockOptionPlan2021Member_lbl" xml:lang="en-US">Stock Option Plan 2021 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_NonEmployeeDirectorAndBoardAdvisorMember" xlink:label="krmd_NonEmployeeDirectorAndBoardAdvisorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_NonEmployeeDirectorAndBoardAdvisorMember" xlink:to="krmd_NonEmployeeDirectorAndBoardAdvisorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_NonEmployeeDirectorAndBoardAdvisorMember_lbl" xml:lang="en-US">Non Employee Director and Board Advisor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl" xml:lang="en-US">Board of Directors Chairman [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_StockOptionPlans2015And2021CombinedMember" xlink:label="krmd_StockOptionPlans2015And2021CombinedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockOptionPlans2015And2021CombinedMember" xlink:to="krmd_StockOptionPlans2015And2021CombinedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_StockOptionPlans2015And2021CombinedMember_lbl" xml:lang="en-US">Stock Option Plans 2015 and 2021 Combined [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_TimeBasedSharesOptionsMember" xlink:label="krmd_TimeBasedSharesOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_TimeBasedSharesOptionsMember" xlink:to="krmd_TimeBasedSharesOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_TimeBasedSharesOptionsMember_lbl" xml:lang="en-US">Time Based Shares Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PerformanceSharesMember_lbl" xml:lang="en-US">Performance Shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_CommonStockWarrantsMember" xlink:label="krmd_CommonStockWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_CommonStockWarrantsMember" xlink:to="krmd_CommonStockWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_CommonStockWarrantsMember_lbl" xml:lang="en-US">Common Stock Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ExercisePrice1Member" xlink:label="krmd_ExercisePrice1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ExercisePrice1Member" xlink:to="krmd_ExercisePrice1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ExercisePrice1Member_lbl" xml:lang="en-US">Exercise Price1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_PerformanceBasedSharesOptionsMember" xlink:label="krmd_PerformanceBasedSharesOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_PerformanceBasedSharesOptionsMember" xlink:to="krmd_PerformanceBasedSharesOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_PerformanceBasedSharesOptionsMember_lbl" xml:lang="en-US">Performance Based Shares Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_RestrictedStockAwardsMember" xlink:label="krmd_RestrictedStockAwardsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_RestrictedStockAwardsMember" xlink:to="krmd_RestrictedStockAwardsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_RestrictedStockAwardsMember_lbl" xml:lang="en-US">Restricted Stock Awards [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_AONPremiumFinanceLLCMember" xlink:label="krmd_AONPremiumFinanceLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AONPremiumFinanceLLCMember" xlink:to="krmd_AONPremiumFinanceLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_AONPremiumFinanceLLCMember_lbl" xml:lang="en-US">AON Premium Finance LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_PromissoryNoteMember" xlink:label="krmd_PromissoryNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_PromissoryNoteMember" xlink:to="krmd_PromissoryNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_PromissoryNoteMember_lbl" xml:lang="en-US">Promissory Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_HSBCVenturesUSAIncMember" xlink:label="krmd_HSBCVenturesUSAIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_HSBCVenturesUSAIncMember" xlink:to="krmd_HSBCVenturesUSAIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_HSBCVenturesUSAIncMember_lbl" xml:lang="en-US">H S B C Ventures U S A Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityAxis_lbl" xml:lang="en-US">Credit Facility [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevolvingCreditFacilityMember" xlink:to="us-gaap_RevolvingCreditFacilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevolvingCreditFacilityMember_lbl" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_TermLoanFacilityMember" xlink:label="krmd_TermLoanFacilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_TermLoanFacilityMember" xlink:to="krmd_TermLoanFacilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_TermLoanFacilityMember_lbl" xml:lang="en-US">Term Loan Facility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_LeaseOneMember" xlink:label="krmd_LeaseOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LeaseOneMember" xlink:to="krmd_LeaseOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_LeaseOneMember_lbl" xml:lang="en-US">Lease One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_LeaseTwoMember" xlink:label="krmd_LeaseTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LeaseTwoMember" xlink:to="krmd_LeaseTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_LeaseTwoMember_lbl" xml:lang="en-US">Lease Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_LeaseThreeMember" xlink:label="krmd_LeaseThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LeaseThreeMember" xlink:to="krmd_LeaseThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_LeaseThreeMember_lbl" xml:lang="en-US">Lease Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityListingParValuePerShare" xlink:label="dei_EntityListingParValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityListingParValuePerShare" xlink:to="dei_EntityListingParValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityListingParValuePerShare_lbl" xml:lang="en-US">Entity Listing, Par Value Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonShares" xlink:to="us-gaap_TreasuryStockCommonShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockCommonShares_lbl" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable less allowance for doubtful accounts of $24,777 as of March 31, 2024 and $24,777 as of December 31, 2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivables_lbl" xml:lang="en-US">Other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">TOTAL CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Intangible assets, net of accumulated amortization of $406,801 and $390,341 as of March 31, 2024 and December 31, 2023, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xml:lang="en-US">Deferred income tax assets, net of allowance for non-realization of deferred tax assets of $6,391,452 and $6,002,777 for March 31, 2024 and December 31, 2023, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued payroll and related taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Financing lease liability &#8211; current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liability &#8211; current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">TOTAL CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Financing lease liability, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">TOTAL LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.01 par value, 75,000,000 shares authorized, 49,143,589 and 49,089,864 shares issued 45,723,087 and 45,669,362 shares outstanding as of March 31, 2024, and December 31, 2023, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockValue_lbl" xml:lang="en-US">Treasury stock, 3,420,502 shares as of March 31, 2024 and December 31, 2023, at cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">TOTAL STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xml:lang="en-US">Accounts receivable, allowance for credit loss, current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Finite-lived intangible assets, accumulated amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRentReceivablesNetNoncurrent" xlink:label="us-gaap_DeferredRentReceivablesNetNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentReceivablesNetNoncurrent" xlink:to="us-gaap_DeferredRentReceivablesNetNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentReceivablesNetNoncurrent_lbl" xml:lang="en-US">Deferred Rent Receivables, Net, Noncurrent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares, issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockPreferredShares" xlink:label="us-gaap_TreasuryStockPreferredShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockPreferredShares" xlink:to="us-gaap_TreasuryStockPreferredShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockPreferredShares_lbl" xml:lang="en-US">Treasury stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">NET REVENUES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">Cost of goods sold</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross Profit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">OPERATING EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total Operating Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Net Operating Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Non-Operating Income/(Expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Loss on currency exchange</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Loss on disposal of fixed assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Interest income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">TOTAL OTHER INCOME</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US">LOSS BEFORE INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income Tax Benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET LOSS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">NET LOSS PER SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense and warrant expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="us-gaap_DeferredIncomeTaxesAndTaxCredits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="us-gaap_DeferredIncomeTaxesAndTaxCredits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxesAndTaxCredits_lbl" xml:lang="en-US">Deferred income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfOtherAssets" xlink:to="us-gaap_GainLossOnSaleOfOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets_lbl" xml:lang="en-US">Loss on disposal of fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_RouLandlordCredit" xlink:label="krmd_RouLandlordCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_RouLandlordCredit" xlink:to="krmd_RouLandlordCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_RouLandlordCredit_lbl" xml:lang="en-US">ROU landlord credit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Increase in Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Decrease / (Increase) in Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Decrease in Prepaid expenses and other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xml:lang="en-US">(Decrease) / Increase in Other liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Increase / (Decrease) in Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US">Increase / (Decrease) in Accrued payroll and related taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US">Decrease in Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">NET CASH USED IN OPERATING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xml:lang="en-US">Purchases of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Purchases of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">NET CASH USED IN INVESTING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_PaymentsOnIndebtedness" xlink:label="krmd_PaymentsOnIndebtedness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_PaymentsOnIndebtedness" xlink:to="krmd_PaymentsOnIndebtedness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="krmd_PaymentsOnIndebtedness_lbl" xml:lang="en-US">Payments on indebtedness</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US">Payments on finance lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">NET CASH USED IN FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">NET DECREASE IN CASH AND CASH EQUIVALENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS, END OF PERIOD</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Information</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_CashPaidDuringPeriodsForAbstract" xlink:label="krmd_CashPaidDuringPeriodsForAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_CashPaidDuringPeriodsForAbstract" xlink:to="krmd_CashPaidDuringPeriodsForAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_CashPaidDuringPeriodsForAbstract_lbl" xml:lang="en-US">Cash paid during the periods for:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Schedule of Non-Cash Operating, Investing and Financing Activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_IssuanceOfCommonStockCompensation" xlink:label="krmd_IssuanceOfCommonStockCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_IssuanceOfCommonStockCompensation" xlink:to="krmd_IssuanceOfCommonStockCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_IssuanceOfCommonStockCompensation_lbl" xml:lang="en-US">Issuance of common stock as compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Issuance of stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Issuance of stock-based compensation (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Compensation expense related to stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US">Compensation related to Restricted Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_CompensationeExpenseRelatedToRestrictedStockAwards" xlink:label="krmd_CompensationeExpenseRelatedToRestrictedStockAwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_CompensationeExpenseRelatedToRestrictedStockAwards" xlink:to="krmd_CompensationeExpenseRelatedToRestrictedStockAwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_CompensationeExpenseRelatedToRestrictedStockAwards_lbl" xml:lang="en-US">Compensation expense related to restricted stock (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Issuance of warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xml:lang="en-US">NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">DEBT OBLIGATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xml:lang="en-US">LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_DisclosureSubsequentEventsAbstract" xlink:label="krmd_DisclosureSubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_DisclosureSubsequentEventsAbstract" xlink:to="krmd_DisclosureSubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_DisclosureSubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">NATURE OF OPERATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">BASIS OF PRESENTATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">PATENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">NET LOSS PER COMMON SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">USE OF ESTIMATES IN THE FINANCIAL STATEMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">REVENUE RECOGNITION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">IMPAIRMENT OF LONG-LIVED ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ScheduleOfSecuritiesTextBlock" xlink:label="krmd_ScheduleOfSecuritiesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ScheduleOfSecuritiesTextBlock" xlink:to="krmd_ScheduleOfSecuritiesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ScheduleOfSecuritiesTextBlock_lbl" xml:lang="en-US">The following securities were not included in the computation of diluted shares outstanding for the three months ended March 31, 2024, and 2023 because the effect would be anti-dilutive:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Therefore, diluted weighted average number of shares outstanding and diluted net loss per share were the same as basic weighted average number of shares outstanding and net loss per share for the three months ended March 31, 2024 and 2023.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ScheduleOfNetSalesByGeography" xlink:label="krmd_ScheduleOfNetSalesByGeography" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ScheduleOfNetSalesByGeography" xlink:to="krmd_ScheduleOfNetSalesByGeography_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ScheduleOfNetSalesByGeography_lbl" xml:lang="en-US">The following table summarizes net revenues by geography for the three months ended March 31, 2024, and 2023:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Property and equipment consists of the following at:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">The following table summarizes the activities for our stock options with time based vesting for the three months ended March 31, 2024, and 2023.</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">The following table summarizes the status of the stock options:</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock" xlink:label="krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock" xlink:to="krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock_lbl" xml:lang="en-US">The following table presents information pertaining to options outstanding at March 31, 2024:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:to="us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_lbl" xml:lang="en-US">The following table summarizes the activities for our unvested performance based stock option awards for the three months ended March 31, 2024, and 2023.</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl" xml:lang="en-US">The following table summarizes the activities for our restricted stock awards and PSUs for the three months ended March 31, 2024, and 2023.</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_lbl" xml:lang="en-US">The following table summarizes the activities for our common stock warrants issued in connection with our loan financing agreement with HSBC for the three months ended March 31, 2024, and 2023.</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">The components of lease expense were as follows:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:to="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_lbl" xml:lang="en-US">Supplemental cash flow information related to leases was as follows:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl" xml:lang="en-US">Supplemental balance sheet information related to leases was as follows:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Maturities of lease liabilities are as follows:</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_CommonStockOptions" xlink:label="krmd_CommonStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_CommonStockOptions" xlink:to="krmd_CommonStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_CommonStockOptions_lbl" xml:lang="en-US">Common stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_PerformanceStockUnits" xlink:label="krmd_PerformanceStockUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_PerformanceStockUnits" xlink:to="krmd_PerformanceStockUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_PerformanceStockUnits_lbl" xml:lang="en-US">PSUs</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_RestrictedStockUnits" xlink:label="krmd_RestrictedStockUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_RestrictedStockUnits" xlink:to="krmd_RestrictedStockUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_RestrictedStockUnits_lbl" xml:lang="en-US">Restricted stock</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_AntiDilutedSecurities" xlink:label="krmd_AntiDilutedSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AntiDilutedSecurities" xlink:to="krmd_AntiDilutedSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_AntiDilutedSecurities_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl" xml:lang="en-US">Weighted Average Outstanding Shares:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xml:lang="en-US">Basic weighted average shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock" xlink:label="krmd_DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock" xlink:to="krmd_DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock_lbl" xml:lang="en-US">Dilutive effect of outstanding stock options and unvested restricted stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xml:lang="en-US">Diluted weighted average shares outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_2_lbl" xml:lang="en-US">Net loss per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_2_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US">Number of segment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashUninsuredAmount" xlink:to="us-gaap_CashUninsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashUninsuredAmount_lbl" xml:lang="en-US">FDIC cash uninsured amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeSecuritiesUSTreasury" xlink:label="us-gaap_InterestIncomeSecuritiesUSTreasury" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeSecuritiesUSTreasury" xlink:to="us-gaap_InterestIncomeSecuritiesUSTreasury_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeSecuritiesUSTreasury_lbl" xml:lang="en-US">Investment securities treasury bill</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_AntiDilutiveStockOptions" xlink:label="krmd_AntiDilutiveStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AntiDilutiveStockOptions" xlink:to="krmd_AntiDilutiveStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_AntiDilutiveStockOptions_lbl" xml:lang="en-US">Anti-dilutive stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_AntiDilutiveSecurities" xlink:label="krmd_AntiDilutiveSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AntiDilutiveSecurities" xlink:to="krmd_AntiDilutiveSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_AntiDilutiveSecurities_lbl" xml:lang="en-US">Anti-dilutive Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Total property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation and amortization expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xml:lang="en-US">Weighted-average volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl" xml:lang="en-US">Expected dividends</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Outstanding at ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Outstanding at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average fair value of options granted during the period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Number outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xml:lang="en-US">Weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Number exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions" xlink:label="krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions" xlink:to="krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions_lbl" xml:lang="en-US">Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Unvested at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested_lbl" xml:lang="en-US">Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures_lbl" xml:lang="en-US">Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Forfeited/canceled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions" xlink:to="krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions_2_lbl" xml:lang="en-US">Unvested at ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Unvested at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_lbl" xml:lang="en-US">Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_lbl" xml:lang="en-US">Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_lbl" xml:lang="en-US">Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_lbl" xml:lang="en-US">Forfeited/canceled</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_lbl" xml:lang="en-US">Forfeited/canceled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_2_lbl" xml:lang="en-US">Outstanding at ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_2_lbl" xml:lang="en-US">Outstanding at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan" xlink:label="krmd_SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan" xlink:to="krmd_SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan_lbl" xml:lang="en-US">Shares issued under plan</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_SharesAvailableForIssuanceShareBasedCompensation" xlink:label="krmd_SharesAvailableForIssuanceShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_SharesAvailableForIssuanceShareBasedCompensation" xlink:to="krmd_SharesAvailableForIssuanceShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_SharesAvailableForIssuanceShareBasedCompensation_lbl" xml:lang="en-US">Shares available for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_NonemployeeServicesTransactionCost" xlink:label="krmd_NonemployeeServicesTransactionCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_NonemployeeServicesTransactionCost" xlink:to="krmd_NonemployeeServicesTransactionCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_NonemployeeServicesTransactionCost_lbl" xml:lang="en-US">Nonemployee services transaction cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementsOverallDescription" xlink:label="us-gaap_DeferredCompensationArrangementsOverallDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementsOverallDescription" xlink:to="us-gaap_DeferredCompensationArrangementsOverallDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementsOverallDescription_lbl" xml:lang="en-US">Share-based goods and non-employee services transaction</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_StockBasedCompensationStockOptions" xlink:label="krmd_StockBasedCompensationStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockBasedCompensationStockOptions" xlink:to="krmd_StockBasedCompensationStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_StockBasedCompensationStockOptions_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Total unrecognized compensation cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US">Fair value of shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xml:lang="en-US">Total stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_UnrecognizedCompensationCost" xlink:label="krmd_UnrecognizedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_UnrecognizedCompensationCost" xlink:to="krmd_UnrecognizedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_UnrecognizedCompensationCost_lbl" xml:lang="en-US">Unrecognized cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Short-Term Debt [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-Term Debt [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayable_lbl" xml:lang="en-US">Notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_NotePayableTerms" xlink:label="krmd_NotePayableTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_NotePayableTerms" xlink:to="krmd_NotePayableTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_NotePayableTerms_lbl" xml:lang="en-US">Note payable terms</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:to="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl" xml:lang="en-US">Description of the frequency of periodic payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLongTermDebtNoncurrent" xlink:label="us-gaap_OtherLongTermDebtNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLongTermDebtNoncurrent" xlink:to="us-gaap_OtherLongTermDebtNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLongTermDebtNoncurrent_lbl" xml:lang="en-US">Balance of AON note</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="us-gaap_LinesOfCreditCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LinesOfCreditCurrent" xlink:to="us-gaap_LinesOfCreditCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LinesOfCreditCurrent_lbl" xml:lang="en-US">Revolving credit facility</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_LinesOfCreditCurrent1" xlink:label="krmd_LinesOfCreditCurrent1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LinesOfCreditCurrent1" xlink:to="krmd_LinesOfCreditCurrent1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_LinesOfCreditCurrent1_lbl" xml:lang="en-US">Term loan facility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xml:lang="en-US">Short-term lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_FinanceLeaseCost1Abstract" xlink:label="krmd_FinanceLeaseCost1Abstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_FinanceLeaseCost1Abstract" xlink:to="krmd_FinanceLeaseCost1Abstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_FinanceLeaseCost1Abstract_lbl" xml:lang="en-US">Finance lease cost:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US">Amortization of right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US">Interest on lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_FinanceLeaseCost" xlink:label="krmd_FinanceLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_FinanceLeaseCost" xlink:to="krmd_FinanceLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_FinanceLeaseCost_lbl" xml:lang="en-US">Total finance lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:to="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash flows from operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xml:lang="en-US">Financing cash flows from finance leases</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_AssetsAndLiabilitiesOperatingLesseeAbstract" xlink:label="krmd_AssetsAndLiabilitiesOperatingLesseeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AssetsAndLiabilitiesOperatingLesseeAbstract" xlink:to="krmd_AssetsAndLiabilitiesOperatingLesseeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_AssetsAndLiabilitiesOperatingLesseeAbstract_lbl" xml:lang="en-US">Operating Leases</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Operating lease current liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Operating lease long term liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_AssetsAndLiabilitiesLesseeFinanceAbstract" xlink:label="krmd_AssetsAndLiabilitiesLesseeFinanceAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AssetsAndLiabilitiesLesseeFinanceAbstract" xlink:to="krmd_AssetsAndLiabilitiesLesseeFinanceAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_AssetsAndLiabilitiesLesseeFinanceAbstract_lbl" xml:lang="en-US">Finance Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentOther" xlink:label="us-gaap_PropertyPlantAndEquipmentOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOther" xlink:to="us-gaap_PropertyPlantAndEquipmentOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentOther_lbl" xml:lang="en-US">Property and equipment, at cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation_lbl" xml:lang="en-US">Accumulated depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Finance lease current liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Finance lease long term liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US">Total finance lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US">Operating leases term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:label="us-gaap_LesseeFinanceLeaseRenewalTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:to="us-gaap_LesseeFinanceLeaseRenewalTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeFinanceLeaseRenewalTerm1_lbl" xml:lang="en-US">Finance leases term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xml:lang="en-US">Operating leases discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseDiscountRate" xlink:label="us-gaap_LesseeFinanceLeaseDiscountRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseDiscountRate" xlink:to="us-gaap_LesseeFinanceLeaseDiscountRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeFinanceLeaseDiscountRate_lbl" xml:lang="en-US">Finance leases discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2024 - Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2024 - Finance Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2025 - Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2025 - Finance Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2026 - Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2026 - Finance Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2027 - Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2027 - Finance Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">2028 - Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">2028 - Finance Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Thereafter - Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Thereafter - Finance Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal" xlink:label="krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal" xlink:to="krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal_lbl" xml:lang="en-US">Total undiscounted lease payments - Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal" xlink:label="krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal" xlink:to="krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal_lbl" xml:lang="en-US">Total undiscounted lease payments - Finance Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_LesseeOperatingLeaseImputedInterest" xlink:label="krmd_LesseeOperatingLeaseImputedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeOperatingLeaseImputedInterest" xlink:to="krmd_LesseeOperatingLeaseImputedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="krmd_LesseeOperatingLeaseImputedInterest_lbl" xml:lang="en-US">Less: imputed interest - Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_LesseeFinancingLeaseImputedInterest" xlink:label="krmd_LesseeFinancingLeaseImputedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeFinancingLeaseImputedInterest" xlink:to="krmd_LesseeFinancingLeaseImputedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="krmd_LesseeFinancingLeaseImputedInterest_lbl" xml:lang="en-US">Less: imputed interest - Finance Leases</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_2_lbl" xml:lang="en-US">Total lease liabilities - Operating Leases</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiability_2_lbl" xml:lang="en-US">Total lease liabilities - Finance Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_LesseeOperatingLeaseRemainingTerm" xlink:label="krmd_LesseeOperatingLeaseRemainingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeOperatingLeaseRemainingTerm" xlink:to="krmd_LesseeOperatingLeaseRemainingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_LesseeOperatingLeaseRemainingTerm_lbl" xml:lang="en-US">Operating lease remaining term</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_LesseeFinanceLeaseRemainingTerm" xlink:label="krmd_LesseeFinanceLeaseRemainingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeFinanceLeaseRemainingTerm" xlink:to="krmd_LesseeFinanceLeaseRemainingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_LesseeFinanceLeaseRemainingTerm_lbl" xml:lang="en-US">Finance lease remaining term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation Allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Statutory rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_FurnitureAndOfficeEquipmentMember" xlink:to="krmd_FurnitureAndOfficeEquipmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_FurnitureAndOfficeEquipmentMember_doc" xml:lang="en-US">The element represents furniture and office equipment member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ManufacturingEquipmentAndToolingMember" xlink:to="krmd_ManufacturingEquipmentAndToolingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ManufacturingEquipmentAndToolingMember_doc" xml:lang="en-US">The element represents manufacturing equipment and tooling member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_PaymentsOnIndebtedness" xlink:to="krmd_PaymentsOnIndebtedness_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_PaymentsOnIndebtedness_doc" xml:lang="en-US">The element represents payments on indebtedness.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_IssuanceOfCommonStockCompensation" xlink:to="krmd_IssuanceOfCommonStockCompensation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_IssuanceOfCommonStockCompensation_doc" xml:lang="en-US">The element represents issuance of common stock compensation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockOptionPlan2015Member" xlink:to="krmd_StockOptionPlan2015Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_StockOptionPlan2015Member_doc" xml:lang="en-US">The element represents stock option plan2015 member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockOptionPlan2021Member" xlink:to="krmd_StockOptionPlan2021Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_StockOptionPlan2021Member_doc" xml:lang="en-US">The element represents stock option plan2021 member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_NonEmployeeDirectorAndBoardAdvisorMember" xlink:to="krmd_NonEmployeeDirectorAndBoardAdvisorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_NonEmployeeDirectorAndBoardAdvisorMember_doc" xml:lang="en-US">The element represents non employee director and board advisor member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_NonemployeeServicesTransactionCost" xlink:to="krmd_NonemployeeServicesTransactionCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_NonemployeeServicesTransactionCost_doc" xml:lang="en-US">The element represents nonemployee services transaction cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_TimeBasedSharesOptionsMember" xlink:to="krmd_TimeBasedSharesOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_TimeBasedSharesOptionsMember_doc" xml:lang="en-US">The element represents time based shares options member.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award grants in period weighted average grant date fair value.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:label="krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:to="krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1_doc" xml:lang="en-US">The element represents stock issued during period shares stock options exercised1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ExercisePrice1Member" xlink:to="krmd_ExercisePrice1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ExercisePrice1Member_doc" xml:lang="en-US">The element represents exercise price1 member.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award options grants in period gross1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_doc" xml:lang="en-US">The element represents share based compensation arrangements by share based payment award options grants in period weighted average exercise price1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_doc" xml:lang="en-US">The element represents share based compensation arrangements by share based payment award options forfeitures in period weighted average exercise price1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_CashPaidDuringPeriodsForAbstract" xlink:to="krmd_CashPaidDuringPeriodsForAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_CashPaidDuringPeriodsForAbstract_doc" xml:lang="en-US">The element represents cash paid during periods for abstract.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award options forfeitures in period2.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award options outstanding number unvested.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_RestrictedStockAwardsMember" xlink:to="krmd_RestrictedStockAwardsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_RestrictedStockAwardsMember_doc" xml:lang="en-US">The element represents restricted stock awards member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award options grants in period gross unvested.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award options vested in period gross.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award options forfeitures in period unvested.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award options outstanding weighted average exercise price unvested.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_doc" xml:lang="en-US">The element represents share based compensation arrangements by share based payment award options grants in period weighted average exercise price unvested.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">The element represents share based compensation arrangements by share based payment award options vested in period weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_doc" xml:lang="en-US">The element represents share based compensation arrangements by share based payment award options forfeitures in period weighted average exercise price unvested.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_FinanceLeaseCost1Abstract" xlink:to="krmd_FinanceLeaseCost1Abstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_FinanceLeaseCost1Abstract_doc" xml:lang="en-US">The element represents finance lease cost1 abstract.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_FinanceLeaseCost" xlink:to="krmd_FinanceLeaseCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_FinanceLeaseCost_doc" xml:lang="en-US">The element represents finance lease cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AssetsAndLiabilitiesOperatingLesseeAbstract" xlink:to="krmd_AssetsAndLiabilitiesOperatingLesseeAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_AssetsAndLiabilitiesOperatingLesseeAbstract_doc" xml:lang="en-US">The element represents assets and liabilities operating lessee abstract.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AssetsAndLiabilitiesLesseeFinanceAbstract" xlink:to="krmd_AssetsAndLiabilitiesLesseeFinanceAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_AssetsAndLiabilitiesLesseeFinanceAbstract_doc" xml:lang="en-US">The element represents assets and liabilities lessee finance abstract.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDue" xlink:label="krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDue" xlink:to="krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDue_doc" xml:lang="en-US">The element represents lessee financing lease lease liability payments due.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeOperatingLeaseImputedInterest" xlink:to="krmd_LesseeOperatingLeaseImputedInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_LesseeOperatingLeaseImputedInterest_doc" xml:lang="en-US">The element represents lessee operating lease imputed interest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeFinancingLeaseImputedInterest" xlink:to="krmd_LesseeFinancingLeaseImputedInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_LesseeFinancingLeaseImputedInterest_doc" xml:lang="en-US">The element represents lessee financing lease imputed interest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AONPremiumFinanceLLCMember" xlink:to="krmd_AONPremiumFinanceLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_AONPremiumFinanceLLCMember_doc" xml:lang="en-US">The element represents a o n premium finance l l c member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_PromissoryNoteMember" xlink:to="krmd_PromissoryNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_PromissoryNoteMember_doc" xml:lang="en-US">The element represents promissory note member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_NotePayableTerms" xlink:to="krmd_NotePayableTerms_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_NotePayableTerms_doc" xml:lang="en-US">The element represents note payable terms.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal" xlink:to="krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal_doc" xml:lang="en-US">The element represents lessee operating lease liability payments due total.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock" xlink:to="krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock_doc" xml:lang="en-US">The element represents schedule of share based compensation stock options activity amended table text block.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_LessorOperatingLeaseOptionToTerminate1" xlink:label="krmd_LessorOperatingLeaseOptionToTerminate1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LessorOperatingLeaseOptionToTerminate1" xlink:to="krmd_LessorOperatingLeaseOptionToTerminate1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_LessorOperatingLeaseOptionToTerminate1_doc" xml:lang="en-US">The element represents lessor operating lease option to terminate1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_RouLandlordCredit" xlink:to="krmd_RouLandlordCredit_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_RouLandlordCredit_doc" xml:lang="en-US">The element represents rou landlord credit.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_BorrowingsFromIndebtedness" xlink:label="krmd_BorrowingsFromIndebtedness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_BorrowingsFromIndebtedness" xlink:to="krmd_BorrowingsFromIndebtedness_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_BorrowingsFromIndebtedness_doc" xml:lang="en-US">The element represents borrowings from indebtedness.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_AmortizationOfIntangibleAssets1" xlink:label="krmd_AmortizationOfIntangibleAssets1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AmortizationOfIntangibleAssets1" xlink:to="krmd_AmortizationOfIntangibleAssets1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_AmortizationOfIntangibleAssets1_doc" xml:lang="en-US">The element represents amortization of intangible assets1.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_DepreciationDepletionAndAmortization1" xlink:label="krmd_DepreciationDepletionAndAmortization1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_DepreciationDepletionAndAmortization1" xlink:to="krmd_DepreciationDepletionAndAmortization1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_DepreciationDepletionAndAmortization1_doc" xml:lang="en-US">The element represents depreciation depletion and amortization1.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_RdCredit" xlink:label="krmd_RdCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_RdCredit" xlink:to="krmd_RdCredit_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_RdCredit_doc" xml:lang="en-US">The element represents rd credit.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_Nol" xlink:label="krmd_Nol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_Nol" xlink:to="krmd_Nol_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_Nol_doc" xml:lang="en-US">The element represents nol.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_AllowanceForDoubtfulOtherReceivables1Current" xlink:label="krmd_AllowanceForDoubtfulOtherReceivables1Current" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AllowanceForDoubtfulOtherReceivables1Current" xlink:to="krmd_AllowanceForDoubtfulOtherReceivables1Current_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_AllowanceForDoubtfulOtherReceivables1Current_doc" xml:lang="en-US">The element represents allowance for doubtful other receivables1 current.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_DescriptionOfMatchingContribution" xlink:label="krmd_DescriptionOfMatchingContribution" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_DescriptionOfMatchingContribution" xlink:to="krmd_DescriptionOfMatchingContribution_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_DescriptionOfMatchingContribution_doc" xml:lang="en-US">The element represents description of matching contribution.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_DescriptionOfLessorOperatingLeaseTerm" xlink:label="krmd_DescriptionOfLessorOperatingLeaseTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_DescriptionOfLessorOperatingLeaseTerm" xlink:to="krmd_DescriptionOfLessorOperatingLeaseTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_DescriptionOfLessorOperatingLeaseTerm_doc" xml:lang="en-US">The element represents description of lessor operating lease term.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_EquipmentAndToolingMember" xlink:label="krmd_EquipmentAndToolingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_EquipmentAndToolingMember" xlink:to="krmd_EquipmentAndToolingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_EquipmentAndToolingMember_doc" xml:lang="en-US">The element represents equipment and tooling member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_UnrecognizedCompensationCost" xlink:to="krmd_UnrecognizedCompensationCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_UnrecognizedCompensationCost_doc" xml:lang="en-US">The element represents unrecognized compensation cost.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ScheduleOfNetRevenuesByGeography" xlink:label="krmd_ScheduleOfNetRevenuesByGeography" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ScheduleOfNetRevenuesByGeography" xlink:to="krmd_ScheduleOfNetRevenuesByGeography_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ScheduleOfNetRevenuesByGeography_doc" xml:lang="en-US">The element represents schedule of net revenues by geography.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_CompensationeExpenseRelatedToRestrictedStockAwards" xlink:to="krmd_CompensationeExpenseRelatedToRestrictedStockAwards_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_CompensationeExpenseRelatedToRestrictedStockAwards_doc" xml:lang="en-US">The element represents compensatione expense related to restricted stock awards.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan" xlink:to="krmd_SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan_doc" xml:lang="en-US">The element represents shares issued under plan in total shares employee stock ownership plan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_SharesAvailableForIssuanceShareBasedCompensation" xlink:to="krmd_SharesAvailableForIssuanceShareBasedCompensation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_SharesAvailableForIssuanceShareBasedCompensation_doc" xml:lang="en-US">The element represents shares available for issuance share based compensation.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_TaxBenefitFromStockBasedCompensation" xlink:label="krmd_TaxBenefitFromStockBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_TaxBenefitFromStockBasedCompensation" xlink:to="krmd_TaxBenefitFromStockBasedCompensation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_TaxBenefitFromStockBasedCompensation_doc" xml:lang="en-US">The element represents tax benefit from stock based compensation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockOptionPlans2015And2021CombinedMember" xlink:to="krmd_StockOptionPlans2015And2021CombinedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_StockOptionPlans2015And2021CombinedMember_doc" xml:lang="en-US">The element represents stock option plans2015 and2021 combined member.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_TaxBenefitFromRestrictedStockCompensation" xlink:label="krmd_TaxBenefitFromRestrictedStockCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_TaxBenefitFromRestrictedStockCompensation" xlink:to="krmd_TaxBenefitFromRestrictedStockCompensation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_TaxBenefitFromRestrictedStockCompensation_doc" xml:lang="en-US">The element represents tax benefit from restricted stock compensation.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_StockBasedCompensationSharesIssuable" xlink:label="krmd_StockBasedCompensationSharesIssuable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockBasedCompensationSharesIssuable" xlink:to="krmd_StockBasedCompensationSharesIssuable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_StockBasedCompensationSharesIssuable_doc" xml:lang="en-US">The element represents stock based compensation shares issuable.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_FDICBankMember" xlink:label="krmd_FDICBankMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_FDICBankMember" xlink:to="krmd_FDICBankMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_FDICBankMember_doc" xml:lang="en-US">The element represents f d i c bank member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_CommonStockOptions" xlink:to="krmd_CommonStockOptions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_CommonStockOptions_doc" xml:lang="en-US">The element represents common stock options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_RestrictedStockUnits" xlink:to="krmd_RestrictedStockUnits_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_RestrictedStockUnits_doc" xml:lang="en-US">The element represents restricted stock units.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ScheduleOfSecuritiesTextBlock" xlink:to="krmd_ScheduleOfSecuritiesTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ScheduleOfSecuritiesTextBlock_doc" xml:lang="en-US">The element represents schedule of securities text block.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AntiDilutedSecurities" xlink:to="krmd_AntiDilutedSecurities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_AntiDilutedSecurities_doc" xml:lang="en-US">The element represents anti diluted securities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock" xlink:to="krmd_DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock_doc" xml:lang="en-US">The element represents dilutive effect of outstanding stock options and unvested restricted stock.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_CashReceivedFromOptionExercise" xlink:label="krmd_CashReceivedFromOptionExercise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_CashReceivedFromOptionExercise" xlink:to="krmd_CashReceivedFromOptionExercise_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_CashReceivedFromOptionExercise_doc" xml:lang="en-US">The element represents cash received from option exercise.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockBasedCompensationStockOptions" xlink:to="krmd_StockBasedCompensationStockOptions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_StockBasedCompensationStockOptions_doc" xml:lang="en-US">The element represents stock based compensation stock options.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBloc" xlink:label="krmd_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBloc" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBloc" xlink:to="krmd_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBloc_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBloc_doc" xml:lang="en-US">The element represents impairment or disposal of long lived assets policy text bloc.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_PatentsAndTrademarksMember" xlink:label="krmd_PatentsAndTrademarksMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_PatentsAndTrademarksMember" xlink:to="krmd_PatentsAndTrademarksMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_PatentsAndTrademarksMember_doc" xml:lang="en-US">The element represents patents and trademarks member.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_AntiDilutedSecuritiesPerformancBased" xlink:label="krmd_AntiDilutedSecuritiesPerformancBased" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AntiDilutedSecuritiesPerformancBased" xlink:to="krmd_AntiDilutedSecuritiesPerformancBased_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_AntiDilutedSecuritiesPerformancBased_doc" xml:lang="en-US">The element represents anti diluted securities performanc based.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_AntiDilutedSecuritiesTimeBased" xlink:label="krmd_AntiDilutedSecuritiesTimeBased" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AntiDilutedSecuritiesTimeBased" xlink:to="krmd_AntiDilutedSecuritiesTimeBased_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_AntiDilutedSecuritiesTimeBased_doc" xml:lang="en-US">The element represents anti diluted securities time based.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_StockOptions" xlink:label="krmd_StockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockOptions" xlink:to="krmd_StockOptions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_StockOptions_doc" xml:lang="en-US">The element represents stock options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_PerformanceBasedSharesOptionsMember" xlink:to="krmd_PerformanceBasedSharesOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_PerformanceBasedSharesOptionsMember_doc" xml:lang="en-US">The element represents performance based shares options member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions" xlink:to="krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions_doc" xml:lang="en-US">The element represents share based compensation arrangement by unvested award options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award options grants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award options forfeitures.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award options vested.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award options unvested weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1_doc" xml:lang="en-US">The element represents share based compensation arrangements by share based payment award options vested in period weighted average exercise price1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LeaseOneMember" xlink:to="krmd_LeaseOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_LeaseOneMember_doc" xml:lang="en-US">The element represents lease one member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LeaseTwoMember" xlink:to="krmd_LeaseTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_LeaseTwoMember_doc" xml:lang="en-US">The element represents lease two member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LeaseThreeMember" xlink:to="krmd_LeaseThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_LeaseThreeMember_doc" xml:lang="en-US">The element represents lease three member.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_WriteoffOfDeferredTaxAsset" xlink:label="krmd_WriteoffOfDeferredTaxAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_WriteoffOfDeferredTaxAsset" xlink:to="krmd_WriteoffOfDeferredTaxAsset_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_WriteoffOfDeferredTaxAsset_doc" xml:lang="en-US">The element represents writeoff of deferred tax asset.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_AllowanceForNonRealizationOfDeferredTaxAsset" xlink:label="krmd_AllowanceForNonRealizationOfDeferredTaxAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AllowanceForNonRealizationOfDeferredTaxAsset" xlink:to="krmd_AllowanceForNonRealizationOfDeferredTaxAsset_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_AllowanceForNonRealizationOfDeferredTaxAsset_doc" xml:lang="en-US">The element represents allowance for non realization of deferred tax asset.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_CustomerOneMember" xlink:label="krmd_CustomerOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_CustomerOneMember" xlink:to="krmd_CustomerOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_CustomerOneMember_doc" xml:lang="en-US">The element represents customer one member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_TermLoanFacilityMember" xlink:to="krmd_TermLoanFacilityMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_TermLoanFacilityMember_doc" xml:lang="en-US">The element represents term loan facility member.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_FinanceLeaseROUAsset" xlink:label="krmd_FinanceLeaseROUAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_FinanceLeaseROUAsset" xlink:to="krmd_FinanceLeaseROUAsset_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_FinanceLeaseROUAsset_doc" xml:lang="en-US">The element represents finance lease rou asset.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal" xlink:to="krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal_doc" xml:lang="en-US">The element represents lessee financing lease lease liability payments due total.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ExecutivesEmployeesConsultantsMember" xlink:label="krmd_ExecutivesEmployeesConsultantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ExecutivesEmployeesConsultantsMember" xlink:to="krmd_ExecutivesEmployeesConsultantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ExecutivesEmployeesConsultantsMember_doc" xml:lang="en-US">The element represents executives employees consultants member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeFinanceLeaseRemainingTerm" xlink:to="krmd_LesseeFinanceLeaseRemainingTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_LesseeFinanceLeaseRemainingTerm_doc" xml:lang="en-US">The element represents lessee finance lease remaining term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeOperatingLeaseRemainingTerm" xlink:to="krmd_LesseeOperatingLeaseRemainingTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_LesseeOperatingLeaseRemainingTerm_doc" xml:lang="en-US">The element represents lessee operating lease remaining term.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_AntiDilutiveCommonStockOptions" xlink:label="krmd_AntiDilutiveCommonStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AntiDilutiveCommonStockOptions" xlink:to="krmd_AntiDilutiveCommonStockOptions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_AntiDilutiveCommonStockOptions_doc" xml:lang="en-US">The element represents anti dilutive common stock options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AntiDilutiveStockOptions" xlink:to="krmd_AntiDilutiveStockOptions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_AntiDilutiveStockOptions_doc" xml:lang="en-US">The element represents anti dilutive stock options.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_AntiDilutivePerformanceBasedStock" xlink:label="krmd_AntiDilutivePerformanceBasedStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AntiDilutivePerformanceBasedStock" xlink:to="krmd_AntiDilutivePerformanceBasedStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_AntiDilutivePerformanceBasedStock_doc" xml:lang="en-US">The element represents anti dilutive performancebased stock.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_AntiDilutiveTimeBasedStock" xlink:label="krmd_AntiDilutiveTimeBasedStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AntiDilutiveTimeBasedStock" xlink:to="krmd_AntiDilutiveTimeBasedStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_AntiDilutiveTimeBasedStock_doc" xml:lang="en-US">The element represents anti dilutive time based stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AntiDilutiveSecurities" xlink:to="krmd_AntiDilutiveSecurities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_AntiDilutiveSecurities_doc" xml:lang="en-US">The element represents anti dilutive securities.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_DepreciationAndAmortizationPropertyAndEquipment" xlink:label="krmd_DepreciationAndAmortizationPropertyAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_DepreciationAndAmortizationPropertyAndEquipment" xlink:to="krmd_DepreciationAndAmortizationPropertyAndEquipment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_DepreciationAndAmortizationPropertyAndEquipment_doc" xml:lang="en-US">The element represents depreciation and amortization property and equipment.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_AntiDilutiveRestrictedStock" xlink:label="krmd_AntiDilutiveRestrictedStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AntiDilutiveRestrictedStock" xlink:to="krmd_AntiDilutiveRestrictedStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_AntiDilutiveRestrictedStock_doc" xml:lang="en-US">The element represents anti dilutive restricted stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_PerformanceStockUnits" xlink:to="krmd_PerformanceStockUnits_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_PerformanceStockUnits_doc" xml:lang="en-US">The element represents performance stock units.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ScheduleOfNetSalesByGeography" xlink:to="krmd_ScheduleOfNetSalesByGeography_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ScheduleOfNetSalesByGeography_doc" xml:lang="en-US">The element represents schedule of net sales by geography.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockValue_2_lbl" xml:lang="en-US">Treasury Stock, Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_2_lbl" xml:lang="en-US">Gross Profit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfOtherAssets" xlink:to="us-gaap_GainLossOnSaleOfOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets_2_lbl" xml:lang="en-US">Gain (Loss) on Disposition of Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_2_lbl" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_PaymentsOnIndebtedness" xlink:to="krmd_PaymentsOnIndebtedness_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_PaymentsOnIndebtedness_3_lbl" xml:lang="en-US">Payments on Indebtedness</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_2_lbl" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions" xlink:to="krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions_4_lbl" xml:lang="en-US">Share Based Compensation Arrangement by Unvested Award Options</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_4_lbl" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Options Unvested Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_3_lbl" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Options Grants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_3_lbl" xml:lang="en-US">Share Based Compensation Arrangements by Share Based Payment Award Options Grants in Period Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested_3_lbl" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Options Vested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures_3_lbl" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Options forfeitures</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_4_lbl" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Options Outstanding Number Unvested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_4_lbl" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Options Outstanding Weighted Average Exercise Price Unvested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_3_lbl" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Options Grants in Period Gross Unvested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_3_lbl" xml:lang="en-US">Share Based Compensation Arrangements by Share Based Payment Award Options Grants in Period Weighted Average Exercise Price Unvested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_3_lbl" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Options Vested in Period Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share Based Compensation Arrangements by Share Based Payment Award Options Vested in Period Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_3_lbl" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Options forfeitures in Period Unvested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_3_lbl" xml:lang="en-US">Share Based Compensation Arrangements by Share Based Payment Award Options forfeitures in Period Weighted Average Exercise Price Unvested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockBasedCompensationStockOptions" xlink:to="krmd_StockBasedCompensationStockOptions_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_StockBasedCompensationStockOptions_3_lbl" xml:lang="en-US">Stock Based Compensation Stock Options</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Other, Accumulated Depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherNet_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Other, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeOperatingLeaseImputedInterest" xlink:to="krmd_LesseeOperatingLeaseImputedInterest_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_LesseeOperatingLeaseImputedInterest_3_lbl" xml:lang="en-US">Lessee Operating Lease Imputed interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeFinancingLeaseImputedInterest" xlink:to="krmd_LesseeFinancingLeaseImputedInterest_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_LesseeFinancingLeaseImputedInterest_3_lbl" xml:lang="en-US">Lessee Financing Lease Imputed interest</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>krmd-20240331_pre.xml
<DESCRIPTION>INLINE XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://korumedical.com/role/Cover" xlink:href="krmd-20240331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/BalanceSheets" xlink:href="krmd-20240331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/BalanceSheetsParenthetical" xlink:href="krmd-20240331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/StatementsOfOperations" xlink:href="krmd-20240331.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/StatementsOfCashFlows" xlink:href="krmd-20240331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/StatementsOfStockholdersEquity" xlink:href="krmd-20240331.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:href="krmd-20240331.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/PropertyAndEquipment" xlink:href="krmd-20240331.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Stock-basedCompensation" xlink:href="krmd-20240331.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/DebtObligations" xlink:href="krmd-20240331.xsd#DebtObligations" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Leases" xlink:href="krmd-20240331.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/IncomeTaxes" xlink:href="krmd-20240331.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/CommitmentsAndContingencies" xlink:href="krmd-20240331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/SubsequentEvents" xlink:href="krmd-20240331.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="krmd-20240331.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="krmd-20240331.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/PropertyAndEquipmentTables" xlink:href="krmd-20240331.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Stock-basedCompensationTables" xlink:href="krmd-20240331.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/LeasesTables" xlink:href="krmd-20240331.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FollowingSecuritiesWereNotIncludedInComputationOfDilutedSharesOutstandingForThreeMonthsEndedMarch312024And2023BecauseEffectWouldBeAnti-dilutiveDetails" xlink:href="krmd-20240331.xsd#FollowingSecuritiesWereNotIncludedInComputationOfDilutedSharesOutstandingForThreeMonthsEndedMarch312024And2023BecauseEffectWouldBeAnti-dilutiveDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ThereforeDilutedWeightedAverageNumberOfSharesOutstandingAndDilutedNetLossPerShareWereSameAsBasicWeightedAverageNumberOfSharesOutstandingAndNetLossPerShareForThreeMonthsEndedMarch312024And2023.Details" xlink:href="krmd-20240331.xsd#ThereforeDilutedWeightedAverageNumberOfSharesOutstandingAndDilutedNetLossPerShareWereSameAsBasicWeightedAverageNumberOfSharesOutstandingAndNetLossPerShareForThreeMonthsEndedMarch312024And2023.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FollowingTableSummarizesNetRevenuesByGeographyForThreeMonthsEndedMarch312024And2023Details" xlink:href="krmd-20240331.xsd#FollowingTableSummarizesNetRevenuesByGeographyForThreeMonthsEndedMarch312024And2023Details" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="krmd-20240331.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails" xlink:href="krmd-20240331.xsd#PropertyAndEquipmentConsistsOfFollowingAtDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="krmd-20240331.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurStockOptionsWithTimeBasedVestingForThreeMonthsEndedMarch312024And2023.Details" xlink:href="krmd-20240331.xsd#FollowingTableSummarizesActivitiesForOurStockOptionsWithTimeBasedVestingForThreeMonthsEndedMarch312024And2023.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FollowingTableSummarizesStatusOfStockOptionsDetails" xlink:href="krmd-20240331.xsd#FollowingTableSummarizesStatusOfStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FollowingTablePresentsInformationPertainingToOptionsOutstandingAtMarch312024Details" xlink:href="krmd-20240331.xsd#FollowingTablePresentsInformationPertainingToOptionsOutstandingAtMarch312024Details" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformanceBasedStockOptionAwardsForThreeMonthsEndedMarch312024And2023.Details" xlink:href="krmd-20240331.xsd#FollowingTableSummarizesActivitiesForOurUnvestedPerformanceBasedStockOptionAwardsForThreeMonthsEndedMarch312024And2023.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurRestrictedStockAwardsAndPsusForThreeMonthsEndedMarch312024And2023.Details" xlink:href="krmd-20240331.xsd#FollowingTableSummarizesActivitiesForOurRestrictedStockAwardsAndPsusForThreeMonthsEndedMarch312024And2023.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurCommonStockWarrantsIssuedInConnectionWithOurLoanFinancingAgreementWithHsbcForThreeMonthsEndedMarch312024And2023.Details" xlink:href="krmd-20240331.xsd#FollowingTableSummarizesActivitiesForOurCommonStockWarrantsIssuedInConnectionWithOurLoanFinancingAgreementWithHsbcForThreeMonthsEndedMarch312024And2023.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="krmd-20240331.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/DebtObligationsDetailsNarrative" xlink:href="krmd-20240331.xsd#DebtObligationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ComponentsOfLeaseExpenseWereAsFollowsDetails" xlink:href="krmd-20240331.xsd#ComponentsOfLeaseExpenseWereAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/SupplementalCashFlowInformationRelatedToLeasesWasAsFollowsDetails" xlink:href="krmd-20240331.xsd#SupplementalCashFlowInformationRelatedToLeasesWasAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails" xlink:href="krmd-20240331.xsd#SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails" xlink:href="krmd-20240331.xsd#MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/LeasesDetailsNarrative" xlink:href="krmd-20240331.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/IncomeTaxesDetailsNarrative" xlink:href="krmd-20240331.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityListingParValuePerShare" xlink:label="loc_deiEntityListingParValuePerShare" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityListingParValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaapTreasuryStockCommonShares" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_us-gaapTreasuryStockCommonShares" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/BalanceSheets" xlink:title="00000002 - Statement - BALANCE SHEETS (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaapOtherReceivables" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOtherReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaapDeferredIncomeTaxAssetsNet" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaapTreasuryStockValue" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapTreasuryStockValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - BALANCE SHEETS (UNAUDITED) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRentReceivablesNetNoncurrent" xlink:label="loc_us-gaapDeferredRentReceivablesNetNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapDeferredRentReceivablesNetNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockPreferredShares" xlink:label="loc_us-gaapTreasuryStockPreferredShares" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapTreasuryStockPreferredShares" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - STATEMENTS OF OPERATIONS (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/StatementsOfCashFlows" xlink:title="00000005 - Statement - STATEMENTS OF CASH FLOWS (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="loc_us-gaapDeferredIncomeTaxesAndTaxCredits" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxesAndTaxCredits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="loc_us-gaapGainLossOnSaleOfOtherAssets" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainLossOnSaleOfOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_RouLandlordCredit" xlink:label="loc_krmdRouLandlordCredit" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_krmdRouLandlordCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaapPaymentsToAcquireProductiveAssets" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireProductiveAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_PaymentsOnIndebtedness" xlink:label="loc_krmdPaymentsOnIndebtedness" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_krmdPaymentsOnIndebtedness" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_CashPaidDuringPeriodsForAbstract" xlink:label="loc_krmdCashPaidDuringPeriodsForAbstract" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_krmdCashPaidDuringPeriodsForAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdCashPaidDuringPeriodsForAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdCashPaidDuringPeriodsForAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_IssuanceOfCommonStockCompensation" xlink:label="loc_krmdIssuanceOfCommonStockCompensation" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_krmdIssuanceOfCommonStockCompensation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/StatementsOfStockholdersEquity" xlink:title="00000006 - Statement - STATEMENTS OF STOCKHOLDERS&apos; EQUITY (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="loc_us-gaapTreasuryStockCommonMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapTreasuryStockCommonMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_CompensationeExpenseRelatedToRestrictedStockAwards" xlink:label="loc_krmdCompensationeExpenseRelatedToRestrictedStockAwards" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_krmdCompensationeExpenseRelatedToRestrictedStockAwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapOrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/PropertyAndEquipment" xlink:title="00000008 - Disclosure - PROPERTY AND EQUIPMENT">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/Stock-basedCompensation" xlink:title="00000009 - Disclosure - STOCK-BASED COMPENSATION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/DebtObligations" xlink:title="00000010 - Disclosure - DEBT OBLIGATIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/Leases" xlink:title="00000011 - Disclosure - LEASES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaapLeasesOfLesseeDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLeasesOfLesseeDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/IncomeTaxes" xlink:title="00000012 - Disclosure - INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/CommitmentsAndContingencies" xlink:title="00000013 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/SubsequentEvents" xlink:title="00000014 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_DisclosureSubsequentEventsAbstract" xlink:label="loc_krmdDisclosureSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdDisclosureSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000015 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaapNatureOfOperations" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNatureOfOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="00000016 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ScheduleOfSecuritiesTextBlock" xlink:label="loc_krmdScheduleOfSecuritiesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_krmdScheduleOfSecuritiesTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ScheduleOfNetSalesByGeography" xlink:label="loc_krmdScheduleOfNetSalesByGeography" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_krmdScheduleOfNetSalesByGeography" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/PropertyAndEquipmentTables" xlink:title="00000017 - Disclosure - PROPERTY AND EQUIPMENT (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/Stock-basedCompensationTables" xlink:title="00000018 - Disclosure - STOCK-BASED COMPENSATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock" xlink:label="loc_krmdScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_krmdScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:label="loc_us-gaapShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="loc_us-gaapScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:label="loc_us-gaapScheduleOfCommonStockOutstandingRollForwardTableTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/LeasesTables" xlink:title="00000019 - Disclosure - LEASES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaapLeaseCostTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLeaseCostTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:label="loc_us-gaapOperatingLeaseLeaseIncomeTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLeaseIncomeTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaapOperatingLeasesOfLesseeDisclosureTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeasesOfLesseeDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/FollowingSecuritiesWereNotIncludedInComputationOfDilutedSharesOutstandingForThreeMonthsEndedMarch312024And2023BecauseEffectWouldBeAnti-dilutiveDetails" xlink:title="00000020 - Disclosure - The following securities were not included in the computation of diluted shares outstanding for the three months ended March 31, 2024, and 2023 because the effect would be anti-dilutive: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_CommonStockOptions" xlink:label="loc_krmdCommonStockOptions" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_krmdCommonStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_PerformanceStockUnits" xlink:label="loc_krmdPerformanceStockUnits" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_krmdPerformanceStockUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_RestrictedStockUnits" xlink:label="loc_krmdRestrictedStockUnits" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_krmdRestrictedStockUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_AntiDilutedSecurities" xlink:label="loc_krmdAntiDilutedSecurities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_krmdAntiDilutedSecurities" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ThereforeDilutedWeightedAverageNumberOfSharesOutstandingAndDilutedNetLossPerShareWereSameAsBasicWeightedAverageNumberOfSharesOutstandingAndNetLossPerShareForThreeMonthsEndedMarch312024And2023.Details" xlink:title="00000021 - Disclosure - Therefore, diluted weighted average number of shares outstanding and diluted net loss per share were the same as basic weighted average number of shares outstanding and net loss per share for the three months ended March 31, 2024 and 2023. (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasicAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock" xlink:label="loc_krmdDilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_krmdDilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/FollowingTableSummarizesNetRevenuesByGeographyForThreeMonthsEndedMarch312024And2023Details" xlink:title="00000022 - Disclosure - The following table summarizes net revenues by geography for the three months ended March 31, 2024, and 2023: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="loc_countryUS" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaapNonUsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_us-gaapNonUsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000023 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaapNumberOfReportableSegments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNumberOfReportableSegments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashUninsuredAmount" xlink:label="loc_us-gaapCashUninsuredAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashUninsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeSecuritiesUSTreasury" xlink:label="loc_us-gaapInterestIncomeSecuritiesUSTreasury" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInterestIncomeSecuritiesUSTreasury" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_AntiDilutiveStockOptions" xlink:label="loc_krmdAntiDilutiveStockOptions" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_krmdAntiDilutiveStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_AntiDilutiveSecurities" xlink:label="loc_krmdAntiDilutiveSecurities" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_krmdAntiDilutiveSecurities" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails" xlink:title="00000024 - Disclosure - Property and equipment consists of the following at: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_FurnitureAndOfficeEquipmentMember" xlink:label="loc_krmdFurnitureAndOfficeEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_krmdFurnitureAndOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ManufacturingEquipmentAndToolingMember" xlink:label="loc_krmdManufacturingEquipmentAndToolingMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_krmdManufacturingEquipmentAndToolingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="00000025 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurStockOptionsWithTimeBasedVestingForThreeMonthsEndedMarch312024And2023.Details" xlink:title="00000026 - Disclosure - The following table summarizes the activities for our stock options with time based vesting for the three months ended March 31, 2024, and 2023. (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_StockOptionPlan2015Member" xlink:label="loc_krmdStockOptionPlan2015Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2015Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_TimeBasedSharesOptionsMember" xlink:label="loc_krmdTimeBasedSharesOptionsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdTimeBasedSharesOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/FollowingTableSummarizesStatusOfStockOptionsDetails" xlink:title="00000027 - Disclosure - The following table summarizes the status of the stock options: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_StockOptionPlan2015Member" xlink:label="loc_krmdStockOptionPlan2015Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2015Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_TimeBasedSharesOptionsMember" xlink:label="loc_krmdTimeBasedSharesOptionsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdTimeBasedSharesOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/FollowingTablePresentsInformationPertainingToOptionsOutstandingAtMarch312024Details" xlink:title="00000028 - Disclosure - The following table presents information pertaining to options outstanding at March 31, 2024: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_StockOptionPlan2015Member" xlink:label="loc_krmdStockOptionPlan2015Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2015Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_TimeBasedSharesOptionsMember" xlink:label="loc_krmdTimeBasedSharesOptionsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdTimeBasedSharesOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ExercisePrice1Member" xlink:label="loc_krmdExercisePrice1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_krmdExercisePrice1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformanceBasedStockOptionAwardsForThreeMonthsEndedMarch312024And2023.Details" xlink:title="00000029 - Disclosure - The following table summarizes the activities for our unvested performance based stock option awards for the three months ended March 31, 2024, and 2023. (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_PerformanceBasedSharesOptionsMember" xlink:label="loc_krmdPerformanceBasedSharesOptionsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdPerformanceBasedSharesOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions" xlink:label="loc_krmdShareBasedCompensationArrangementByUnvestedAwardOptions" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByUnvestedAwardOptions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions" xlink:label="loc_krmdShareBasedCompensationArrangementByUnvestedAwardOptions_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByUnvestedAwardOptions_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurRestrictedStockAwardsAndPsusForThreeMonthsEndedMarch312024And2023.Details" xlink:title="00000030 - Disclosure - The following table summarizes the activities for our restricted stock awards and PSUs for the three months ended March 31, 2024, and 2023. (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_RestrictedStockAwardsMember" xlink:label="loc_krmdRestrictedStockAwardsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdRestrictedStockAwardsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_StockOptionPlan2021Member" xlink:label="loc_krmdStockOptionPlan2021Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2021Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurCommonStockWarrantsIssuedInConnectionWithOurLoanFinancingAgreementWithHsbcForThreeMonthsEndedMarch312024And2023.Details" xlink:title="00000031 - Disclosure - The following table summarizes the activities for our common stock warrants issued in connection with our loan financing agreement with HSBC for the three months ended March 31, 2024, and 2023. (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_CommonStockWarrantsMember" xlink:label="loc_krmdCommonStockWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdCommonStockWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_StockOptionPlan2021Member" xlink:label="loc_krmdStockOptionPlan2021Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2021Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000032 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_StockOptionPlan2015Member" xlink:label="loc_krmdStockOptionPlan2015Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2015Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_StockOptionPlan2021Member" xlink:label="loc_krmdStockOptionPlan2021Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2021Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_StockOptionPlans2015And2021CombinedMember" xlink:label="loc_krmdStockOptionPlans2015And2021CombinedMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlans2015And2021CombinedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_NonEmployeeDirectorAndBoardAdvisorMember" xlink:label="loc_krmdNonEmployeeDirectorAndBoardAdvisorMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_krmdNonEmployeeDirectorAndBoardAdvisorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="loc_srtBoardOfDirectorsChairmanMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtBoardOfDirectorsChairmanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_TimeBasedSharesOptionsMember" xlink:label="loc_krmdTimeBasedSharesOptionsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdTimeBasedSharesOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaapPerformanceSharesMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapPerformanceSharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_CommonStockWarrantsMember" xlink:label="loc_krmdCommonStockWarrantsMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdCommonStockWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan" xlink:label="loc_krmdSharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdSharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_SharesAvailableForIssuanceShareBasedCompensation" xlink:label="loc_krmdSharesAvailableForIssuanceShareBasedCompensation" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdSharesAvailableForIssuanceShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_NonemployeeServicesTransactionCost" xlink:label="loc_krmdNonemployeeServicesTransactionCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdNonemployeeServicesTransactionCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementsOverallDescription" xlink:label="loc_us-gaapDeferredCompensationArrangementsOverallDescription" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapDeferredCompensationArrangementsOverallDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_StockBasedCompensationStockOptions" xlink:label="loc_krmdStockBasedCompensationStockOptions" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdStockBasedCompensationStockOptions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_UnrecognizedCompensationCost" xlink:label="loc_krmdUnrecognizedCompensationCost" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdUnrecognizedCompensationCost" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/DebtObligationsDetailsNarrative" xlink:title="00000033 - Disclosure - DEBT OBLIGATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_AONPremiumFinanceLLCMember" xlink:label="loc_krmdAONPremiumFinanceLLCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_krmdAONPremiumFinanceLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_HSBCVenturesUSAIncMember" xlink:label="loc_krmdHSBCVenturesUSAIncMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_krmdHSBCVenturesUSAIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_PromissoryNoteMember" xlink:label="loc_krmdPromissoryNoteMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_krmdPromissoryNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaapCreditFacilityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapCreditFacilityAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaapRevolvingCreditFacilityMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_us-gaapRevolvingCreditFacilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_TermLoanFacilityMember" xlink:label="loc_krmdTermLoanFacilityMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_krmdTermLoanFacilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_NotePayableTerms" xlink:label="loc_krmdNotePayableTerms" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_krmdNotePayableTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="loc_us-gaapDebtInstrumentFrequencyOfPeriodicPayment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFrequencyOfPeriodicPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLongTermDebtNoncurrent" xlink:label="loc_us-gaapOtherLongTermDebtNoncurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapOtherLongTermDebtNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="loc_us-gaapLinesOfCreditCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapLinesOfCreditCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_LinesOfCreditCurrent1" xlink:label="loc_krmdLinesOfCreditCurrent1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_krmdLinesOfCreditCurrent1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ComponentsOfLeaseExpenseWereAsFollowsDetails" xlink:title="00000034 - Disclosure - The components of lease expense were as follows: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaapShortTermLeaseCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapShortTermLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_FinanceLeaseCost1Abstract" xlink:label="loc_krmdFinanceLeaseCost1Abstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_krmdFinanceLeaseCost1Abstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdFinanceLeaseCost1Abstract" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="loc_us-gaapFinanceLeaseInterestExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdFinanceLeaseCost1Abstract" xlink:to="loc_us-gaapFinanceLeaseInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_FinanceLeaseCost" xlink:label="loc_krmdFinanceLeaseCost" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdFinanceLeaseCost1Abstract" xlink:to="loc_krmdFinanceLeaseCost" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/SupplementalCashFlowInformationRelatedToLeasesWasAsFollowsDetails" xlink:title="00000035 - Disclosure - Supplemental cash flow information related to leases was as follows: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:label="loc_us-gaapCashFlowOperatingActivitiesLesseeAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapCashFlowOperatingActivitiesLesseeAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowOperatingActivitiesLesseeAbstract" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:label="loc_us-gaapFinanceLeaseInterestPaymentOnLiability" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowOperatingActivitiesLesseeAbstract" xlink:to="loc_us-gaapFinanceLeaseInterestPaymentOnLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails" xlink:title="00000036 - Disclosure - Supplemental balance sheet information related to leases was as follows: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_AssetsAndLiabilitiesOperatingLesseeAbstract" xlink:label="loc_krmdAssetsAndLiabilitiesOperatingLesseeAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_krmdAssetsAndLiabilitiesOperatingLesseeAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdAssetsAndLiabilitiesOperatingLesseeAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdAssetsAndLiabilitiesOperatingLesseeAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdAssetsAndLiabilitiesOperatingLesseeAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdAssetsAndLiabilitiesOperatingLesseeAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_AssetsAndLiabilitiesLesseeFinanceAbstract" xlink:label="loc_krmdAssetsAndLiabilitiesLesseeFinanceAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_krmdAssetsAndLiabilitiesLesseeFinanceAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentOther" xlink:label="loc_us-gaapPropertyPlantAndEquipmentOther" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdAssetsAndLiabilitiesLesseeFinanceAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:label="loc_us-gaapPropertyPlantAndEquipmentOtherAccumulatedDepreciation" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdAssetsAndLiabilitiesLesseeFinanceAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentOtherNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdAssetsAndLiabilitiesLesseeFinanceAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentOtherNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaapFinanceLeaseLiability" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRenewalTerm" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseRenewalTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:label="loc_us-gaapLesseeFinanceLeaseRenewalTerm1" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeFinanceLeaseRenewalTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaapLesseeOperatingLeaseDiscountRate" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseDiscountRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseDiscountRate" xlink:label="loc_us-gaapLesseeFinanceLeaseDiscountRate" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeFinanceLeaseDiscountRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails" xlink:title="00000037 - Disclosure - Maturities of lease liabilities are as follows: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFour" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFive" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal" xlink:label="loc_krmdLesseeOperatingLeaseLiabilityPaymentsDueTotal" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_krmdLesseeOperatingLeaseLiabilityPaymentsDueTotal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal" xlink:label="loc_krmdLesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_krmdLesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_LesseeOperatingLeaseImputedInterest" xlink:label="loc_krmdLesseeOperatingLeaseImputedInterest" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_krmdLesseeOperatingLeaseImputedInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_LesseeFinancingLeaseImputedInterest" xlink:label="loc_krmdLesseeFinancingLeaseImputedInterest" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_krmdLesseeFinancingLeaseImputedInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaapFinanceLeaseLiability" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/LeasesDetailsNarrative" xlink:title="00000038 - Disclosure - LEASES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaapLeaseContractualTermAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapLeaseContractualTermAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaapLeaseContractualTermDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeaseContractualTermAxis" xlink:to="loc_us-gaapLeaseContractualTermDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_LeaseOneMember" xlink:label="loc_krmdLeaseOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeaseContractualTermDomain" xlink:to="loc_krmdLeaseOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_LeaseTwoMember" xlink:label="loc_krmdLeaseTwoMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeaseContractualTermDomain" xlink:to="loc_krmdLeaseTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_LeaseThreeMember" xlink:label="loc_krmdLeaseThreeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeaseContractualTermDomain" xlink:to="loc_krmdLeaseThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_LesseeOperatingLeaseRemainingTerm" xlink:label="loc_krmdLesseeOperatingLeaseRemainingTerm" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_krmdLesseeOperatingLeaseRemainingTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20240331.xsd#krmd_LesseeFinanceLeaseRemainingTerm" xlink:label="loc_krmdLesseeFinanceLeaseRemainingTerm" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_krmdLesseeFinanceLeaseRemainingTerm" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000039 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140173429210768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>May 01, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-12305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">KORU MEDICAL SYSTEMS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000704440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-3044880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 Corporate Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Mahwah<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">469-2042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.01 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">KRMD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,764,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingParValuePerShare', window );">Entity Listing, Par Value Per Share</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury Stock, Common, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,420,502<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The par value per share of security quoted in same currency as Trading currency. Example: '0.01'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140173429821584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 10,820,317<span></span>
</td>
<td class="nump">$ 11,482,240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable less allowance for doubtful accounts of $24,777 as of March 31, 2024 and $24,777 as of December 31, 2023</a></td>
<td class="nump">4,392,511<span></span>
</td>
<td class="nump">4,045,211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">3,147,312<span></span>
</td>
<td class="nump">3,481,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Other receivables</a></td>
<td class="nump">288,714<span></span>
</td>
<td class="nump">28,889<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">830,408<span></span>
</td>
<td class="nump">1,218,288<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">TOTAL CURRENT ASSETS</a></td>
<td class="nump">19,479,262<span></span>
</td>
<td class="nump">20,255,929<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,755,530<span></span>
</td>
<td class="nump">3,837,657<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net of accumulated amortization of $406,801 and $390,341 as of March 31, 2024 and December 31, 2023, respectively</a></td>
<td class="nump">737,901<span></span>
</td>
<td class="nump">754,361<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">3,428,885<span></span>
</td>
<td class="nump">3,514,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income tax assets, net of allowance for non-realization of deferred tax assets of $6,391,452 and $6,002,777 for March 31, 2024 and December 31, 2023, respectively</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">98,970<span></span>
</td>
<td class="nump">98,970<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">27,500,548<span></span>
</td>
<td class="nump">28,460,972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,774,185<span></span>
</td>
<td class="nump">975,193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">1,459,405<span></span>
</td>
<td class="nump">1,711,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Note payable</a></td>
<td class="nump">159,031<span></span>
</td>
<td class="nump">314,344<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other liabilities</a></td>
<td class="nump">457,653<span></span>
</td>
<td class="nump">512,520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll and related taxes</a></td>
<td class="nump">519,441<span></span>
</td>
<td class="nump">462,941<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Financing lease liability &#8211; current</a></td>
<td class="nump">111,103<span></span>
</td>
<td class="nump">109,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability &#8211; current</a></td>
<td class="nump">372,109<span></span>
</td>
<td class="nump">368,313<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">TOTAL CURRENT LIABILITIES</a></td>
<td class="nump">4,852,927<span></span>
</td>
<td class="nump">4,454,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Financing lease liability, net of current portion</a></td>
<td class="nump">288,253<span></span>
</td>
<td class="nump">316,623<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">3,241,837<span></span>
</td>
<td class="nump">3,336,300<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">8,383,017<span></span>
</td>
<td class="nump">8,107,201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value, 75,000,000 shares authorized, 49,143,589 and 49,089,864 shares issued 45,723,087 and 45,669,362 shares outstanding as of March 31, 2024, and December 31, 2023, respectively</a></td>
<td class="nump">491,436<span></span>
</td>
<td class="nump">490,899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">47,717,888<span></span>
</td>
<td class="nump">47,018,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, 3,420,502 shares as of March 31, 2024 and December 31, 2023, at cost</a></td>
<td class="num">(3,843,562)<span></span>
</td>
<td class="num">(3,843,562)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(25,248,231)<span></span>
</td>
<td class="num">(23,312,273)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">19,117,531<span></span>
</td>
<td class="nump">20,353,771<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">$ 27,500,548<span></span>
</td>
<td class="nump">$ 28,460,972<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140173517051184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS (UNAUDITED) (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Accounts receivable, allowance for credit loss, current</a></td>
<td class="nump">$ 24,777<span></span>
</td>
<td class="nump">$ 24,777<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="nump">406,801<span></span>
</td>
<td class="nump">390,341<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRentReceivablesNetNoncurrent', window );">Deferred Rent Receivables, Net, Noncurrent</a></td>
<td class="nump">$ 6,391,452<span></span>
</td>
<td class="nump">$ 6,002,777<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="nump">49,143,589<span></span>
</td>
<td class="nump">49,089,864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="nump">45,723,087<span></span>
</td>
<td class="nump">45,669,362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockPreferredShares', window );">Treasury stock, shares</a></td>
<td class="nump">3,420,502<span></span>
</td>
<td class="nump">3,420,502<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentReceivablesNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of rental income recognized over rental payment required by lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479341/842-30-25-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481178/840-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentReceivablesNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockPreferredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued preferred shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockPreferredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140173429633056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">NET REVENUES</a></td>
<td class="nump">$ 8,197,798<span></span>
</td>
<td class="nump">$ 7,392,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">3,094,500<span></span>
</td>
<td class="nump">3,245,570<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross Profit</a></td>
<td class="nump">5,103,298<span></span>
</td>
<td class="nump">4,147,035<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">5,357,620<span></span>
</td>
<td class="nump">5,425,877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,475,674<span></span>
</td>
<td class="nump">1,564,869<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">231,370<span></span>
</td>
<td class="nump">213,117<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total Operating Expenses</a></td>
<td class="nump">7,064,664<span></span>
</td>
<td class="nump">7,203,863<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Net Operating Loss</a></td>
<td class="num">(1,961,366)<span></span>
</td>
<td class="num">(3,056,828)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Non-Operating Income/(Expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Loss on currency exchange</a></td>
<td class="num">(11,479)<span></span>
</td>
<td class="num">(680)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of fixed assets, net</a></td>
<td class="num">(300)<span></span>
</td>
<td class="num">(56,279)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest income, net</a></td>
<td class="nump">37,187<span></span>
</td>
<td class="nump">125,502<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">TOTAL OTHER INCOME</a></td>
<td class="nump">25,408<span></span>
</td>
<td class="nump">68,543<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">LOSS BEFORE INCOME TAXES</a></td>
<td class="num">(1,935,958)<span></span>
</td>
<td class="num">(2,988,285)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Benefit</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">577,400<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">$ (1,935,958)<span></span>
</td>
<td class="num">$ (2,410,885)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET LOSS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic</a></td>
<td class="nump">45,712,224<span></span>
</td>
<td class="nump">45,487,593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted</a></td>
<td class="nump">45,712,224<span></span>
</td>
<td class="nump">45,487,593<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140173429848288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (1,935,958)<span></span>
</td>
<td class="num">$ (2,410,885)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense and warrant expense</a></td>
<td class="nump">699,718<span></span>
</td>
<td class="nump">881,222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">231,370<span></span>
</td>
<td class="nump">213,117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(577,400)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherAssets', window );">Loss on disposal of fixed assets</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">56,279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_RouLandlordCredit', window );">ROU landlord credit</a></td>
<td class="num">(5,497)<span></span>
</td>
<td class="num">(5,497)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Increase in Accounts receivable</a></td>
<td class="num">(607,125)<span></span>
</td>
<td class="num">(647,994)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Decrease / (Increase) in Inventory</a></td>
<td class="nump">333,989<span></span>
</td>
<td class="num">(233,551)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Decrease in Prepaid expenses and other assets</a></td>
<td class="nump">387,880<span></span>
</td>
<td class="nump">288,786<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">(Decrease) / Increase in Other liabilities</a></td>
<td class="num">(54,867)<span></span>
</td>
<td class="nump">4,207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Increase / (Decrease) in Accounts payable</a></td>
<td class="nump">798,992<span></span>
</td>
<td class="num">(888,679)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Increase / (Decrease) in Accrued payroll and related taxes</a></td>
<td class="nump">56,500<span></span>
</td>
<td class="num">(41,984)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Decrease in Accrued expenses</a></td>
<td class="num">(252,022)<span></span>
</td>
<td class="num">(1,298,204)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">NET CASH USED IN OPERATING ACTIVITIES</a></td>
<td class="num">(346,720)<span></span>
</td>
<td class="num">(4,660,583)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Purchases of property and equipment</a></td>
<td class="num">(133,083)<span></span>
</td>
<td class="num">(272,605)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchases of intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(11,232)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">NET CASH USED IN INVESTING ACTIVITIES</a></td>
<td class="num">(133,083)<span></span>
</td>
<td class="num">(283,837)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_PaymentsOnIndebtedness', window );">Payments on indebtedness</a></td>
<td class="num">(155,313)<span></span>
</td>
<td class="num">(214,892)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments on finance lease liability</a></td>
<td class="num">(26,807)<span></span>
</td>
<td class="num">(24,080)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">NET CASH USED IN FINANCING ACTIVITIES</a></td>
<td class="num">(182,120)<span></span>
</td>
<td class="num">(238,972)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET DECREASE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(661,923)<span></span>
</td>
<td class="num">(5,183,392)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD</a></td>
<td class="nump">11,482,240<span></span>
</td>
<td class="nump">17,408,257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">CASH AND CASH EQUIVALENTS, END OF PERIOD</a></td>
<td class="nump">10,820,317<span></span>
</td>
<td class="nump">12,224,865<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_CashPaidDuringPeriodsForAbstract', window );"><strong>Cash paid during the periods for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">12,296<span></span>
</td>
<td class="nump">12,326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Schedule of Non-Cash Operating, Investing and Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_IssuanceOfCommonStockCompensation', window );">Issuance of common stock as compensation</a></td>
<td class="nump">$ 123,804<span></span>
</td>
<td class="nump">$ 175,776<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_CashPaidDuringPeriodsForAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents cash paid during periods for abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_CashPaidDuringPeriodsForAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_IssuanceOfCommonStockCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents issuance of common stock compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_IssuanceOfCommonStockCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_PaymentsOnIndebtedness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents payments on indebtedness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_PaymentsOnIndebtedness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_RouLandlordCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents rou landlord credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_RouLandlordCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140173429692080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Treasury Stock, Common [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2022</a></td>
<td class="nump">$ 488,619<span></span>
</td>
<td class="nump">$ 44,252,117<span></span>
</td>
<td class="num">$ (9,571,211)<span></span>
</td>
<td class="num">$ (3,843,562)<span></span>
</td>
<td class="nump">$ 31,325,963<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">48,861,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of stock-based compensation</a></td>
<td class="nump">$ 489<span></span>
</td>
<td class="nump">175,287<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">175,776<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of stock-based compensation (in shares)</a></td>
<td class="nump">48,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Compensation expense related to stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">535,059<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">535,059<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Compensation related to Restricted Stock</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">169,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_CompensationeExpenseRelatedToRestrictedStockAwards', window );">Compensation expense related to restricted stock (in shares)</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,410,885)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,410,885)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2023</a></td>
<td class="nump">$ 489,608<span></span>
</td>
<td class="nump">45,132,350<span></span>
</td>
<td class="num">(11,982,096)<span></span>
</td>
<td class="num">(3,843,562)<span></span>
</td>
<td class="nump">29,796,300<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="nump">48,960,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2023</a></td>
<td class="nump">$ 490,899<span></span>
</td>
<td class="nump">47,018,707<span></span>
</td>
<td class="num">(23,312,273)<span></span>
</td>
<td class="num">(3,843,562)<span></span>
</td>
<td class="nump">20,353,771<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">49,089,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of stock-based compensation</a></td>
<td class="nump">$ 537<span></span>
</td>
<td class="nump">123,267<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">123,804<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of stock-based compensation (in shares)</a></td>
<td class="nump">53,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Compensation expense related to stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">393,113<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">393,113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Compensation related to Restricted Stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">130,676<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">130,676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Issuance of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">52,125<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">52,125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,935,958)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,935,958)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2024</a></td>
<td class="nump">$ 491,436<span></span>
</td>
<td class="nump">$ 47,717,888<span></span>
</td>
<td class="num">$ (25,248,231)<span></span>
</td>
<td class="num">$ (3,843,562)<span></span>
</td>
<td class="nump">$ 19,117,531<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2024</a></td>
<td class="nump">49,143,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_CompensationeExpenseRelatedToRestrictedStockAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents compensatione expense related to restricted stock awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_CompensationeExpenseRelatedToRestrictedStockAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140173428391024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_808_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zHbZTY15EU52" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 1 &#8212; <span id="xdx_825_zps1R66qG5Q4">NATURE OF OPERATIONS AND SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_84C_eus-gaap--NatureOfOperations_zuNRR9X8WuT5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_860_zL58AmV7DqSg">NATURE OF OPERATIONS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">KORU MEDICAL SYSTEMS, INC. (the &#8220;Company,&#8221;
&#8220;KORU Medical,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;) designs, manufactures and markets proprietary portable
and innovative medical devices primarily for the subcutaneous drug delivery market as governed by the United States Food and Drug Administration
(the &#8220;FDA&#8221;) quality and regulatory system and international regulations and standards for quality system management. The Company
operates as <span id="xdx_903_eus-gaap--NumberOfReportableSegments_dxH_uN_c20240101__20240331_zHYjAdyxPnMa" title="Number of segment::XDX::1">one</span> segment.</p>

<p id="xdx_85A_zlKzyNhotq45" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zxTa5f2NTFU5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_863_z3u1ztSDWWPc">BASIS OF PRESENTATION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying financial statements should be read
in conjunction with the Company&#8217;s annual report on Form 10-K for the year ended December 31, 2023 (&#8220;Annual Report&#8221;).
&#160;In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;), the Company has
omitted footnote disclosures that would substantially duplicate the disclosures contained in the audited financial statements of the Company.
The accompanying interim financial statements are unaudited and reflect all adjustments which are in the opinion of management necessary
for a fair statement of the Company&#8217;s financial position, results of operations, and cash flows for the periods presented. &#160;All
such adjustments are of a normal, recurring nature. &#160;The Company&#8217;s results of operations and cash flows for the interim periods
are not necessarily indicative of the results of operations and cash flows that it may achieve in future periods.</p>

<p id="xdx_858_zjxYcOOJfiPk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zZ86aZl4CBLi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_86B_zxJfOor2QNue">CASH AND CASH EQUIVALENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For purposes of the statements of cash flows, the
Company considers all short-term investments with an original maturity of three months or less to be cash equivalents. &#160;The Company
has historically held cash balances in excess of $<span id="xdx_90E_eus-gaap--CashUninsuredAmount_iI_c20240331_znGjeFWwJNr7" title="FDIC cash uninsured amount">250,000</span> at its primary commercial bank, which exceeds FDIC insurance limits. To reduce
the risk of uninsured deposits, the Company entered an insured cash sweep program with KeyBank during the second quarter of 2023 to automatically
invest its uninsured bank cash balances over $250,000 into FDIC insured banks so there is no more than $250,000 maintained at any one
bank. As of March 31, 2024 the Company has an investment balance of $<span id="xdx_907_eus-gaap--InterestIncomeSecuritiesUSTreasury_dm_c20240101__20240331_zAroHWx5QOCk" title="Investment securities treasury bill">10.2 million</span> in a US Treasury bill that matures every 90 days.</p>

<p id="xdx_853_zwcCH9ltGUkf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_842_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zpHXUHJP89Z8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_868_zfJNXKfqZn1b">PATENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Costs incurred in obtaining patents have been capitalized
and are being amortized over the legal life of the patents.</p>

<p id="xdx_852_zT8HRlDMNaOc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_84B_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zqiFo0vrTd6d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_864_zLIdpY0GWn3i">STOCK-BASED COMPENSATION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company maintains a stock option plan and an omnibus
equity incentive plan under which it grants stock options to certain executives, key employees and consultants. The fair value of each
option grant is estimated on the date of the grant using the Black-Scholes option-pricing model. &#160;All options are charged against
income at their fair value. &#160;The entire compensation expense of the award is recognized over the vesting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company also maintains a non-employee director
compensation plan. Shares of stock granted for director fees are recorded at the fair value of the shares at the grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company issues restricted stock awards. Restricted
stock awards are equity classified and measured at the fair market value of the underlying stock at the grant date. The fair value of
restricted stock awards vesting at certain market capitalization thresholds were estimated on the date of grant using the Brownian Motion
Monte Carlo lattice model. The fair value of restricted stock awards with time-based vesting were estimated on the date of grant at the
current stock price. The fair value of restricted stock awards vesting at certain annual sales growth thresholds were estimated as of
the date of Board acknowledgement of the achievement, at the current stock price. We recognize restricted stock expense using the straight-line
attribution method over the requisite service period and account for forfeitures as they occur.</p>

<p id="xdx_858_zPuK4iHPQXOj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zEjvUKTCnSuj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_86B_zzX85zWjkZU3">NET LOSS PER COMMON SHARE</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic net loss per common share is calculated by dividing
net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed
by dividing net loss by the weighted average number of common and common equivalent shares outstanding during the period. The Company&#8217;s
potentially dilutive common shares are those that result from diluted common stock options and unvested restricted stock awards. The calculation
of diluted net loss per share excluded stock options of <span id="xdx_90A_ecustom--AntiDilutiveStockOptions_pid_dxL_uShares_c20240101__20240331_zAyKVLY6I0Kb" title="Anti-dilutive stock options::XDX::0"><span style="-sec-ix-hidden: xdx2ixbrl0452">zero</span></span> and <span id="xdx_906_ecustom--AntiDilutiveStockOptions_pid_uShares_c20230101__20230331_z2JVos5KlZMg" title="Anti-dilutive stock options">14,626</span>, respectively, in weighted-average shares for each of the three
months ended March 31, 2024 and 2023, as their effect was anti-dilutive as a result of the net loss incurred for those periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The calculation of diluted net loss per share excluded
stock options, performance-based restricted stock and performance-based restricted stock units (PSUs) of <span id="xdx_90C_ecustom--AntiDilutiveSecurities_pid_uShares_c20240101__20240331_zLD40VIT7Xpi" title="Anti-dilutive securities">904,496</span> and <span id="xdx_904_ecustom--AntiDilutiveSecurities_pid_uShares_c20230101__20230331_zYK7EYycKdx4" title="Anti-dilutive Securities">914,626</span> respectively,
in weighted-average shares for each of the three months ended March 31, 2024 and 2023, as their effect was anti-dilutive as a result of
the net loss incurred for those periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_89F_ecustom--ScheduleOfSecuritiesTextBlock_zzpQsQwqywxl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B1_zFRbRMeqbCI6">The following securities were not included in the
computation of diluted shares outstanding for the three months ended March 31, 2024, and 2023 because the effect would be anti-dilutive:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.25in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 64%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_491_20240101__20240331_z5gHa56Js7j9" style="width: 15%; text-align: right">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_495_20230101__20230331_znrL5Y2snEGd" style="width: 15%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Three Months Ended</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>March 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_ecustom--CommonStockOptions_pid_uShares_zXCYQ9M0n2Ak" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Common stock options</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0462">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">14,626</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_ecustom--PerformanceStockUnits_pid_uShares_zTxSUpVHYgl1" style="vertical-align: bottom">
    <td>PSUs</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">54,496</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0466">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_ecustom--RestrictedStockUnits_pid_zd0Ut9uoSEBj" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Restricted stock </td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">850,000</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">900,000</td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_ecustom--AntiDilutedSecurities_pid_zwi8ws9Cj7l8" style="vertical-align: bottom">
    <td><b>Total</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">904,496</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">914,626</td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8A9_znhncoWTWmPj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_897_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zBaLzXTzUa93" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B6_z7l4QIjCFLal">Therefore, diluted weighted average number of shares
outstanding and diluted net loss per share were the same as basic weighted average number of shares outstanding and net loss per share
for the three months ended March 31, 2024 and 2023.</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.25in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_49E_20240101__20240331_zKWPQDLuseWi" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49C_20230101__20230331_zwiXwTi9WQqb" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Three Months Ended</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>March 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 64%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: right">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_zRGQTXHoMhT9" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Net loss</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">$</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(1,935,958</td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">$</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(2,410,885</td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasicAbstract_iB_zgy58JSQ1or" style="vertical-align: bottom">
    <td>Weighted Average Outstanding Shares:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_uShares_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJkv6CGHEuqk" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.2in">Basic weighted average shares outstanding</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">45,712,224</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">45,487,593</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock_pid_uShares_zU067aM1fsOl" style="vertical-align: bottom">
    <td style="padding-left: 0.2in">Dilutive effect of outstanding stock options and unvested restricted stock</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0485">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0486">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_uShares_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zd27J1f9JnPk" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.2in">Diluted weighted average shares outstanding</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">45,712,224</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">45,487,593</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--EarningsPerShareAbstract_iB_zOB9mDzjNIdh" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Net loss per share</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--EarningsPerShareBasic_pid_uUSDPShares_zcSlm2QFwCO3" style="vertical-align: bottom">
    <td style="padding-left: 0.2in">Basic</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(0.04</td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(0.05</td>
    <td style="border-bottom: white 2.25pt double">)</td></tr>
  <tr id="xdx_404_eus-gaap--EarningsPerShareDiluted_pid_uUSDPShares_zpl67c48EQjj" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.2in">Diluted</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(0.04</td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(0.05</td>
    <td style="border-bottom: white 2.25pt double">)</td></tr>
  </table>

<p id="xdx_8A2_zOZuMH9KPgh" style="margin-top: 0; margin-bottom: 0">&#160;</p>
<p id="xdx_850_zWUC8JD5Vj4h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_848_eus-gaap--UseOfEstimates_zwBJwuyIaRwk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_867_zXdhu3aGikK9">USE OF ESTIMATES IN THE FINANCIAL STATEMENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity
with United States generally accepted accounting principles (&#8220;GAAP&#8221;) requires management to make estimates and assumptions
that affect the amounts reported in the financial statements and accompanying notes. &#160;Actual results could differ from those estimates.
Important estimates include but are not limited to asset lives, deferred tax valuation allowances, inventory valuation, and customer rebate
and incentive accruals. The results of operations for the three months ended March 31, 2024 are not necessarily indicative of the results
that may be expected for the entire 2024 fiscal year.</p>

<p id="xdx_853_zDMfURqrRNTe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p id="xdx_848_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zBnku6HMugG2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_861_zAVc8rBfNITh">REVENUE RECOGNITION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our revenues are derived from three business sources:
(i) domestic core (which consists of US and Canada), (ii) international core, and (iii) novel therapies. &#160;Our core domestic and international
revenues consist of sales of our syringe drivers, tubing and needles (&#8220;Product Revenue&#8221;) for the delivery of subcutaneous
drugs that are FDA cleared for use with the KORU Medical infusion system, with the primary delivery for immunoglobulin to treat Primary
Immunodeficiency Diseases (&#8220;PIDD&#8221;) and Chronic Inflammatory Demyelinating Polyneuropathy (&#8220;CIDP&#8221;). Novel therapies
consist of Product Revenue for feasibility/clinical trials (pre-clinical studies, Phase I, Phase II, Phase III) of biopharmaceutical companies
in the drug development process as well as non-recurring engineering services (&#8220;NRE&#8221;) revenues (including testing and registration
services) received from biopharmaceutical companies to ready or customize the FREEDOM System for clinical and commercial use across multiple
drug categories.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For Product Revenue, we recognize revenues when shipment
occurs, and at which point the customer obtains control and ownership of the goods. &#160;Shipping costs generally are billed to customers
and are included in Product Revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company generally does not accept return of goods
shipped unless it is a Company error. &#160;The only credits provided to customers are for defective merchandise. &#160;The Company warrants
the syringe driver from defects in materials and workmanship under normal use and the warranty does not include a performance obligation.
&#160;The costs under the warranty are expensed as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Rebates are provided to distributors for the difference
in selling price to distributor and pricing specified to select customers. &#160;In addition, rebates are provided to customers for meeting
growth targets. &#160;Provisions for both distributor pricing and customer growth rebates are variable consideration and are recorded
as a reduction of revenue in the same period the related sales are recorded or when it is probable the growth target will be achieved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We recognize NRE revenue under an input method, which
recognizes revenue on the basis of our efforts or inputs (for example, resources consumed, labor hours expended, costs incurred, or time
elapsed) to the satisfaction of a performance obligation relative to the total expected inputs to the satisfaction of that performance
obligation (i.e. completion milestone). The input method that we use is based on costs incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Contracts are often modified to account for changes
in contract specifications and requirements. Contract modifications exist when the modification either creates new, or changes existing,
enforceable rights and obligations. Generally, when contract modifications create new performance obligations, the modification is considered
to be a separate contract and revenue is recognized prospectively. When contract modifications change existing performance obligations,
the impact on the existing transaction price and measure of progress for the performance obligation to which it relates is generally recognized
as an adjustment to revenue (either as an increase in or a reduction of revenue) on a cumulative catch-up basis. Contract assets primarily
represent revenue earnings over time that are not yet billable based on the terms of the contracts. Contract liabilities (i.e., deferred
revenue) consist of fees invoiced or paid by the Company&#8217;s customers for which the associated performance obligations have not been
satisfied and revenue has not been recognized based on the Company&#8217;s revenue recognition criteria described above. As of March 31,
2024, the Company has recognized a contract asset of zero.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_89B_ecustom--ScheduleOfNetSalesByGeography_zDNyTfMVxHZc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8BB_zofRxwMyRalc">The following table summarizes net revenues by geography
for the three months ended March 31, 2024, and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>Three Months Ended March 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 46%"><b>Revenues</b></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 22%; text-align: right">&#160;</td>
    <td style="width: 6%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 22%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.2in">Domestic</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_984_eus-gaap--Revenues_c20240101__20240331__srt--StatementGeographicalAxis__country--US_zfekj6YiphU1" style="text-align: right" title="Net Revenue">6,384,083</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_989_eus-gaap--Revenues_c20230101__20230331__srt--StatementGeographicalAxis__country--US_zU239wHzX3td" style="text-align: right" title="Net Revenue">6,283,965</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.2in">International</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_989_eus-gaap--Revenues_c20240101__20240331__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zszLQcyBXTo6" style="border-bottom: black 1pt solid; text-align: right" title="Net Revenues">1,813,715</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_989_eus-gaap--Revenues_c20230101__20230331__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zligqYQgmNRk" style="border-bottom: black 1pt solid; text-align: right" title="Net Revenues">1,108,640</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td><b>Total</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_98C_eus-gaap--Revenues_c20240101__20240331_zBlWjzy5lZTl" style="border-bottom: black 2.25pt double; text-align: right" title="Revenues">8,197,798</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_98F_eus-gaap--Revenues_c20230101__20230331_zgjEkojcqhJ3" style="border-bottom: black 2.25pt double; text-align: right" title="Revenues">7,392,605</td>
    <td>&#160;</td></tr>
  </table>

<p id="xdx_8A2_z4HPq9rP1jhi" style="margin-top: 0; margin-bottom: 0">&#160;</p>
<p id="xdx_857_z8UF6jlgSFE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zJbmPfiRquv2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_86F_zQB5mnbGtWH1">ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers the applicability and
impact of all recently issued accounting pronouncements. &#160;Recent accounting pronouncements not specifically identified in our disclosures
are either not applicable to the Company or are not expected to have a material effect on our financial condition or results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2016, the FASB issued ASU No. 2016-13, <i>Financial
Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i>, which amends guidance on reporting
credit losses for assets held at amortized cost basis and available for sale debt securities. &#160;For assets held at amortized cost
basis, Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its
current estimate of all expected credit losses. &#160;The allowance for credit losses is a valuation account that is deducted from the
amortized cost basis of the financial assets to present the net amount expected to be collected. &#160;For available for sale debt securities,
credit losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as
an allowance rather than as a write-down. &#160;This ASU affects entities holding financial assets and net investment in leases that are
not accounted for at fair value through net income. &#160;The amendments affect loans, debt securities, trade receivables, net investments
in leases, off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that
have the contractual right to receive cash. &#160;The Company adopted the pronouncement on January 1, 2023, and there was no impact on
its financial statements.</p>

<p id="xdx_853_zVK9dDlVTpoc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_848_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zjylkD9Qp3Wb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_864_zsUqUv4pUBy">FAIR VALUE MEASUREMENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fair value is the exit price that would be received
to sell an asset or paid to transfer a liability. &#160;Fair value is a market-based measurement that should be determined using assumptions
that market participants would use in pricing an asset or liability. Valuation techniques used to measure fair value should maximize the
use of observable inputs and minimize the use of unobservable inputs. &#160;To measure fair value, the Company uses the following fair
value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: center">&#8226;</td>
    <td style="width: 7in; text-align: justify">Level 1 &#8211; Quoted prices in active markets for identical assets or liabilities.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td style="text-align: justify">Level 2 &#8211; Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data by correlation or other means.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td style="text-align: justify">Level 3 &#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. &#160;Value is determined using pricing models, discounted cash flow methodologies, or similar techniques and includes instruments for which the determination of fair value requires significant judgment or estimation.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The carrying amounts of cash and cash equivalents,
including investments in short-term U.S. Treasury bills, accounts receivable, prepaid expenses, accounts payable and accrued expenses
are considered to be representative of their fair values because of the short-term nature of those instruments. &#160;There were no transfers
between levels in the fair value hierarchy during the three months ended March 31, 2024 and 2023.</p>

<p id="xdx_85A_z4NSgm49D4Wd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_84B_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z50C5i0C6KEg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_86B_zEgjNVcrMTh8">IMPAIRMENT OF LONG-LIVED ASSETS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company reviews long-lived assets for impairment
whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. &#160;An impairment
loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition
are less than the carrying amount. &#160;The impairment loss, if recognized, would be based on the excess of the carrying value of the
impaired asset over its respective fair value. &#160;The Company did not record any impairment losses through March 31, 2024.</p>

<p id="xdx_85F_z5G37SYemi95" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 250<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/250/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140173426586080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zJchNRUsOyHk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 2 &#8212; <span id="xdx_82F_zmPySt8BEpfh">PROPERTY AND EQUIPMENT</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_891_eus-gaap--PropertyPlantAndEquipmentTextBlock_zYohctDB84N3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8BC_zZFzrzgyaOqi">Property and equipment consists of the following at:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 6in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>March 31, 2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 55%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 19%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 19%">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Furniture and office equipment</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20240331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zxn6LKV20sN3" style="text-align: right">1,423,093</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zWUXpZxHSpy7" style="text-align: right">1,412,164</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Leasehold improvements</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20240331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z6zGUIqg1786" style="text-align: right">1,953,653</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zO7mQR53vrZ" style="text-align: right">1,953,653</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Manufacturing equipment and tooling</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20240331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentAndToolingMember_zqNOXgZ6cnze" style="border-bottom: black 1pt solid; text-align: right">3,311,833</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentAndToolingMember_zUgaSnHXixM9" style="border-bottom: black 1pt solid; text-align: right">3,193,113</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 0.2in">Total property and equipment</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20240331_zSlcSOC85Vi9" style="text-align: right" title="Total property and equipment">6,688,579</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231_zsEKGEvpY8Zi" style="text-align: right" title="Total property and equipment">6,558,930</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Less: accumulated depreciation and amortization</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_984_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20240331_zOTht4UYY9Ec" style="border-bottom: black 1pt solid; text-align: right" title="Less: accumulated depreciation and amortization">(2,933,049</td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_988_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20231231_zJITZYSBPNy5" style="border-bottom: black 1pt solid; text-align: right" title="Less: accumulated depreciation and amortization">(2,721,273</td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Property and equipment, net</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20240331_z4cl2qc71P59" style="border-bottom: black 2.25pt double; text-align: right" title="Property and equipment, net">3,755,530</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20231231_zlbjEsW8Rbb3" style="border-bottom: black 2.25pt double; text-align: right" title="Property and equipment, net">3,837,657</td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8AB_zo8Dra3pFcp1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Depreciation and amortization expense was $<span id="xdx_904_eus-gaap--Depreciation_c20240101__20240331_zIsc01H3fYM2" title="Depreciation and amortization expense">214,910</span>
and $<span id="xdx_900_eus-gaap--Depreciation_c20230101__20230331_zq4sM5F5JsF8" title="Depreciation and amortization expense">197,233</span> for the three months ended March 31, 2024 and 2023, respectively.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140173428357248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text"><p id="xdx_805_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zo3NqYgGZ74e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 3 &#8212; <span id="xdx_82F_z2ZimLmWL1qg">STOCK-BASED COMPENSATION</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company maintains a stock option plan and omnibus
equity incentive plan under which it grants stock options to certain executives, key employees and consultants. It also has granted stock
options outside of the plans as inducement awards. The fair value of each option grant is estimated on the date of the grant using the
Black-Scholes option-pricing model. &#160;All options are charged against income at their fair value. &#160;The entire compensation expense
of the award is recognized over the vesting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company issues performance share units (PSUs) under its omnibus equity
incentive plan. Performance share units are equity classified and measured at the fair market value of the underlying stock at the grant
date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Shares of stock granted for director fees under the
non-employee director compensation plan and under its omnibus equity incentive plan are recorded at the fair value of the shares at the
grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company issues restricted stock awards under its
omnibus equity incentive plan and outside the plan as incentive awards. Restricted stock awards are equity classified and measured at
the fair market value of the underlying stock at the grant date. The fair value of restricted stock awards vesting at certain market capitalization
thresholds were estimated on the date of grant using the Brownian Motion Monte Carlo lattice model. The fair value of other restricted
stock awards were estimated on the date of grant at the current stock price. We recognize restricted stock expense using the straight-line
attribution method over the requisite service period and account for forfeitures as they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has three equity incentive plans: the
2015 Stock Option Plan, as amended (the &#8220;2015 Plan&#8221;), the 2021 Omnibus Equity Incentive Plan (the &#8220;2021 Plan&#8221;),
and the Non-Employee Director Compensation Plan. The Company has also issued restricted stock and stock options as employment inducement
awards to its Chief Executive Officer and Chief Commercial Officer, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2015 plan provides for the grant of incentive
stock options and nonqualified stock options. As of March 31, 2024, there were <span id="xdx_90D_ecustom--SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan_pid_uShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z8JkAgpVAmZh" title="Shares issued under plan">2,120,000</span> shares reserved for outstanding awards and <span id="xdx_90F_ecustom--SharesAvailableForIssuanceShareBasedCompensation_iI_pid_uShares_c20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zCq5W8k1PF11" title="Shares available for issuance">604,250</span>
shares available for issuance under the 2015 Plan. Additional options may be issued under the 2015 Plan as outstanding options are forfeited.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2021 Plan provides for the grant of incentive
stock options, nonqualified stock options, stock awards, restricted stock awards, restricted stock units and/or stock appreciation rights
to employees, consultants and directors. As of March 31, 2024, there were <span id="xdx_90D_ecustom--SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan_pid_uShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zAaNyZXEewM" title="Shares issued under plan">656,744</span> shares reserved for outstanding awards and <span id="xdx_909_ecustom--SharesAvailableForIssuanceShareBasedCompensation_iI_pid_uShares_c20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zibuOTaz1fv2" title="Shares available for issuance">152,811</span> shares
available for issuance under the 2021 Plan. Additional awards may be issued under the 2021 Plan as outstanding awards are forfeited.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each non-employee director of the Company (other than
the Chairman of the Board) is eligible to receive $<span id="xdx_909_ecustom--NonemployeeServicesTransactionCost_pid_uShares_c20240101__20240331__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorAndBoardAdvisorMember_zc2412wPPQ9" title="Nonemployee services transaction cost">110,000</span> annually, <span id="xdx_900_eus-gaap--DeferredCompensationArrangementsOverallDescription_c20240101__20240331__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorAndBoardAdvisorMember_zPH2ZzmWWyi3" title="Share-based goods and non-employee services transaction">to be paid quarterly $12,500 in cash and $15,000 in common stock.</span>
&#160;The Chairman of the Board is eligible to receive $<span id="xdx_902_ecustom--NonemployeeServicesTransactionCost_pid_uShares_c20240101__20240331__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zd3co86c6aQc" title="Nonemployee services transaction cost">140,000</span> annually, <span id="xdx_90E_eus-gaap--DeferredCompensationArrangementsOverallDescription_c20240101__20240331__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zGmDiHNjbIV" title="Share-based goods and non-employee services transaction">to be paid quarterly $12,500 in cash and $22,500 in common stock.
</span>Non-employee director compensation is paid pursuant to the Non-Employee Director Compensation Plan. All payments were and are pro-rated
for partial service.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Time Based Stock Options</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_898_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zlWrq3Mfyb6b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8BD_zvPKrWKfE2Hk">The following table summarizes the activities for
our stock options with time based vesting for the three months ended March 31, 2024, and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 4.5in; border-collapse: collapse">
  <tr style="background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>March 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 44%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 22%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 22%">&#160;</td>
    <td style="width: 2%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Dividend yield</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zZSuCsvVBIS8" title="Dividend yield">0.00</span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zfjBMFk5KbQ" title="Dividend yield">0.00</span>%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Expected Volatility</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zDaUabp6Fyul" title="Expected volatility">46.18</span> - <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zg0C9AWaVRP4" title="Expected volatility">46.21</span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zuoZ3Pq4ySTa" title="Expected volatility">61.3</span>%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Weighted-average volatility</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp0_uPure_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zV5OjUQjvGC6" title="Weighted-average volatility">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp0_uPure_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zVyys5zzYZ89" title="Weighted-average volatility">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Expected dividends</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_d0_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zB6E6iySGl1c" title="Expected dividends">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_d0_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z4DBuV6Vbh0e" title="Expected dividends">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Expected term (in years)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zZeIzhdCHAfb" title="Expected term (in years)::XDX::P10Y"><span style="-sec-ix-hidden: xdx2ixbrl0591">10</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z1byDkyDfC2i" title="Expected term (in years)::XDX::P10Y"><span style="-sec-ix-hidden: xdx2ixbrl0593">10</span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Risk-free rate</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zcSsb2JN5pRg" title="Risk-free rate">4.2</span>% - <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zPRdMSdg4Jm6" title="Risk-free rate">4.3</span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zMcAlCg3jvX7" title="Risk-free rate">3.53</span>%</td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8A0_z2l7PKyaBFtk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z9u1GmXy9bRd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B2_zJ8DmKTKjUPd">The following table summarizes the status of the stock
options:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="9" style="border-bottom: black 1pt solid; text-align: center"><b>Three Months Ended March 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 54%">Outstanding at January 1</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zYoiTVrmYcPf" style="width: 9%; text-align: right" title="Outstanding at beginning">3,256,250</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zxKkDVi3IAXf" style="width: 9%; text-align: right" title="Outstanding at beginning">3.66</td>
    <td style="width: 2%">&#160;</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zAAYvVJlyYVa" style="width: 9%; text-align: right" title="Outstanding at beginning">3,035,000</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zhNzoga14ma6" style="width: 9%; text-align: right" title="Outstanding at beginning">3.93</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Granted</td>
    <td>&#160;</td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_ziK7kuxQgc29" style="text-align: right" title="Granted">65,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zwe0tBog49Ag" style="text-align: right" title="Granted">2.21</td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z2neB2rU5jE2" style="text-align: right" title="Granted">40,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zrO57WfTOI1a" style="text-align: right" title="Granted">3.91</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Exercised</td>
    <td>&#160;</td>
    <td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zNFGcmXnfZei" style="text-align: right" title="Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0619">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zdOs5FzRoU5i" style="text-align: right" title="Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0621">&#8212;</span></td>
    <td>&#160;</td>
    <td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zrmoyx70kaA9" style="text-align: right" title="Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0623">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zDYgCzgwe9oe" style="text-align: right" title="Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0625">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Forfeited</td>
    <td>&#160;</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zuML3OHLNHic" style="text-align: right" title="Forfeited">381,250</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zAQujz4UAVL9" style="text-align: right" title="Forfeited">7.0</td>
    <td>&#160;</td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zcdYDgDNjF92" style="text-align: right" title="Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0631">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z2FoRJB8U7gj" style="text-align: right" title="Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0633">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Outstanding at March 31</td>
    <td>&#160;</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zSkdBzXYYMvk" style="text-align: right" title="Outstanding at ending">2,940,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zUMNnfyoqoXg" style="text-align: right" title="Outstanding at ending">3.19</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zmLssqaTjuyl" style="text-align: right" title="Outstanding at ending">3,075,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zJz1aNHxEbHe" style="text-align: right" title="Outstanding at ending">3.92</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Options exercisable at March 31</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zwxrpXUOKwrc" style="text-align: right" title="Options exercisable">1,393,750</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zOKzHkx1nZw6" style="text-align: right" title="Options exercisable">3.59</td>
    <td>&#160;</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zQkyiePyAbxj" style="text-align: right" title="Options exercisable">1,010,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zrDnZxmsiV75" style="text-align: right" title="Options exercisable">4.63</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Weighted average fair value of options granted during the period</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zZmrFPqZ2UWa" style="text-align: right" title="Weighted average fair value of options granted during the period">1.39</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zY8ko5SEmoPj" style="text-align: right" title="Weighted average fair value of options granted during the period">2.83</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Stock-based compensation expense</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zQAFevKilFAh" style="text-align: right" title="Stock-based compensation expense">393,113</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zvRaPBX5SuA3" style="text-align: right" title="Stock-based compensation expense">535,059</td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8AF_zRbcbz427Ulg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Total stock-based compensation expense was $<span id="xdx_906_ecustom--StockBasedCompensationStockOptions_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zTiGHoCLI8r7" title="Stock-based compensation expense">393,113</span>
and $<span id="xdx_906_ecustom--StockBasedCompensationStockOptions_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zwgMAJ6yWV0d" title="Stock-based compensation expense">535,059</span> for the three months ended March 31, 2024, and 2023, respectively. No cash was received from option exercises for the three
months ended March 31, 2024, and 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_89E_ecustom--ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock_zPvoFlRomfAk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table presents information pertaining
to options outstanding at March 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid"><b>Range of Exercise Price</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Number<br/>
Outstanding</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Remaining<br/>
Contractual<br/>
Life</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Number<br/>
Exercisable</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 29%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>$2.18 - $4.37</td>
    <td>&#160;</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_uShares_c20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zsp8OekKpoVc" style="text-align: right" title="Number outstanding">2,940,000</td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dxL_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zrPHLUL09Mje" title="Weighted average remaining contractual life::XDX::P6Y10M25D"><span style="-sec-ix-hidden: xdx2ixbrl0667">6.9</span></span> years</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_uUSDPShares_c20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zaUD8pR3q3Sa" style="text-align: right" title="Weighted average exercise price">3.19</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_uShares_c20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_z0inQJXrmbri" style="text-align: right" title="Number exercisable">1,393,750</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_uUSDPShares_c20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zcgmIrpLA4ic" style="text-align: right" title="Weighted average exercise price">3.59</td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8A3_z7lVE1Cfr7Xh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2024, there was $<span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20240331__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z0n9toIWnu0i" title="Total unrecognized compensation cost">2,719,478</span> of total
unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the Plans. &#160;That cost is
expected to be recognized over a weighted-average period of 46 months. &#160;The total fair value of shares vested as of March 31, 2024,
and March 31, 2023, was $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_c20240331__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember_zjVbUYwyoaZ1" title="Fair value of shares">3,884,426</span> and $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_c20230331__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember_zneaG83Fw18k" title="Fair value of shares">3,511,874</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<div id="xdx_235_zrZVBeJ1vi28">
<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 12 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc"><span style="color: Blue">Table of Contents</span></a></i></p>

<p id="xdx_234_zIIQrbiZSOd2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Performance Based Stock Options</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_89D_eus-gaap--ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_zfdU1nleHWD3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;<span id="xdx_8B8_zXaeFjqp7yzf">The following table summarizes the activities
for our unvested performance based stock option awards for the three months ended March 31, 2024, and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="9" style="border-bottom: black 1pt solid; text-align: center"><b>Three Months Ended March 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Grant-Date<br/>
Fair Value</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Grant-Date<br/>
Fair Value</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 41%">Unvested at January 1</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByUnvestedAwardOptions_iS_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zotXsiT7eLUi" style="width: 12%; text-align: right" title="Unvested at beginning">200,000</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zJQQjo9OzeD5" style="width: 11%; text-align: right" title="Unvested at beginning">1.48</td>
    <td style="width: 3%">&#160;</td>
    <td id="xdx_984_ecustom--ShareBasedCompensationArrangementByUnvestedAwardOptions_iS_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zR9hL9pdviS8" style="width: 12%; text-align: right" title="Outstanding at beginning"><span style="-sec-ix-hidden: xdx2ixbrl0689">&#8212;</span></td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zprybgccS3Z" style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0690">&#8212;</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Granted</td>
    <td>&#160;</td>
    <td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_pid_d0_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zTEEWu3cIbFi" style="text-align: right" title="Granted">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zeya2LFwdaRd" style="text-align: right" title="Granted">&#8212;</td>
    <td>&#160;</td>
    <td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_pid_d0_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zXWOaTaNmEe1" style="text-align: right" title="Granted">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zsi3lmH5hgo2" style="text-align: right">&#8212;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Vested</td>
    <td>&#160;</td>
    <td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested_pid_d0_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zUsOlgAh1JPh" style="text-align: right" title="Vested">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zpuvY05Z4xj5" style="text-align: right" title="Vested">&#8212;</td>
    <td>&#160;</td>
    <td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested_pid_d0_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zK59qA2YlLx3" style="text-align: right" title="Forfeited">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zWxMuPh3Rqcj" style="text-align: right">&#8212;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Forfeited/canceled</td>
    <td>&#160;</td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures_pid_d0_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zpZ0uITitbJl" style="text-align: right" title="Forfeited/canceled">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zk41Ro850OGl" style="text-align: right" title="Forfeited/canceled">&#8212;</td>
    <td>&#160;</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures_pid_d0_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zFpVkK1Ao6x6" style="text-align: right" title="Forfeited">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zbsX2bw9yNdd" style="text-align: right">&#8212;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Unvested at March 31</td>
    <td>&#160;</td>
    <td id="xdx_981_ecustom--ShareBasedCompensationArrangementByUnvestedAwardOptions_iE_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zA0woV7FpRF1" style="text-align: right" title="Unvested at ending">200,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_z11bZTkeKju3" style="text-align: right" title="Unvested at ending">1.48</td>
    <td>&#160;</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByUnvestedAwardOptions_iE_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zL8NJNwlP4Oc" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0716">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zy5RGvR7rdu5" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0717">&#8212;</span></td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8A6_zfCIxTX6T4ci" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Total stock-based compensation expense was $<span id="xdx_903_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zS1xOOjuCjil" title="Total stock-based compensation expense">8,121</span>
and <span id="xdx_90A_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_dxL_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zkkRoYDuQnf4" title="Total stock-based compensation expense::XDX::0"><span style="-sec-ix-hidden: xdx2ixbrl0721">zero</span></span> for the three months ended March 31, 2024, and 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2024, there was $<span id="xdx_905_ecustom--UnrecognizedCompensationCost_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zDZFp88xtrTf" title="Unrecognized compensation cost">168,223</span> of unrecognized
compensation cost related to unvested employee performance based options. This amount is expected to be recognized over a weighted-average
period of 36 months.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Restricted Stock Awards and PSUs</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_892_eus-gaap--ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_z9ygRDHDD4y4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B1_zutCAf93qVe5">The following table summarizes the activities for
our restricted stock awards and PSUs for the three months ended March 31, 2024, and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="9" style="border-bottom: black 1pt solid; text-align: center"><b>Three Months Ended March 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Grant-Date Fair Value</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Grant-Date Fair Value</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 41%">Unvested at January 1</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zKYWgn2mgeg7" style="width: 12%; text-align: right" title="Outstanding at beginning">904,496</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_znguJnC4jSch" style="width: 11%; text-align: right" title="Outstanding at beginning">1.80</td>
    <td style="width: 3%">&#160;</td>
    <td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_ziNpjHxQAwWe" style="width: 12%; text-align: right" title="Outstanding at beginning">950,000</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_pid_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zCIwRk1DycGk" style="width: 11%; text-align: right" title="Outstanding at beginning">3.04</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Granted</td>
    <td>&#160;</td>
    <td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zR0yXwCX9oBb" style="text-align: right" title="Granted"><span style="-sec-ix-hidden: xdx2ixbrl0735">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zzILKzaYeEi6" style="text-align: right" title="Granted"><span style="-sec-ix-hidden: xdx2ixbrl0737">&#8212;</span></td>
    <td>&#160;</td>
    <td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zKrUnVs8DfHf" style="text-align: right" title="Granted"><span style="-sec-ix-hidden: xdx2ixbrl0739">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z9q5qkqj6DKj" style="text-align: right" title="Granted"><span style="-sec-ix-hidden: xdx2ixbrl0741">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Vested</td>
    <td>&#160;</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z2bO08kSVx91" style="text-align: right" title="Vested"><span style="-sec-ix-hidden: xdx2ixbrl0743">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_ze8tsIucLVlg" style="text-align: right" title="Vested"><span style="-sec-ix-hidden: xdx2ixbrl0745">&#8212;</span></td>
    <td>&#160;</td>
    <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zgTceYgH9i3g" style="text-align: right" title="Vested">50,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zZVhFi4utnhl" style="text-align: right" title="Vested">3.31</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Forfeited/canceled</td>
    <td>&#160;</td>
    <td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z8APshZWAndi" style="text-align: right" title="Forfeited/canceled"><span style="-sec-ix-hidden: xdx2ixbrl0751">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z1FZxq0fktp9" style="text-align: right" title="Forfeited/canceled"><span style="-sec-ix-hidden: xdx2ixbrl0753">&#8212;</span></td>
    <td>&#160;</td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zHJ4BQvdTDKd" style="text-align: right" title="Forfeited/canceled"><span style="-sec-ix-hidden: xdx2ixbrl0755">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zxVVVZJpYx27" style="text-align: right" title="Forfeited/canceled"><span style="-sec-ix-hidden: xdx2ixbrl0757">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Unvested at March 31</td>
    <td>&#160;</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zLmPv1DufjFf" style="text-align: right" title="Outstanding at ending">904,496</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zIuBm8uUqbT5" style="text-align: right" title="Outstanding at ending">1.80</td>
    <td>&#160;</td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zkPMoHvDvW7a" style="text-align: right" title="Outstanding at ending">900,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_pid_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zuylbHtfoaT3" style="text-align: right" title="Outstanding at ending">2.93</td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8A1_zKkyMje4eMt8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Total stock-based compensation expense was $<span id="xdx_905_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zDGx7mNi5eIg" title="Total stock-based compensation expense">122,551</span>
and $<span id="xdx_901_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zlfXfy1yf1Fb" title="Total stock-based compensation expense">170,387</span> for the three months ended March 31, 2024, and 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2024, and 2023, there was $<span id="xdx_906_ecustom--UnrecognizedCompensationCost_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zVLYduJ3g3u2" title="Unrecognized compensation cost">755,513</span>
and $<span id="xdx_90D_ecustom--UnrecognizedCompensationCost_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zpR1pnKUb0G" title="Unrecognized compensation cost">1,447,790</span> of unrecognized compensation cost related to unvested employee restricted stock awards and PSUs. This amount is expected
to be recognized over a weighted-average period of 21 months.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Common Stock Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_898_eus-gaap--ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_zIKqcXIf9dk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B4_zELoc4sie5I8">The following table summarizes the activities for
our common stock warrants issued in connection with our loan financing agreement with HSBC for the three months ended March 31, 2024,
and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="9" style="border-bottom: black 1pt solid; text-align: center"><b>Three Months Ended March 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Grant-Date Fair Value</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Grant-Date Fair Value</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 41%">Unvested at January 1</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z32p3x7EvNAi" style="width: 12%; text-align: right" title="Outstanding at beginning"><span style="-sec-ix-hidden: xdx2ixbrl0778">&#8212;</span></td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z6WNsuByy9Hb" style="width: 11%; text-align: right" title="Outstanding at beginning"><span style="-sec-ix-hidden: xdx2ixbrl0780">&#8212;</span></td>
    <td style="width: 3%">&#160;</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zAxpnMBih8G7" style="width: 12%; text-align: right" title="Outstanding at beginning"><span style="-sec-ix-hidden: xdx2ixbrl0782">&#8212;</span></td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_pid_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zfk2gwBzJGb9" style="width: 11%; text-align: right" title="Outstanding at beginning"><span style="-sec-ix-hidden: xdx2ixbrl0784">&#8212;</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Granted</td>
    <td>&#160;</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zSA31aYSHUY8" style="text-align: right" title="Granted">76,104</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zc5SR8rOvrJf" style="text-align: right" title="Granted">1.37</td>
    <td>&#160;</td>
    <td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zzCkLpkxkpX2" style="text-align: right" title="Granted"><span style="-sec-ix-hidden: xdx2ixbrl0790">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z8GphMB98u8h" style="text-align: right" title="Granted"><span style="-sec-ix-hidden: xdx2ixbrl0792">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Vested</td>
    <td>&#160;</td>
    <td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_ziSVH8pmo6B6" style="text-align: right" title="Vested">38,052</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zjFtWrc3Q9D6" style="text-align: right" title="Vested">1.37</td>
    <td>&#160;</td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zFmp0xx4pNtk" style="text-align: right" title="Vested"><span style="-sec-ix-hidden: xdx2ixbrl0798">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zxbtd3qnDml7" style="text-align: right" title="Vested"><span style="-sec-ix-hidden: xdx2ixbrl0800">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Forfeited/canceled</td>
    <td>&#160;</td>
    <td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zLxCz4v7LCIk" style="text-align: right" title="Forfeited/canceled"><span style="-sec-ix-hidden: xdx2ixbrl0802">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z2l0CNeiBtLb" style="text-align: right" title="Forfeited/canceled"><span style="-sec-ix-hidden: xdx2ixbrl0804">&#8212;</span></td>
    <td>&#160;</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z0tyiOTYMoB1" style="text-align: right" title="Forfeited/canceled"><span style="-sec-ix-hidden: xdx2ixbrl0806">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zoF53Nge4OY3" style="text-align: right" title="Forfeited/canceled"><span style="-sec-ix-hidden: xdx2ixbrl0808">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Unvested at March 31</td>
    <td>&#160;</td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zdQalfv0smS7" style="text-align: right" title="Outstanding at ending">38,052</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z0AnyDlHUsy4" style="text-align: right" title="Outstanding at ending">1.37</td>
    <td>&#160;</td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z3qLHiDO5Hm8" style="text-align: right" title="Outstanding at ending"><span style="-sec-ix-hidden: xdx2ixbrl0814">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_pid_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zXGxwUbpLKxa" style="text-align: right" title="Outstanding at ending"><span style="-sec-ix-hidden: xdx2ixbrl0816">&#8212;</span></td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8AF_zVLUdOWcsDWh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2024, and 2023, there was $<span id="xdx_904_ecustom--UnrecognizedCompensationCost_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember_z7HXh3eYmTX7" title="Unrecognized cost">52,125</span>
and <span id="xdx_901_ecustom--UnrecognizedCompensationCost_dxL_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember_zb5XL6m2x191" title="Unrecognized cost::XDX::0"><span style="-sec-ix-hidden: xdx2ixbrl0820">zero</span></span> of unrecognized cost related to unvested warrants.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140173428293920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT OBLIGATIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT OBLIGATIONS</a></td>
<td class="text"><p id="xdx_807_eus-gaap--DebtDisclosureTextBlock_z3cf6wwfzpNb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 4 &#8212; <span id="xdx_824_zkyWV8c7dytc">DEBT OBLIGATIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 28, 2023, the Company entered into a
commercial insurance premium finance and security agreement with AON Premium Finance, LLC in the aggregate principal amount of
$<span id="xdx_906_eus-gaap--NotesPayable_iI_dm_c20230728__dei--LegalEntityAxis__custom--AONPremiumFinanceLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_z27QFGKX2xac" title="Notes payable">0.57
million</span> bearing an annual percentage rate of <span id="xdx_901_ecustom--NotePayableTerms_pid_dp_uPure_c20230726__20230728__dei--LegalEntityAxis__custom--AONPremiumFinanceLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zEt4adGtrBvk" title="Note payable terms">9.5</span>%,
to finance its insurance premiums. <span id="xdx_908_eus-gaap--DebtInstrumentFrequencyOfPeriodicPayment_c20230726__20230728__dei--LegalEntityAxis__custom--AONPremiumFinanceLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zrZ35925XQj8" title="Description of the frequency of periodic payments">Monthly
payments are due on the first of each month beginning August 1, 2023 through June 1, 2024.</span> The balance of the AON note was
$<span id="xdx_906_eus-gaap--OtherLongTermDebtNoncurrent_iI_c20231231__dei--LegalEntityAxis__custom--AONPremiumFinanceLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zaQRudaPpskk" title="Balance of AON note">314,344</span>
as of December 31, 2023 and $<span id="xdx_903_eus-gaap--OtherLongTermDebtNoncurrent_iI_c20240331__dei--LegalEntityAxis__custom--AONPremiumFinanceLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zg1HcVxIsuOe" title="Balance of AON note">159,031</span>
as of March 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 8, 2024, the Company entered into a loan
and security agreement with HSBC Ventures USA Inc., as lender, providing for a $<span id="xdx_90A_eus-gaap--LinesOfCreditCurrent_iI_c20240308__dei--LegalEntityAxis__custom--HSBCVenturesUSAIncMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zDHRn3zBUwmk" title="Revolving credit facility">5,000,000</span> revolving credit facility and a $<span id="xdx_905_ecustom--LinesOfCreditCurrent1_iI_c20240308__dei--LegalEntityAxis__custom--HSBCVenturesUSAIncMember__us-gaap--CreditFacilityAxis__custom--TermLoanFacilityMember_zKis0mgO2FS9" title="Term loan facility">5,000,000</span> term
loan facility. Borrowings are secured by a first-priority lien on substantially all of the assets of the Company, subject to customary
exceptions. The revolving credit facility matures on December 31, 2025 and the term loan matures on December 1, 2028. Our former revolving
credit facility with Key Bank expired during the quarter ended September 30, 2023. As of March 31, 2024, there were no outstanding borrowings
under the term loan nor the revolving credit facility.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140173428293136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesOfLesseeDisclosureTextBlock', window );">LEASES</a></td>
<td class="text"><p id="xdx_801_eus-gaap--LeasesOfLesseeDisclosureTextBlock_zk5BZxcXN6ff" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 5 &#8212; <span id="xdx_82B_zpMVH4UhthY9">LEASES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have finance and operating leases for our corporate
office and certain office and computer equipment. &#160;Our two operating leases have remaining lease terms of <span id="xdx_90A_ecustom--LesseeOperatingLeaseRemainingTerm_dxL_c20240101__20240331__us-gaap--LeaseContractualTermAxis__custom--LeaseOneMember_zS39fX1ATpHh" title="Operating lease remaining term::XDX::P8Y4M24D"><span style="-sec-ix-hidden: xdx2ixbrl0840">8.4</span></span> years and <span id="xdx_908_ecustom--LesseeOperatingLeaseRemainingTerm_dxL_c20240101__20240331__us-gaap--LeaseContractualTermAxis__custom--LeaseTwoMember_zuxS5Y2FwZri" title="Operating lease remaining term::XDX::P4Y9M18D"><span style="-sec-ix-hidden: xdx2ixbrl0842">4.8</span></span> years,
respectively. Our three finance leases have remaining lease terms of <span id="xdx_902_ecustom--LesseeFinanceLeaseRemainingTerm_dxL_c20240101__20240331__us-gaap--LeaseContractualTermAxis__custom--LeaseOneMember_zTn177XUF3r6" title="Finance lease remaining term::XDX::P3Y2M12D"><span style="-sec-ix-hidden: xdx2ixbrl0844">3.2</span></span> years, <span id="xdx_905_ecustom--LesseeFinanceLeaseRemainingTerm_dxL_c20240101__20240331__us-gaap--LeaseContractualTermAxis__custom--LeaseTwoMember_zPLpD3ncnP1c" title="Finance lease remaining term::XDX::P2Y9M0D"><span style="-sec-ix-hidden: xdx2ixbrl0846">2.75</span></span> years, and <span id="xdx_900_ecustom--LesseeFinanceLeaseRemainingTerm_dxL_c20240101__20240331__us-gaap--LeaseContractualTermAxis__custom--LeaseThreeMember_zpkUK7LeVvpe" title="Finance lease remaining term::XDX::P4Y6M0D"><span style="-sec-ix-hidden: xdx2ixbrl0848">4.5</span></span> years, respectively, as of March 31,
2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_89E_eus-gaap--LeaseCostTableTextBlock_zauTH8fo6kWa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8BE_z1UUuMP6ctD5">The components of lease expense were as follows:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 4.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_496_20240101__20240331_zPZhZXkiyey3" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_490_20230101__20230331_zB4RJACsSBi2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Three Months Ended</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>March 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 62%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: right">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseCost_maLCzGTc_zFrhS2aSiqqb" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Operating lease cost</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">111,548</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">112,522</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ShortTermLeaseCost_maLCzGTc_zSXcYUba4MP6" style="vertical-align: bottom">
    <td>Short-term lease cost</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">3,460</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">52,894</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LeaseCost_zKRTYi0GRENg" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Total lease cost</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">115,008</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">165,416</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_ecustom--FinanceLeaseCost1Abstract_iB_zZm9UtAhC4va" style="vertical-align: bottom">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">Finance lease cost:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_i01_maFLCzAT2_z6I3gfDgKNQ5" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.2in">Amortization of right-of-use assets</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">28,896</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">27,223</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--FinanceLeaseInterestExpense_i01_maFLCzAT2_zMns9RB1ItPk" style="vertical-align: bottom">
    <td style="padding-left: 0.2in">Interest on lease liabilities</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">6,053</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">6,720</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_ecustom--FinanceLeaseCost_i01_zqGwjQy9Sim2" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Total finance lease cost</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">34,949</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">33,943</td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8A3_zfUOYrNp5RPd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p id="xdx_89F_eus-gaap--OperatingLeaseLeaseIncomeTableTextBlock_zKNpO7m0QyU3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B8_zC6gKwzRWUK5">Supplemental cash flow information related to leases
was as follows:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 6.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_495_20240101__20240331_zVppJ63WtQ94" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_490_20230101__20230331_zpl9Na4lfwZ6" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Three Months Ended</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>March 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashFlowOperatingActivitiesLesseeAbstract_iB" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 70%; padding-left: 8.25pt; text-indent: -8.25pt">Cash paid for amounts included in the measurement of lease liabilities:</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeasePayments_i01_zsEqvrMPSCH6" style="vertical-align: bottom">
    <td>Operating cash flows from operating leases</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">120,365</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">113,813</td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FinanceLeaseInterestPaymentOnLiability_i01_zc6FMQiffytl" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Financing cash flows from finance leases</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">32,859</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">30,800</td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8A2_znLkcIgBIoLb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_899_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_zvPao6Y57qB7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B2_zHobzA7gJrza">Supplemental balance sheet information related to
leases was as follows:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49E_20240331_zd6RSgwy3vY7" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_492_20231231_zfj7QKjQoz3f" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>March 31,<br/>
2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,<br/>
2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 55%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 17%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 17%">&#160;</td>
    <td style="width: 2%">&#160;</td></tr>
  <tr id="xdx_402_ecustom--AssetsAndLiabilitiesOperatingLesseeAbstract_iB_zUKGoupTq6x7" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt"><b>Operating Leases</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_z7iI4XVnolG1" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Operating lease right-of-use assets</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">3,428,885</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">3,514,055</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityCurrent_i01I_z2Bc90rfh79b" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Operating lease current liabilities</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">372,109</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">368,313</td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_zpCmZ4XeYpzd" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Operating lease long term liabilities</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">3,241,837</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">3,336,300</td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiability_i01I_zloCrfDY96a4" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">Total operating lease liabilities</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">3,613,946</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">3,704,613</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_ecustom--AssetsAndLiabilitiesLesseeFinanceAbstract_iB_zYpNM6sUPA98" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt"><b>Finance Leases</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentOther_i01I_z2bIO0JnclQ6" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Property and equipment, at cost</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">577,929</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">577,929</td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentOtherAccumulatedDepreciation_i01NI_di_z1PbQqb7pPHk" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Accumulated depreciation</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(190,358</td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(161,461</td>
    <td>)</td></tr>
  <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentOtherNet_i01I_zohKRMyBndKd" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Property and equipment, net</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">387,571</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">416,468</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FinanceLeaseLiabilityCurrent_iI_zQQS7vFSwB8i" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Finance lease current liabilities</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">111,103</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">109,540</td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_zumSjJzwUjP6" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Finance lease long term liabilities</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">288,253</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">316,623</td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--FinanceLeaseLiability_iI_zYz94yTFuF22" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">Total finance lease liabilities</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">399,356</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">426,163</td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5in; border-collapse: collapse">
  <tr>
    <td style="vertical-align: bottom; width: 55%">&#160;</td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 19%; text-align: center"><b>March 31,<br/>
2024</b></td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: top; width: 19%; text-align: center"><b>December 31,<br/>
2023</b></td>
    <td style="vertical-align: top; width: 2%">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom"><b>Weighted Average Remaining Lease Term</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-left: 0.2in">Operating leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span id="xdx_90D_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dxL_c20240331_z8uD2GUNGQ71" title="Operating leases term::XDX::P6Y7M6D"><span style="-sec-ix-hidden: xdx2ixbrl0923">6.6</span></span> Years</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span id="xdx_907_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dxL_c20231231_z8y6Zc5zuA8f" title="::XDX::P6Y10M25D"><span style="-sec-ix-hidden: xdx2ixbrl0924">6.9</span></span> Years</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 0.2in">Finance leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span id="xdx_90B_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dxL_c20240331_zjyamX7bpi3a" title="Finance leases  term::XDX::P3Y7M6D"><span style="-sec-ix-hidden: xdx2ixbrl0926">3.6</span></span> Years</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span id="xdx_90F_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dxL_c20231231_ziSWWq7j83ck" title="::XDX::P6Y8M12D"><span style="-sec-ix-hidden: xdx2ixbrl0927">3.7</span></span> Years</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom"><b>Weighted Average Discount Rate</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-left: 0.2in">Operating leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span id="xdx_904_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20240331_zSIydO3clCqg" title="Operating leases discount rate">5.73</span>%</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span id="xdx_907_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20231231_zWAR3Jqmunb1">5.76</span>%</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 0.2in">Finance leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span id="xdx_900_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_pid_dp_uPure_c20240331_z6TiDvQXNJu3" title="Finance leases discount rate">6.17</span>%</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span id="xdx_90A_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_pid_dp_uPure_c20231231_z9i6Vxe0410h">6.19</span>%</td>
    <td style="vertical-align: top">&#160;</td></tr>
  </table>
<p id="xdx_8AD_zvGn0RGtdUqh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_892_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zZh9W77sRRAa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B6_zQqUwkv5Smyl">Maturities of lease liabilities are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom"><b>Year Ending December 31,</b></td>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>Operating Leases</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>Finance Leases</b></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; width: 52%">Remainder of 2024</td>
    <td style="vertical-align: top; width: 3%">&#160;</td>
    <td style="vertical-align: bottom; width: 2%">$</td>
    <td id="xdx_98B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20240331_zanzfq8GuNhb" style="vertical-align: bottom; width: 18%; text-align: right" title="2024 - Operating Leases">384,041</td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td id="xdx_98E_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20240331_zN3jqj0wcU1i" style="vertical-align: bottom; width: 18%; text-align: right" title="2024 - Finance Leases">98,578</td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>2025</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_c20240331_z7s6l8TSl4Wg" style="text-align: right" title="2025 - Operating Leases">512,055</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_c20240331_zRUoU2hVhPb2" style="text-align: right" title="2025 - Finance Leases">131,437</td>
    <td>&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2026</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_c20240331_zg5vTq2XkmZg" style="vertical-align: bottom; text-align: right" title="2026 - Operating Leases">512,055</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_986_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_c20240331_zoX17dI2XQ79" style="vertical-align: bottom; text-align: right" title="2026 - Finance Leases">131,437</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">2027</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_c20240331_z2KRKq1vCqLj" style="vertical-align: bottom; text-align: right" title="2027 - Operating Leases">512,055</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_c20240331_zounU9bLy9Pl" style="vertical-align: bottom; text-align: right" title="2027 - Finance Leases">74,194</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2028</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_c20240331_zpTHKbaDDgVb" style="vertical-align: bottom; text-align: right" title="2028 - Operating Leases">511,009</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98C_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_iI_c20240331_zweTlmwMVuXk" style="vertical-align: bottom; text-align: right" title="2028 - Finance Leases">6,179</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">Thereafter</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_989_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_c20240331_zsGbBJNckw15" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Thereafter - Operating Leases">1,833,604</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_98E_eus-gaap--FinanceLeaseLiabilityPaymentsDueAfterYearFive_iI_c20240331_zHAmz4lUIWrk" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Thereafter - Finance Leases"><span style="-sec-ix-hidden: xdx2ixbrl0959">&#8212;</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">Total undiscounted lease payments</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_980_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueTotal_iI_c20240331_zxoLT9s7r5pi" style="vertical-align: bottom; text-align: right" title="Total undiscounted lease payments - Operating Leases">4,264,819</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_982_ecustom--LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal_iI_c20240331_zWaFrJrbLQSk" style="vertical-align: bottom; text-align: right" title="Total undiscounted lease payments - Finance Leases">441,825</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-left: 16.45pt">Less: imputed interest</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_985_ecustom--LesseeOperatingLeaseImputedInterest_iNI_di_c20240331_zydmttaezh5g" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Less: imputed interest - Operating Leases">(650,873</td>
    <td style="vertical-align: bottom">)</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_983_ecustom--LesseeFinancingLeaseImputedInterest_iNI_di_c20240331_zmxAZ4l6Q9g2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Less: imputed interest - Finance Leases">(42,469</td>
    <td style="vertical-align: bottom">)</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">Total lease liabilities</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">$</td>
    <td id="xdx_983_eus-gaap--OperatingLeaseLiability_iI_c20240331_z5NJJfYHuG68" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Total lease liabilities - Operating Leases">3,613,946</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">$</td>
    <td id="xdx_98B_eus-gaap--FinanceLeaseLiability_iI_c20240331_zuHy3SmrjCza" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Total lease liabilities - Finance Leases">399,356</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zuNGCSXdVu49" style="margin-top: 0; margin-bottom: 0">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/840/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140173428426432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p id="xdx_803_eus-gaap--IncomeTaxDisclosureTextBlock_z0BD5KGS1Mw2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 6 &#8212; <span id="xdx_822_zJwD9oNZlMie">INCOME TAXES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For interim income tax reporting, the Company estimates
its annual effective tax rate and applies it to fiscal year-to-date pretax loss, excluding unusual or infrequently occurring discrete
items. Tax jurisdictions with losses for which tax benefits cannot be realized are excluded. The Company reported an income tax expense
of <span id="xdx_902_eus-gaap--DeferredIncomeTaxExpenseBenefit_dmxL_c20240101__20240331_zJQ3QkPBTldk" title="Income tax expense::XDX::0"><span style="-sec-ix-hidden: xdx2ixbrl0975">zero</span></span> and income tax benefit of $<span id="xdx_906_eus-gaap--DeferredIncomeTaxExpenseBenefit_dm_c20230101__20230331_zd6i30huUq2f" title="Income tax benefit">0.6 million</span> for the periods ended March 31, 2024 and 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We evaluate our deferred tax assets to determine if
they are more likely than not to be realized by assessing both positive and negative evidence in accordance with ASC Topic 740, Income
Taxes.&#160; After considering our cumulative pretax loss (the three-year period ending with the current year), as well as analyzing all
available evidence,&#160;we have recorded a valuation allowance of $<span id="xdx_902_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_dm_c20231231_zpyTEC5j3tVi" title="Valuation Allowance">6.0 million</span> against our net deferred tax assets during the year ended
December 31, 2023.&#160; As of March 31, 2024, the valuation allowance is $<span id="xdx_90A_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_dm_c20240331_zXoUjDjdRf8g" title="Valuation Allowance">6.4 million</span> As we continue to assess the realizability of our
deferred tax assets, reported pretax income and new evidence may result in a partial or full reduction of the valuation allowance in future
periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Recurring items cause our effective tax rate to differ
from the U.S. federal statutory rate of <span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20240101__20240331_zH6tqN3GBnFi" title="Statutory rate">21</span>%, including U.S. federal R&amp;D credits, U.S. state tax rates, and stock-based compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Beginning in 2022, certain research and development
costs are required to be capitalized and amortized over a five-year period under the Tax Cuts and Jobs Act enacted in December 2017. This
change will impact the expected U.S. federal and state income tax expense and cash taxes to be paid for our fiscal 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company files income tax returns in the U.S. federal
jurisdiction and in various state jurisdictions. Income tax returns for years prior to fiscal 2020 are no longer subject to examination
by tax authorities.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140173520219520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zLsfjh654rbc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 7 &#8212; <span id="xdx_823_z9rHQQEUoJdf">COMMITMENTS AND CONTINGENCIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>LEGAL PROCEEDINGS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has been and may again become involved
in legal proceedings, claims and litigation arising in the ordinary course of business. &#160;KORU Medical Systems Inc. is not presently a party to
any litigation or other legal proceeding that is believed to be material to its financial condition.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140173426408944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_DisclosureSubsequentEventsAbstract', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p id="xdx_809_eus-gaap--SubsequentEventsTextBlock_zN7pEo3Y175" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 8 &#8212; <span id="xdx_828_zHS0OdBt4v4k">SUBSEQUENT EVENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 8, 2024, the Company&#8217;s appeal to BSI
in connection with a prior audit matter was upheld resulting in no disruption of sales of the Company to the market and patients. Our
products remain certified, marketed and sold in the EU. The Company intends to address the identified nonconformance through the routine
BSI assessment process.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_DisclosureSubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_DisclosureSubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140173537885856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">NATURE OF OPERATIONS</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--NatureOfOperations_zuNRR9X8WuT5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_860_zL58AmV7DqSg">NATURE OF OPERATIONS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">KORU MEDICAL SYSTEMS, INC. (the &#8220;Company,&#8221;
&#8220;KORU Medical,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;) designs, manufactures and markets proprietary portable
and innovative medical devices primarily for the subcutaneous drug delivery market as governed by the United States Food and Drug Administration
(the &#8220;FDA&#8221;) quality and regulatory system and international regulations and standards for quality system management. The Company
operates as <span id="xdx_903_eus-gaap--NumberOfReportableSegments_dxH_uN_c20240101__20240331_zHYjAdyxPnMa" title="Number of segment::XDX::1">one</span> segment.</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">BASIS OF PRESENTATION</a></td>
<td class="text"><p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zxTa5f2NTFU5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_863_z3u1ztSDWWPc">BASIS OF PRESENTATION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying financial statements should be read
in conjunction with the Company&#8217;s annual report on Form 10-K for the year ended December 31, 2023 (&#8220;Annual Report&#8221;).
&#160;In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;), the Company has
omitted footnote disclosures that would substantially duplicate the disclosures contained in the audited financial statements of the Company.
The accompanying interim financial statements are unaudited and reflect all adjustments which are in the opinion of management necessary
for a fair statement of the Company&#8217;s financial position, results of operations, and cash flows for the periods presented. &#160;All
such adjustments are of a normal, recurring nature. &#160;The Company&#8217;s results of operations and cash flows for the interim periods
are not necessarily indicative of the results of operations and cash flows that it may achieve in future periods.</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">CASH AND CASH EQUIVALENTS</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zZ86aZl4CBLi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_86B_zxJfOor2QNue">CASH AND CASH EQUIVALENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For purposes of the statements of cash flows, the
Company considers all short-term investments with an original maturity of three months or less to be cash equivalents. &#160;The Company
has historically held cash balances in excess of $<span id="xdx_90E_eus-gaap--CashUninsuredAmount_iI_c20240331_znGjeFWwJNr7" title="FDIC cash uninsured amount">250,000</span> at its primary commercial bank, which exceeds FDIC insurance limits. To reduce
the risk of uninsured deposits, the Company entered an insured cash sweep program with KeyBank during the second quarter of 2023 to automatically
invest its uninsured bank cash balances over $250,000 into FDIC insured banks so there is no more than $250,000 maintained at any one
bank. As of March 31, 2024 the Company has an investment balance of $<span id="xdx_907_eus-gaap--InterestIncomeSecuritiesUSTreasury_dm_c20240101__20240331_zAroHWx5QOCk" title="Investment securities treasury bill">10.2 million</span> in a US Treasury bill that matures every 90 days.</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">PATENTS</a></td>
<td class="text"><p id="xdx_842_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zpHXUHJP89Z8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_868_zfJNXKfqZn1b">PATENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Costs incurred in obtaining patents have been capitalized
and are being amortized over the legal life of the patents.</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zqiFo0vrTd6d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_864_zLIdpY0GWn3i">STOCK-BASED COMPENSATION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company maintains a stock option plan and an omnibus
equity incentive plan under which it grants stock options to certain executives, key employees and consultants. The fair value of each
option grant is estimated on the date of the grant using the Black-Scholes option-pricing model. &#160;All options are charged against
income at their fair value. &#160;The entire compensation expense of the award is recognized over the vesting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company also maintains a non-employee director
compensation plan. Shares of stock granted for director fees are recorded at the fair value of the shares at the grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company issues restricted stock awards. Restricted
stock awards are equity classified and measured at the fair market value of the underlying stock at the grant date. The fair value of
restricted stock awards vesting at certain market capitalization thresholds were estimated on the date of grant using the Brownian Motion
Monte Carlo lattice model. The fair value of restricted stock awards with time-based vesting were estimated on the date of grant at the
current stock price. The fair value of restricted stock awards vesting at certain annual sales growth thresholds were estimated as of
the date of Board acknowledgement of the achievement, at the current stock price. We recognize restricted stock expense using the straight-line
attribution method over the requisite service period and account for forfeitures as they occur.</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">NET LOSS PER COMMON SHARE</a></td>
<td class="text"><p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zEjvUKTCnSuj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_86B_zzX85zWjkZU3">NET LOSS PER COMMON SHARE</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic net loss per common share is calculated by dividing
net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed
by dividing net loss by the weighted average number of common and common equivalent shares outstanding during the period. The Company&#8217;s
potentially dilutive common shares are those that result from diluted common stock options and unvested restricted stock awards. The calculation
of diluted net loss per share excluded stock options of <span id="xdx_90A_ecustom--AntiDilutiveStockOptions_pid_dxL_uShares_c20240101__20240331_zAyKVLY6I0Kb" title="Anti-dilutive stock options::XDX::0"><span style="-sec-ix-hidden: xdx2ixbrl0452">zero</span></span> and <span id="xdx_906_ecustom--AntiDilutiveStockOptions_pid_uShares_c20230101__20230331_z2JVos5KlZMg" title="Anti-dilutive stock options">14,626</span>, respectively, in weighted-average shares for each of the three
months ended March 31, 2024 and 2023, as their effect was anti-dilutive as a result of the net loss incurred for those periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The calculation of diluted net loss per share excluded
stock options, performance-based restricted stock and performance-based restricted stock units (PSUs) of <span id="xdx_90C_ecustom--AntiDilutiveSecurities_pid_uShares_c20240101__20240331_zLD40VIT7Xpi" title="Anti-dilutive securities">904,496</span> and <span id="xdx_904_ecustom--AntiDilutiveSecurities_pid_uShares_c20230101__20230331_zYK7EYycKdx4" title="Anti-dilutive Securities">914,626</span> respectively,
in weighted-average shares for each of the three months ended March 31, 2024 and 2023, as their effect was anti-dilutive as a result of
the net loss incurred for those periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_89F_ecustom--ScheduleOfSecuritiesTextBlock_zzpQsQwqywxl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B1_zFRbRMeqbCI6">The following securities were not included in the
computation of diluted shares outstanding for the three months ended March 31, 2024, and 2023 because the effect would be anti-dilutive:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.25in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 64%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_491_20240101__20240331_z5gHa56Js7j9" style="width: 15%; text-align: right">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_495_20230101__20230331_znrL5Y2snEGd" style="width: 15%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Three Months Ended</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>March 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_ecustom--CommonStockOptions_pid_uShares_zXCYQ9M0n2Ak" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Common stock options</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0462">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">14,626</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_ecustom--PerformanceStockUnits_pid_uShares_zTxSUpVHYgl1" style="vertical-align: bottom">
    <td>PSUs</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">54,496</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0466">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_ecustom--RestrictedStockUnits_pid_zd0Ut9uoSEBj" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Restricted stock </td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">850,000</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">900,000</td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_ecustom--AntiDilutedSecurities_pid_zwi8ws9Cj7l8" style="vertical-align: bottom">
    <td><b>Total</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">904,496</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">914,626</td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8A9_znhncoWTWmPj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_897_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zBaLzXTzUa93" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B6_z7l4QIjCFLal">Therefore, diluted weighted average number of shares
outstanding and diluted net loss per share were the same as basic weighted average number of shares outstanding and net loss per share
for the three months ended March 31, 2024 and 2023.</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.25in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_49E_20240101__20240331_zKWPQDLuseWi" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49C_20230101__20230331_zwiXwTi9WQqb" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Three Months Ended</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>March 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 64%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: right">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_zRGQTXHoMhT9" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Net loss</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">$</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(1,935,958</td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">$</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(2,410,885</td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasicAbstract_iB_zgy58JSQ1or" style="vertical-align: bottom">
    <td>Weighted Average Outstanding Shares:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_uShares_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJkv6CGHEuqk" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.2in">Basic weighted average shares outstanding</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">45,712,224</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">45,487,593</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock_pid_uShares_zU067aM1fsOl" style="vertical-align: bottom">
    <td style="padding-left: 0.2in">Dilutive effect of outstanding stock options and unvested restricted stock</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0485">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0486">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_uShares_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zd27J1f9JnPk" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.2in">Diluted weighted average shares outstanding</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">45,712,224</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">45,487,593</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--EarningsPerShareAbstract_iB_zOB9mDzjNIdh" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Net loss per share</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--EarningsPerShareBasic_pid_uUSDPShares_zcSlm2QFwCO3" style="vertical-align: bottom">
    <td style="padding-left: 0.2in">Basic</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(0.04</td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(0.05</td>
    <td style="border-bottom: white 2.25pt double">)</td></tr>
  <tr id="xdx_404_eus-gaap--EarningsPerShareDiluted_pid_uUSDPShares_zpl67c48EQjj" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.2in">Diluted</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(0.04</td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(0.05</td>
    <td style="border-bottom: white 2.25pt double">)</td></tr>
  </table>

<p id="xdx_8A2_zOZuMH9KPgh" style="margin-top: 0; margin-bottom: 0">&#160;</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">USE OF ESTIMATES IN THE FINANCIAL STATEMENTS</a></td>
<td class="text"><p id="xdx_848_eus-gaap--UseOfEstimates_zwBJwuyIaRwk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_867_zXdhu3aGikK9">USE OF ESTIMATES IN THE FINANCIAL STATEMENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity
with United States generally accepted accounting principles (&#8220;GAAP&#8221;) requires management to make estimates and assumptions
that affect the amounts reported in the financial statements and accompanying notes. &#160;Actual results could differ from those estimates.
Important estimates include but are not limited to asset lives, deferred tax valuation allowances, inventory valuation, and customer rebate
and incentive accruals. The results of operations for the three months ended March 31, 2024 are not necessarily indicative of the results
that may be expected for the entire 2024 fiscal year.</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">REVENUE RECOGNITION</a></td>
<td class="text"><p id="xdx_848_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zBnku6HMugG2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_861_zAVc8rBfNITh">REVENUE RECOGNITION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our revenues are derived from three business sources:
(i) domestic core (which consists of US and Canada), (ii) international core, and (iii) novel therapies. &#160;Our core domestic and international
revenues consist of sales of our syringe drivers, tubing and needles (&#8220;Product Revenue&#8221;) for the delivery of subcutaneous
drugs that are FDA cleared for use with the KORU Medical infusion system, with the primary delivery for immunoglobulin to treat Primary
Immunodeficiency Diseases (&#8220;PIDD&#8221;) and Chronic Inflammatory Demyelinating Polyneuropathy (&#8220;CIDP&#8221;). Novel therapies
consist of Product Revenue for feasibility/clinical trials (pre-clinical studies, Phase I, Phase II, Phase III) of biopharmaceutical companies
in the drug development process as well as non-recurring engineering services (&#8220;NRE&#8221;) revenues (including testing and registration
services) received from biopharmaceutical companies to ready or customize the FREEDOM System for clinical and commercial use across multiple
drug categories.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For Product Revenue, we recognize revenues when shipment
occurs, and at which point the customer obtains control and ownership of the goods. &#160;Shipping costs generally are billed to customers
and are included in Product Revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company generally does not accept return of goods
shipped unless it is a Company error. &#160;The only credits provided to customers are for defective merchandise. &#160;The Company warrants
the syringe driver from defects in materials and workmanship under normal use and the warranty does not include a performance obligation.
&#160;The costs under the warranty are expensed as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Rebates are provided to distributors for the difference
in selling price to distributor and pricing specified to select customers. &#160;In addition, rebates are provided to customers for meeting
growth targets. &#160;Provisions for both distributor pricing and customer growth rebates are variable consideration and are recorded
as a reduction of revenue in the same period the related sales are recorded or when it is probable the growth target will be achieved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We recognize NRE revenue under an input method, which
recognizes revenue on the basis of our efforts or inputs (for example, resources consumed, labor hours expended, costs incurred, or time
elapsed) to the satisfaction of a performance obligation relative to the total expected inputs to the satisfaction of that performance
obligation (i.e. completion milestone). The input method that we use is based on costs incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Contracts are often modified to account for changes
in contract specifications and requirements. Contract modifications exist when the modification either creates new, or changes existing,
enforceable rights and obligations. Generally, when contract modifications create new performance obligations, the modification is considered
to be a separate contract and revenue is recognized prospectively. When contract modifications change existing performance obligations,
the impact on the existing transaction price and measure of progress for the performance obligation to which it relates is generally recognized
as an adjustment to revenue (either as an increase in or a reduction of revenue) on a cumulative catch-up basis. Contract assets primarily
represent revenue earnings over time that are not yet billable based on the terms of the contracts. Contract liabilities (i.e., deferred
revenue) consist of fees invoiced or paid by the Company&#8217;s customers for which the associated performance obligations have not been
satisfied and revenue has not been recognized based on the Company&#8217;s revenue recognition criteria described above. As of March 31,
2024, the Company has recognized a contract asset of zero.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_89B_ecustom--ScheduleOfNetSalesByGeography_zDNyTfMVxHZc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8BB_zofRxwMyRalc">The following table summarizes net revenues by geography
for the three months ended March 31, 2024, and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>Three Months Ended March 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 46%"><b>Revenues</b></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 22%; text-align: right">&#160;</td>
    <td style="width: 6%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 22%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.2in">Domestic</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_984_eus-gaap--Revenues_c20240101__20240331__srt--StatementGeographicalAxis__country--US_zfekj6YiphU1" style="text-align: right" title="Net Revenue">6,384,083</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_989_eus-gaap--Revenues_c20230101__20230331__srt--StatementGeographicalAxis__country--US_zU239wHzX3td" style="text-align: right" title="Net Revenue">6,283,965</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.2in">International</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_989_eus-gaap--Revenues_c20240101__20240331__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zszLQcyBXTo6" style="border-bottom: black 1pt solid; text-align: right" title="Net Revenues">1,813,715</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_989_eus-gaap--Revenues_c20230101__20230331__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zligqYQgmNRk" style="border-bottom: black 1pt solid; text-align: right" title="Net Revenues">1,108,640</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td><b>Total</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_98C_eus-gaap--Revenues_c20240101__20240331_zBlWjzy5lZTl" style="border-bottom: black 2.25pt double; text-align: right" title="Revenues">8,197,798</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_98F_eus-gaap--Revenues_c20230101__20230331_zgjEkojcqhJ3" style="border-bottom: black 2.25pt double; text-align: right" title="Revenues">7,392,605</td>
    <td>&#160;</td></tr>
  </table>

<p id="xdx_8A2_z4HPq9rP1jhi" style="margin-top: 0; margin-bottom: 0">&#160;</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zJbmPfiRquv2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_86F_zQB5mnbGtWH1">ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers the applicability and
impact of all recently issued accounting pronouncements. &#160;Recent accounting pronouncements not specifically identified in our disclosures
are either not applicable to the Company or are not expected to have a material effect on our financial condition or results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2016, the FASB issued ASU No. 2016-13, <i>Financial
Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i>, which amends guidance on reporting
credit losses for assets held at amortized cost basis and available for sale debt securities. &#160;For assets held at amortized cost
basis, Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its
current estimate of all expected credit losses. &#160;The allowance for credit losses is a valuation account that is deducted from the
amortized cost basis of the financial assets to present the net amount expected to be collected. &#160;For available for sale debt securities,
credit losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as
an allowance rather than as a write-down. &#160;This ASU affects entities holding financial assets and net investment in leases that are
not accounted for at fair value through net income. &#160;The amendments affect loans, debt securities, trade receivables, net investments
in leases, off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that
have the contractual right to receive cash. &#160;The Company adopted the pronouncement on January 1, 2023, and there was no impact on
its financial statements.</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><p id="xdx_848_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zjylkD9Qp3Wb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_864_zsUqUv4pUBy">FAIR VALUE MEASUREMENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fair value is the exit price that would be received
to sell an asset or paid to transfer a liability. &#160;Fair value is a market-based measurement that should be determined using assumptions
that market participants would use in pricing an asset or liability. Valuation techniques used to measure fair value should maximize the
use of observable inputs and minimize the use of unobservable inputs. &#160;To measure fair value, the Company uses the following fair
value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: center">&#8226;</td>
    <td style="width: 7in; text-align: justify">Level 1 &#8211; Quoted prices in active markets for identical assets or liabilities.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td style="text-align: justify">Level 2 &#8211; Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data by correlation or other means.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td style="text-align: justify">Level 3 &#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. &#160;Value is determined using pricing models, discounted cash flow methodologies, or similar techniques and includes instruments for which the determination of fair value requires significant judgment or estimation.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The carrying amounts of cash and cash equivalents,
including investments in short-term U.S. Treasury bills, accounts receivable, prepaid expenses, accounts payable and accrued expenses
are considered to be representative of their fair values because of the short-term nature of those instruments. &#160;There were no transfers
between levels in the fair value hierarchy during the three months ended March 31, 2024 and 2023.</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">IMPAIRMENT OF LONG-LIVED ASSETS</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z50C5i0C6KEg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_86B_zEgjNVcrMTh8">IMPAIRMENT OF LONG-LIVED ASSETS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company reviews long-lived assets for impairment
whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. &#160;An impairment
loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition
are less than the carrying amount. &#160;The impairment loss, if recognized, would be based on the excess of the carrying value of the
impaired asset over its respective fair value. &#160;The Company did not record any impairment losses through March 31, 2024.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140173424813824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ScheduleOfSecuritiesTextBlock', window );">The following securities were not included in the computation of diluted shares outstanding for the three months ended March 31, 2024, and 2023 because the effect would be anti-dilutive:</a></td>
<td class="text"><p id="xdx_89F_ecustom--ScheduleOfSecuritiesTextBlock_zzpQsQwqywxl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B1_zFRbRMeqbCI6">The following securities were not included in the
computation of diluted shares outstanding for the three months ended March 31, 2024, and 2023 because the effect would be anti-dilutive:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.25in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 64%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_491_20240101__20240331_z5gHa56Js7j9" style="width: 15%; text-align: right">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_495_20230101__20230331_znrL5Y2snEGd" style="width: 15%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Three Months Ended</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>March 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_ecustom--CommonStockOptions_pid_uShares_zXCYQ9M0n2Ak" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Common stock options</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0462">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">14,626</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_ecustom--PerformanceStockUnits_pid_uShares_zTxSUpVHYgl1" style="vertical-align: bottom">
    <td>PSUs</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">54,496</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0466">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_ecustom--RestrictedStockUnits_pid_zd0Ut9uoSEBj" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Restricted stock </td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">850,000</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">900,000</td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_ecustom--AntiDilutedSecurities_pid_zwi8ws9Cj7l8" style="vertical-align: bottom">
    <td><b>Total</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">904,496</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">914,626</td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Therefore, diluted weighted average number of shares outstanding and diluted net loss per share were the same as basic weighted average number of shares outstanding and net loss per share for the three months ended March 31, 2024 and 2023.</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zBaLzXTzUa93" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B6_z7l4QIjCFLal">Therefore, diluted weighted average number of shares
outstanding and diluted net loss per share were the same as basic weighted average number of shares outstanding and net loss per share
for the three months ended March 31, 2024 and 2023.</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.25in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_49E_20240101__20240331_zKWPQDLuseWi" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49C_20230101__20230331_zwiXwTi9WQqb" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Three Months Ended</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>March 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 64%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: right">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_zRGQTXHoMhT9" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Net loss</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">$</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(1,935,958</td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">$</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(2,410,885</td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasicAbstract_iB_zgy58JSQ1or" style="vertical-align: bottom">
    <td>Weighted Average Outstanding Shares:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_uShares_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJkv6CGHEuqk" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.2in">Basic weighted average shares outstanding</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">45,712,224</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">45,487,593</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock_pid_uShares_zU067aM1fsOl" style="vertical-align: bottom">
    <td style="padding-left: 0.2in">Dilutive effect of outstanding stock options and unvested restricted stock</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0485">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0486">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_uShares_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zd27J1f9JnPk" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.2in">Diluted weighted average shares outstanding</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">45,712,224</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">45,487,593</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--EarningsPerShareAbstract_iB_zOB9mDzjNIdh" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Net loss per share</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--EarningsPerShareBasic_pid_uUSDPShares_zcSlm2QFwCO3" style="vertical-align: bottom">
    <td style="padding-left: 0.2in">Basic</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(0.04</td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(0.05</td>
    <td style="border-bottom: white 2.25pt double">)</td></tr>
  <tr id="xdx_404_eus-gaap--EarningsPerShareDiluted_pid_uUSDPShares_zpl67c48EQjj" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.2in">Diluted</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(0.04</td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(0.05</td>
    <td style="border-bottom: white 2.25pt double">)</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ScheduleOfNetSalesByGeography', window );">The following table summarizes net revenues by geography for the three months ended March 31, 2024, and 2023:</a></td>
<td class="text"><p id="xdx_89B_ecustom--ScheduleOfNetSalesByGeography_zDNyTfMVxHZc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8BB_zofRxwMyRalc">The following table summarizes net revenues by geography
for the three months ended March 31, 2024, and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>Three Months Ended March 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 46%"><b>Revenues</b></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 22%; text-align: right">&#160;</td>
    <td style="width: 6%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 22%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.2in">Domestic</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_984_eus-gaap--Revenues_c20240101__20240331__srt--StatementGeographicalAxis__country--US_zfekj6YiphU1" style="text-align: right" title="Net Revenue">6,384,083</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_989_eus-gaap--Revenues_c20230101__20230331__srt--StatementGeographicalAxis__country--US_zU239wHzX3td" style="text-align: right" title="Net Revenue">6,283,965</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.2in">International</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_989_eus-gaap--Revenues_c20240101__20240331__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zszLQcyBXTo6" style="border-bottom: black 1pt solid; text-align: right" title="Net Revenues">1,813,715</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_989_eus-gaap--Revenues_c20230101__20230331__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zligqYQgmNRk" style="border-bottom: black 1pt solid; text-align: right" title="Net Revenues">1,108,640</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td><b>Total</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_98C_eus-gaap--Revenues_c20240101__20240331_zBlWjzy5lZTl" style="border-bottom: black 2.25pt double; text-align: right" title="Revenues">8,197,798</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_98F_eus-gaap--Revenues_c20230101__20230331_zgjEkojcqhJ3" style="border-bottom: black 2.25pt double; text-align: right" title="Revenues">7,392,605</td>
    <td>&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ScheduleOfNetSalesByGeography">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents schedule of net sales by geography.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ScheduleOfNetSalesByGeography</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ScheduleOfSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents schedule of securities text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ScheduleOfSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140173425564000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and equipment consists of the following at:</a></td>
<td class="text"><p id="xdx_891_eus-gaap--PropertyPlantAndEquipmentTextBlock_zYohctDB84N3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8BC_zZFzrzgyaOqi">Property and equipment consists of the following at:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 6in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>March 31, 2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 55%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 19%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 19%">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Furniture and office equipment</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20240331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zxn6LKV20sN3" style="text-align: right">1,423,093</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zWUXpZxHSpy7" style="text-align: right">1,412,164</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Leasehold improvements</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20240331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z6zGUIqg1786" style="text-align: right">1,953,653</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zO7mQR53vrZ" style="text-align: right">1,953,653</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Manufacturing equipment and tooling</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20240331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentAndToolingMember_zqNOXgZ6cnze" style="border-bottom: black 1pt solid; text-align: right">3,311,833</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentAndToolingMember_zUgaSnHXixM9" style="border-bottom: black 1pt solid; text-align: right">3,193,113</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 0.2in">Total property and equipment</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20240331_zSlcSOC85Vi9" style="text-align: right" title="Total property and equipment">6,688,579</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231_zsEKGEvpY8Zi" style="text-align: right" title="Total property and equipment">6,558,930</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Less: accumulated depreciation and amortization</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_984_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20240331_zOTht4UYY9Ec" style="border-bottom: black 1pt solid; text-align: right" title="Less: accumulated depreciation and amortization">(2,933,049</td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_988_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20231231_zJITZYSBPNy5" style="border-bottom: black 1pt solid; text-align: right" title="Less: accumulated depreciation and amortization">(2,721,273</td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Property and equipment, net</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20240331_z4cl2qc71P59" style="border-bottom: black 2.25pt double; text-align: right" title="Property and equipment, net">3,755,530</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20231231_zlbjEsW8Rbb3" style="border-bottom: black 2.25pt double; text-align: right" title="Property and equipment, net">3,837,657</td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140173429420720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">The following table summarizes the activities for our stock options with time based vesting for the three months ended March 31, 2024, and 2023.</a></td>
<td class="text"><p id="xdx_898_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zlWrq3Mfyb6b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8BD_zvPKrWKfE2Hk">The following table summarizes the activities for
our stock options with time based vesting for the three months ended March 31, 2024, and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 4.5in; border-collapse: collapse">
  <tr style="background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>March 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 44%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 22%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 22%">&#160;</td>
    <td style="width: 2%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Dividend yield</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zZSuCsvVBIS8" title="Dividend yield">0.00</span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zfjBMFk5KbQ" title="Dividend yield">0.00</span>%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Expected Volatility</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zDaUabp6Fyul" title="Expected volatility">46.18</span> - <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zg0C9AWaVRP4" title="Expected volatility">46.21</span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zuoZ3Pq4ySTa" title="Expected volatility">61.3</span>%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Weighted-average volatility</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp0_uPure_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zV5OjUQjvGC6" title="Weighted-average volatility">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp0_uPure_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zVyys5zzYZ89" title="Weighted-average volatility">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Expected dividends</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_d0_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zB6E6iySGl1c" title="Expected dividends">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_d0_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z4DBuV6Vbh0e" title="Expected dividends">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Expected term (in years)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zZeIzhdCHAfb" title="Expected term (in years)::XDX::P10Y"><span style="-sec-ix-hidden: xdx2ixbrl0591">10</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z1byDkyDfC2i" title="Expected term (in years)::XDX::P10Y"><span style="-sec-ix-hidden: xdx2ixbrl0593">10</span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Risk-free rate</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zcSsb2JN5pRg" title="Risk-free rate">4.2</span>% - <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zPRdMSdg4Jm6" title="Risk-free rate">4.3</span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zMcAlCg3jvX7" title="Risk-free rate">3.53</span>%</td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">The following table summarizes the status of the stock options:</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z9u1GmXy9bRd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B2_zJ8DmKTKjUPd">The following table summarizes the status of the stock
options:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="9" style="border-bottom: black 1pt solid; text-align: center"><b>Three Months Ended March 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 54%">Outstanding at January 1</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zYoiTVrmYcPf" style="width: 9%; text-align: right" title="Outstanding at beginning">3,256,250</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zxKkDVi3IAXf" style="width: 9%; text-align: right" title="Outstanding at beginning">3.66</td>
    <td style="width: 2%">&#160;</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zAAYvVJlyYVa" style="width: 9%; text-align: right" title="Outstanding at beginning">3,035,000</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zhNzoga14ma6" style="width: 9%; text-align: right" title="Outstanding at beginning">3.93</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Granted</td>
    <td>&#160;</td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_ziK7kuxQgc29" style="text-align: right" title="Granted">65,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zwe0tBog49Ag" style="text-align: right" title="Granted">2.21</td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z2neB2rU5jE2" style="text-align: right" title="Granted">40,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zrO57WfTOI1a" style="text-align: right" title="Granted">3.91</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Exercised</td>
    <td>&#160;</td>
    <td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zNFGcmXnfZei" style="text-align: right" title="Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0619">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zdOs5FzRoU5i" style="text-align: right" title="Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0621">&#8212;</span></td>
    <td>&#160;</td>
    <td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zrmoyx70kaA9" style="text-align: right" title="Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0623">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zDYgCzgwe9oe" style="text-align: right" title="Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0625">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Forfeited</td>
    <td>&#160;</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zuML3OHLNHic" style="text-align: right" title="Forfeited">381,250</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zAQujz4UAVL9" style="text-align: right" title="Forfeited">7.0</td>
    <td>&#160;</td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zcdYDgDNjF92" style="text-align: right" title="Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0631">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z2FoRJB8U7gj" style="text-align: right" title="Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0633">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Outstanding at March 31</td>
    <td>&#160;</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zSkdBzXYYMvk" style="text-align: right" title="Outstanding at ending">2,940,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zUMNnfyoqoXg" style="text-align: right" title="Outstanding at ending">3.19</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zmLssqaTjuyl" style="text-align: right" title="Outstanding at ending">3,075,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zJz1aNHxEbHe" style="text-align: right" title="Outstanding at ending">3.92</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Options exercisable at March 31</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zwxrpXUOKwrc" style="text-align: right" title="Options exercisable">1,393,750</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zOKzHkx1nZw6" style="text-align: right" title="Options exercisable">3.59</td>
    <td>&#160;</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zQkyiePyAbxj" style="text-align: right" title="Options exercisable">1,010,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zrDnZxmsiV75" style="text-align: right" title="Options exercisable">4.63</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Weighted average fair value of options granted during the period</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zZmrFPqZ2UWa" style="text-align: right" title="Weighted average fair value of options granted during the period">1.39</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zY8ko5SEmoPj" style="text-align: right" title="Weighted average fair value of options granted during the period">2.83</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Stock-based compensation expense</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zQAFevKilFAh" style="text-align: right" title="Stock-based compensation expense">393,113</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zvRaPBX5SuA3" style="text-align: right" title="Stock-based compensation expense">535,059</td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock', window );">The following table presents information pertaining to options outstanding at March 31, 2024:</a></td>
<td class="text"><p id="xdx_89E_ecustom--ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock_zPvoFlRomfAk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table presents information pertaining
to options outstanding at March 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid"><b>Range of Exercise Price</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Number<br/>
Outstanding</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Remaining<br/>
Contractual<br/>
Life</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Number<br/>
Exercisable</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 29%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>$2.18 - $4.37</td>
    <td>&#160;</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_uShares_c20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zsp8OekKpoVc" style="text-align: right" title="Number outstanding">2,940,000</td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dxL_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zrPHLUL09Mje" title="Weighted average remaining contractual life::XDX::P6Y10M25D"><span style="-sec-ix-hidden: xdx2ixbrl0667">6.9</span></span> years</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_uUSDPShares_c20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zaUD8pR3q3Sa" style="text-align: right" title="Weighted average exercise price">3.19</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_uShares_c20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_z0inQJXrmbri" style="text-align: right" title="Number exercisable">1,393,750</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_uUSDPShares_c20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zcgmIrpLA4ic" style="text-align: right" title="Weighted average exercise price">3.59</td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock', window );">The following table summarizes the activities for our unvested performance based stock option awards for the three months ended March 31, 2024, and 2023.</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_zfdU1nleHWD3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;<span id="xdx_8B8_zXaeFjqp7yzf">The following table summarizes the activities
for our unvested performance based stock option awards for the three months ended March 31, 2024, and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="9" style="border-bottom: black 1pt solid; text-align: center"><b>Three Months Ended March 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Grant-Date<br/>
Fair Value</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Grant-Date<br/>
Fair Value</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 41%">Unvested at January 1</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByUnvestedAwardOptions_iS_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zotXsiT7eLUi" style="width: 12%; text-align: right" title="Unvested at beginning">200,000</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zJQQjo9OzeD5" style="width: 11%; text-align: right" title="Unvested at beginning">1.48</td>
    <td style="width: 3%">&#160;</td>
    <td id="xdx_984_ecustom--ShareBasedCompensationArrangementByUnvestedAwardOptions_iS_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zR9hL9pdviS8" style="width: 12%; text-align: right" title="Outstanding at beginning"><span style="-sec-ix-hidden: xdx2ixbrl0689">&#8212;</span></td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zprybgccS3Z" style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0690">&#8212;</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Granted</td>
    <td>&#160;</td>
    <td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_pid_d0_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zTEEWu3cIbFi" style="text-align: right" title="Granted">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zeya2LFwdaRd" style="text-align: right" title="Granted">&#8212;</td>
    <td>&#160;</td>
    <td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_pid_d0_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zXWOaTaNmEe1" style="text-align: right" title="Granted">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zsi3lmH5hgo2" style="text-align: right">&#8212;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Vested</td>
    <td>&#160;</td>
    <td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested_pid_d0_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zUsOlgAh1JPh" style="text-align: right" title="Vested">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zpuvY05Z4xj5" style="text-align: right" title="Vested">&#8212;</td>
    <td>&#160;</td>
    <td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested_pid_d0_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zK59qA2YlLx3" style="text-align: right" title="Forfeited">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zWxMuPh3Rqcj" style="text-align: right">&#8212;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Forfeited/canceled</td>
    <td>&#160;</td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures_pid_d0_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zpZ0uITitbJl" style="text-align: right" title="Forfeited/canceled">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zk41Ro850OGl" style="text-align: right" title="Forfeited/canceled">&#8212;</td>
    <td>&#160;</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures_pid_d0_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zFpVkK1Ao6x6" style="text-align: right" title="Forfeited">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zbsX2bw9yNdd" style="text-align: right">&#8212;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Unvested at March 31</td>
    <td>&#160;</td>
    <td id="xdx_981_ecustom--ShareBasedCompensationArrangementByUnvestedAwardOptions_iE_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zA0woV7FpRF1" style="text-align: right" title="Unvested at ending">200,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_z11bZTkeKju3" style="text-align: right" title="Unvested at ending">1.48</td>
    <td>&#160;</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByUnvestedAwardOptions_iE_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zL8NJNwlP4Oc" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0716">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zy5RGvR7rdu5" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0717">&#8212;</span></td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock', window );">The following table summarizes the activities for our restricted stock awards and PSUs for the three months ended March 31, 2024, and 2023.</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_z9ygRDHDD4y4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B1_zutCAf93qVe5">The following table summarizes the activities for
our restricted stock awards and PSUs for the three months ended March 31, 2024, and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="9" style="border-bottom: black 1pt solid; text-align: center"><b>Three Months Ended March 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Grant-Date Fair Value</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Grant-Date Fair Value</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 41%">Unvested at January 1</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zKYWgn2mgeg7" style="width: 12%; text-align: right" title="Outstanding at beginning">904,496</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_znguJnC4jSch" style="width: 11%; text-align: right" title="Outstanding at beginning">1.80</td>
    <td style="width: 3%">&#160;</td>
    <td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_ziNpjHxQAwWe" style="width: 12%; text-align: right" title="Outstanding at beginning">950,000</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_pid_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zCIwRk1DycGk" style="width: 11%; text-align: right" title="Outstanding at beginning">3.04</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Granted</td>
    <td>&#160;</td>
    <td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zR0yXwCX9oBb" style="text-align: right" title="Granted"><span style="-sec-ix-hidden: xdx2ixbrl0735">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zzILKzaYeEi6" style="text-align: right" title="Granted"><span style="-sec-ix-hidden: xdx2ixbrl0737">&#8212;</span></td>
    <td>&#160;</td>
    <td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zKrUnVs8DfHf" style="text-align: right" title="Granted"><span style="-sec-ix-hidden: xdx2ixbrl0739">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z9q5qkqj6DKj" style="text-align: right" title="Granted"><span style="-sec-ix-hidden: xdx2ixbrl0741">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Vested</td>
    <td>&#160;</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z2bO08kSVx91" style="text-align: right" title="Vested"><span style="-sec-ix-hidden: xdx2ixbrl0743">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_ze8tsIucLVlg" style="text-align: right" title="Vested"><span style="-sec-ix-hidden: xdx2ixbrl0745">&#8212;</span></td>
    <td>&#160;</td>
    <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zgTceYgH9i3g" style="text-align: right" title="Vested">50,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zZVhFi4utnhl" style="text-align: right" title="Vested">3.31</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Forfeited/canceled</td>
    <td>&#160;</td>
    <td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z8APshZWAndi" style="text-align: right" title="Forfeited/canceled"><span style="-sec-ix-hidden: xdx2ixbrl0751">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z1FZxq0fktp9" style="text-align: right" title="Forfeited/canceled"><span style="-sec-ix-hidden: xdx2ixbrl0753">&#8212;</span></td>
    <td>&#160;</td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zHJ4BQvdTDKd" style="text-align: right" title="Forfeited/canceled"><span style="-sec-ix-hidden: xdx2ixbrl0755">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zxVVVZJpYx27" style="text-align: right" title="Forfeited/canceled"><span style="-sec-ix-hidden: xdx2ixbrl0757">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Unvested at March 31</td>
    <td>&#160;</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zLmPv1DufjFf" style="text-align: right" title="Outstanding at ending">904,496</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zIuBm8uUqbT5" style="text-align: right" title="Outstanding at ending">1.80</td>
    <td>&#160;</td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zkPMoHvDvW7a" style="text-align: right" title="Outstanding at ending">900,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_pid_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zuylbHtfoaT3" style="text-align: right" title="Outstanding at ending">2.93</td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock', window );">The following table summarizes the activities for our common stock warrants issued in connection with our loan financing agreement with HSBC for the three months ended March 31, 2024, and 2023.</a></td>
<td class="text"><p id="xdx_898_eus-gaap--ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_zIKqcXIf9dk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B4_zELoc4sie5I8">The following table summarizes the activities for
our common stock warrants issued in connection with our loan financing agreement with HSBC for the three months ended March 31, 2024,
and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="9" style="border-bottom: black 1pt solid; text-align: center"><b>Three Months Ended March 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Grant-Date Fair Value</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Grant-Date Fair Value</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 41%">Unvested at January 1</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z32p3x7EvNAi" style="width: 12%; text-align: right" title="Outstanding at beginning"><span style="-sec-ix-hidden: xdx2ixbrl0778">&#8212;</span></td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z6WNsuByy9Hb" style="width: 11%; text-align: right" title="Outstanding at beginning"><span style="-sec-ix-hidden: xdx2ixbrl0780">&#8212;</span></td>
    <td style="width: 3%">&#160;</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zAxpnMBih8G7" style="width: 12%; text-align: right" title="Outstanding at beginning"><span style="-sec-ix-hidden: xdx2ixbrl0782">&#8212;</span></td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_pid_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zfk2gwBzJGb9" style="width: 11%; text-align: right" title="Outstanding at beginning"><span style="-sec-ix-hidden: xdx2ixbrl0784">&#8212;</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Granted</td>
    <td>&#160;</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zSA31aYSHUY8" style="text-align: right" title="Granted">76,104</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zc5SR8rOvrJf" style="text-align: right" title="Granted">1.37</td>
    <td>&#160;</td>
    <td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zzCkLpkxkpX2" style="text-align: right" title="Granted"><span style="-sec-ix-hidden: xdx2ixbrl0790">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z8GphMB98u8h" style="text-align: right" title="Granted"><span style="-sec-ix-hidden: xdx2ixbrl0792">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Vested</td>
    <td>&#160;</td>
    <td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_ziSVH8pmo6B6" style="text-align: right" title="Vested">38,052</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zjFtWrc3Q9D6" style="text-align: right" title="Vested">1.37</td>
    <td>&#160;</td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zFmp0xx4pNtk" style="text-align: right" title="Vested"><span style="-sec-ix-hidden: xdx2ixbrl0798">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zxbtd3qnDml7" style="text-align: right" title="Vested"><span style="-sec-ix-hidden: xdx2ixbrl0800">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Forfeited/canceled</td>
    <td>&#160;</td>
    <td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zLxCz4v7LCIk" style="text-align: right" title="Forfeited/canceled"><span style="-sec-ix-hidden: xdx2ixbrl0802">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z2l0CNeiBtLb" style="text-align: right" title="Forfeited/canceled"><span style="-sec-ix-hidden: xdx2ixbrl0804">&#8212;</span></td>
    <td>&#160;</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z0tyiOTYMoB1" style="text-align: right" title="Forfeited/canceled"><span style="-sec-ix-hidden: xdx2ixbrl0806">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zoF53Nge4OY3" style="text-align: right" title="Forfeited/canceled"><span style="-sec-ix-hidden: xdx2ixbrl0808">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Unvested at March 31</td>
    <td>&#160;</td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zdQalfv0smS7" style="text-align: right" title="Outstanding at ending">38,052</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z0AnyDlHUsy4" style="text-align: right" title="Outstanding at ending">1.37</td>
    <td>&#160;</td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z3qLHiDO5Hm8" style="text-align: right" title="Outstanding at ending"><span style="-sec-ix-hidden: xdx2ixbrl0814">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_pid_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zXGxwUbpLKxa" style="text-align: right" title="Outstanding at ending"><span style="-sec-ix-hidden: xdx2ixbrl0816">&#8212;</span></td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents schedule of share based compensation stock options activity amended table text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in restricted stock units (RSUs).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for outstanding performance shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (c)<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140173520164256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">The components of lease expense were as follows:</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--LeaseCostTableTextBlock_zauTH8fo6kWa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8BE_z1UUuMP6ctD5">The components of lease expense were as follows:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 4.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_496_20240101__20240331_zPZhZXkiyey3" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_490_20230101__20230331_zB4RJACsSBi2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Three Months Ended</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>March 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 62%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: right">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseCost_maLCzGTc_zFrhS2aSiqqb" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Operating lease cost</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">111,548</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">112,522</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ShortTermLeaseCost_maLCzGTc_zSXcYUba4MP6" style="vertical-align: bottom">
    <td>Short-term lease cost</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">3,460</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">52,894</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LeaseCost_zKRTYi0GRENg" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Total lease cost</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">115,008</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">165,416</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_ecustom--FinanceLeaseCost1Abstract_iB_zZm9UtAhC4va" style="vertical-align: bottom">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">Finance lease cost:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_i01_maFLCzAT2_z6I3gfDgKNQ5" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.2in">Amortization of right-of-use assets</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">28,896</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">27,223</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--FinanceLeaseInterestExpense_i01_maFLCzAT2_zMns9RB1ItPk" style="vertical-align: bottom">
    <td style="padding-left: 0.2in">Interest on lease liabilities</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">6,053</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">6,720</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_ecustom--FinanceLeaseCost_i01_zqGwjQy9Sim2" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Total finance lease cost</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">34,949</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">33,943</td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock', window );">Supplemental cash flow information related to leases was as follows:</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--OperatingLeaseLeaseIncomeTableTextBlock_zKNpO7m0QyU3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B8_zC6gKwzRWUK5">Supplemental cash flow information related to leases
was as follows:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 6.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_495_20240101__20240331_zVppJ63WtQ94" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_490_20230101__20230331_zpl9Na4lfwZ6" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Three Months Ended</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>March 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashFlowOperatingActivitiesLesseeAbstract_iB" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 70%; padding-left: 8.25pt; text-indent: -8.25pt">Cash paid for amounts included in the measurement of lease liabilities:</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeasePayments_i01_zsEqvrMPSCH6" style="vertical-align: bottom">
    <td>Operating cash flows from operating leases</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">120,365</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">113,813</td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FinanceLeaseInterestPaymentOnLiability_i01_zc6FMQiffytl" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Financing cash flows from finance leases</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">32,859</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">30,800</td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock', window );">Supplemental balance sheet information related to leases was as follows:</a></td>
<td class="text"><p id="xdx_899_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_zvPao6Y57qB7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B2_zHobzA7gJrza">Supplemental balance sheet information related to
leases was as follows:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49E_20240331_zd6RSgwy3vY7" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_492_20231231_zfj7QKjQoz3f" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>March 31,<br/>
2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,<br/>
2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 55%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 17%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 17%">&#160;</td>
    <td style="width: 2%">&#160;</td></tr>
  <tr id="xdx_402_ecustom--AssetsAndLiabilitiesOperatingLesseeAbstract_iB_zUKGoupTq6x7" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt"><b>Operating Leases</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_z7iI4XVnolG1" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Operating lease right-of-use assets</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">3,428,885</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">3,514,055</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityCurrent_i01I_z2Bc90rfh79b" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Operating lease current liabilities</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">372,109</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">368,313</td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_zpCmZ4XeYpzd" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Operating lease long term liabilities</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">3,241,837</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">3,336,300</td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiability_i01I_zloCrfDY96a4" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">Total operating lease liabilities</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">3,613,946</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">3,704,613</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_ecustom--AssetsAndLiabilitiesLesseeFinanceAbstract_iB_zYpNM6sUPA98" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt"><b>Finance Leases</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentOther_i01I_z2bIO0JnclQ6" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Property and equipment, at cost</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">577,929</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">577,929</td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentOtherAccumulatedDepreciation_i01NI_di_z1PbQqb7pPHk" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Accumulated depreciation</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(190,358</td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(161,461</td>
    <td>)</td></tr>
  <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentOtherNet_i01I_zohKRMyBndKd" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Property and equipment, net</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">387,571</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">416,468</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FinanceLeaseLiabilityCurrent_iI_zQQS7vFSwB8i" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Finance lease current liabilities</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">111,103</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">109,540</td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_zumSjJzwUjP6" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Finance lease long term liabilities</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">288,253</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">316,623</td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--FinanceLeaseLiability_iI_zYz94yTFuF22" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">Total finance lease liabilities</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">399,356</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">426,163</td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5in; border-collapse: collapse">
  <tr>
    <td style="vertical-align: bottom; width: 55%">&#160;</td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 19%; text-align: center"><b>March 31,<br/>
2024</b></td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: top; width: 19%; text-align: center"><b>December 31,<br/>
2023</b></td>
    <td style="vertical-align: top; width: 2%">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom"><b>Weighted Average Remaining Lease Term</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-left: 0.2in">Operating leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span id="xdx_90D_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dxL_c20240331_z8uD2GUNGQ71" title="Operating leases term::XDX::P6Y7M6D"><span style="-sec-ix-hidden: xdx2ixbrl0923">6.6</span></span> Years</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span id="xdx_907_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dxL_c20231231_z8y6Zc5zuA8f" title="::XDX::P6Y10M25D"><span style="-sec-ix-hidden: xdx2ixbrl0924">6.9</span></span> Years</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 0.2in">Finance leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span id="xdx_90B_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dxL_c20240331_zjyamX7bpi3a" title="Finance leases  term::XDX::P3Y7M6D"><span style="-sec-ix-hidden: xdx2ixbrl0926">3.6</span></span> Years</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span id="xdx_90F_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dxL_c20231231_ziSWWq7j83ck" title="::XDX::P6Y8M12D"><span style="-sec-ix-hidden: xdx2ixbrl0927">3.7</span></span> Years</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom"><b>Weighted Average Discount Rate</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-left: 0.2in">Operating leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span id="xdx_904_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20240331_zSIydO3clCqg" title="Operating leases discount rate">5.73</span>%</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span id="xdx_907_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20231231_zWAR3Jqmunb1">5.76</span>%</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 0.2in">Finance leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span id="xdx_900_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_pid_dp_uPure_c20240331_z6TiDvQXNJu3" title="Finance leases discount rate">6.17</span>%</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span id="xdx_90A_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_pid_dp_uPure_c20231231_z9i6Vxe0410h">6.19</span>%</td>
    <td style="vertical-align: top">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Maturities of lease liabilities are as follows:</a></td>
<td class="text"><p id="xdx_892_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zZh9W77sRRAa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B6_zQqUwkv5Smyl">Maturities of lease liabilities are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom"><b>Year Ending December 31,</b></td>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>Operating Leases</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>Finance Leases</b></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; width: 52%">Remainder of 2024</td>
    <td style="vertical-align: top; width: 3%">&#160;</td>
    <td style="vertical-align: bottom; width: 2%">$</td>
    <td id="xdx_98B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20240331_zanzfq8GuNhb" style="vertical-align: bottom; width: 18%; text-align: right" title="2024 - Operating Leases">384,041</td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td id="xdx_98E_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20240331_zN3jqj0wcU1i" style="vertical-align: bottom; width: 18%; text-align: right" title="2024 - Finance Leases">98,578</td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>2025</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_c20240331_z7s6l8TSl4Wg" style="text-align: right" title="2025 - Operating Leases">512,055</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_c20240331_zRUoU2hVhPb2" style="text-align: right" title="2025 - Finance Leases">131,437</td>
    <td>&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2026</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_c20240331_zg5vTq2XkmZg" style="vertical-align: bottom; text-align: right" title="2026 - Operating Leases">512,055</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_986_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_c20240331_zoX17dI2XQ79" style="vertical-align: bottom; text-align: right" title="2026 - Finance Leases">131,437</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">2027</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_c20240331_z2KRKq1vCqLj" style="vertical-align: bottom; text-align: right" title="2027 - Operating Leases">512,055</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_c20240331_zounU9bLy9Pl" style="vertical-align: bottom; text-align: right" title="2027 - Finance Leases">74,194</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2028</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_c20240331_zpTHKbaDDgVb" style="vertical-align: bottom; text-align: right" title="2028 - Operating Leases">511,009</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98C_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_iI_c20240331_zweTlmwMVuXk" style="vertical-align: bottom; text-align: right" title="2028 - Finance Leases">6,179</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">Thereafter</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_989_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_c20240331_zsGbBJNckw15" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Thereafter - Operating Leases">1,833,604</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_98E_eus-gaap--FinanceLeaseLiabilityPaymentsDueAfterYearFive_iI_c20240331_zHAmz4lUIWrk" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Thereafter - Finance Leases"><span style="-sec-ix-hidden: xdx2ixbrl0959">&#8212;</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">Total undiscounted lease payments</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_980_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueTotal_iI_c20240331_zxoLT9s7r5pi" style="vertical-align: bottom; text-align: right" title="Total undiscounted lease payments - Operating Leases">4,264,819</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_982_ecustom--LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal_iI_c20240331_zWaFrJrbLQSk" style="vertical-align: bottom; text-align: right" title="Total undiscounted lease payments - Finance Leases">441,825</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-left: 16.45pt">Less: imputed interest</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_985_ecustom--LesseeOperatingLeaseImputedInterest_iNI_di_c20240331_zydmttaezh5g" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Less: imputed interest - Operating Leases">(650,873</td>
    <td style="vertical-align: bottom">)</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_983_ecustom--LesseeFinancingLeaseImputedInterest_iNI_di_c20240331_zmxAZ4l6Q9g2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Less: imputed interest - Finance Leases">(42,469</td>
    <td style="vertical-align: bottom">)</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">Total lease liabilities</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">$</td>
    <td id="xdx_983_eus-gaap--OperatingLeaseLiability_iI_c20240331_z5NJJfYHuG68" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Total lease liabilities - Operating Leases">3,613,946</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">$</td>
    <td id="xdx_98B_eus-gaap--FinanceLeaseLiability_iI_c20240331_zuHy3SmrjCza" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Total lease liabilities - Finance Leases">399,356</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of income from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-6A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481440/840-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481418/840-10-55-40<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481501/840-20-50-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481501/840-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140173516985856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The following securities were not included in the computation of diluted shares outstanding for the three months ended March 31, 2024, and 2023 because the effect would be anti-dilutive: (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_CommonStockOptions', window );">Common stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">14,626<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_PerformanceStockUnits', window );">PSUs</a></td>
<td class="nump">54,496<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_RestrictedStockUnits', window );">Restricted stock</a></td>
<td class="nump">850,000<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_AntiDilutedSecurities', window );">Total</a></td>
<td class="nump">904,496<span></span>
</td>
<td class="nump">914,626<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_AntiDilutedSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents anti diluted securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_AntiDilutedSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_CommonStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents common stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_CommonStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_PerformanceStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents performance stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_PerformanceStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_RestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_RestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140173429902704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Therefore, diluted weighted average number of shares outstanding and diluted net loss per share were the same as basic weighted average number of shares outstanding and net loss per share for the three months ended March 31, 2024 and 2023. (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (1,935,958)<span></span>
</td>
<td class="num">$ (2,410,885)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Weighted Average Outstanding Shares:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average shares outstanding</a></td>
<td class="nump">45,712,224<span></span>
</td>
<td class="nump">45,487,593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock', window );">Dilutive effect of outstanding stock options and unvested restricted stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average shares outstanding</a></td>
<td class="nump">45,712,224<span></span>
</td>
<td class="nump">45,487,593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Weighted Average Outstanding Shares:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average shares outstanding</a></td>
<td class="nump">45,712,224<span></span>
</td>
<td class="nump">45,487,593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average shares outstanding</a></td>
<td class="nump">45,712,224<span></span>
</td>
<td class="nump">45,487,593<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents dilutive effect of outstanding stock options and unvested restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140173519492672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The following table summarizes net revenues by geography for the three months ended March 31, 2024, and 2023: (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 8,197,798<span></span>
</td>
<td class="nump">$ 7,392,605<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">6,384,083<span></span>
</td>
<td class="nump">6,283,965<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 1,813,715<span></span>
</td>
<td class="nump">$ 1,108,640<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140173516940272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>Number </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of segment | Number</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">FDIC cash uninsured amount | $</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeSecuritiesUSTreasury', window );">Investment securities treasury bill | $</a></td>
<td class="nump">$ 10,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_AntiDilutiveStockOptions', window );">Anti-dilutive stock options | shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,626<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_AntiDilutiveSecurities', window );">Anti-dilutive Securities | shares</a></td>
<td class="nump">904,496<span></span>
</td>
<td class="nump">914,626<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_AntiDilutiveSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents anti dilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_AntiDilutiveSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_AntiDilutiveStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents anti dilutive stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_AntiDilutiveStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeSecuritiesUSTreasury">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest income on US treasury securities. US treasury securities are negotiable debt obligations of the US government, secured by its full faith and credit and issued at various schedules and maturities. The income from treasury securities is exempt from state and local, but not federal, taxes. There are three types of securities issued by the US treasury (bonds, bills, and notes), which are distinguished by the amount of time from the initial sale of the bond to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeSecuritiesUSTreasury</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140173429930576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and equipment consists of the following at: (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 6,688,579<span></span>
</td>
<td class="nump">$ 6,558,930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(2,933,049)<span></span>
</td>
<td class="num">(2,721,273)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,755,530<span></span>
</td>
<td class="nump">3,837,657<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krmd_FurnitureAndOfficeEquipmentMember', window );">Furniture and Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">1,423,093<span></span>
</td>
<td class="nump">1,412,164<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">1,953,653<span></span>
</td>
<td class="nump">1,953,653<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krmd_ManufacturingEquipmentAndToolingMember', window );">Manufacturing Equipment and Tooling [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 3,311,833<span></span>
</td>
<td class="nump">$ 3,193,113<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krmd_FurnitureAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=krmd_FurnitureAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krmd_ManufacturingEquipmentAndToolingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=krmd_ManufacturingEquipmentAndToolingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140173428290208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 214,910<span></span>
</td>
<td class="nump">$ 197,233<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140173426993584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The following table summarizes the activities for our stock options with time based vesting for the three months ended March 31, 2024, and 2023. (Details) - Stock Option Plan 2015 [Member] - Time Based Shares Options [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Weighted-average volatility</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments', window );">Expected dividends</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.53%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">46.18%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">46.21%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">4.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=krmd_TimeBasedSharesOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=krmd_TimeBasedSharesOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140173422469824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The following table summarizes the status of the stock options: (Details) - Stock Option Plan 2015 [Member] - Time Based Shares Options [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning</a></td>
<td class="nump">3,256,250<span></span>
</td>
<td class="nump">3,035,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning</a></td>
<td class="nump">$ 3.66<span></span>
</td>
<td class="nump">$ 3.93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">65,000<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">$ 2.21<span></span>
</td>
<td class="nump">$ 3.91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="nump">381,250<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited</a></td>
<td class="nump">$ 7.0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at ending</a></td>
<td class="nump">2,940,000<span></span>
</td>
<td class="nump">3,075,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at ending</a></td>
<td class="nump">$ 3.19<span></span>
</td>
<td class="nump">$ 3.92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable</a></td>
<td class="nump">1,393,750<span></span>
</td>
<td class="nump">1,010,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable</a></td>
<td class="nump">$ 3.59<span></span>
</td>
<td class="nump">$ 4.63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of options granted during the period</a></td>
<td class="nump">$ 1.39<span></span>
</td>
<td class="nump">$ 2.83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 393,113<span></span>
</td>
<td class="nump">$ 535,059<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=krmd_TimeBasedSharesOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=krmd_TimeBasedSharesOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140173519275392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The following table presents information pertaining to options outstanding at March 31, 2024: (Details) - Stock Option Plan 2015 [Member] - Time Based Shares Options [Member] - Exercise Price1 [Member]<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number outstanding | shares</a></td>
<td class="nump">2,940,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">6 years 10 months 25 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price | $ / shares</a></td>
<td class="nump">$ 3.19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number exercisable | shares</a></td>
<td class="nump">1,393,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price | $ / shares</a></td>
<td class="nump">$ 3.59<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=krmd_TimeBasedSharesOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=krmd_TimeBasedSharesOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=krmd_ExercisePrice1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=krmd_ExercisePrice1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140173512497680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The following table summarizes the activities for our unvested performance based stock option awards for the three months ended March 31, 2024, and 2023. (Details) - Performance Based Shares Options [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions', window );">Outstanding at beginning</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice', window );">Unvested at beginning</a></td>
<td class="nump">$ 1.48<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants', window );">Granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1', window );">Granted</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested', window );">Forfeited</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1', window );">Vested</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures', window );">Forfeited</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1', window );">Forfeited/canceled</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions', window );">Unvested at ending</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice', window );">Unvested at ending</a></td>
<td class="nump">$ 1.48<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award options forfeitures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award options grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award options unvested weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by unvested award options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangements by share based payment award options forfeitures in period weighted average exercise price1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangements by share based payment award options grants in period weighted average exercise price1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangements by share based payment award options vested in period weighted average exercise price1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=krmd_PerformanceBasedSharesOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=krmd_PerformanceBasedSharesOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140173520204304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The following table summarizes the activities for our restricted stock awards and PSUs for the three months ended March 31, 2024, and 2023. (Details) - Restricted Stock Awards [Member] - Stock Option Plan 2021 [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested', window );">Outstanding at beginning</a></td>
<td class="nump">904,496<span></span>
</td>
<td class="nump">950,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested', window );">Outstanding at beginning</a></td>
<td class="nump">$ 1.80<span></span>
</td>
<td class="nump">$ 3.04<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested', window );">Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested', window );">Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross', window );">Vested</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice', window );">Vested</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3.31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested', window );">Forfeited/canceled</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested', window );">Forfeited/canceled</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested', window );">Outstanding at ending</a></td>
<td class="nump">904,496<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested', window );">Outstanding at ending</a></td>
<td class="nump">$ 1.80<span></span>
</td>
<td class="nump">$ 2.93<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award options forfeitures in period unvested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award options grants in period gross unvested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award options outstanding number unvested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award options outstanding weighted average exercise price unvested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award options vested in period gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangements by share based payment award options forfeitures in period weighted average exercise price unvested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangements by share based payment award options grants in period weighted average exercise price unvested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangements by share based payment award options vested in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=krmd_RestrictedStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=krmd_RestrictedStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krmd_StockOptionPlan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140173429453024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The following table summarizes the activities for our common stock warrants issued in connection with our loan financing agreement with HSBC for the three months ended March 31, 2024, and 2023. (Details) - Common Stock Warrants [Member] - Stock Option Plan 2021 [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested', window );">Outstanding at beginning</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested', window );">Outstanding at beginning</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested', window );">Granted</a></td>
<td class="nump">76,104<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested', window );">Granted</a></td>
<td class="nump">$ 1.37<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross', window );">Vested</a></td>
<td class="nump">38,052<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice', window );">Vested</a></td>
<td class="nump">$ 1.37<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested', window );">Forfeited/canceled</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested', window );">Forfeited/canceled</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested', window );">Outstanding at ending</a></td>
<td class="nump">38,052<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested', window );">Outstanding at ending</a></td>
<td class="nump">$ 1.37<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award options forfeitures in period unvested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award options grants in period gross unvested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award options outstanding number unvested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award options outstanding weighted average exercise price unvested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award options vested in period gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangements by share based payment award options forfeitures in period weighted average exercise price unvested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangements by share based payment award options grants in period weighted average exercise price unvested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangements by share based payment award options vested in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=krmd_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=krmd_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krmd_StockOptionPlan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140173517041648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 8,121<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_UnrecognizedCompensationCost', window );">Unrecognized cost</a></td>
<td class="nump">168,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
<td class="nump">122,551<span></span>
</td>
<td class="nump">170,387<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_UnrecognizedCompensationCost', window );">Unrecognized cost</a></td>
<td class="nump">755,513<span></span>
</td>
<td class="nump">1,447,790<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=krmd_CommonStockWarrantsMember', window );">Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_UnrecognizedCompensationCost', window );">Unrecognized cost</a></td>
<td class="nump">$ 52,125<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=krmd_NonEmployeeDirectorAndBoardAdvisorMember', window );">Non Employee Director and Board Advisor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_NonemployeeServicesTransactionCost', window );">Nonemployee services transaction cost</a></td>
<td class="nump">110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementsOverallDescription', window );">Share-based goods and non-employee services transaction</a></td>
<td class="text">to be paid quarterly $12,500 in cash and $15,000 in common stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember', window );">Board of Directors Chairman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_NonemployeeServicesTransactionCost', window );">Nonemployee services transaction cost</a></td>
<td class="nump">140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementsOverallDescription', window );">Share-based goods and non-employee services transaction</a></td>
<td class="text">to be paid quarterly $12,500 in cash and $22,500 in common stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member', window );">Stock Option Plan 2015 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan', window );">Shares issued under plan</a></td>
<td class="nump">2,120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_SharesAvailableForIssuanceShareBasedCompensation', window );">Shares available for issuance</a></td>
<td class="nump">604,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2021Member', window );">Stock Option Plan 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan', window );">Shares issued under plan</a></td>
<td class="nump">656,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_SharesAvailableForIssuanceShareBasedCompensation', window );">Shares available for issuance</a></td>
<td class="nump">152,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krmd_StockOptionPlans2015And2021CombinedMember', window );">Stock Option Plans 2015 and 2021 Combined [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Fair value of shares</a></td>
<td class="nump">$ 3,884,426<span></span>
</td>
<td class="nump">3,511,874<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krmd_StockOptionPlans2015And2021CombinedMember', window );">Stock Option Plans 2015 and 2021 Combined [Member] | Time Based Shares Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_StockBasedCompensationStockOptions', window );">Stock-based compensation expense</a></td>
<td class="nump">393,113<span></span>
</td>
<td class="nump">$ 535,059<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation cost</a></td>
<td class="nump">$ 2,719,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_NonemployeeServicesTransactionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents nonemployee services transaction cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_NonemployeeServicesTransactionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_SharesAvailableForIssuanceShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents shares available for issuance share based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_SharesAvailableForIssuanceShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents shares issued under plan in total shares employee stock ownership plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_StockBasedCompensationStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents stock based compensation stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_StockBasedCompensationStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_UnrecognizedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents unrecognized compensation cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_UnrecognizedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementsOverallDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General description of deferred compensation arrangements. Deferred compensation represents currently earned compensation that, under the terms of a profit-sharing, rabbi trust, pension, employee contract, or equity-based (including stock or unit option) plan, is not actually paid until a later date and is therefore not taxable until that date. May also include some split-dollar life insurance arrangements. This type of arrangement is usually made to help employees postpone paying taxes on the income and also to retain employees longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementsOverallDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=krmd_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=krmd_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=krmd_NonEmployeeDirectorAndBoardAdvisorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=krmd_NonEmployeeDirectorAndBoardAdvisorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krmd_StockOptionPlan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krmd_StockOptionPlans2015And2021CombinedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krmd_StockOptionPlans2015And2021CombinedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=krmd_TimeBasedSharesOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=krmd_TimeBasedSharesOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140173429698560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT OBLIGATIONS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Jul. 28, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 08, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=krmd_AONPremiumFinanceLLCMember', window );">AON Premium Finance LLC [Member] | Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable</a></td>
<td class="nump">$ 570,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_NotePayableTerms', window );">Note payable terms</a></td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment', window );">Description of the frequency of periodic payments</a></td>
<td class="text">Monthly
payments are due on the first of each month beginning August 1, 2023 through June 1, 2024.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermDebtNoncurrent', window );">Balance of AON note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 159,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 314,344<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=krmd_HSBCVenturesUSAIncMember', window );">H S B C Ventures U S A Inc [Member] | Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=krmd_HSBCVenturesUSAIncMember', window );">H S B C Ventures U S A Inc [Member] | Term Loan Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_LinesOfCreditCurrent1', window );">Term loan facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_LinesOfCreditCurrent1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_LinesOfCreditCurrent1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_NotePayableTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents note payable terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_NotePayableTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the frequency of periodic payments (monthly, quarterly, annual).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFrequencyOfPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LinesOfCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LinesOfCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt classified as other, payable after one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=krmd_AONPremiumFinanceLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=krmd_AONPremiumFinanceLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=krmd_PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=krmd_PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=krmd_HSBCVenturesUSAIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=krmd_HSBCVenturesUSAIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=krmd_TermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=krmd_TermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140173426953264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The components of lease expense were as follows: (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 111,548<span></span>
</td>
<td class="nump">$ 112,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">3,460<span></span>
</td>
<td class="nump">52,894<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">115,008<span></span>
</td>
<td class="nump">165,416<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_FinanceLeaseCost1Abstract', window );"><strong>Finance lease cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right-of-use assets</a></td>
<td class="nump">28,896<span></span>
</td>
<td class="nump">27,223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">6,053<span></span>
</td>
<td class="nump">6,720<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_FinanceLeaseCost', window );">Total finance lease cost</a></td>
<td class="nump">$ 34,949<span></span>
</td>
<td class="nump">$ 33,943<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_FinanceLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents finance lease cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_FinanceLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_FinanceLeaseCost1Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents finance lease cost1 abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_FinanceLeaseCost1Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140173520341232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental cash flow information related to leases was as follows: (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 120,365<span></span>
</td>
<td class="nump">$ 113,813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Financing cash flows from finance leases</a></td>
<td class="nump">$ 32,859<span></span>
</td>
<td class="nump">$ 30,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowOperatingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140173427367312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental balance sheet information related to leases was as follows: (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_AssetsAndLiabilitiesOperatingLesseeAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 3,428,885<span></span>
</td>
<td class="nump">$ 3,514,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease current liabilities</a></td>
<td class="nump">372,109<span></span>
</td>
<td class="nump">368,313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease long term liabilities</a></td>
<td class="nump">3,241,837<span></span>
</td>
<td class="nump">3,336,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">3,613,946<span></span>
</td>
<td class="nump">3,704,613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_AssetsAndLiabilitiesLesseeFinanceAbstract', window );"><strong>Finance Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentOther', window );">Property and equipment, at cost</a></td>
<td class="nump">577,929<span></span>
</td>
<td class="nump">577,929<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation', window );">Accumulated depreciation</a></td>
<td class="num">(190,358)<span></span>
</td>
<td class="num">(161,461)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentOtherNet', window );">Property and equipment, net</a></td>
<td class="nump">387,571<span></span>
</td>
<td class="nump">416,468<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease current liabilities</a></td>
<td class="nump">111,103<span></span>
</td>
<td class="nump">109,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease long term liabilities</a></td>
<td class="nump">288,253<span></span>
</td>
<td class="nump">316,623<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total finance lease liabilities</a></td>
<td class="nump">$ 399,356<span></span>
</td>
<td class="nump">$ 426,163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating leases term</a></td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="text">6 years 10 months 25 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseRenewalTerm1', window );">Finance leases term</a></td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Operating leases discount rate</a></td>
<td class="nump">5.73%<span></span>
</td>
<td class="nump">5.76%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseDiscountRate', window );">Finance leases discount rate</a></td>
<td class="nump">6.17%<span></span>
</td>
<td class="nump">6.19%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_AssetsAndLiabilitiesLesseeFinanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents assets and liabilities lessee finance abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_AssetsAndLiabilitiesLesseeFinanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_AssetsAndLiabilitiesOperatingLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents assets and liabilities operating lessee abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_AssetsAndLiabilitiesOperatingLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of finance lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseRenewalTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseRenewalTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentOtherNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentOtherNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140173429749968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Maturities of lease liabilities are as follows: (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024 - Operating Leases</a></td>
<td class="nump">$ 384,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024 - Finance Leases</a></td>
<td class="nump">98,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025 - Operating Leases</a></td>
<td class="nump">512,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2025 - Finance Leases</a></td>
<td class="nump">131,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026 - Operating Leases</a></td>
<td class="nump">512,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2026 - Finance Leases</a></td>
<td class="nump">131,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027 - Operating Leases</a></td>
<td class="nump">512,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2027 - Finance Leases</a></td>
<td class="nump">74,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2028 - Operating Leases</a></td>
<td class="nump">511,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2028 - Finance Leases</a></td>
<td class="nump">6,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter - Operating Leases</a></td>
<td class="nump">1,833,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter - Finance Leases</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal', window );">Total undiscounted lease payments - Operating Leases</a></td>
<td class="nump">4,264,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal', window );">Total undiscounted lease payments - Finance Leases</a></td>
<td class="nump">441,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_LesseeOperatingLeaseImputedInterest', window );">Less: imputed interest - Operating Leases</a></td>
<td class="num">(650,873)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_LesseeFinancingLeaseImputedInterest', window );">Less: imputed interest - Finance Leases</a></td>
<td class="num">(42,469)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities - Operating Leases</a></td>
<td class="nump">3,613,946<span></span>
</td>
<td class="nump">$ 3,704,613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total lease liabilities - Finance Leases</a></td>
<td class="nump">$ 399,356<span></span>
</td>
<td class="nump">$ 426,163<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_LesseeFinancingLeaseImputedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents lessee financing lease imputed interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_LesseeFinancingLeaseImputedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents lessee financing lease lease liability payments due total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_LesseeOperatingLeaseImputedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents lessee operating lease imputed interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_LesseeOperatingLeaseImputedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents lessee operating lease liability payments due total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140173520224992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=krmd_LeaseOneMember', window );">Lease One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_LesseeOperatingLeaseRemainingTerm', window );">Operating lease remaining term</a></td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_LesseeFinanceLeaseRemainingTerm', window );">Finance lease remaining term</a></td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=krmd_LeaseTwoMember', window );">Lease Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_LesseeOperatingLeaseRemainingTerm', window );">Operating lease remaining term</a></td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_LesseeFinanceLeaseRemainingTerm', window );">Finance lease remaining term</a></td>
<td class="text">2 years 9 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=krmd_LeaseThreeMember', window );">Lease Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_LesseeFinanceLeaseRemainingTerm', window );">Finance lease remaining term</a></td>
<td class="text">4 years 6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_LesseeFinanceLeaseRemainingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents lessee finance lease remaining term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_LesseeFinanceLeaseRemainingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_LesseeOperatingLeaseRemainingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents lessee operating lease remaining term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_LesseeOperatingLeaseRemainingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=krmd_LeaseOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=krmd_LeaseOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=krmd_LeaseTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=krmd_LeaseTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=krmd_LeaseThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=krmd_LeaseThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140173536274288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation Allowance</a></td>
<td class="nump">$ 6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>51
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MX"S@4J\ G\^$4-L%_075?QH,_P502P,$%     @ :X"A6%^+WE0N!P  E!P
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M-0X;$WJTMT\M=HRX+AW*>LN7=+P!'EPS;XK"T@%3X!;6FPV+(6,NPT-KO^5
M.LZ!]>IY;=7TN<V#A@CW3E]LA@1+.M32TY8%J1S5)\O5E\4_/G^YN;RZ6U:[
M4GY$5_^ZOU[]UPIXE%+??$KVD[R=AMXR*QUGUD4:Q] FY"8-OCGH'7X/C>!.
M9>A)185VD!30%>#R%^5;!0"0*LPVS<*_]-I!W'> /1WA^165P"WV?,=S^<$X
MS/.2;[AP)+0+V).UG7!<UW>82P]V:6%RZ%W7Y9*W=9[.WVU :)_PN0^8W>[:
MLME!, ,G"+05!G1<&,S7Z[#<H2I"Y;',69B@0.U"HR(K7(M"D))(S^NJ=:LE
M)I[$ V*+M2J!C:N$%?2/>9&]'!8%<SC%CL#-;+WE;$ 9%*2YE=Q87S"<,8\S
MT3O@^1'+TV!;<<'&Q<7\Z&0$&N4P".U8^_+@#!09]VA/8UI-&2.4R@%B8*V8
M8.-BHBZH;RM7K*\-B$^(%'WD?4N*F6"P @> 'QW'_XB..&("-+^]?&L@_>/W
M@5;69FEO9:='KXS*]W6PJ!_#) ?>W<!0_%Y",K+Z%5A]8])=]1;I(34FC:O+
MK59KG94&\/TFA59E?U.^F&I>1,[^!U!+ P04    " !K@*%8CH[=2(H#   U
M"@  &    'AL+W=O<FMS:&5E=',O<VAE970S+GAM;*U6VV[;.!#]%4*[*!+
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MZ$+5=Y1Z8N2Z.N;GTN"EH1JN\%X'RAK@]X64YGEB;P[-37'X'U!+ P04
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ME)9VV0R6#\#^]F0O'?%$FY>LZ N!G85K5>%:TMEPN)2$R>X:['""4R\"7A(
M+^ ]-\P6=*8VHOBM]B2INFF@9@T)[#2D6Z8IGJ1!Q7H@9;WF>?!2?Y^S#? K
MU^5#UH=$5 <M"KQ,=,/4&E0%=KJA6<9 3!4JM=8H4K(SS.?-#[U"P+/TQB1E
MX;_Y Z&V*"TJ2(6JV4RNR ZJ$'8D%YZH(Y0R=@GCE; ZX*P DAVPW_G^B6(J
M) M;)$S%T RCF5^1(5)4RU [Z**:+I)W9;[OJ\E^X>U%2!2UQO\,!P94#:/)
M5&"I*KIA(:N#:JV;4"Z<2Y)\KJD6,MJ_*O,KWFA<5#POA78>?BV?4*Z?V=P
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MC,3YY1Y[ 4XS _Y^2PC[N,D&J$Y;1_\!4$L#!!0    ( &N H5B/]A8S-0<
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MLGA18IU?_#T(I<0J?UQR%G&I!>#WA1!J]Z(_L+\[[OT/4$L#!!0    ( &N
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M=-'896RYGJOJ8JC#T!10='SD35UV3A]V6_W]C7!#\IQD7%\;WV%;]1IH_AF
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M2YS_348M(?-+H11&+10YL9*82GZ*SS(2#MHE)\ #!@J*-#D4/E3^V:AO:4&
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MIE$H !)4V1\:#=9QF]P.W%6!/0^2J'A./9^H)BJ%2L&B+C4G=E16@9&I*;1
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M_Q\#NHQS__EQ#0S>OIFRB+V'\[!P[%+7'AS:DRJZA<8:4#G8 B%7)=UF6>]
MV/F(1I46PZS@%E.LMJB/%C[ZV.I:VE9C!ZOR7*9X@OX31'[,N!_.>"]'S(_&
M\>A7I.M6J#(#635:/:'S-N0P2[@_3OB+1!3J-J?QM=J1>H%V^:Q2I;-RGT>1
M/^6<I&A&OXB/'I45)33GJQ[[X^G43R8SDI)DZL]X2)R,F=,N2=NJ+87%C%8
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M:4&5XC..#H!PEXRJ6N*-,=\:#]7C'LI5&R<<,#H4*S3$(JM98"+B88SZQ!"
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M,P"Q17=T#V3_-:=ZR)+(J76%O G"NN=&&\>-]P=-#_-3Y/J+".234W6#/:+
MI4S83R8[$MB1QW-HX;/=X$4,,DC19\4SEW6-6'/)#VQX69)-H#<+R3<FQ3/
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M_76C7T37IB,>PP$7AO18XX;&7@SPO7(NWBYD@\.=;_$O4$L#!!0    ( &N
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M<#0^@/976KN#X1,<_Q.ZOP%02P,$%     @ :X"A6!\C 4_' @  _ 4  !D
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MQ\&AI4LEOY$\YC6B[@_L[7 WI\'=G.[T$Q>CZ:^4N]##^%^/DR^CS^ O-D;
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M_T'PY+(@6J\2$YS0QD89-SO104*V'5'"V.U-+V0)0L'P [F+7)&8FG$'9%,
M<H6IG.\I?AJ-[D*3FI(AE&6KE59A#?.U2?)8;2#-KPM6HXCB6,+Z1EE=@>=9
MUVIM&HB;6W\NS0J-0NQ=0B ;I16W:[D=E9+#S!2<8CA8<@P-6/6B24%3 4"Y
M0=4Y>@')G_#]KUP5Q#$@#*A E>0*-Y, &XN5*OE.J3*+(L% 0OV4F-HZ)?7M
MPWO7"J2Q'J!FY P.=F,)7WL#?0:(<>%Y<X?M)_S3S_3Q6#C8IYM)RI-37T=6
M3?5+8.?*XN0$>^"[,MI!:PPYV&D ]^,OXYO'L;@?7]Q^NIELZXSLAK(YG=T
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M5:4+>ES*!%P.+H#W^)&3_P,/")\\?_A?4$L#!!0    ( &N H5@)QM316 0
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M)5E\_OIA>;VXN2-O[]A*@#F9!A:;N-0@W0*>MX#Q"X"47"MI"T,6,H/LW_H
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MM'>G+!.D.JQZX ]&(S\9CM%*DI$_IB%R,F:"$R:MRUHP"QD.!ER^E+-V]"
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M=)R,8276O"G,I=Q]%/MX0FLODX5V3]BU<V,VAJS11I9[9410YE7[SW_LU^%
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MP4QUD.^WE(K'BAJ@N19Y/P!02P,$%     @ :X"A6&NM-[2- P  W0X  !D
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M@XD@<IVF5.R&D/!MW_&=YXH'MHR5KG 'O15=PA34U]5$8,DM42*60B89SXB
M1=^Y\V]'?D<GF(A_&&SEP3/14F:</^K"IZCO>)H1)#!7&H+BWP9&D"0:"7G\
M6X Z99LZ\?#Y&?U/(Q[%S*B$$4^^L4C%?:?KD @6=)VH![[]"PI!+8TWYXDT
MOV1;Q'H.F:^EXFF1C Q2EN7_]*DPXB !<>H3@B(A.$YHOI 0%@FA$9HS,[+N
MJ:*#GN!;(G0THND'XXW)1C4LT]TX50+?,LQ3@R\QD 5/L#=9MB2*SA(HNI3]
M!Y(H?&V<9HIA$8<-X6L<!8K/'PE?Z9Z0R%C%1&'G&D,CL@&I-)J.U@ J%@ D
MY9F*)8$LPI Q%?.8A/X'$GA!\P.A6:2?P@:YN@=%62+?DVLR-<U\-LV024(S
MC/%;Y/L8TAF('QCQ1;<Z-*U.8RJ0XN>"U$'0U^D]N7KWON<J-$S+=N>%.</<
MG. %<T(RSDE_U*2K^2X:7;H=/+L]#*R *+M1JJ[A,SH]/;30"<O.#PU>^ *>
ML>PZMV_$4UP:)#5>WPE!LR7@=%5DMB.'<1.Z,]5W6RHB\OUOA"2?%*3R1YV_
M>?O-^O;U$G4K5W0.?0?7( EB \[@]]_\MO='G3D7 JM8U2RM:MK0!_<X!2(<
MNV3'((GJI.;Y79.O%\_-P.NYFT/^MH@*J59)JF4E]?%IA:NAGG$\P8Y+F-K5
M,;."G-L).=C-H8A&VP_KA;1+(6VKD&]FM87HFFY X.[QBJ#VJU;;(BH,.R7#
MSFE61\5 D'7$<HR.A9@MHD*L6Q+KGD9,@4C)%<O(#JB0M:N='<GW\M2Z7G]+
M9D7.32GGQ@KUP.3C]4+O%X(JJ!-AS3]W--_4C&8O;+TPG'UOOZMZ5AECEK%T
MG9:[4.W>8X4X5\FET*J"#XX1_B_>2@H"E[+K0FA5NX*]7<$E5NX"I3H^FVV_
M>[2JV%M[JYK],<*W;KTG3-H"X&BB-8-C'?_'%N_O]WC?OLF/Z=/KL]8*<?8P
MO!!:5?#^_."W?O6LO>CAXU)H5;OVIQ3??DPY==:V:V=MX!^/=FMK;U6S/]'X
M]B/-";.V4SMKPV,=UG;.U>$>7&93$$MSQY=DSM>9RF]:96WY'>'.W)Z/ZH?Z
M^X*Y).]A\H\3>(]:,KPC)K! 2*_1P6$E\OM^7E!\9:[,,Z[P FX>8Z 1"!V
M[Q><J^>";J#\ZC+X"5!+ P04    " !K@*%8#U23TRH$  !H#P  &0   'AL
M+W=O<FMS:&5E=',O<VAE970R-RYX;6RM5VV/VC@0_BM6[G1JI5L2)Y# 'B M
MN^U=I:Z*2GO]4/6#(0-$F\2<;6#W?GW'3C8$8M+N;K] ;,^,GV=LS\MPS\6=
M7 ,H<I^EN1PY:Z4VEZXK%VO(F.SP#>2XLN0B8PJ'8N7*C0 6&Z4L=7W/"]V,
M);DS'IJYJ1@/^5:E20Y30>0VRYAXF$#*]R.'.H\3'Y/56ND)=SS<L!7,0'W>
M3 6.W,I*G&20RX3G1,!RY%S1RVL::04C\6\">UG[)IK*G/,[/7@7CQQ/(X(4
M%DJ;8/BW@VM(4VT)<?Q7&G6J/;5B_?O1^EM#'LG,F81KGGY)8K4>.7V'Q+!D
MVU1]Y/M_H"34T_86/)7FE^Q+6<\ABZU4/"N5$4&6Y,4_NR\=45- .W8%OU3P
M3Q6Z9Q2"4B$P1 MDAM8-4VP\%'Q/A)9&:_K#^,9H(YLDU\<X4P)7$]13XT]K
M($N>XFDF^8HH-D^A/-+D?Y!$X;)43&TEX<MRQ!=WA&_T(<A+\NH&%$M2^9I<
MD)E9^F"6R#1E.?$]VB-?;R&;@_B&$I_P!I )>CTFLS43N$$A+>M"GV<WY-7O
MKX>N0GX:I;LHN4P*+OX9+@&YY;E:2_(FCR$^UG?1+Y5S_$?G3/Q6@[=,=$A
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M#4ME%.]^>28 X0B+#$&5S.M1+J2NA22,(-&M88XKFJ8T7<%%ME+S#BA>>TK
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M\LT(R0*Y;J#.+YF:U18[^J-D^9E[_!]02P,$%     @ :X"A6/4;R.TS P
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MA=K-@D&P7[CGZ]*ZA3"=UFR-2[0/]9VF6=BAY+Q":;B2H+&8!5>#R6+DXGW
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M)7UA4+L VB^4LON).Z#[9J5_ %!+ P04    " !K@*%81>=]( X$  "F#P
M&0   'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6RME_UOFS@8Q_\5BSN=-FDM
M&(.!7A)I2S7=23>M6F]W/[O@)-8 ,]LTZW]_-A!"B"'+J575\/(\WWR^CU^>
M>K'GXIO<4:K CR(OY=+9*57=N:Y,=[0@\I97M-1O-EP41.E;L75E)2C)FJ0B
M=WW/PVY!6.FL%LVS![%:\%KEK*0/ LBZ*(AX^4!SOE\ZT#D\^,*V.V4>N*M%
M1;;TD:JOU8/0=VZODK&"EI+Q$@BZ63KOX=T:1B:AB?B'T;T<7 -CY8GS;^;F
MSVSI>(:(YC151H+HCV>ZIGENE#3']T[4Z;_3) ZO#^H?&_/:S!.1=,WS?UFF
M=DLG=D!&-Z3.U1>^_X-VAD*CE_)<-G_!OHOU')#64O&B2]8$!2O;3_*C*\0@
MP0\F$OPNP1\GX(D$U"6@QFA+UMBZ)XJL%H+O@3#16LU<-+5ILK4;5IIA?%1"
MOV4Z3ZT>ZZK*J1X717)=CYR4*07M!&)E.TO: <N)HAE0'.145TV"/9% _VYX
MKF>"O -O[JDB+)=OP0WX^G@/WOSZ=N$J36B^QTT[F@\MC3]!\XF(6X#@.^![
M?F!)7\^GW].T3T>GZ:ZN2U\<OR^.W^BA";W/%17:?[D%?S6F;89:A<"N8!;A
MG:Q(2I>.7F62BF?JK'[[!6+O=YN]5Q([,8MZLVA.?6"V&6$@S *XX9N;6M\0
M*:FR^F]%HT;4[!G/*Q3X<1R'"_=Y:,T2%\+ "X]Q)]1!3QU<19W60NC)#')&
MGEC.%+./6BL:#FDB'WK)"-H2AF,$D9TY[)G#JYASKB\5%<4EZO <QP]@C*(1
MMB4.(8P\S\Z->VX\R_TW-YL$']//,V-+"2%* CQBML1%7H"G:AWUS-'L$O[(
MRF9+FU[ T6LNX%<2.[$:]U;CV>%Y$&9HU L@90;H]YI59EM_!X@"*9?*YCT^
M*WH818D_7@87PTYXDYXWF>5]GZ9U4;=]):.Z("EKFHT--#DCN(&)A\)X1&J+
MPU!/(SLJ](YMTOM?Q2VIM;"=VLETCJ,P@B->2UP <8#C"=Y!6X>SO(=Y?]6N
MV&D.::#^\="8VA+G)6$PL;_ 8[^%LQUN1/W3^V*G.N31+<@/S[C/XQ#$V)_8
M8^"Q=<+YWMGNC)M3^@O,EH:8)"@<[XN6N,#'$$\Q'QLGO*ISRJ;25M)Y'0Q>
M*!$21*#@I=I)@$%&7FR>US^I!+V#E!]:M$[]'ILNG.^Z)W-KQNV\"KK"[;S2
MP6U\4(+^1;/'3@WG6_79X&9,IKS66X!^3*V^6\%D,,^\6R^,SM;01!R>F(_'
M1@UGF^-X?"X#1S80#,?_#$W%C;N7.SA$F1.L/HML62DUST8G>K>1'D[1'@K;
M&\6KYESUQ)4^I367.WV0IL($Z/<;SM7AQAS5^J/YZC]02P,$%     @ :X"A
M6$GXE&3C P  6Q,  !D   !X;"]W;W)K<VAE971S+W-H965T,S<N>&ULM9A=
MCYLX%(;_BL56JU;:&3"8K]DD4CNCJBNUVE&G[5ZL]L(A3F(5,&L[D_;?KPT,
M)) X%MK<)!A\SO'CEX_7GNT9_RZVA$CPH\A+,7>V4E9WKBNR+2FPN&45*=65
M->,%EJK)-ZZH.,&K.JC(7=_S(K? M'06L_K<(U_,V$[FM"2/'(A=46#^\QW)
MV7[N0.?EQ&>ZV4I]PEW,*KPA3T1^K1ZY:KE=EA4M2"DH*P$GZ[GS%M[=^YX.
MJ'M\HV0O#HZ!1EDR]ETW_EC-'4^/B.0DDSH%5G_/Y)[DN<ZDQO%OF]3I:NK
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M>OG7'ZS;-:E5V1S\6?=78/8%4$L! A0#%     @ :X"A6 =!36*!    L0
M !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M" !K@*%8C*PN)^X    K @  $0              @ &O    9&]C4')O<',O
M8V]R92YX;6Q02P$"% ,4    " !K@*%8F5R<(Q &  "<)P  $P
M    @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( &N H5AZ
MF?-+#@8  '4@   8              " @0T(  !X;"]W;W)K<VAE971S+W-H
M965T,2YX;6Q02P$"% ,4    " !K@*%87XO>5"X'  "4'   &
M    @(%1#@  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @
M:X"A6(Z.W4B* P  -0H  !@              ("!M14  'AL+W=O<FMS:&5E
M=',O<VAE970S+GAM;%!+ 0(4 Q0    ( &N H5CGV1^#B@4  'D5   8
M          " @749  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M    " !K@*%8C_86,S4'  !''@  &               @($U'P  >&PO=V]R
M:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ :X"A6 W!$K/:!0  *"0
M !@              ("!H"8  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+
M 0(4 Q0    ( &N H5A7/DRI&Q4  *PW   8              " @; L  !X
M;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " !K@*%8N6RU;1T#
M  "B!@  &               @($!0@  >&PO=V]R:W-H965T<R]S:&5E=#@N
M>&UL4$L! A0#%     @ :X"A6!UPFS ["0  P!L  !@              ("!
M5$4  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( &N H5BI
MJ1X(#0,  ' &   9              " @<5.  !X;"]W;W)K<VAE971S+W-H
M965T,3 N>&UL4$L! A0#%     @ :X"A6/FPJW)6!0  M@P  !D
M     ("!"5(  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &N H5@)QM316 0  ,(,   9              "
M@:YX  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ :X"A
M6"E8!/+^ @  ?08  !D              ("!/7T  'AL+W=O<FMS:&5E=',O
M<VAE970Q-RYX;6Q02P$"% ,4    " !K@*%8=RQ%4%8%  "N%   &0
M        @(%R@   >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0
M   ( &N H5C1]YXB3@4  '<.   9              " @?^%  !X;"]W;W)K
M<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ :X"A6)LR+P$! P  2@@
M !D              ("!A(L  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q0
M2P$"% ,4    " !K@*%81LOX5<<#  "+#P  &0              @(&\C@
M>&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( &N H5A&HRB4
MS@(  /D'   9              " @;J2  !X;"]W;W)K<VAE971S+W-H965T
M,C(N>&UL4$L! A0#%     @ :X"A6!S_[YXV P  (@D  !D
M ("!OY4  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " !K
M@*%8:ZTWM(T#  #=#@  &0              @($LF0  >&PO=V]R:W-H965T
M<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( &N H5AD)NGI=@(  , %   9
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M970R.2YX;6Q02P$"% ,4    " !K@*%8C(C'7IT#  !X#0  &0
M    @(%.KP  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    (
M &N H5B,!*Q4J@,  #0.   9              " @2*S  !X;"]W;W)K<VAE
M971S+W-H965T,S$N>&UL4$L! A0#%     @ :X"A6/67+4@?!@  /B4  !D
M             ("! [<  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"
M% ,4    " !K@*%8SMP[UCT$  #R%@  &0              @(%9O0  >&PO
M=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( &N H5CU&\CM,P,
M .0)   9              " @<W!  !X;"]W;W)K<VAE971S+W-H965T,S0N
M>&UL4$L! A0#%     @ :X"A6-(QK&&O @  OP8  !D              ("!
M-\4  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " !K@*%8
M1>=]( X$  "F#P  &0              @($=R   >&PO=V]R:W-H965T<R]S
M:&5E=#,V+GAM;%!+ 0(4 Q0    ( &N H5A)^)1DXP,  %L3   9
M      " @6+,  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%
M  @ :X"A6,,+7+>* @  D @  !D              ("!?-   'AL+W=O<FMS
M:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " !K@*%82'$/G[L"  "C"
M&0              @($]TP  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+
M 0(4 Q0    ( &N H5CA8$KF'0,  $@1   -              "  2_6  !X
M;"]S='EL97,N>&UL4$L! A0#%     @ :X"A6)>*NQS     $P(   L
M         ( !=]D  %]R96QS+RYR96QS4$L! A0#%     @ :X"A6+.1JXX$
M!   9QH   \              ( !8-H  'AL+W=O<FMB;V]K+GAM;%!+ 0(4
M Q0    ( &N H5A N\,MAP$  +P7   :              "  9'>  !X;"]?
M<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( &N H5C_>6J2GP$
M !T8   3              "  5#@  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%
3!@     O "\ P P  "#B      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>95</ContextCount>
  <ElementCount>255</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>31</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="form_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - BALANCE SHEETS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/BalanceSheets</Role>
      <ShortName>BALANCE SHEETS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - BALANCE SHEETS (UNAUDITED) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>BALANCE SHEETS (UNAUDITED) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - STATEMENTS OF OPERATIONS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/StatementsOfOperations</Role>
      <ShortName>STATEMENTS OF OPERATIONS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - STATEMENTS OF CASH FLOWS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/StatementsOfCashFlows</Role>
      <ShortName>STATEMENTS OF CASH FLOWS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/StatementsOfStockholdersEquity</Role>
      <ShortName>STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/PropertyAndEquipment</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/Stock-basedCompensation</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - DEBT OBLIGATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/DebtObligations</Role>
      <ShortName>DEBT OBLIGATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/Leases</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="form_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://korumedical.com/role/PropertyAndEquipment</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="form_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/Stock-basedCompensationTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://korumedical.com/role/Stock-basedCompensation</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="form_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/LeasesTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://korumedical.com/role/Leases</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="form_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - The following securities were not included in the computation of diluted shares outstanding for the three months ended March 31, 2024, and 2023 because the effect would be anti-dilutive: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/FollowingSecuritiesWereNotIncludedInComputationOfDilutedSharesOutstandingForThreeMonthsEndedMarch312024And2023BecauseEffectWouldBeAnti-dilutiveDetails</Role>
      <ShortName>The following securities were not included in the computation of diluted shares outstanding for the three months ended March 31, 2024, and 2023 because the effect would be anti-dilutive: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="form_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Therefore, diluted weighted average number of shares outstanding and diluted net loss per share were the same as basic weighted average number of shares outstanding and net loss per share for the three months ended March 31, 2024 and 2023. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/ThereforeDilutedWeightedAverageNumberOfSharesOutstandingAndDilutedNetLossPerShareWereSameAsBasicWeightedAverageNumberOfSharesOutstandingAndNetLossPerShareForThreeMonthsEndedMarch312024And2023.Details</Role>
      <ShortName>Therefore, diluted weighted average number of shares outstanding and diluted net loss per share were the same as basic weighted average number of shares outstanding and net loss per share for the three months ended March 31, 2024 and 2023. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="form_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - The following table summarizes net revenues by geography for the three months ended March 31, 2024, and 2023: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/FollowingTableSummarizesNetRevenuesByGeographyForThreeMonthsEndedMarch312024And2023Details</Role>
      <ShortName>The following table summarizes net revenues by geography for the three months ended March 31, 2024, and 2023: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="form_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="form_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Property and equipment consists of the following at: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails</Role>
      <ShortName>Property and equipment consists of the following at: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="form_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/PropertyAndEquipmentDetailsNarrative</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://korumedical.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="form_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - The following table summarizes the activities for our stock options with time based vesting for the three months ended March 31, 2024, and 2023. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurStockOptionsWithTimeBasedVestingForThreeMonthsEndedMarch312024And2023.Details</Role>
      <ShortName>The following table summarizes the activities for our stock options with time based vesting for the three months ended March 31, 2024, and 2023. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="form_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - The following table summarizes the status of the stock options: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/FollowingTableSummarizesStatusOfStockOptionsDetails</Role>
      <ShortName>The following table summarizes the status of the stock options: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="form_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - The following table presents information pertaining to options outstanding at March 31, 2024: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/FollowingTablePresentsInformationPertainingToOptionsOutstandingAtMarch312024Details</Role>
      <ShortName>The following table presents information pertaining to options outstanding at March 31, 2024: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="form_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - The following table summarizes the activities for our unvested performance based stock option awards for the three months ended March 31, 2024, and 2023. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformanceBasedStockOptionAwardsForThreeMonthsEndedMarch312024And2023.Details</Role>
      <ShortName>The following table summarizes the activities for our unvested performance based stock option awards for the three months ended March 31, 2024, and 2023. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="form_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - The following table summarizes the activities for our restricted stock awards and PSUs for the three months ended March 31, 2024, and 2023. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurRestrictedStockAwardsAndPsusForThreeMonthsEndedMarch312024And2023.Details</Role>
      <ShortName>The following table summarizes the activities for our restricted stock awards and PSUs for the three months ended March 31, 2024, and 2023. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="form_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - The following table summarizes the activities for our common stock warrants issued in connection with our loan financing agreement with HSBC for the three months ended March 31, 2024, and 2023. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurCommonStockWarrantsIssuedInConnectionWithOurLoanFinancingAgreementWithHsbcForThreeMonthsEndedMarch312024And2023.Details</Role>
      <ShortName>The following table summarizes the activities for our common stock warrants issued in connection with our loan financing agreement with HSBC for the three months ended March 31, 2024, and 2023. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="form_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/Stock-basedCompensationDetailsNarrative</Role>
      <ShortName>STOCK-BASED COMPENSATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://korumedical.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="form_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - DEBT OBLIGATIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/DebtObligationsDetailsNarrative</Role>
      <ShortName>DEBT OBLIGATIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://korumedical.com/role/DebtObligations</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="form_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - The components of lease expense were as follows: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/ComponentsOfLeaseExpenseWereAsFollowsDetails</Role>
      <ShortName>The components of lease expense were as follows: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="form_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - Supplemental cash flow information related to leases was as follows: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/SupplementalCashFlowInformationRelatedToLeasesWasAsFollowsDetails</Role>
      <ShortName>Supplemental cash flow information related to leases was as follows: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="form_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - Supplemental balance sheet information related to leases was as follows: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails</Role>
      <ShortName>Supplemental balance sheet information related to leases was as follows: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="form_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - Maturities of lease liabilities are as follows: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails</Role>
      <ShortName>Maturities of lease liabilities are as follows: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="form_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - LEASES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/LeasesDetailsNarrative</Role>
      <ShortName>LEASES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://korumedical.com/role/LeasesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="form_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - INCOME TAXES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>INCOME TAXES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://korumedical.com/role/IncomeTaxes</ParentRole>
      <Position>39</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 17 fact(s) appearing in ix:hidden were eligible for transformation: krmd:AntiDilutiveStockOptions, krmd:LesseeFinanceLeaseRemainingTerm, krmd:LesseeOperatingLeaseRemainingTerm, krmd:UnrecognizedCompensationCost, us-gaap:DeferredIncomeTaxExpenseBenefit, us-gaap:EmployeeBenefitsAndShareBasedCompensation, us-gaap:LesseeFinanceLeaseRenewalTerm1, us-gaap:LesseeOperatingLeaseRenewalTerm, us-gaap:NumberOfReportableSegments, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1, us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 -  form_10-q.htm 58, 59, 64, 65, 72, 77, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 113</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="form_10-q.htm">form_10-q.htm</File>
    <File>krmd-20240331.xsd</File>
    <File>krmd-20240331_cal.xml</File>
    <File>krmd-20240331_def.xml</File>
    <File>krmd-20240331_lab.xml</File>
    <File>krmd-20240331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="413">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>58
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form_10-q.htm": {
   "nsprefix": "krmd",
   "nsuri": "http://korumedical.com/20240331",
   "dts": {
    "inline": {
     "local": [
      "form_10-q.htm"
     ]
    },
    "schema": {
     "local": [
      "krmd-20240331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "krmd-20240331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "krmd-20240331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "krmd-20240331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "krmd-20240331_pre.xml"
     ]
    }
   },
   "keyStandard": 211,
   "keyCustom": 44,
   "axisStandard": 12,
   "axisCustom": 0,
   "memberStandard": 13,
   "memberCustom": 18,
   "hidden": {
    "total": 89,
    "http://fasb.org/us-gaap/2024": 45,
    "http://xbrl.sec.gov/dei/2024": 5,
    "http://korumedical.com/20240331": 39
   },
   "contextCount": 95,
   "entityCount": 1,
   "segmentCount": 31,
   "elementCount": 382,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 413,
    "http://xbrl.sec.gov/dei/2024": 30
   },
   "report": {
    "R1": {
     "role": "http://korumedical.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://korumedical.com/role/BalanceSheets",
     "longName": "00000002 - Statement - BALANCE SHEETS (UNAUDITED)",
     "shortName": "BALANCE SHEETS (UNAUDITED)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://korumedical.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - BALANCE SHEETS (UNAUDITED) (Parenthetical)",
     "shortName": "BALANCE SHEETS (UNAUDITED) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://korumedical.com/role/StatementsOfOperations",
     "longName": "00000004 - Statement - STATEMENTS OF OPERATIONS (UNAUDITED)",
     "shortName": "STATEMENTS OF OPERATIONS (UNAUDITED)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://korumedical.com/role/StatementsOfCashFlows",
     "longName": "00000005 - Statement - STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "shortName": "STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://korumedical.com/role/StatementsOfStockholdersEquity",
     "longName": "00000006 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)",
     "shortName": "STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies",
     "longName": "00000007 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://korumedical.com/role/PropertyAndEquipment",
     "longName": "00000008 - Disclosure - PROPERTY AND EQUIPMENT",
     "shortName": "PROPERTY AND EQUIPMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://korumedical.com/role/Stock-basedCompensation",
     "longName": "00000009 - Disclosure - STOCK-BASED COMPENSATION",
     "shortName": "STOCK-BASED COMPENSATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://korumedical.com/role/DebtObligations",
     "longName": "00000010 - Disclosure - DEBT OBLIGATIONS",
     "shortName": "DEBT OBLIGATIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://korumedical.com/role/Leases",
     "longName": "00000011 - Disclosure - LEASES",
     "shortName": "LEASES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://korumedical.com/role/IncomeTaxes",
     "longName": "00000012 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://korumedical.com/role/CommitmentsAndContingencies",
     "longName": "00000013 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://korumedical.com/role/SubsequentEvents",
     "longName": "00000014 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "00000015 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables",
     "longName": "00000016 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "krmd:ScheduleOfSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "krmd:ScheduleOfSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://korumedical.com/role/PropertyAndEquipmentTables",
     "longName": "00000017 - Disclosure - PROPERTY AND EQUIPMENT (Tables)",
     "shortName": "PROPERTY AND EQUIPMENT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://korumedical.com/role/Stock-basedCompensationTables",
     "longName": "00000018 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://korumedical.com/role/LeasesTables",
     "longName": "00000019 - Disclosure - LEASES (Tables)",
     "shortName": "LEASES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://korumedical.com/role/FollowingSecuritiesWereNotIncludedInComputationOfDilutedSharesOutstandingForThreeMonthsEndedMarch312024And2023BecauseEffectWouldBeAnti-dilutiveDetails",
     "longName": "00000020 - Disclosure - The following securities were not included in the computation of diluted shares outstanding for the three months ended March 31, 2024, and 2023 because the effect would be anti-dilutive: (Details)",
     "shortName": "The following securities were not included in the computation of diluted shares outstanding for the three months ended March 31, 2024, and 2023 because the effect would be anti-dilutive: (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-03-31",
      "name": "krmd:CommonStockOptions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "krmd:ScheduleOfSecuritiesTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-03-31",
      "name": "krmd:CommonStockOptions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "krmd:ScheduleOfSecuritiesTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://korumedical.com/role/ThereforeDilutedWeightedAverageNumberOfSharesOutstandingAndDilutedNetLossPerShareWereSameAsBasicWeightedAverageNumberOfSharesOutstandingAndNetLossPerShareForThreeMonthsEndedMarch312024And2023.Details",
     "longName": "00000021 - Disclosure - Therefore, diluted weighted average number of shares outstanding and diluted net loss per share were the same as basic weighted average number of shares outstanding and net loss per share for the three months ended March 31, 2024 and 2023. (Details)",
     "shortName": "Therefore, diluted weighted average number of shares outstanding and diluted net loss per share were the same as basic weighted average number of shares outstanding and net loss per share for the three months ended March 31, 2024 and 2023. (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-03-31_us-gaap_CommonStockMember",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "unique": true
     }
    },
    "R22": {
     "role": "http://korumedical.com/role/FollowingTableSummarizesNetRevenuesByGeographyForThreeMonthsEndedMarch312024And2023Details",
     "longName": "00000022 - Disclosure - The following table summarizes net revenues by geography for the three months ended March 31, 2024, and 2023: (Details)",
     "shortName": "The following table summarizes net revenues by geography for the three months ended March 31, 2024, and 2023: (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-03-31_country_US",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "krmd:ScheduleOfNetSalesByGeography",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "unique": true
     }
    },
    "R23": {
     "role": "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "00000023 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "shortName": "NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "23",
     "firstAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:CashUninsuredAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:CashUninsuredAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails",
     "longName": "00000024 - Disclosure - Property and equipment consists of the following at: (Details)",
     "shortName": "Property and equipment consists of the following at: (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://korumedical.com/role/PropertyAndEquipmentDetailsNarrative",
     "longName": "00000025 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)",
     "shortName": "PROPERTY AND EQUIPMENT (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurStockOptionsWithTimeBasedVestingForThreeMonthsEndedMarch312024And2023.Details",
     "longName": "00000026 - Disclosure - The following table summarizes the activities for our stock options with time based vesting for the three months ended March 31, 2024, and 2023. (Details)",
     "shortName": "The following table summarizes the activities for our stock options with time based vesting for the three months ended March 31, 2024, and 2023. (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://korumedical.com/role/FollowingTableSummarizesStatusOfStockOptionsDetails",
     "longName": "00000027 - Disclosure - The following table summarizes the status of the stock options: (Details)",
     "shortName": "The following table summarizes the status of the stock options: (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://korumedical.com/role/FollowingTablePresentsInformationPertainingToOptionsOutstandingAtMarch312024Details",
     "longName": "00000028 - Disclosure - The following table presents information pertaining to options outstanding at March 31, 2024: (Details)",
     "shortName": "The following table presents information pertaining to options outstanding at March 31, 2024: (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "AsOf2024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "krmd:ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "krmd:ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformanceBasedStockOptionAwardsForThreeMonthsEndedMarch312024And2023.Details",
     "longName": "00000029 - Disclosure - The following table summarizes the activities for our unvested performance based stock option awards for the three months ended March 31, 2024, and 2023. (Details)",
     "shortName": "The following table summarizes the activities for our unvested performance based stock option awards for the three months ended March 31, 2024, and 2023. (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_custom_PerformanceBasedSharesOptionsMember",
      "name": "krmd:ShareBasedCompensationArrangementByUnvestedAwardOptions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_custom_PerformanceBasedSharesOptionsMember",
      "name": "krmd:ShareBasedCompensationArrangementByUnvestedAwardOptions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurRestrictedStockAwardsAndPsusForThreeMonthsEndedMarch312024And2023.Details",
     "longName": "00000030 - Disclosure - The following table summarizes the activities for our restricted stock awards and PSUs for the three months ended March 31, 2024, and 2023. (Details)",
     "shortName": "The following table summarizes the activities for our restricted stock awards and PSUs for the three months ended March 31, 2024, and 2023. (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member",
      "name": "krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member",
      "name": "krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurCommonStockWarrantsIssuedInConnectionWithOurLoanFinancingAgreementWithHsbcForThreeMonthsEndedMarch312024And2023.Details",
     "longName": "00000031 - Disclosure - The following table summarizes the activities for our common stock warrants issued in connection with our loan financing agreement with HSBC for the three months ended March 31, 2024, and 2023. (Details)",
     "shortName": "The following table summarizes the activities for our common stock warrants issued in connection with our loan financing agreement with HSBC for the three months ended March 31, 2024, and 2023. (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-03-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member",
      "name": "krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-03-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member",
      "name": "krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative",
     "longName": "00000032 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)",
     "shortName": "STOCK-BASED COMPENSATION (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-03-31_us-gaap_PerformanceSharesMember",
      "name": "us-gaap:EmployeeBenefitsAndShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-03-31_us-gaap_PerformanceSharesMember",
      "name": "us-gaap:EmployeeBenefitsAndShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://korumedical.com/role/DebtObligationsDetailsNarrative",
     "longName": "00000033 - Disclosure - DEBT OBLIGATIONS (Details Narrative)",
     "shortName": "DEBT OBLIGATIONS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "AsOf2023-07-28_custom_AONPremiumFinanceLLCMember_custom_PromissoryNoteMember",
      "name": "us-gaap:NotesPayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-07-28_custom_AONPremiumFinanceLLCMember_custom_PromissoryNoteMember",
      "name": "us-gaap:NotesPayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://korumedical.com/role/ComponentsOfLeaseExpenseWereAsFollowsDetails",
     "longName": "00000034 - Disclosure - The components of lease expense were as follows: (Details)",
     "shortName": "The components of lease expense were as follows: (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://korumedical.com/role/SupplementalCashFlowInformationRelatedToLeasesWasAsFollowsDetails",
     "longName": "00000035 - Disclosure - Supplemental cash flow information related to leases was as follows: (Details)",
     "shortName": "Supplemental cash flow information related to leases was as follows: (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://korumedical.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails",
     "longName": "00000036 - Disclosure - Supplemental balance sheet information related to leases was as follows: (Details)",
     "shortName": "Supplemental balance sheet information related to leases was as follows: (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:PropertyPlantAndEquipmentOther",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails",
     "longName": "00000037 - Disclosure - Maturities of lease liabilities are as follows: (Details)",
     "shortName": "Maturities of lease liabilities are as follows: (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://korumedical.com/role/LeasesDetailsNarrative",
     "longName": "00000038 - Disclosure - LEASES (Details Narrative)",
     "shortName": "LEASES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R39": {
     "role": "http://korumedical.com/role/IncomeTaxesDetailsNarrative",
     "longName": "00000039 - Disclosure - INCOME TAXES (Details Narrative)",
     "shortName": "INCOME TAXES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-03-31",
      "name": "us-gaap:DeferredIncomeTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-03-31",
      "name": "us-gaap:DeferredIncomeTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-q.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "krmd_AONPremiumFinanceLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "AONPremiumFinanceLLCMember",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AON Premium Finance LLC [Member]",
        "documentation": "The element represents a o n premium finance l l c member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r537"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable less allowance for doubtful accounts of $24,777 as of March 31, 2024 and $24,777 as of December 31, 2023",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r596"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated depreciation and amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r109",
      "r407"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r584",
      "r585",
      "r586",
      "r587",
      "r641",
      "r693"
     ]
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation expense related to stock options",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation related to Restricted Stock",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r65"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesStatusOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r285"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable, allowance for credit loss, current",
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r174",
      "r178"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "krmd_AntiDilutedSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "AntiDilutedSecurities",
     "presentation": [
      "http://korumedical.com/role/FollowingSecuritiesWereNotIncludedInComputationOfDilutedSharesOutstandingForThreeMonthsEndedMarch312024And2023BecauseEffectWouldBeAnti-dilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total",
        "documentation": "The element represents anti diluted securities."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_AntiDilutiveSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "AntiDilutiveSecurities",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Anti-dilutive Securities",
        "documentation": "The element represents anti dilutive securities."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_AntiDilutiveStockOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "AntiDilutiveStockOptions",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Anti-dilutive stock options",
        "documentation": "The element represents anti dilutive stock options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ASSETS",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r81",
      "r112",
      "r132",
      "r158",
      "r161",
      "r167",
      "r168",
      "r175",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r316",
      "r318",
      "r330",
      "r403",
      "r453",
      "r515",
      "r516",
      "r537",
      "r557",
      "r608",
      "r609",
      "r652"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_AssetsAndLiabilitiesLesseeFinanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "AssetsAndLiabilitiesLesseeFinanceAbstract",
     "presentation": [
      "http://korumedical.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Leases",
        "documentation": "The element represents assets and liabilities lessee finance abstract."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_AssetsAndLiabilitiesOperatingLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "AssetsAndLiabilitiesOperatingLesseeAbstract",
     "presentation": [
      "http://korumedical.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases",
        "documentation": "The element represents assets and liabilities operating lessee abstract."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL CURRENT ASSETS",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r117",
      "r132",
      "r175",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r316",
      "r318",
      "r330",
      "r537",
      "r608",
      "r609",
      "r652"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://korumedical.com/role/FollowingTablePresentsInformationPertainingToOptionsOutstandingAtMarch312024Details",
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurCommonStockWarrantsIssuedInConnectionWithOurLoanFinancingAgreementWithHsbcForThreeMonthsEndedMarch312024And2023.Details",
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurRestrictedStockAwardsAndPsusForThreeMonthsEndedMarch312024And2023.Details",
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurStockOptionsWithTimeBasedVestingForThreeMonthsEndedMarch312024And2023.Details",
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformanceBasedStockOptionAwardsForThreeMonthsEndedMarch312024And2023.Details",
      "http://korumedical.com/role/FollowingTableSummarizesStatusOfStockOptionsDetails",
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r248",
      "r249",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "BASIS OF PRESENTATION",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "BoardOfDirectorsChairmanMember",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board of Directors Chairman [Member]"
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r107",
      "r507"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH AND CASH EQUIVALENTS",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD",
        "periodEndLabel": "CASH AND CASH EQUIVALENTS, END OF PERIOD",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r53",
      "r130"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET DECREASE IN CASH AND CASH EQUIVALENTS",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r53"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Non-Cash Operating, Investing and Financing Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowOperatingActivitiesLesseeAbstract",
     "presentation": [
      "http://korumedical.com/role/SupplementalCashFlowInformationRelatedToLeasesWasAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_CashPaidDuringPeriodsForAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "CashPaidDuringPeriodsForAbstract",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid during the periods for:",
        "documentation": "The element represents cash paid during periods for abstract."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashUninsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashUninsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FDIC cash uninsured amount",
        "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://korumedical.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r189",
      "r190",
      "r492",
      "r600",
      "r605"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://korumedical.com/role/StatementsOfStockholdersEquity",
      "http://korumedical.com/role/ThereforeDilutedWeightedAverageNumberOfSharesOutstandingAndDilutedNetLossPerShareWereSameAsBasicWeightedAverageNumberOfSharesOutstandingAndNetLossPerShareForThreeMonthsEndedMarch312024And2023.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r548",
      "r549",
      "r550",
      "r552",
      "r553",
      "r554",
      "r555",
      "r584",
      "r585",
      "r587",
      "r641",
      "r692",
      "r693"
     ]
    },
    "krmd_CommonStockOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "CommonStockOptions",
     "presentation": [
      "http://korumedical.com/role/FollowingSecuritiesWereNotIncludedInComputationOfDilutedSharesOutstandingForThreeMonthsEndedMarch312024And2023BecauseEffectWouldBeAnti-dilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock options",
        "documentation": "The element represents common stock options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://korumedical.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://korumedical.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r440"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://korumedical.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares, issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://korumedical.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r38",
      "r440",
      "r459",
      "r693",
      "r694"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, $0.01 par value, 75,000,000 shares authorized, 49,143,589 and 49,089,864 shares issued 45,723,087 and 45,669,362 shares outstanding as of March 31, 2024, and December 31, 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r404",
      "r537"
     ]
    },
    "krmd_CommonStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "CommonStockWarrantsMember",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurCommonStockWarrantsIssuedInConnectionWithOurLoanFinancingAgreementWithHsbcForThreeMonthsEndedMarch312024And2023.Details",
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_CompensationeExpenseRelatedToRestrictedStockAwards": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "CompensationeExpenseRelatedToRestrictedStockAwards",
     "presentation": [
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation expense related to restricted stock (in shares)",
        "documentation": "The element represents compensatione expense related to restricted stock awards."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of goods sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46",
      "r368"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r606"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r606",
      "r607"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://korumedical.com/role/DebtObligations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DEBT OBLIGATIONS",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r131",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r195",
      "r196",
      "r206",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r222",
      "r229",
      "r230",
      "r231",
      "r341"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r30",
      "r31",
      "r73",
      "r74",
      "r134",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r213",
      "r218",
      "r219",
      "r220",
      "r221",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r534",
      "r581",
      "r601",
      "r602",
      "r603",
      "r644",
      "r645"
     ]
    },
    "us-gaap_DebtInstrumentFrequencyOfPeriodicPayment": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFrequencyOfPeriodicPayment",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of the frequency of periodic payments",
        "documentation": "Description of the frequency of periodic payments (monthly, quarterly, annual)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r28"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r134",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r213",
      "r218",
      "r219",
      "r220",
      "r221",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r534",
      "r581",
      "r601",
      "r602",
      "r603",
      "r644",
      "r645"
     ]
    },
    "us-gaap_DeferredCompensationArrangementsOverallDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCompensationArrangementsOverallDescription",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based goods and non-employee services transaction",
        "documentation": "General description of deferred compensation arrangements. Deferred compensation represents currently earned compensation that, under the terms of a profit-sharing, rabbi trust, pension, employee contract, or equity-based (including stock or unit option) plan, is not actually paid until a later date and is therefore not taxable until that date. May also include some split-dollar life insurance arrangements. This type of arrangement is usually made to help employees postpone paying taxes on the income and also to retain employees longer."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred income tax assets, net of allowance for non-realization of deferred tax assets of $6,391,452 and $6,002,777 for March 31, 2024 and December 31, 2023, respectively",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r290"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax benefit",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r99",
      "r583"
     ]
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred income taxes",
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_DeferredRentReceivablesNetNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRentReceivablesNetNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Rent Receivables, Net, Noncurrent",
        "documentation": "Amount of excess of rental income recognized over rental payment required by lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r650"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r297"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/PropertyAndEquipmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization expense",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r19"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      },
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows",
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r158",
      "r164",
      "r168",
      "r515",
      "r516"
     ]
    },
    "krmd_DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock",
     "presentation": [
      "http://korumedical.com/role/ThereforeDilutedWeightedAverageNumberOfSharesOutstandingAndDilutedNetLossPerShareWereSameAsBasicWeightedAverageNumberOfSharesOutstandingAndNetLossPerShareForThreeMonthsEndedMarch312024And2023.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive effect of outstanding stock options and unvested restricted stock",
        "documentation": "The element represents dilutive effect of outstanding stock options and unvested restricted stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCK-BASED COMPENSATION",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r246",
      "r277",
      "r278",
      "r280",
      "r528"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_DisclosureSubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "DisclosureSubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r571"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r569",
      "r571",
      "r572"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r570"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r571"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r571"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r561"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations",
      "http://korumedical.com/role/ThereforeDilutedWeightedAverageNumberOfSharesOutstandingAndDilutedNetLossPerShareWereSameAsBasicWeightedAverageNumberOfSharesOutstandingAndNetLossPerShareForThreeMonthsEndedMarch312024And2023.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NET LOSS PER SHARE",
        "verboseLabel": "Net loss per share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations",
      "http://korumedical.com/role/ThereforeDilutedWeightedAverageNumberOfSharesOutstandingAndDilutedNetLossPerShareWereSameAsBasicWeightedAverageNumberOfSharesOutstandingAndNetLossPerShareForThreeMonthsEndedMarch312024And2023.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r149",
      "r151",
      "r153",
      "r154",
      "r155",
      "r157",
      "r312",
      "r315",
      "r327",
      "r328",
      "r400",
      "r411",
      "r511"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations",
      "http://korumedical.com/role/ThereforeDilutedWeightedAverageNumberOfSharesOutstandingAndDilutedNetLossPerShareWereSameAsBasicWeightedAverageNumberOfSharesOutstandingAndNetLossPerShareForThreeMonthsEndedMarch312024And2023.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r151",
      "r153",
      "r154",
      "r155",
      "r157",
      "r312",
      "r315",
      "r327",
      "r328",
      "r400",
      "r411",
      "r511"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NET LOSS PER COMMON SHARE",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r156"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://korumedical.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statutory rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r292",
      "r303",
      "r529"
     ]
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total stock-based compensation expense",
        "documentation": "Amount of expense for employee benefit and equity-based compensation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued payroll and related taxes",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total unrecognized compensation cost",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r279"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r564"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "dei_EntityListingParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingParValuePerShare",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Par Value Per Share",
        "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r575"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://korumedical.com/role/StatementsOfStockholdersEquity",
      "http://korumedical.com/role/ThereforeDilutedWeightedAverageNumberOfSharesOutstandingAndDilutedNetLossPerShareWereSameAsBasicWeightedAverageNumberOfSharesOutstandingAndNetLossPerShareForThreeMonthsEndedMarch312024And2023.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r103",
      "r120",
      "r121",
      "r122",
      "r135",
      "r136",
      "r137",
      "r139",
      "r144",
      "r146",
      "r148",
      "r160",
      "r176",
      "r177",
      "r183",
      "r232",
      "r301",
      "r302",
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r315",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r342",
      "r343",
      "r359",
      "r410",
      "r416",
      "r417",
      "r418",
      "r425",
      "r479"
     ]
    },
    "krmd_ExercisePrice1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "ExercisePrice1Member",
     "presentation": [
      "http://korumedical.com/role/FollowingTablePresentsInformationPertainingToOptionsOutstandingAtMarch312024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price1 [Member]",
        "documentation": "The element represents exercise price1 member."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FAIR VALUE MEASUREMENTS",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_FinanceLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "FinanceLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ComponentsOfLeaseExpenseWereAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total finance lease cost",
        "documentation": "The element represents finance lease cost."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_FinanceLeaseCost1Abstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "FinanceLeaseCost1Abstract",
     "presentation": [
      "http://korumedical.com/role/ComponentsOfLeaseExpenseWereAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease cost:",
        "documentation": "The element represents finance lease cost1 abstract."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ComponentsOfLeaseExpenseWereAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest on lease liabilities",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r351",
      "r536"
     ]
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/SupplementalCashFlowInformationRelatedToLeasesWasAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing cash flows from finance leases",
        "documentation": "Amount of interest paid on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r354"
     ]
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails",
      "http://korumedical.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total finance lease liabilities",
        "verboseLabel": "Total lease liabilities - Finance Leases",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r345",
      "r355"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets",
      "http://korumedical.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing lease liability \u2013 current",
        "verboseLabel": "Finance lease current liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets",
      "http://korumedical.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing lease liability, net of current portion",
        "verboseLabel": "Finance lease long term liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Thereafter - Finance Leases",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2024 - Finance Leases",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2028 - Finance Leases",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027 - Finance Leases",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026 - Finance Leases",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025 - Finance Leases",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments on finance lease liability",
        "label": "Finance Lease, Principal Payments",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r354"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ComponentsOfLeaseExpenseWereAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of right-of-use assets",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r351",
      "r536"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-lived intangible assets, accumulated amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r181",
      "r182",
      "r519"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets, net of accumulated amortization of $406,801 and $390,341 as of March 31, 2024 and December 31, 2023, respectively",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r599"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on currency exchange",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r332",
      "r333",
      "r334",
      "r476"
     ]
    },
    "krmd_FurnitureAndOfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "FurnitureAndOfficeEquipmentMember",
     "presentation": [
      "http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Office Equipment [Member]",
        "documentation": "The element represents furniture and office equipment member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on disposal of fixed assets",
        "label": "Gain (Loss) on Disposition of Other Assets",
        "documentation": "Amount of gain (loss) on sale or disposal of other assets."
       }
      }
     },
     "auth_ref": [
      "r580"
     ]
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on disposal of fixed assets, net",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross Profit",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r47",
      "r80",
      "r132",
      "r175",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r330",
      "r513",
      "r515",
      "r589",
      "r591",
      "r592",
      "r593",
      "r594",
      "r608"
     ]
    },
    "krmd_HSBCVenturesUSAIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "HSBCVenturesUSAIncMember",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "H S B C Ventures U S A Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IMPAIRMENT OF LONG-LIVED ASSETS",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r62"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "LOSS BEFORE INCOME TAXES",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r412",
      "r513",
      "r589",
      "r591",
      "r592",
      "r593",
      "r594"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://korumedical.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r288",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r298",
      "r304",
      "r306",
      "r307",
      "r308",
      "r424",
      "r529"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income Tax Benefit",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r100",
      "r147",
      "r148",
      "r158",
      "r165",
      "r168",
      "r291",
      "r292",
      "r305",
      "r413",
      "r529"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r129",
      "r299",
      "r300"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase / (Decrease) in Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Increase in Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Decrease in Accrued expenses",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase / (Decrease) in Accrued payroll and related taxes",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease / (Increase) in Inventory",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(Decrease) / Increase in Other liabilities",
        "documentation": "Amount of increase (decrease) in current liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease in Prepaid expenses and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PATENTS",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r366",
      "r367",
      "r369",
      "r510",
      "r598"
     ]
    },
    "us-gaap_InterestIncomeSecuritiesUSTreasury": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeSecuritiesUSTreasury",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment securities treasury bill",
        "documentation": "Interest income on US treasury securities. US treasury securities are negotiable debt obligations of the US government, secured by its full faith and credit and issued at various schedules and maturities. The income from treasury securities is exempt from state and local, but not federal, taxes. There are three types of securities issued by the US treasury (bonds, bills, and notes), which are distinguished by the amount of time from the initial sale of the bond to maturity."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r127",
      "r128"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r508",
      "r537"
     ]
    },
    "krmd_IssuanceOfCommonStockCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "IssuanceOfCommonStockCompensation",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock as compensation",
        "documentation": "The element represents issuance of common stock compensation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of warrants",
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://korumedical.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r357",
      "r578"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://korumedical.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r357",
      "r578"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ComponentsOfLeaseExpenseWereAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total lease cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r350",
      "r536"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://korumedical.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The components of lease expense were as follows:",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "krmd_LeaseOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "LeaseOneMember",
     "presentation": [
      "http://korumedical.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease One [Member]",
        "documentation": "The element represents lease one member."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_LeaseThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "LeaseThreeMember",
     "presentation": [
      "http://korumedical.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Three [Member]",
        "documentation": "The element represents lease three member."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_LeaseTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "LeaseTwoMember",
     "presentation": [
      "http://korumedical.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Two [Member]",
        "documentation": "The element represents lease two member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r356"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeasesOfLesseeDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesOfLesseeDisclosureTextBlock",
     "presentation": [
      "http://korumedical.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LEASES",
        "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeFinanceLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeFinanceLeaseDiscountRate",
     "presentation": [
      "http://korumedical.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance leases discount rate",
        "documentation": "Discount rate used by lessee to determine present value of finance lease payments."
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "krmd_LesseeFinanceLeaseRemainingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "LesseeFinanceLeaseRemainingTerm",
     "presentation": [
      "http://korumedical.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease remaining term",
        "documentation": "The element represents lessee finance lease remaining term."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeFinanceLeaseRenewalTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeFinanceLeaseRenewalTerm1",
     "presentation": [
      "http://korumedical.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance leases term",
        "documentation": "Term of lessee's finance lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r646"
     ]
    },
    "krmd_LesseeFinancingLeaseImputedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "LesseeFinancingLeaseImputedInterest",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest - Finance Leases",
        "documentation": "The element represents lessee financing lease imputed interest.",
        "label": "Lessee Financing Lease Imputed interest"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total undiscounted lease payments - Finance Leases",
        "documentation": "The element represents lessee financing lease lease liability payments due total."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://korumedical.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating leases discount rate",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "krmd_LesseeOperatingLeaseImputedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "LesseeOperatingLeaseImputedInterest",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest - Operating Leases",
        "documentation": "The element represents lessee operating lease imputed interest.",
        "label": "Lessee Operating Lease Imputed interest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://korumedical.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturities of lease liabilities are as follows:",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r649"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Thereafter - Operating Leases",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2024 - Operating Leases",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueTotal",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total undiscounted lease payments - Operating Leases",
        "documentation": "The element represents lessee operating lease liability payments due total."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2028 - Operating Leases",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027 - Operating Leases",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026 - Operating Leases",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025 - Operating Leases",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "krmd_LesseeOperatingLeaseRemainingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "LesseeOperatingLeaseRemainingTerm",
     "presentation": [
      "http://korumedical.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease remaining term",
        "documentation": "The element represents lessee operating lease remaining term."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://korumedical.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating leases term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r646"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r30",
      "r31",
      "r32",
      "r33",
      "r34",
      "r35",
      "r36",
      "r132",
      "r175",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r317",
      "r318",
      "r319",
      "r330",
      "r439",
      "r512",
      "r557",
      "r608",
      "r652",
      "r653"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r75",
      "r406",
      "r537",
      "r582",
      "r597",
      "r643"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL CURRENT LIABILITIES",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r106",
      "r132",
      "r175",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r317",
      "r318",
      "r319",
      "r330",
      "r537",
      "r608",
      "r652",
      "r653"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT LIABILITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LinesOfCreditCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LinesOfCreditCurrent",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revolving credit facility",
        "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r73"
     ]
    },
    "krmd_LinesOfCreditCurrent1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "LinesOfCreditCurrent1",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term loan facility"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_ManufacturingEquipmentAndToolingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "ManufacturingEquipmentAndToolingMember",
     "presentation": [
      "http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Manufacturing Equipment and Tooling [Member]",
        "documentation": "The element represents manufacturing equipment and tooling member."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurStockOptionsWithTimeBasedVestingForThreeMonthsEndedMarch312024And2023.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r191",
      "r192",
      "r193",
      "r194",
      "r242",
      "r286",
      "r329",
      "r364",
      "r414",
      "r415",
      "r421",
      "r430",
      "r431",
      "r482",
      "r484",
      "r486",
      "r487",
      "r489",
      "r502",
      "r503",
      "r518",
      "r525",
      "r527",
      "r530",
      "r531",
      "r532",
      "r533",
      "r546",
      "r610",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurStockOptionsWithTimeBasedVestingForThreeMonthsEndedMarch312024And2023.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r191",
      "r192",
      "r193",
      "r194",
      "r242",
      "r286",
      "r329",
      "r364",
      "r414",
      "r415",
      "r421",
      "r430",
      "r431",
      "r482",
      "r484",
      "r486",
      "r487",
      "r489",
      "r502",
      "r503",
      "r518",
      "r525",
      "r527",
      "r530",
      "r531",
      "r532",
      "r546",
      "r610",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NATURE OF OPERATIONS",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r101"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NET CASH USED IN FINANCING ACTIVITIES",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET CASH USED IN INVESTING ACTIVITIES",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET CASH USED IN OPERATING ACTIVITIES",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54",
      "r55"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://korumedical.com/role/StatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows",
      "http://korumedical.com/role/StatementsOfOperations",
      "http://korumedical.com/role/StatementsOfStockholdersEquity",
      "http://korumedical.com/role/ThereforeDilutedWeightedAverageNumberOfSharesOutstandingAndDilutedNetLossPerShareWereSameAsBasicWeightedAverageNumberOfSharesOutstandingAndNetLossPerShareForThreeMonthsEndedMarch312024And2023.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET LOSS",
        "label": "Net Loss",
        "verboseLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r55",
      "r77",
      "r104",
      "r118",
      "r119",
      "r122",
      "r132",
      "r138",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r147",
      "r148",
      "r152",
      "r175",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r312",
      "r315",
      "r328",
      "r330",
      "r409",
      "r461",
      "r477",
      "r478",
      "r556",
      "r608"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_NonEmployeeDirectorAndBoardAdvisorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "NonEmployeeDirectorAndBoardAdvisorMember",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Employee Director and Board Advisor [Member]",
        "documentation": "The element represents non employee director and board advisor member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonUsMember",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesNetRevenuesByGeographyForThreeMonthsEndedMarch312024And2023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-US [Member]",
        "documentation": "Countries excluding the United States of America (US)."
       }
      }
     },
     "auth_ref": [
      "r695",
      "r696",
      "r697",
      "r698"
     ]
    },
    "krmd_NonemployeeServicesTransactionCost": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "NonemployeeServicesTransactionCost",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonemployee services transaction cost",
        "documentation": "The element represents nonemployee services transaction cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL OTHER INCOME",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Operating Income/(Expense)"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_NotePayableTerms": {
     "xbrltype": "percentItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "NotePayableTerms",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note payable terms",
        "documentation": "The element represents note payable terms."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes payable",
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r74",
      "r661",
      "r662"
     ]
    },
    "us-gaap_NotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note payable",
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of segment",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r514",
      "r517",
      "r590"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Operating Expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OPERATING EXPENSES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Operating Loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r513",
      "r589",
      "r591",
      "r592",
      "r593",
      "r594"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ComponentsOfLeaseExpenseWereAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r536"
     ]
    },
    "us-gaap_OperatingLeaseLeaseIncomeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLeaseIncomeTableTextBlock",
     "presentation": [
      "http://korumedical.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental cash flow information related to leases was as follows:",
        "documentation": "Tabular disclosure of components of income from operating lease."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r358"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails",
      "http://korumedical.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total operating lease liabilities",
        "verboseLabel": "Total lease liabilities - Operating Leases",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets",
      "http://korumedical.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability \u2013 current",
        "verboseLabel": "Operating lease current liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets",
      "http://korumedical.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability, net of current portion",
        "verboseLabel": "Operating lease long term liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/SupplementalCashFlowInformationRelatedToLeasesWasAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating cash flows from operating leases",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r354"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets",
      "http://korumedical.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasesOfLesseeDisclosureTextBlock",
     "presentation": [
      "http://korumedical.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental balance sheet information related to leases was as follows:",
        "documentation": "Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r84",
      "r85",
      "r87",
      "r88"
     ]
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57",
      "r58",
      "r71"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other liabilities",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r537"
     ]
    },
    "us-gaap_OtherLongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLongTermDebtNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance of AON note",
        "documentation": "Amount of long-term debt classified as other, payable after one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r438"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income, net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other receivables",
        "documentation": "Amount due from parties in nontrade transactions, classified as other."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r448",
      "r516",
      "r663"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r571"
     ]
    },
    "krmd_PaymentsOnIndebtedness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "PaymentsOnIndebtedness",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments on indebtedness",
        "documentation": "The element represents payments on indebtedness.",
        "label": "Payments on Indebtedness"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of intangible assets",
        "label": "Payments to Acquire Intangible Assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireProductiveAssets",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Productive Assets",
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r638",
      "r639",
      "r640"
     ]
    },
    "krmd_PerformanceBasedSharesOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "PerformanceBasedSharesOptionsMember",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformanceBasedStockOptionAwardsForThreeMonthsEndedMarch312024And2023.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance Based Shares Options [Member]",
        "documentation": "The element represents performance based shares options member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_PerformanceStockUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "PerformanceStockUnits",
     "presentation": [
      "http://korumedical.com/role/FollowingSecuritiesWereNotIncludedInComputationOfDilutedSharesOutstandingForThreeMonthsEndedMarch312024And2023BecauseEffectWouldBeAnti-dilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PSUs",
        "documentation": "The element represents performance stock units."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://korumedical.com/role/FollowingTablePresentsInformationPertainingToOptionsOutstandingAtMarch312024Details",
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurCommonStockWarrantsIssuedInConnectionWithOurLoanFinancingAgreementWithHsbcForThreeMonthsEndedMarch312024And2023.Details",
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurRestrictedStockAwardsAndPsusForThreeMonthsEndedMarch312024And2023.Details",
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurStockOptionsWithTimeBasedVestingForThreeMonthsEndedMarch312024And2023.Details",
      "http://korumedical.com/role/FollowingTableSummarizesStatusOfStockOptionsDetails",
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://korumedical.com/role/FollowingTablePresentsInformationPertainingToOptionsOutstandingAtMarch312024Details",
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurCommonStockWarrantsIssuedInConnectionWithOurLoanFinancingAgreementWithHsbcForThreeMonthsEndedMarch312024And2023.Details",
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurRestrictedStockAwardsAndPsusForThreeMonthsEndedMarch312024And2023.Details",
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurStockOptionsWithTimeBasedVestingForThreeMonthsEndedMarch312024And2023.Details",
      "http://korumedical.com/role/FollowingTableSummarizesStatusOfStockOptionsDetails",
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r565"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r567"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r179",
      "r180",
      "r509"
     ]
    },
    "krmd_PromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "PromissoryNoteMember",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Promissory Note [Member]",
        "documentation": "The element represents promissory note member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r356"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://korumedical.com/role/PropertyAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PROPERTY AND EQUIPMENT",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r94",
      "r97",
      "r98"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total property and equipment",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r108",
      "r408"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets",
      "http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r356",
      "r402",
      "r408",
      "r537"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentOther",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, at cost",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentOtherAccumulatedDepreciation",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated depreciation",
        "label": "Property, Plant and Equipment, Other, Accumulated Depreciation",
        "documentation": "Amount of accumulated depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentOtherNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentOtherNet",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Other, Net",
        "documentation": "Amount after depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://korumedical.com/role/PropertyAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment consists of the following at:",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r356"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurStockOptionsWithTimeBasedVestingForThreeMonthsEndedMarch312024And2023.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r191",
      "r192",
      "r193",
      "r194",
      "r241",
      "r242",
      "r272",
      "r273",
      "r274",
      "r286",
      "r329",
      "r362",
      "r363",
      "r364",
      "r414",
      "r415",
      "r421",
      "r430",
      "r431",
      "r482",
      "r484",
      "r486",
      "r487",
      "r489",
      "r502",
      "r503",
      "r518",
      "r525",
      "r527",
      "r530",
      "r531",
      "r532",
      "r533",
      "r546",
      "r550",
      "r604",
      "r610",
      "r642",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurStockOptionsWithTimeBasedVestingForThreeMonthsEndedMarch312024And2023.Details"
     ],
     "auth_ref": [
      "r191",
      "r192",
      "r193",
      "r194",
      "r241",
      "r242",
      "r272",
      "r273",
      "r274",
      "r286",
      "r329",
      "r362",
      "r363",
      "r364",
      "r414",
      "r415",
      "r421",
      "r430",
      "r431",
      "r482",
      "r484",
      "r486",
      "r487",
      "r489",
      "r502",
      "r503",
      "r518",
      "r525",
      "r527",
      "r530",
      "r531",
      "r532",
      "r533",
      "r546",
      "r550",
      "r604",
      "r610",
      "r642",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r504",
      "r515",
      "r660"
     ]
    },
    "krmd_RestrictedStockAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "RestrictedStockAwardsMember",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurRestrictedStockAwardsAndPsusForThreeMonthsEndedMarch312024And2023.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Awards [Member]",
        "documentation": "The element represents restricted stock awards member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "krmd_RestrictedStockUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "RestrictedStockUnits",
     "presentation": [
      "http://korumedical.com/role/FollowingSecuritiesWereNotIncludedInComputationOfDilutedSharesOutstandingForThreeMonthsEndedMarch312024And2023BecauseEffectWouldBeAnti-dilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted stock",
        "documentation": "The element represents restricted stock units."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r65",
      "r405",
      "r419",
      "r420",
      "r423",
      "r441",
      "r537"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r135",
      "r136",
      "r137",
      "r139",
      "r144",
      "r146",
      "r148",
      "r176",
      "r177",
      "r183",
      "r301",
      "r302",
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r315",
      "r320",
      "r322",
      "r323",
      "r325",
      "r326",
      "r342",
      "r343",
      "r416",
      "r418",
      "r425",
      "r693"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "REVENUE RECOGNITION",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r505"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesNetRevenuesByGeographyForThreeMonthsEndedMarch312024And2023Details",
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NET REVENUES",
        "verboseLabel": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r79",
      "r123",
      "r132",
      "r158",
      "r162",
      "r163",
      "r166",
      "r168",
      "r169",
      "r170",
      "r172",
      "r175",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r330",
      "r401",
      "r515",
      "r608"
     ]
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevolvingCreditFacilityMember",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revolving Credit Facility [Member]",
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_RouLandlordCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "RouLandlordCredit",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ROU landlord credit",
        "documentation": "The element represents rou landlord credit."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The following table summarizes the activities for our common stock warrants issued in connection with our loan financing agreement with HSBC for the three months ended March 31, 2024, and 2023.",
        "documentation": "Tabular disclosure of the change in common stock outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Therefore, diluted weighted average number of shares outstanding and diluted net loss per share were the same as basic weighted average number of shares outstanding and net loss per share for the three months ended March 31, 2024 and 2023.",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r588"
     ]
    },
    "krmd_ScheduleOfNetSalesByGeography": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "ScheduleOfNetSalesByGeography",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The following table summarizes net revenues by geography for the three months ended March 31, 2024, and 2023:",
        "documentation": "The element represents schedule of net sales by geography."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r356"
     ]
    },
    "krmd_ScheduleOfSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "ScheduleOfSecuritiesTextBlock",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The following securities were not included in the computation of diluted shares outstanding for the three months ended March 31, 2024, and 2023 because the effect would be anti-dilutive:",
        "documentation": "The element represents schedule of securities text block."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://korumedical.com/role/FollowingTablePresentsInformationPertainingToOptionsOutstandingAtMarch312024Details",
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurCommonStockWarrantsIssuedInConnectionWithOurLoanFinancingAgreementWithHsbcForThreeMonthsEndedMarch312024And2023.Details",
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurRestrictedStockAwardsAndPsusForThreeMonthsEndedMarch312024And2023.Details",
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurStockOptionsWithTimeBasedVestingForThreeMonthsEndedMarch312024And2023.Details",
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformanceBasedStockOptionAwardsForThreeMonthsEndedMarch312024And2023.Details",
      "http://korumedical.com/role/FollowingTableSummarizesStatusOfStockOptionsDetails",
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r245",
      "r247",
      "r248",
      "r249",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275"
     ]
    },
    "krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The following table presents information pertaining to options outstanding at March 31, 2024:",
        "documentation": "The element represents schedule of share based compensation stock options activity amended table text block."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The following table summarizes the status of the stock options:",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r8",
      "r66"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The following table summarizes the activities for our stock options with time based vesting for the three months ended March 31, 2024, and 2023.",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShortTermDebtTable",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt [Table]",
        "documentation": "Disclosure of information about short-term debt arrangement. Includes, but is not limited to, description of arrangement, lender, repayment term, weighted-average interest rate, borrowed amount, and description and amount of refinancing of short-term obligation when obligation is excluded from current liability."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The following table summarizes the activities for our restricted stock awards and PSUs for the three months ended March 31, 2024, and 2023.",
        "documentation": "Tabular disclosure of the change in restricted stock units (RSUs)."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r559"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r562"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r568"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesNetRevenuesByGeographyForThreeMonthsEndedMarch312024And2023Details"
     ],
     "auth_ref": [
      "r170",
      "r171",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r427",
      "r428",
      "r429",
      "r483",
      "r485",
      "r488",
      "r490",
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r506",
      "r526",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r547",
      "r550",
      "r611",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, general and administrative",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense and warrant expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurStockOptionsWithTimeBasedVestingForThreeMonthsEndedMarch312024And2023.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected dividends",
        "documentation": "The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends."
       }
      }
     },
     "auth_ref": [
      "r273"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurStockOptionsWithTimeBasedVestingForThreeMonthsEndedMarch312024And2023.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r273"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurStockOptionsWithTimeBasedVestingForThreeMonthsEndedMarch312024And2023.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r272"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurStockOptionsWithTimeBasedVestingForThreeMonthsEndedMarch312024And2023.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r274"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurStockOptionsWithTimeBasedVestingForThreeMonthsEndedMarch312024And2023.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average volatility",
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r272"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://korumedical.com/role/FollowingTablePresentsInformationPertainingToOptionsOutstandingAtMarch312024Details",
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurCommonStockWarrantsIssuedInConnectionWithOurLoanFinancingAgreementWithHsbcForThreeMonthsEndedMarch312024And2023.Details",
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurRestrictedStockAwardsAndPsusForThreeMonthsEndedMarch312024And2023.Details",
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurStockOptionsWithTimeBasedVestingForThreeMonthsEndedMarch312024And2023.Details",
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformanceBasedStockOptionAwardsForThreeMonthsEndedMarch312024And2023.Details",
      "http://korumedical.com/role/FollowingTableSummarizesStatusOfStockOptionsDetails",
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r245",
      "r247",
      "r248",
      "r249",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesStatusOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r253"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesStatusOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r253"
     ]
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformanceBasedStockOptionAwardsForThreeMonthsEndedMarch312024And2023.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Forfeited",
        "documentation": "The element represents share based compensation arrangement by share based payment award options forfeitures.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Options forfeitures"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesStatusOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forfeited",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r257"
     ]
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurCommonStockWarrantsIssuedInConnectionWithOurLoanFinancingAgreementWithHsbcForThreeMonthsEndedMarch312024And2023.Details",
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurRestrictedStockAwardsAndPsusForThreeMonthsEndedMarch312024And2023.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Forfeited/canceled",
        "documentation": "The element represents share based compensation arrangement by share based payment award options forfeitures in period unvested.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Options forfeitures in Period Unvested"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformanceBasedStockOptionAwardsForThreeMonthsEndedMarch312024And2023.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted",
        "documentation": "The element represents share based compensation arrangement by share based payment award options grants.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Grants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesStatusOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r255"
     ]
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurCommonStockWarrantsIssuedInConnectionWithOurLoanFinancingAgreementWithHsbcForThreeMonthsEndedMarch312024And2023.Details",
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurRestrictedStockAwardsAndPsusForThreeMonthsEndedMarch312024And2023.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted",
        "documentation": "The element represents share based compensation arrangement by share based payment award options grants in period gross unvested.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Grants in Period Gross Unvested"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesStatusOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average fair value of options granted during the period",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r265"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesStatusOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning",
        "periodEndLabel": "Outstanding at ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r252"
     ]
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurCommonStockWarrantsIssuedInConnectionWithOurLoanFinancingAgreementWithHsbcForThreeMonthsEndedMarch312024And2023.Details",
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurRestrictedStockAwardsAndPsusForThreeMonthsEndedMarch312024And2023.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning",
        "periodEndLabel": "Outstanding at ending",
        "documentation": "The element represents share based compensation arrangement by share based payment award options outstanding number unvested.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Outstanding Number Unvested"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesStatusOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning",
        "periodEndLabel": "Outstanding at ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r252"
     ]
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurCommonStockWarrantsIssuedInConnectionWithOurLoanFinancingAgreementWithHsbcForThreeMonthsEndedMarch312024And2023.Details",
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurRestrictedStockAwardsAndPsusForThreeMonthsEndedMarch312024And2023.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning",
        "periodEndLabel": "Outstanding at ending",
        "documentation": "The element represents share based compensation arrangement by share based payment award options outstanding weighted average exercise price unvested.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Outstanding Weighted Average Exercise Price Unvested"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformanceBasedStockOptionAwardsForThreeMonthsEndedMarch312024And2023.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Unvested at beginning",
        "periodEndLabel": "Unvested at ending",
        "documentation": "The element represents share based compensation arrangement by share based payment award options unvested weighted average exercise price.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Unvested Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformanceBasedStockOptionAwardsForThreeMonthsEndedMarch312024And2023.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Forfeited",
        "documentation": "The element represents share based compensation arrangement by share based payment award options vested.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Vested"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of shares",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r268"
     ]
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurCommonStockWarrantsIssuedInConnectionWithOurLoanFinancingAgreementWithHsbcForThreeMonthsEndedMarch312024And2023.Details",
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurRestrictedStockAwardsAndPsusForThreeMonthsEndedMarch312024And2023.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Vested",
        "documentation": "The element represents share based compensation arrangement by share based payment award options vested in period gross.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Vested in Period Gross"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "ShareBasedCompensationArrangementByUnvestedAwardOptions",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformanceBasedStockOptionAwardsForThreeMonthsEndedMarch312024And2023.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning",
        "periodEndLabel": "Unvested at ending",
        "documentation": "The element represents share based compensation arrangement by unvested award options.",
        "label": "Share Based Compensation Arrangement by Unvested Award Options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://korumedical.com/role/FollowingTablePresentsInformationPertainingToOptionsOutstandingAtMarch312024Details",
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurCommonStockWarrantsIssuedInConnectionWithOurLoanFinancingAgreementWithHsbcForThreeMonthsEndedMarch312024And2023.Details",
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurRestrictedStockAwardsAndPsusForThreeMonthsEndedMarch312024And2023.Details",
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurStockOptionsWithTimeBasedVestingForThreeMonthsEndedMarch312024And2023.Details",
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformanceBasedStockOptionAwardsForThreeMonthsEndedMarch312024And2023.Details",
      "http://korumedical.com/role/FollowingTableSummarizesStatusOfStockOptionsDetails",
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r248",
      "r249",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesStatusOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercised",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r256"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesStatusOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Forfeited",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r257"
     ]
    },
    "krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformanceBasedStockOptionAwardsForThreeMonthsEndedMarch312024And2023.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forfeited/canceled",
        "documentation": "The element represents share based compensation arrangements by share based payment award options forfeitures in period weighted average exercise price1."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurCommonStockWarrantsIssuedInConnectionWithOurLoanFinancingAgreementWithHsbcForThreeMonthsEndedMarch312024And2023.Details",
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurRestrictedStockAwardsAndPsusForThreeMonthsEndedMarch312024And2023.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Forfeited/canceled",
        "documentation": "The element represents share based compensation arrangements by share based payment award options forfeitures in period weighted average exercise price unvested.",
        "label": "Share Based Compensation Arrangements by Share Based Payment Award Options forfeitures in Period Weighted Average Exercise Price Unvested"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesStatusOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r255"
     ]
    },
    "krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformanceBasedStockOptionAwardsForThreeMonthsEndedMarch312024And2023.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted",
        "documentation": "The element represents share based compensation arrangements by share based payment award options grants in period weighted average exercise price1.",
        "label": "Share Based Compensation Arrangements by Share Based Payment Award Options Grants in Period Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurCommonStockWarrantsIssuedInConnectionWithOurLoanFinancingAgreementWithHsbcForThreeMonthsEndedMarch312024And2023.Details",
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurRestrictedStockAwardsAndPsusForThreeMonthsEndedMarch312024And2023.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted",
        "documentation": "The element represents share based compensation arrangements by share based payment award options grants in period weighted average exercise price unvested.",
        "label": "Share Based Compensation Arrangements by Share Based Payment Award Options Grants in Period Weighted Average Exercise Price Unvested"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurCommonStockWarrantsIssuedInConnectionWithOurLoanFinancingAgreementWithHsbcForThreeMonthsEndedMarch312024And2023.Details",
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurRestrictedStockAwardsAndPsusForThreeMonthsEndedMarch312024And2023.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Vested",
        "documentation": "The element represents share based compensation arrangements by share based payment award options vested in period weighted average exercise price.",
        "label": "Share Based Compensation Arrangements by Share Based Payment Award Options Vested in Period Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformanceBasedStockOptionAwardsForThreeMonthsEndedMarch312024And2023.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested",
        "documentation": "The element represents share based compensation arrangements by share based payment award options vested in period weighted average exercise price1."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "STOCK-BASED COMPENSATION",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r250",
      "r269",
      "r270",
      "r271",
      "r272",
      "r275",
      "r281",
      "r282",
      "r283",
      "r284"
     ]
    },
    "us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The following table summarizes the activities for our unvested performance based stock option awards for the three months ended March 31, 2024, and 2023.",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for outstanding performance shares."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://korumedical.com/role/FollowingTablePresentsInformationPertainingToOptionsOutstandingAtMarch312024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://korumedical.com/role/FollowingTablePresentsInformationPertainingToOptionsOutstandingAtMarch312024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "presentation": [
      "http://korumedical.com/role/FollowingTablePresentsInformationPertainingToOptionsOutstandingAtMarch312024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number exercisable",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "presentation": [
      "http://korumedical.com/role/FollowingTablePresentsInformationPertainingToOptionsOutstandingAtMarch312024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number outstanding",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r68"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurStockOptionsWithTimeBasedVestingForThreeMonthsEndedMarch312024And2023.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected term (in years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r271"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "presentation": [
      "http://korumedical.com/role/FollowingTablePresentsInformationPertainingToOptionsOutstandingAtMarch312024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average exercise price",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price",
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "presentation": [
      "http://korumedical.com/role/FollowingTablePresentsInformationPertainingToOptionsOutstandingAtMarch312024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price",
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r68"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://korumedical.com/role/FollowingTablePresentsInformationPertainingToOptionsOutstandingAtMarch312024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life",
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "krmd_SharesAvailableForIssuanceShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "SharesAvailableForIssuanceShareBasedCompensation",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares available for issuance",
        "documentation": "The element represents shares available for issuance share based compensation."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued under plan",
        "documentation": "The element represents shares issued under plan in total shares employee stock ownership plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtLineItems",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ComponentsOfLeaseExpenseWereAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term lease cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r536"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r566"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://korumedical.com/role/StatementsOfStockholdersEquity",
      "http://korumedical.com/role/ThereforeDilutedWeightedAverageNumberOfSharesOutstandingAndDilutedNetLossPerShareWereSameAsBasicWeightedAverageNumberOfSharesOutstandingAndNetLossPerShareForThreeMonthsEndedMarch312024And2023.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r38",
      "r41",
      "r42",
      "r103",
      "r120",
      "r121",
      "r122",
      "r135",
      "r136",
      "r137",
      "r139",
      "r144",
      "r146",
      "r148",
      "r160",
      "r176",
      "r177",
      "r183",
      "r232",
      "r301",
      "r302",
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r315",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r342",
      "r343",
      "r359",
      "r410",
      "r416",
      "r417",
      "r418",
      "r425",
      "r479"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesNetRevenuesByGeographyForThreeMonthsEndedMarch312024And2023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r170",
      "r171",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r427",
      "r428",
      "r429",
      "r483",
      "r485",
      "r488",
      "r490",
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r506",
      "r526",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r547",
      "r550",
      "r611",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesNetRevenuesByGeographyForThreeMonthsEndedMarch312024And2023Details",
      "http://korumedical.com/role/LeasesDetailsNarrative",
      "http://korumedical.com/role/StatementsOfStockholdersEquity",
      "http://korumedical.com/role/ThereforeDilutedWeightedAverageNumberOfSharesOutstandingAndDilutedNetLossPerShareWereSameAsBasicWeightedAverageNumberOfSharesOutstandingAndNetLossPerShareForThreeMonthsEndedMarch312024And2023.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r136",
      "r137",
      "r160",
      "r343",
      "r368",
      "r422",
      "r426",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r440",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r449",
      "r450",
      "r451",
      "r452",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r460",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r479",
      "r551"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesNetRevenuesByGeographyForThreeMonthsEndedMarch312024And2023Details",
      "http://korumedical.com/role/LeasesDetailsNarrative",
      "http://korumedical.com/role/StatementsOfStockholdersEquity",
      "http://korumedical.com/role/ThereforeDilutedWeightedAverageNumberOfSharesOutstandingAndDilutedNetLossPerShareWereSameAsBasicWeightedAverageNumberOfSharesOutstandingAndNetLossPerShareForThreeMonthsEndedMarch312024And2023.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r136",
      "r137",
      "r160",
      "r173",
      "r343",
      "r368",
      "r422",
      "r426",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r440",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r449",
      "r450",
      "r451",
      "r452",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r460",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r479",
      "r551"
     ]
    },
    "krmd_StockBasedCompensationStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "StockBasedCompensationStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation expense",
        "documentation": "The element represents stock based compensation stock options.",
        "label": "Stock Based Compensation Stock Options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of stock-based compensation (in shares)",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r37",
      "r38",
      "r65"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesStatusOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r37",
      "r38",
      "r65",
      "r256"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of stock-based compensation",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r37",
      "r38",
      "r65"
     ]
    },
    "krmd_StockOptionPlan2015Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "StockOptionPlan2015Member",
     "presentation": [
      "http://korumedical.com/role/FollowingTablePresentsInformationPertainingToOptionsOutstandingAtMarch312024Details",
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurStockOptionsWithTimeBasedVestingForThreeMonthsEndedMarch312024And2023.Details",
      "http://korumedical.com/role/FollowingTableSummarizesStatusOfStockOptionsDetails",
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Plan 2015 [Member]",
        "documentation": "The element represents stock option plan2015 member."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_StockOptionPlan2021Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "StockOptionPlan2021Member",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurCommonStockWarrantsIssuedInConnectionWithOurLoanFinancingAgreementWithHsbcForThreeMonthsEndedMarch312024And2023.Details",
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurRestrictedStockAwardsAndPsusForThreeMonthsEndedMarch312024And2023.Details",
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Plan 2021 [Member]",
        "documentation": "The element represents stock option plan2021 member."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_StockOptionPlans2015And2021CombinedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "StockOptionPlans2015And2021CombinedMember",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Plans 2015 and 2021 Combined [Member]",
        "documentation": "The element represents stock option plans2015 and2021 combined member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets",
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL STOCKHOLDERS\u2019 EQUITY",
        "periodStartLabel": "Beginning balance, value",
        "periodEndLabel": "Ending balance, value",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r41",
      "r42",
      "r59",
      "r442",
      "r459",
      "r480",
      "r481",
      "r537",
      "r557",
      "r582",
      "r597",
      "r643",
      "r693"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://korumedical.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r361"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Information"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_TermLoanFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "TermLoanFacilityMember",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term Loan Facility [Member]",
        "documentation": "The element represents term loan facility member."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_TimeBasedSharesOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "TimeBasedSharesOptionsMember",
     "presentation": [
      "http://korumedical.com/role/FollowingTablePresentsInformationPertainingToOptionsOutstandingAtMarch312024Details",
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurStockOptionsWithTimeBasedVestingForThreeMonthsEndedMarch312024And2023.Details",
      "http://korumedical.com/role/FollowingTableSummarizesStatusOfStockOptionsDetails",
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Time Based Shares Options [Member]",
        "documentation": "The element represents time based shares options member."
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r595",
      "r651"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock, Common, Shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_TreasuryStockPreferredShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockPreferredShares",
     "presentation": [
      "http://korumedical.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury stock, shares",
        "documentation": "Number of previously issued preferred shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_TreasuryStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockValue",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Treasury stock, 3,420,502 shares as of March 31, 2024 and December 31, 2023, at cost",
        "label": "Treasury Stock, Value",
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r38",
      "r41"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "US",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesNetRevenuesByGeographyForThreeMonthsEndedMarch312024And2023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_UnrecognizedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20240331",
     "localname": "UnrecognizedCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized cost",
        "documentation": "The element represents unrecognized compensation cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "USE OF ESTIMATES IN THE FINANCIAL STATEMENTS",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r92",
      "r93",
      "r95",
      "r96"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations",
      "http://korumedical.com/role/ThereforeDilutedWeightedAverageNumberOfSharesOutstandingAndDilutedNetLossPerShareWereSameAsBasicWeightedAverageNumberOfSharesOutstandingAndNetLossPerShareForThreeMonthsEndedMarch312024And2023.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Diluted",
        "label": "Diluted weighted average shares outstanding",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r155"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations",
      "http://korumedical.com/role/ThereforeDilutedWeightedAverageNumberOfSharesOutstandingAndDilutedNetLossPerShareWereSameAsBasicWeightedAverageNumberOfSharesOutstandingAndNetLossPerShareForThreeMonthsEndedMarch312024And2023.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic",
        "label": "Basic weighted average shares outstanding",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r155"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "presentation": [
      "http://korumedical.com/role/ThereforeDilutedWeightedAverageNumberOfSharesOutstandingAndDilutedNetLossPerShareWereSameAsBasicWeightedAverageNumberOfSharesOutstandingAndNetLossPerShareForThreeMonthsEndedMarch312024And2023.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Outstanding Shares:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(c)",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "250",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/250/tableOfContent"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/840/tableOfContent"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481440/840-10-50-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Subparagraph": "(Note 3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481418/840-10-55-40"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481178/840-20-25-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481501/840-20-50-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481501/840-20-50-2"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-6A"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-5"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-4"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r579": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r580": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r581": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r585": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r586": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r587": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r588": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r591": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r592": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r593": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r594": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r595": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r596": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r598": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r599": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r601": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r605": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r606": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r607": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r608": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r609": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r610": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r611": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r612": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r614": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r638": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2"
  },
  "r641": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r644": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r647": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r648": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r649": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r650": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479341/842-30-25-11"
  },
  "r651": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r652": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r653": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r654": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r655": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r656": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r657": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r658": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r659": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r660": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r666": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r667": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r668": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r669": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r673": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r674": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r675": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r676": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r677": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r678": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r679": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r680": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r681": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>59
<FILENAME>0001161697-24-000226-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001161697-24-000226-xbrl.zip
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MB#_]+1<W1^:O%KAJ\(SACY\;NW-I$3'$9CP3GW,]S2BYH\"'T/C )1KPY[H
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M+=8TC)_VDV\?!^-ZQE:S]6[85N,X_ E02P,$%     @ :X"A6 BTFX5W P
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M.FS#I]^JD@0")'2"@>;-=+<-4E565MZ5E?GS_WR.).(=J)JHR/_\ASZG_D,
MN:\(HOS\SW_RK4*E\I__<W'R<ZC#Q^"CLO;/Z5#7QS^^?__X^#C_8,\5]?D[
MG<OEOG^B9T[-AWY\NC['4!3]_;%ZV^H/P8@_$V5-Y^4^F+TDB?*K]_CHV]FC
M/542%QY%G]B3L-]7AH;?"O,7G ^GOYM?+CRJNSZ:,A_5[4=%3>$8.K,.#O.)
MV0N?7L_2"&:X0O!XV;R=/ZZ[/S]_]+NN\K(V4-01K\,M1".ESBCFC$D[!CG3
M0']A(/C[^;/R[CM.]HRE[7%6-F=QI>CK'J_-,"Z )73;<\(OX!L,9S^H@H'G
ML.GO\%O[04,[>^;Y\>SA :_U\(/6%PNCPL]410*:Z]/XFX7'!5T]TR=CH+F#
M K_^CKY&[S!G%.M 2U\Q9%V=N*_5^G)A*DW55X&"'RX\]*J.A-E3KXIJC( @
M]GGIO*^,\(,4"T% C EXX>*$0/_]U$5= A<W]6:'J)J/$ZV)IH.11A(5N7].
ME.'V$C1U=D?<&;RJ U6:$$TP5E2=@#M/X'6=H=%_?C?'.ODY CI/(#C.P)LA
MOO]S6E!D'<CZ61NBXY3HF[_]<ZJ#3_T[E@#?X5O?3;!^_J^S,Z(L DGX0;2
M_C=1XT?@!_$I?/Y-5(KXAR[%%+N=UK^9XE4^WX#_H.F)L[. +[.Y+D)5=PE%
M71M%P4?B"N9+-$5'>#N5ZP)(V!!^^/_\",@"_*.7)?ZY.^ E#808B7:,5#!4
M%8TC:G!A3X!72[)0Y'70-;^^;5&?59&:5N_^^2?$#(QCAJ+2-T8+4Y3A)UHW
MW#:DRIY#-H J*H(YZ%U4C)9D2(^3 AQ4Y:6*+(#/&S#I4O"_#,5Q'!5\V$RJ
M^UA\[!;-<?];@F37[(G3_Q8D$8ZN$=^*?_T7<]"WP2N/F$-5X'.0G?[Z+TW!
MG^X(A!GX \7"OR")H(?_B^1FMXL?>#N'\P2')WT)J;_8I;N6IC#A@A^%&(+I
MMH:\"N"F=;%>-,?0\&<AAD%\6&Q80[$K ,4:.]=M&"KH<LY!QO"3$$-PW5J7
MZM:,40^HYFL]19@0FCZ1P#^G RB(?D#9-M:)MCB"L-7 !]%41KQ,FA^0<&A5
M'""9*8CO]FN"J(TE?O*#D!49H._$SQ](=@$5"E7\BR@(0$82%OT&GX( P''Z
MIN3[U)M(>Y55983(XHRBX?]UQ?S9U!(BE.-EOJ\C8J784T*&:X/S O''@I@X
MO<!RXN?WA5F2FI=SSNLE5$XOSLYH!KZ\(2!23B \Y,[IA:E^-@) VAL AY0Z
MO;C;% 8R3@!<9=KIQ5RH>0-15N&(T$JS1K/LGQ]%, !P:P6HZY41:/.?>4T#
MNE8#^ND"O'FM/EB&$?(8(R+FI*@LI!9#%LUG(>-#FT3[(8L25/*J 9!^3Q@0
MUB2[54!2<0&9 5#Z' -9 Y= !@-Q"0J_[9M#Q-!LXJ@!6EX6X+\%^*&H:Y%!
M2S&)(0MH#5X45G8K.# L2VT)&-8$QOS)'10Z+B@M7>F_5C3- $+14*%C; J+
M>UXR -:6E]#M$0K*")$8]I[6X6V.M:XU0;<);6SHA@DE7I7A\%H5(!VWLA(N
MM_,K::N UPQU@B>"XXP4V6,QJ=@4DA=>#$U'(EQK*WD!,@]\!DIR2"T5N<"/
M19V7W!>%H:N/T8]:$[DUFJ@#:!V\BWU@8J0)^LJS+$; @+EH/(/7RF-+M=U<
M>4 J3F4.<_DA2#^[%0S,>1W]C8)A!45;KV BT7,ZMH#=XG("$FDZMI[?XIJ"
M4UXZMF5GPUD?X-F@Z?+ JRH/5UE65(N3M+I:D'AQM %2BRT[-@E_4-J*K<8W
MN8C@Q)2)K<&A46>:>;>*ECRQ9&+S<!SX/%C>"];8C!D'UA![GMX1$W3%[@_+
MA;G8HF3C*PF^+;GM6!0;LJF\,>#+Y!RU'46]]94'HV*.VFM?(@'2YZC8$LE?
M<L8A4#JVG(D#7R@MQ-&QQ4@<6(/O.1/?\L"G"/6!>?C)]R1(N,^8":*&O#@6
MLJ( ^N*(E[1_3BNUL@/&VNG%+*1L0^0-)#K0_)&7=;$H2H8NO@,GIT6&#\4'
MO> SSWQ.+ZB00#K(/RYX:685GL#;BH&!,@>G+T##&$/4D;W"J;Y!0RZ=C@N-
MO7>EP0#T]?J@;N@H(P7EU3CQ!6WWCOP.-!U ::GIJMB'/^$'(F-R(6J^0[#[
M8ST;"NO^)S$.4[</E9PRZCK ;TB\C))<3!EC/X"."K&F,Z>W5NHNAU(Y^G39
M)D1O]98U91XY9\\ R9?+R?R1!C]!'^4_>%4H\Z**+<<\-"A'YJSHS *AM W4
M$7UZT:"IITCG4JLB=S/88'<'&^%,=G-U3M(N?0*U+T*H GI2FT!HFL[%8.2%
M/5BQW1Q[H%F;<+F\"4NHT"JRB:T'(#X/X4;DWX'*/P/[^P;< ?"5Z&*6XI"-
MR"A+ADJVPW9IACT,*MD6NE))48D?RGPP5E;4 1!U0YWC["OQLG!,^F5DY(*4
M724DE@U+2%LW6.QG%G!&>ZPGG0FFOLUY\H8^5%1Q"J )* !U"4QM8<8FVGV'
M#6G!N+2Q33#B113K0 FFB+P,7D*ZGH&Z/OU$4U4F50RL\+$9&X!#;?O528.N
M*2J,F:)B8]3A:P0FF&P<=1YT06NYRUYM<)9*;O4Y*J;<37Q+EZ1#A$5EZ-AN
MXI=M:1*KSR2D2DNCL:1,@)V=A1S+1 +HSH@ !LUC(<ARG(=&EH-+H:,B<??T
M"A_EV?KO2E6TV3:'LZ^7O'(\QY)J6-$OC(=^R+"QPPJQK8-%Q*PC^5W 5USN
M^!):\C2>DL7-YE7AEFAI._CBXKJVB=#2/4;# BU](7]Q<?S>9&AH$2')Q462
MQ5-<AS<1VG%Q['9 1J?B.+W)T%!(CW<7D!;:\=T%@MJ.H$YMWDC:3[QDOAHO
MCOB#>?CKCI7%&RGV0AWGG':F751,9+([A(GPDF;C^,EN*TZ0(+4PF\-&[%/Q
M7:"6#>*'VP5J2<S)2A S"_&VPW2QDL06LPMT%-3!V@I&-J^G-NQ>;0%+66HG
MM%5BSE62F-F\YMH)URI)E.V$,DO,@4@2,U]^SK*36-DE5R*04[4I3-#<#F$B
MAE.U,?RDDY L'5DU$_JGBUA"=Q838H(5R%&J=\2CN2CI%K< [F]=!A[0<-2I
M$R&W0-, J(_A/NMPX_'+LS0&E+MP>M'(/G%5AEN3N1 9S/:'X@4F$QI,[BE7
MI;.; ',--CD7,,NBC,YK78%DGY@JS6P9E^F00#(0D]1&8!RJP!.5V9!0<D_I
MT%"N+QN38U;R?]T)3P8?9F8/3NS)5-/1P/ H&I-CN"A@^.471<%'VAV0Q6V9
M@4%C D\>'2MI7;Y0I)^RZ]G,(XW#.>2MR/=$2=0GEJ[4B@;(#W2@XDI/XKM[
M4HH7*E.QKTROE-U)IB!0+I.*H)^^.^N*(;A5!!V N-/P]ZB4Y@\-UTB%0Q&X
M\.D/R/T#D[UQA494V.;\4X.6A/DUJD[YSZDFCL:2C9#ORR.;4VF*H5HSP8=P
M/;8?UNK-:E7>J[<*3=IO 5S!ROYP]K$HH"\&(E )O C@6GJT4+E9+':U_/)L
MLN]NLUESC;$IO@("M,54'=4TNYBOQ!YG_MWR6\"L@W8Q7_%\;L'YAOVQ<W;[
M,PN5GNB=DWH* K4_*#4KZNH7<]AGXUO?)(J<_:*W1>0X*2=YY-B2?A^1P]H%
M!A-'CN<EL[U!TX+,8B/(+';3,HO98\IC-D9YB][[7B*'W9+,6G-O_DO0-N<]
M\_;W_'/K&P%"\CF6Q+ZHFW 2@@@?Q,7R'??%()NAUTMO!JKHJ8S&BHQLWORG
MJ)U>V(^MK/GG=]<I',!]=X5N9V6PQV:O+T)P^!N_=OU_"A%X%#0Y_-UW7_B?
MLNW>13T.?^<]UWZHF\\<M?S.:/F-V[O+FWW4\KNGY;=.!$<MOPM:?NO;?M3R
MNZ/E-[?Y$6JR'O[V?ZF^W^%CCI@%<@^?<';&7MAG(CK:&U]F;^PSV1SME2^V
M5W:?>,+4_#U\HMD=*V>W#D9C%F ^?,+932MGSXCH:.7LAI6S9V1SM')VR<K9
M+>)93+0[VC8[<&*S\<3!8P1F1VV3KR2"HVVQ"R<V6]_VHVVP.R<V6\@8/VKY
M7='R6TBU/6KY7=?R6R>"HY;?!2V_]6T_:OG=T?*;VWSOV^.*(>OJI-MI[>-^
M:ZH^W^LKH#RK_'@H]GG)W&=K<3\ZK>/!U?IXX)$,-DL&NQ79\SW\KBER9X\-
M !]ZF'7XG*_R*!^"G1<<">//E!A+(2*KYDS9@!8S*GB6EX7Z8"#V ;*WQ@@/
M^TLC-A$T5 5B2I^@NEDZ7.!L:9>3]F0,3(K!I71\T7"X0:.%HKU'<MAI<MCX
MW:YE*P)7^1DJDE 9C57EW2S(^8=0PKR2DB<.#ETJ',E@E\E@:]+ 4@Y57C8&
MJ&4CZI8[PQ7$6UM1)/C1'T(06$,$P\6ARX<C8>P786R\,%/X#K=[315P)35^
MY-Q^SW4>PQ-K-,N1.@Y-4826![.JU@>^X_8ZC_(@C#PX4L>!RX.:(MO]H8NB
M"OJZHD*;Z5+A52$OO(N:HNXO :"0=5O4)5 ?5&1!?!<%PPY78RH(NO:CR%A/
M2A#/78RU^L#&HU88\B+J#7Z0U(.^6K_@(\E$L48T9)A!%D3RN*",>BBUR$2<
M_4(;[@]N$F*VV+#:@^POD0774=ZX\:6U,(#@KBM+KO4ZI!\)W2<[Y$CH1T*/
M1>C[<)I]).\C>>^8XQ.34(]$>%AT$%4?'^G@T-.X[;/V!E '"O+@^L"4C_M/
M $M*8$87[BL]FO+!$CF/A'(TA0.6S]-T5>SKT. ZC,N@'F3BNLZC- E:?>A(
M)$=)$K$+^@'1"39//1=ZE":!PHQ'0CE*E'AI8<< 78CDH$,)R.VQQ#L2\I&0
M/0CY#Y+(. 6C*LKBR!@=27MW2#O(Y"B9I,G+SV">6[*PDT=%L"W^X3^/_',8
M_./<R2/_K+E!=#2?]IY'-G40MZ4F9T="/!+B.D+<>+>]8V3D2(A[D*)R),0C
M(6ZISF6BGI7U3.D3J'U1 PU5[(,_Y%+9?A!IF,GQ^'@F5!<4?LNCF<Q9\X8^
M5%1Q"H2.+ !U.=/L<K)  @Z/#2_!C3X.3M!O-H9QY+0CI^T!I^U=C,21!7>(
MYI8;F0=8\A\2ESAN_@YM_A<T7S^2P8Z0P0ZK#;\<A2/Q[!3Q[%9>@+O/?229
MKR:9+XS\'3=_AS9_"UUE%@S.I3QYC*PE#_\@JS2Y4<4:7"3J;.]!A:AM^SU'
M,CR2X4YY8$>"/!+D ?B"1S(^DO'>>J5'XCT2[P[XQT<R/)+A#GCJGG=0_S@B
MC'X;]^!(<+M>^I$$CR2X,Q[ZD1B/Q+CGWOF1A(\DO)>>^9%PCX3[Q5[YD02/
M)+A]CYS*G#%9F\+R]5I#!2/1&)5%&>42W-X6%FFP 0T 4=,4=5)3=+"_Y"<
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M()KU:KY&FA_ "4K-2MDWF'E&,,29/?S.Q>2S(1"(#F4<^VQ&R)TA0 O42\E
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M41\*8?;1#V .G3\2_R<H_M8G$@9"CE=2X6H^)Q<TGY-:S.9$E<_(+$.1+#I
M6$DHW'ED6/U.%Y&1HB(C@R:Y+$,R'!4<&>Z,P#HEC7GY06M"BPXN#OHN-:#;
MMV*7Z']P6QH*UY_IVS&;A.0)SQHVL(0Z@Y:04,$M7I*4#YP+@DYD!<7HZ0-C
M=K,#GUVMY%5GG%BPWR\K:M%Z>Q4S,[14K$1>\Y9P[R7UNWI5SU.#62*O"Z#D
M$I!]W"20D!0-.F1]^][O>EH,!69P!DVEHM(DPY&9C!MSFMF^KADY2+2M;$8Y
M[F98[EMV\J2EWU/U9GT/-L-=0 2]>1!M,USRGY)5S3Y(6R-N0A L$Q5'',GF
M&#)%N]T.V&D\N-,*&QT/%)<BF3!X<-<E3L:MR.\0?-3K&:SHCH??5VP_+[ZP
M&KU!VVD&P79WT[GP$%0<V2YB29K+0+/([9[%3JW;E6K3D4T@%EI -,FZWNT)
M1;64@VKKZ&[CG ^U9<JM7-XI+,C>J*,OLGHP@ [E%< 12'*3E_$3G,#3D<4T
MD\V2&9K[8O(.M')W$H\LF)DLF<WFDK3P&RH8\Z)0^AP#60,>IKU48U]O1>F]
M,.$W*)XM4 A@PN)/R,%BK&L#>V'"LX&HPA6?(9@BLK&=92F20PV[PS+%?F/1
MG<'2D=UH:/5D22A@DK1\%N)UB+?:D+ETB[D@ETVG]UIWRC6G[Z#X0!51N8@$
M(G?M>CM_2X2,W^TB,2R@+P0K92,308[D,CF224>PH/83@>Y<%-D"92B22:7(
M'!-;59475)4RAOPP:4B\K.=E 07<QNCDVW0HZ,J<EPJBFFWV'[GJI]\AB[_"
MHM<H+!,@'+0 -C0D(:-2G=LT1=9A)CC#9()>[W:QO#-PNU-LB-CC;N#!E>XS
MD0U3ELRR&3*="A&0]C_M*:-J<N!6? ="1=9Y^5F$UJ;)TJN$G_K]7*_6+B_K
MOZ1-NB/>/#$'D> QC)@=4&R)[_>-$2H7B:JTCE#EK"EO-Z]9B?AE@R$@/Q\S
M[QAR*0:K7*9NN%XNGQD+L["?.>B9A$8EQ%6@O:#U(\'PP(9@T,C!/XY*D]DU
M12]<HZZE1/; "KTRDPK(=/KC*V&X+WO@+ARBAV5R%,ER:_; *QR^$I0EH;N/
M&LNA&R+2EH-9ZZ51"%KFHN(Q T5L+DR09U?PX$Y/D1V^3(HCV73L8)=3TEHW
MN.3G6\!KH(GP4!]T-'-=RYI&:]3K'RI;^OV\01-K!A$A(9#,O3E3!F>HTILI
M)[8<]5F'HN#DGXUA:W$X"N16.VJW$>%*_]D8QE:*YD@J%0(1_N'>(A@ Z"8)
MJ+_B"+3Y3R]#Z\UHE%6=UI\RB7CKX3G#AA0W_AL!0N<_5RRNA5-,5.]8!1"T
MN=DEV&/,7_8]#+?G;>)*[+/H)\1039'[KF?@&>-]8@PGQN.]'U$%&3P$DT4.
M Z5)-D>37,J[5)6KQ92+B"?+1GK-%PJES^M[,4MO#%'N3!C9L$R3%,6L/5A&
MI+<#1HWST@TJ+GPF?IX-10'RU \";AXC?O94"6*"0Z$9?$7%K9/.-B%)!8;$
M7:QEED^Q+%'FH+X%B7;W+E5459WT*WXG6;$4.CZN"JBY=S&8YHK*$#(ILO^0
MRY*Y3(0(RWXCT55>Y2*?$8=%8M#@/N(E,ZIO,M.G7JY(!6;\>@T2#.8G$<1G
MSID4W#F4!8=Z4KGG0?J_&3D,'9Q5<M$/B#-DBJ+(%)?T<=A.(L^=1>*<,7-I
M"K))B-./8\J^CP*^%?F>*.'&4GE9<%8.,NL&+5P1X4'Z];/%OE8?,TE=$;FM
MY"\KMY5VI=0B\K4BT6K7"S?7]=MBJ=FRRK\0I;M.I?UTO$9RR#3)NM.D^UT2
MO?29*O%43W/<=DSB+HF#& \8U267//H&/UG(3C;3;&X+TW*/ZTY_=TKMN^JC
MS*3Z&TRSF24\CTU@_)&5T%T)=R0$M@=H*G+,C(8>*D?2D6)FVU^\FSZGJ<C&
M4"Z3(ND<&]?FI1?)636 L"I EBG:N.$KS5_E2P6U1OVB.R$(TN Y94GG<;OC
M*0311SXG0?&K',E17QTH#H<$=^*/?$@".1_=C&)BG\BG'.2/2Q"N%^63JV'V
M]R33N).8#8IR!$AP,9[DIKJ@( 1-1PXWTI"B*?:KS_Z"+MZ=EB.GI;$T1[)<
MB+1G=TI.+\<%_<6XF--+CP:G_1I^:9*[- =TRV==[F@*3O%TY( 5ET()12&T
M]Y<CP)7JZ<BV6XIFR!03.V3G=,9+H[&D3 !H IP(XD__ZH/QZ_TQ.Y1KXF8-
M<VRK0(&N*I*$CTE4$T1T0+=MHO?%4@CRCQR,2J%<7->DF=U'A3LC1+;GN#1#
MYL*@PI\1S )D )_@VXN:>/# ^^^K3+F:-])J[VMT@%4M;98*8FN#B5E3CO[;
MOIJ[]40@3QR&X)#H-Q:@?4M37ZT@0F/!G3FB&X94CDS%KWW >29#^;&'_O3X
MJ:KE:J;GEW@;RPY:2H>*S@,[>2JX%N,AF"EZCF:&@<P4XM;"@:'3E2N9Z#=R
MTUF2I6.'GK)K@]:S"U46*T*>G+ZW7KO3!XW)=DIB^ZV6B,9:NE 5)HB]B]01
MQYYC8E18R*:@&1,F'G, 2'1GJQCE&;@41S*91"\INFKPA60A4]^9O/51+!4R
M1K%:[@0O=N5MP<TR%JW)"-Q879%WP(:)D.-#,]$KYF2S)//EWGX41+B3>&2K
MEJ739)J)K3G*_O;<:CZ<1>+R\\.OA]3'[_O??B'<& X/ESI/C?5E:\_\=(VY
M%YEA=E&(^FY,",Z+'EPE&8Y&U_<.0S%%PZD[$\<H1,.R:9*E8KME:7<#<)9T
M9W(LY-Q\JS2=Z')W^O+Z,C"&VCT8#(/K)]/ .R##+CCC+/>R#U%W@F2S+$E%
M*<*XC]AS91$VLCV<A>YFAF2BUBQ*P*LY^)0GIPVP+O$.ISP]U:]SV?OZM?8>
M/-)_L2Z9[F#1Z@R56>WD$7(72N-":?QV [I3Z;)X\SQZ'V;51(H2AX^;S5L\
MF(T;SG1EC)LW6+_:\H-"?<+06@C<=YY<O>)#N2^[P:MU%;=B$# &&D#%;>_1
M#9^Q*'0-R.T-_(GFO/'S\/RB5[7;]]S-L[-CACD5G<Q4UB4L5NJ\-(>%MX?[
MG&]16__)0LC&H.9#I59>E([6(C8%K:L>Y(+&NKRAI<Y=I;G[]:@3Z]\QKQ+O
M"&226"8#QIT,S.GRACY45'$*A-GVKU+95)[F?C\_2K5?V54J\R#H(,-;E,6\
M76>-HGQ5;W,A]FIY@N 4Q06U51;W*#0U!8+0G8J"V@/N$&92)!P%_0E,1_9M
M.PT/<<+/@%ZEI_*Z#:]HFK%VLZL5.=-_ZI3HU^RLCL.BR#1!( D1#Q4:WR8$
M(7 =]$#5'==<CJ0YEDRY5M6;7_5<1B(;#8D60QHW5$%\3#^ "D@2/^[<$C08
MY8D?*ILCLVFWO"-3A)D;;NWW"J;RZS!5-W1-A_B%6GP-S;'L\UNGQA0^1-][
ML>MF"$%30>-6'CA+D1D&^D39->6676BJ& -3MCVA3I2[Q_(5/QTFCBEWZ@IZ
M8NN)J70Z1[(NE=9LS6A1ES*'SK52"AGL5O%XRZ'49<LXA$<>O=@/NKK.IK\X
MB!QHY>X68^0@'I>CR&PN=M$Y9ZYO7C";7?-2@Q>%BES@QZ+.2X[5+3L[]YU/
M,,@\Y;/T1I/%9G 1J%(F_)[HFZ!M.;O;%S\AQ&[D2".7(3-TALR&J=NY2^AP
MY8/HS4 @.B@Z2V:H1 O1M57 :X8Z6?3S:Y6N('9'FDW^1:IJ#!X?;XKON:_Q
M]6TP;7MTG5N]L*2&:A75L/2JMT'"4>-,[7>I0[^_S(S@Y6DUV]U8FCX=8WI+
MRY>JX)75[O5[YM5_^K7DN@Z X'P;N$-(%(<L-(CNO!3/3D%%ER@R1;E=B0[B
MD(4J[L;K<%E:XFF,WT+@.:2M$KWC!DMFD??E6VGWKZ]?N3M=14[B"+=R?^G<
M!#HORD H\:H,!:6STF$1#,2^J"\;*E>#Q\8G7QWE;C?9L,P!!ZHWA0#9T8,A
M'S+Q1W (A@EAZ:#F\/^<GJVDBJ1(ALN2C.]MJ+\.%K6N'!FF?X@7:EG4/85D
M,G[Y)^MXL[3VV&F6M&@QH_/LFGK^*#U5E,]TQZ_;0IB\Q1B'5+MX3KN*TN#<
M%[WS")TC:>AGI*)<0=QC++HS6O0*,Q3)IE@RDTFT4X]?B95YMLB,TS+,58^M
MRL\-.O@MW=4L$=^"*G$(X^LJ#OGA,P2_1<^'/+Q"3I'0ZLZ D;,K8Y5X^JZC
M>\\7)_,S]8&"##Z:@FAIBR/H[=3 !]%41KQ,FA^01 NHXL ^;L<G[T[$O1B:
M+@XF<]DWOCA)<GR[L7I["'#7SQ%TS5!W5D)&-[D)Z*$1R$>'#SVK.*"FXN1*
M?0@T<#(PLY;AYQHZ64;M!+3S!$!<7*W'6)4JE"^UT@/1K%?S-=+\ (Y5:E;*
MOLL](UCBS!Y^J"Z1M=73'+YK60Y7*C]QLRC,SX< 4?</@AE__DW8_= IZM^G
MWQW9%3WH2KV>]0 D2_"#X*4/?H(<?%=D94/AZJ=X\9,GABJBX7]!IEDJI&F!
M>HF<MXLV;OT*-[" . GW1K9\<A[YZQ[P[ ']SF-)FG(ZBS3T+F[JS0Y1+14K
M!63H/;7:I2HDDDJM<&Y6\]H4.+V+5CL/)RO5VBVB7B;JC5(SWZ[4:ZU-S_NM
M4\MWBI5VJ?B78RHLF>!CD@0Q@RX:8-F'?K?\5?R[;3ZP5+%+TVQWRI2UE^+T
M\W(X0767C!&<?H(?^4&T;)8GS@BOM1(.8$[#+];BI<QY"OG0%G-">I;XL0:9
MR/[I-%#.WZJG;@\/.76=EK0Y.M93,\,L5^KB:"E-T=WN/&Y*<>7:9:/Y^>MA
M7N#*'I+YMZLR]0>&20CD% *4G8',FB#?<+E1<?QRP[PQR8&\!$S@C,[P:9N(
M?)"4^.=T7J;<@Z7:4+@"H@KI=J@1)5D PMI2@%L&>LD6NUSG^C@6-8NX?ME:
M L$?QNL+NG3$=H&*.7XIB.Q7;<S^9MZ6%J*^[T V@-8=\5>-J?1[V)U>,:WF
MJ/[>K/*)A(_<([Z9\YS+O27ST].+6JE--$OWI5HG2(7'A"KLV:A8=*#*JC(R
M_5(:_E]7/'W4R$D'69+.9<A,+LK1\S:6SII+-W]R67CD0_<,[I:>#E-@SIV@
M<PN)3YI>'UPIBH#=8Z"^BWV@M:"'W!UI-HGWKLJOCWR?>P OL4\N6,^3"P0*
M\B*>$3!(D@E[&>/SQF@T3HG3)I#*<2B@<QC!TY"(]>'#.%T'&2Y%IN*7M7>F
M)ERIBJ8U5&6 S@W;W9%N\=Z(KU=NI]-GM3N]D]FL A]YY/V:;&Y,T6 H"1/,
MO:0A!YHC<F/D>E(I5#:(9*+HK7W$I!_[18Y1<R2-\JW8B&HPEOI:SQT';PF[
M]JZSFH9K"R7UJ\K;S?0^_?3^DDA)_2B[806,:E=$Z;%1JK7^F.+G+2!)$$E7
M0(8[)$%5F1=&HBRBW4%IV=9^H>,YI%U*4SG;Z$X[+7$D](V,.O5KH!+'Q+-
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M"$,)HC96-.CH*0-B('X"@>!QLVU<9'G+O!4,E9'8B@G3/]7+J/#-W=@D3\5
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M#=[T8+[6W6QZ$,>+LQ'M]OB\2T#&M;$!&#[]_NA?YC,W:ZOL)P#)K#0^<^J
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M#YF=$Q+/F1C)@#3)L8=3GRDB?D,XE-DXN849.D-FLWYB>Y?0G4PR7A1+*IM
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MDS6@+.&)3HMH.U=M&@98JD&$ !P)R%&$P$\"60/0[_GH%ZYSDG[5>1WLFS6
M'.J5389FO=B30%[3@*Z5113[N(76EF"J]"5+@%DDV?7O=J?CZ\?.]:]&-O<[
MNP4K )IJ@U^UQYO!VV^9[IU>-/+M@]#Y.",:DC.RPDW'1^DA$85$Z9C'1TA0
M\D #MP< =#[-1 AQ"@0<+T-&=0^@9Z&B4W7TN2DLD>"2P#-4%9(XF%G7UH!!
MF('I3MO9ZZ94K-;X>G_OF&$E5N-^@:UNGTM 00@Q \F[ 46ZYLH>*_V#PHW6
MG;Z)985Z5]M"6M@"PW#=Z6U%&#]15P\R*YY>M-KUPLW99;Y5@I9SO=HHU5J'
M$\BQ=;2MX*&F7KBS3(SA1F W$MF_(UGL&=H)P"?^B/?,S3(?,F1H1UNF%?0Q
MGW&3R<4+T,B0Z0,5302M+Z@\T=L0X%< #:?16%(FP JM(+L<^K,\MIH1H#@J
M\(YNTB.>!-![/;$@Q!,ATP6J9:@D451",>,- HJ56!QL/H6.UDQ+ZQ+E09RU
M^D,%!7W,H<Z@P8B:$D +2 "2(QPP@Q^)C3XDX6=D"#TC?.G0%D.F +*+X+@0
MR#FD3GL?80J][';[S0*11U?/T$)4\^[G@DQ"E@L6;=A)/S\,JH,6C;) >E"6
MG=F$0 @087WH&)TL( W1VCEAIE;.:M:8VXLC:NKL/6* J4D%&*&J8!JO^@HQ
M8</;',_ZWB061#X'@F@172;25N]68I*#'#:_!'GB_ (CS^+VOL1KFC@0K:#?
M")N/2RBU3H\6,(O%@H3CBM;0*SA>9? 3#TAG;  'L06)->E,PYMD@MQR#64H
M0?<=N3:>PF%%,*C*ARQ">595\&$6:FP"$<FKDD)(O X],&#+AU6YY 6V&6.&
MVV<55[*7$00T$U\GV,Y!G@L>%TDJ-\1Y0N""."O6KO%( C[#9>,XN!?:>,1M
M)T[P+A4DKZ 8E94/"0C/"_%:*[R(/B+M+7==P@.8R[M5Z&T1.=\?=,J(LIK.
M).B.GL -4:%.PEL^ OI0<8A,U;Y8#[T]?+/>$IZF.C./CK# @'\&0+1.6U&4
M%*HCI0^A#1@*;1@WG'C=N'NLOVS!W@.??<D0P,5/07R?P<&P5'<Z'(T:<FER
M#Q[H4Z]$MYC):9EC<MH7):?]_ [W^P*3HDT!&[#_4]2R_6^G-C> BI7N^J"X
M\W:-SYO=:>GEO7/3+L@M8Q-\XQ(.GSYF4].'E]??'?;THE9J$[?U5HMHE)K(
ML*_6:T3K.M\L[;UACT['^X1L76-%4@^'0!7K"@XR,?N\U#?,F@N]";28WD5T
M5^9D]HZ5]/&!>11)?RA4^6= R+/4!N>(4#7,+]PXXYF6M4H41<E PZR'"1HK
MZ*D3!T1$>(A,]P'_.(^]!X33Y?#N9*P@EK>.8-$ZD,>SN'H>!TP5#9B!-/,L
MCAA #C3? #.(%MTA!*J!@Y) \#;.$%#V?B&+!"Y5<,.GB4A+. A+4\&7EB.M
M^7DADCQ<8-%:F[,V#;X_)GS>KFWO.\U/;NYOG](5ZJ8WB[6B$<]FZ%J Q<J&
MH8+?JTPQIQ=3H"HSSK3"_!!]RXM*!US4NDMQ4^;7O:*E;J3?U><@"UI;?,0+
MBBC7*E-![^RXWT.C.3+-N%TAP>C$Y^=CZ#E!0*4)B2)J-K.=V<QFT3LRFI +
M;AM[^ SLQ#H# ZLM #F\56A5I&5@09,5# 8H:^ #GPXX<8L^L'G(FF!&Y[-X
MGWE:CEANZ=AZ#^7U$H,3P1C\9($&2?0$I@VY;WL9JQ(%[D* QQ#A:,2W1JNC
M_>4F. H>/#8[#?'M"#Z]+7+4?:6=>1R+7APV&RTX>\U?B70(DPIZ'\B=O7(4
M1W*N5[2\Q147&I4KPNKI)E-ZFO1OA$_. Y6MQ%'I)Z>"UG3W0.1Z0;4HIT["
MRBEB,W+J9,?D5-*>07KF&6!B:?6'0# D4!_,2<7#*<B5YT2^]C5HH(_OM+N/
MM\G'I[1YC^ 2,D^YV6M6P5NO4$F;<GB@2)+R@:-5\R-B' I!.5AP6TWCRLQH
M.S%-UA6I[6)LVME=OB1(SFB0Z($^;VAFNI]-A796Y0(I_EAT63;;93=USFRT
MS6Z:2[#-KF\CSQS===-/J>=K/I7^I65><BN]/5/_]BCIXP=,0KU'<ZFNFQZ0
MU=O4$Z/)I:O5CJ^10?;N4!IT=P-7U)JUN$JYEOE;VW%ZI6W5%P(=IAR+8U$S
M*?#U:PG>8\QC+8B/UBYC,W.R@5$WXR5T!<11C7.T6)IUP?B:/A:>[G)52F;R
MT<I-IQ=+D]G]0L.5B [1>R2@<YUFPE?1C=D Q:[*N83N**9F.E[3*4]+,Q01
M.2(IC;E[A9>&KDTMT5'[L]49WU\_/4MTX/I"%\@9VTZE0KPYKLN(YE6E8U8_
M]7*J$L9%4&X)7G/:G58<QO!2Z=DYJ4P%JJ/G#*55NGQ)1-0TEUW\':U+MH8B
MW9 5D2#C>:?9J/5X]Q>E?C(X7GFL'!42H>Z,E7$)I<"5+492IA]B]D/+%5XR
M4C:X\/7L>[Y3)8Z"A':<"(G&/9EX392\@V0'C58?#LHP&PJ8!:Z*LR;%(9^#
MSN50[BL/[8=18QLI#HD&KC+<2DKK+ BU?$2-3T[SLF!M*C[W]XIJ.2\J1!RQ
M.[WD;Z>/[6F'1\U3-Q[P2G>G&8F[J[P4RK>0KE# 2\6I%>0L=+7F?-6,:ITX
MHUHH5+7FJ +'S7#2#C_"\=(>/IGVG8-8GF-U[)/  ;59/.U\KZ-D<6Q<VTU>
M'U8JN4;";AX:=\5;0P,/XMJX3 *@.(,!<[ *KM&N#_'QHRWF'N[>>F'!.@:T
MC@&M0PMH[7"H?3>BYUL(B,]=D:QW?X/FU5W[\5JI#MNY1#S[A)L5A+*=-UQC
MW-\5B5^_DR9S;(K,I?PJ!T>K0K\[N/3S/T+4Y$R\7GO"8G\GFL"$,#OF8L-Y
M4>[!LI'SIHEL5Z=:*6]N^A<]E!7?U[OB97?Z/$EE?[7N:$4-'N"P9R.LZ0C'
M#-9=FQ\'C/AB5,0O!/:'2=32__7ZGBY<79>,MT0.F>PA%OL24.>,*-MYPBO>
MV*H/MIV#!UN:A=J!=9ICKC>"%J#/QHO#<"DR0S,D@XS%+^TS%A^%D=NS9>,=
MR$$4<MD,F<JQ<>/!CH,6.ZNMA)-HZ@,'!ISGCWE9Z%C9V$NA\<4#O Z5SO!5
M>J#5I< B=BTCVO#963ZHB)-# (=(&O^J8['LSC2%S<8]H*/]E8$=\UWIN)*X
M.A"8S"]ZD/LE-S:O#HI>(< ("B%,M#[6ZQ&*UX?<U(0U3+S#QS@:YM#W)+K*
MBMG>)Z;*.OH_<XWM>7EPP<6I7^9&Q>E+K2(,$PVBS(\7#AC+[!HL.YP:Z-0W
M;(.GWY)&S%WYHU!GDS%X\#R[>^3K$VYQQ5JT$%8NU(TNU]!+PY9#U#GEHQ4\
MT&*VH5E"Z([TH4EL*WPB8+E066J^&^$3!0N_$>Z\S*WA94MWKG+S6$IG^ERV
M=/>22')9$)OR8%C=6D]$9@\:93TR>^S-\&/W4&;X%[*[G:"S/D.'@3;1;Z-Z
MG;MI/,]-(C,]Y$Q7QCA%Q/K5GGVQF=7:&B=4=_K0*61_%5/W+]QPSQ* 4M1*
M38N.AC)UK-(VRTU8G(=WBP]VIQ^7OSZ,285O?FRBZ/5RQ8I,=_HH# V6OQ)?
M;W*G%YT6[KY2:K4KU3QJX%2IX09.[FV;]KR(!;J,-U;!F%=GU^M<Z]&;G040
M+XOZY 076EIL5?(,9.A3HNH-?+\/QCBP,>L;@:H0P2''J 227;K_*I]OS'J6
MX")"*/KAJ%BOHZ)EK_/B2&9,CM<T8V3&Z$YP&0C>#.;A:DBX-+)F]368U^EW
MK[!OE2>:U>/'C<-FY>CZNMDAP:SWWL<7 @41SJ6:%2?,VZ8SV,Y/*B/<T00"
M/@?8NLA(] R=L O,X\+'$#94;1C5+B4DLSJ? .#8Z"ZKSG_B0E/FAO#HHB0N
M,TSBVKXR;N8R^]ZJNX\CL! T%?3@Q%:O&KMN(%RE"A=CU;AP+V$?(L\K3*'\
M$ZOD[01=ID15IOKZ[+;NK%H?'G8@HH*[N.U$P&*XQ>J@TWQ3F[4V^+IZ4*7N
M5'^\>JVD.X+(9#95#RI[K =UR/6@4M1*$[,F@*QN #0<6CVR=QZ@T"U8C+Z^
M/)13MX8;J#N]E%^-]'75>+[:2).[)=V+RMK<][/JY:!6:0]/+YJE^U*M4R*:
MI4+]"GYT" 5@ZP:2RW@7S!I&D&M1H6I;CR"!V[.Z$1*:8JA0KOXX^2;^!8W5
M$=(EB,+@:]_,HJ^XEX)F"O!."XO_ E2: O\727P3X5N+W;WZ..\8/06_A-_*
MRCN0<"%Z?BS.]1T"$L\RFW.E4=C);!$6"#B3&)<UQ"=I4#!-4*DG. 9:GXI*
M]AN]>6XQ$)SJOZ$J@@'UMD6?,TO U@VS7FEH$D<GM1/42<WJL8*062[FB;X$
MM8:E5]!-_EFO(6?C.+B8@8&;!YFMS,CY8W8'@]F<:"!Q-#)DY5E2>H:$[ @%
ME[#7B8;Y,-3WZ'NHM5&;2+D_(8JB!GC-N<1*L3A;%]ZGH:K($+45>2#QHY'9
MEZT(1A,X+\(R1!7DQXD,#%49\_IP,ANJ4"G.C*5SHK:XAR>._5A"JUEX$8(E
M]D34QNU['\Z$L:&KT!Z"L$+C[VSVH:8;@HA(NS&$*R$JLQ\</U5PL9J>J(RA
M8S;B^\# (0W"M*00.);59;6\@Z J8VS0C54%M]?@4:D'U,5(PY5HYRU^@ P9
M"8#_S]Z[-J>*= W#W_T5U+YGGIJI(AD!C_N:2I6)FIB#.9CS%PL5E43!@"31
M7__TZFZ.@@*"ASV[WO=^KMD&FNYUZG5>&ND+H9'!>B8(FG<UA[I(*?$OHF'A
M!F-FZTTR6<J>DV>N!*]U)9OSEAP!L T#M68P:H0H5] W$TY5OZO5JM=73(O,
MPP/X6N S>Z+1*1A BF)7 X_W&"E#H/YBZF5@NM1 U8#]]E>LP308#[4AEG*W
M&:58^AI*T,1-QF20P3T_Z< HF,&%I=I$E16S?2G594FC>3)V2U,)=-4O9&7
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ME;%>T:WG:?=OJ)&S%%>ICVA@B@>+X5608H&;FGV+8W1IXY:-1"\G$Q/&$OK
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M+%';'0F\,Z1\/N?$YMEWK7,F[0$IQTAQ3HO <_%2@3SA.K_&#@GZ,.G^&8D
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M=W;=)QYBN4NMG!TB#NU5R)?Y_//MFVUI5M%]J\G8C $6 +G8-\\"/TSH:8"
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MCIUI;?FX/7\=EQ^FE>%)[E,,?=^:SU&GQL%(ZD]_,L7#,J(W2F@R,CG!O7%
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M2E+'H!9BF.PQ5QQ+Z,^XS2/B=80>GF6ZDC9%EP](#PE?%G#TGH2T1!7/F\C
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MQ /K(:J, YX8UY)YAY,U')!Q> @,A9+J%&\860#O9%O$0X1=&EU9ZQICM#S
MWR8<\//*7?"3HW4FX 3L8D4A,X:['0&*!/OA47150VS.A!XPFJ:.]M@;A#0@
M!A$GI$<0W8J(@T\PETSS9&2*A^%27&$&P@J2K-,@!=,C<0YY#/]"=(,Y0=6H
MB "]SHDVH%H5)DXCPL+JX&"D=M#.ADAI1/_J(J3"T1"#CC"ILT@UU#"F"(T-
M)'6B@D'6)294?X0P"58BSOR&;GD:C:M.L&:)B9GP-0F[8'K!ODV$8$W\LD!
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MF-ZC9I9+R47(8\@0TL"=WR:J#DWB^DBK_<83#1UG^?_M75EOVS@0?O>O$+K
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M5M37^N<*\+5]$,&_%A$3X1\#]7??]LR!XX&H/,TX=ZY\#81S:?DMU_8NFSU
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M]!W7:W;OD?E=8:22?JT,X#2/D!:/5.!\0O4OLF5+L:^3,/TB'LEC>69*1MM
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M/.=WUSW]6#^99XL7[TUL82:/#</)_2V_?YPGN)V*-K5X7)"0>ITN/N:Q9,+
M=!P[=Q%?T;JJV^ETA6YH )#;V85U@.P^"N3F<OQ@@>P^>T1V]S8BWW7>J(A&
MT\%\[JCL[FU4'@J8>D<_L4=>_<;L&).]VJ=S=Z#9<2JV-?:7TYQ2Y<>$R ,7
M@R4>-"ABX.B/RQ4_G;O(1!2LSS(&$H@P/#!E.9*0P*^F]V7L1BPUT'L/@O5
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M!INQ"?_&_;_4+N)=O:#NCTA:P=M/@_ K8'0Z608K_#G/%M'[_P%02P,$%
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MF9Y!@_KOX92U:C_ <^B9MI.I$K515V:<\8(*-4,8AO!_0'N^H/\:="]GSN'
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MG4CY;3QK(+K9WG!"L]VOV$ZH:..9@PP6"\N(FBN8G+J"? P(0PI0 !4\4JS
MHV !O\@/'@*X98@N[5]Z37WKT&"/:,UAL!]\*7)M/O,E$'LF+4=&MHJVV\[8
M9LI 1$+D3NENW84R.=_JG$F8$Z[('NHGC6D &["'">39X40I!=+ 59D'2<14
M;]T5PLM,&:Z5:RG-FZ;,='TKG+HMI7*E$[)%S=)HDC6V5&,HCM]V3J4)(6'Y
MMI*JZ1Z-<B)6;LH)ILS,T\.U8GL;(%+5H=+W.926^D4R=YIWTJNGMW:B5;IE
M4[[4HR;MJA3T=M^+5 [ ;7E:HW%\E6();VT&&0UI*)=5:2F:USK@47[1FXDS
M&93Z&R:T^#Y)[./]"_])^82#J'%S" =4!#@JT/QUDDU]H71H#<6_"M6I9'3)
MK_(FGW#*T/H55=G27\KTGBC2QL6$-&=%$GA"?VYT>K@RGS(U&R_2^!=-9FMV
M Y[09]O[8K6RB>@+T\;\:^0,0OQE$._9E\:PITO.[0=["MWIC>G)\OIU=]W:
MO?K:DON-:$PYFD<M8G]'#FW&L;WG%KPTV;GVTY(Z4R[96*G@:X\)M>*P4@S:
M;[=3W>XE7[>)+V'Y.E@01;K73EM::\UD#8KZZ\97A&R*/BDB^ACB92?#26OI
M<S\]LSY5B=RQM8?S*AV)-S;Y>8$A[+L>Q)!X#0;]M*[WTSEKUYC(1V-O""KR
M.AI[2<$GX=>#AOE[*6%TX]NB<A!&">\DNE"?X(JV?J->\SLUOU/S.S6_4\WS
M.\WOU/Q.S>_4_$[-[]3\3LWOU/S.DIM:S>]4Q(M4#L":WYD>RC6_LV5^9Q/9
MG%"TV+>T!-_B4D-R1]15:X^I*I=KE6IH?W@JFV*N'1[WGN@"TR;P&MM6':<
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M]J^L W19%C12L\:.#D:49#'0@<$=<Z"J-9Y15PXEW&JL*+ E;@6GE.+6N&0
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MUK(82\"5:8P;OX-H<0FH5AZ'F)TUHW*.5N._9#A*Q>Z[\INUD;T)IQS(BQ]
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M8#?HT0&OASPR:3"LT4)LASLI.SS^2%502@2=L^E#$J?I;1)OI"= :A(V^2*
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M'-C*?3BDB.VPF\ -C?Q?^1,K]!1(/H*EB^0R] +ILFO',JQNJ/<QK[;7WJ4
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MWE'/5@B^ RKZZ%M-0W;.UD=>S:Q 9EFKC^79[_%!_C7U, =G*8R_?J*]T?8
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M2R5MK?/K(9<TD8O"XHL6IR%Q'LIR$*TP\YS 1S!HLHV3+/B#V;;8S(B5T6-
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M[N)K%G),WJ[Q0CJD*RKJT@&RWS10'824P6)!X8JR/^[\$%W*J*@MKGU&!$>
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MV1&2_>"7.4%NE) WWJ&SOLV[=0TA61U)%5U"CK]E5LLN).3O[RNZW-$?=)D
MN/[EX[U$P!^<"V=[4$3_?C6X&XROA\[LY^%P/G/^\#@>/-Z,YL.;_WUX>N F
MAK65;;+<'FQ-<;IGEN01SJKKU8;I,H,HHJRH=2B7@TH^; 1I;:^IUQA\[$K%
MRE:#NGQ4BH/E,):#6\> 0%5P(M@K ^PQ6_H'>S;KQ0W8,F007[N$O-'9CT]]
M8F(TJX,E0];B #=1R1+^,J\:W6%YB,KZ%* QBL4;SAP/:2VP#,H-V-+1'YRD
M4<C24V+R1F43D[)?"BRM<@,2ZO0#!SWS>.9F(5D55TN"I5EN +Y(3W "I@1M
M7'^1/="C'),$Q<'R+S>@0JHQ.!][FFBNM0 3,3>9#.HT+.!.95\B^LO%7:JU
M4$(N7HQC-^ EX7I0^J;I-& /S18>-I7.(_):8)F=3=;,.HJ#]R>Z%?-C=.>_
ML.?O8C=<^73X3=63\J.J!Y8%VH0A/>7!.<J>;PY7_!VK!_8V^&3Y&*622E8$
M\FIPN:--*-+2'9RAFVQ(WC[CI=&#9'7@DDR;<*/6&IP8OJ[,Q,*AIUHV"(K#
M): VZBHR7<&92 53K=@@,T^;^\/.8'56?+\Q3%\D?L8!A3ABRY7X3>W6U&\!
M+N'UX2YH4YS ^UM!8&T/M:P.7";MI@P(";35C9V[ :?N&W.":#M R^7A4G'K
M8UWO *W7W 9B2$*'](I:4FY$5>"2=Q] CUQ_<(;&.$;:_::V,%Q:[Z:L2'0&
MYX.O14WZB[ "7'[OIKPH= ?G9KC>!/@-H>PU<A.6-*K"I0-ORI<V'N#,I8M6
MM/?P^IN2-'DMN#SB3?G200&<JGV_E3Y9JGIP^<<;#X=:2( 39C(,'C+N=>:W
M,"9&:Z [-7]&[>"@X_I35H3+A=[J0&FA:U P0F@Y;-55X7*JM^.XT$8'G,>"
MHEIC)V3N]=:=2F<P=C;Q_K;@[^T@\WL[[)Z E[=P&TH5Y%HI"9='7A]?K-#!
M$AH&BP4_1'"#J>LO1N&UN_%I;R[(*_$4:M2%2TW?E"I]1,#)V[N3H^A%=67A
M,MTW)4>LL?GL]6,Z>X5HQ9TGD//7 XI=/T2+H4M"=F%WX'G).N%.G1NT9,G2
MQ<3JU(7+N=^4:'U$P'MA53>310=DKOZFY(@U/N$UI&K)U3R. /)Q@-9W"U)L
M6J4?^O;HE /[C&)69JOAWE72C]I729T_[#777RUM>QT;!/B5<7>+R0U.GN)E
M$E0O)ZD/O\V:.>&+J4WP I]J)6'/A07"8,VRG?PNRO2]\S$:MP5]X_4 PIM#
M!\YZ'JW[@%CBU>U-JS&*=1RM>K6AK\@>P*P)/.!<%K;1=$*<$*[W0I70I.I%
M$5>&OCY[ ),&X-A$9)H'9)#$SYCXO^_66U("JY6@K]RV0YP(#/L(XUG:3<C*
M*T!?SVV3J'T0["-)GAQ-I%63U&B=G52U25?7*=,.]L).\VVO42ZH2BWH:[\'
M<*8#AQVYHG:OA4R6V5EU\;7/O9W^GTH[_=E\,!_>#\=TES^Y=2;3X<-@/IJ,
M+4@?E=YIV\JJWM8+*T#YPE]0F,BZSJX$\/Y; 77%I;VO&/C =8TCVK\_8;S@
M7CU$7GP/13,<2!<%XCK0NV,S.M3:@Q/TB> HFA*\E)W_[!6"WL::45"CWPD?
M(&S#G;($)!J)[B15H+>Q9DPJ=0?O2S,4!.R]!Q1220/:XP>+M1_Z3$KVF$PF
MM\3YK5D?>A>K9@(WTLL2&A\HFO3S+$7<#9U/ \SSDBC94U2#WM&:DJ:% CA7
M-XCB2'<.#$7Z]P!Q.$--_[Q>;>C-K2ES)IB $UA1SF F@]_#FE(CU/8<UB3I
M='Z':Q_/*@-0+ R=L*KA.J2J[PFS.,8AWE<L,U'U"E.C*G3"*S.&M;$ 'SUO
M,4'^*DS/T+TW_O 5>[D0AY]</V2F>866M,S<_2HYI39I!#PQECXYN+F6EM";
M2S8)9VZ )LN]I'G;C'F2?;MF??",6DU)-0,(G$]^^5VHJV365-0#3\'5E#\]
M0,!Y:T!9"VQUYG=IRI8)4:>V_MDMYFXI7->8/6.84#UWAS;I]+!-YX>B>S_$
M)'\O&$4LB^E^*VG@ZCV*G_&")=".XKUWXT7')$<2 CSAF-FB#("@DS=GBD+6
M0Z]0B*0N?F$%\-1F3<Q$J/A)7^$9HUAGCUTJ!I[PS'#S5:?D"??$_'91'EVG
MWD^+:X G1S.C4J4Z^+JN+."5&_F>/C%9<?#D:$J<Y;3L:6T=)S=^D,2R&$)A
M!?#D: ?R4M(<G)DOB"481XO!"UUQK5#ZJO1D68F:4X]PYBV!)TXS&_F:0G4R
M'"M&2L-FP-.L->:K&>VB$==L;4,_\H0C!+JZ$6B<#5T&\<7&#8'G>NO69E0(
MMFPUP*&Q["F^VP"_"B)C?Y!&QEX/9C\[MW>3+Q9$QA:"FK<Z&=UZK:D%MMED
MLDP)?O$7[*GJQXA=Z]N>?@Z\V'])KVNK3P@;M&7/O5<AD=6=:T/$P*?];CT+
MG?FQFP-NYG. RIOT_Y+,(\EN65)-1]0DHSE^0![]M\\?PMS)/<>M]=?NOPP=
M1-R:Z1R+)'!KS%T%:'&-U\RUJHBM$Y6'#CH^&F%8"PY+V+4HCK*[]VYAF#^I
M<,S*JV4\&P_]\YK^T)>=7:IK0D= @_&O!RDX]^5@FL*3:?HA1GN5H".G@1C7
M !+R'/)7LEYP]K__^/&26P#[R2\/.+ESPT5 24DMLX9T5K"F''08]K%Y%L!@
M23^FBK+[T>@&I7\65,L2C6I=V-5N SI\N[6UO#EP%G)=S;!EPG)=;0N"MTUI
M4?$J!NFD T2JBK*HII!^2)IU7E$-/.2[ P.HP>7,F)\2M'']1;[ZS",\PX76
MLJYI>^"1Y!W8B@F29V9$7,,L0Z/6 Q8&38 'K7=@*@J\+%XN9$\E-EDK;*N"
M![9WN%(HX6,AD^*7^DQ(E;5B0\1XV_RJ4;.0ZNJ3L_ELM'L/J1G]IBW;$!W>
M09=O@"ZXF>AO@]LXJ+<@KKS-XU]#Y$XX'EV@;'K]I9VX#FE;X#'L[45V:& &
M/BK0=0OWB\[QP/LM\0FB2BP2)B]2[0$UJH*'OA_ ##95]@QV>!4MRWG:#:RA
M6A4\X+X[:Q#A=-+6H ]7&U. !4'\K=F'.7+GMV+(DO:VLF*0M@5^.Z"]%8,&
M9H>N& 2GN_F(-J%&ND!/=.@)46VH)RLM*@P><W\ K%BMWAD,Z<57K:?$IZ!L
MV".3;XK$ XIJNKQWE['B8-[U%#T#"]"'JHU16M\VCO&F1ONCLS7[."8O^S]+
M6?'B!H@?7E,E?8\:'/O%(%SL_Z!0<HJ(SS)<E#U=7I L>#)"[YFN;M$#!7*X
M7"+9!'YL.73-ZQ@O@>B:%PQ7)[S"/ BP+30W?K3!D1M\(CC9L+2U?N2E:6+0
MHOKV0LNF;2R%KF$?X\V4HQAV0YX:F_6&=R2J)8E[XSXJ=;]\T#=OF]R\Q\:H
M%0,?AK#KS5FRV00<:#?(@1Z%2TS6KN:3K[H-Z)I49\[F!B9EB$Y'FW^^V&4A
M3 G=\JS2%49TBXF$'%9/74V7DLX\OB:4Z*EDR7H_SUG'A*7;%=D9?JF@]@6[
MUCDQ KA\"E^KK@4T;"_M:#!1+:M+1ON^RX/($"D-SD?>R?-K'EN'>[BHV;VS
MJ3? 4:*3=>WPEG6Y/L8#OR9+GC;P[&CB8D]G,G\=56CW3*/B_C&KJ%%/EZW.
M?)JM08^-]!;R!9P"AHOZC .*>I3F9=W*NI<+YL_27#"S^>3ZGS]/[FZ&#[/_
MY=)U^-^<X;\>1_/_6)4:IJJK48X8676@34 NW%P>1%PNI^J$%6/M>MQ4,U->
MX)<T*EZ& >:"=E#$[T%J\%$H:QDG>Q8E K\@?C&( )B U(#8\(M#-L@-OOHZ
M7-17.T5:ZC4II 4"2C&Z+]8-7KN^)+N%H+AEA,B,K9QHM%ZA0OX%J,=BMVN6
M>\32X$E6Z]6BT-FHFC AU!A\HS58+/A+W.QTW%^,PBR87L6+HAITVJ<F'&DA
M <[7 XII)T:+/(FPBBA1>>CT3$T8DNL.3LW>:_5ICU>Q(ZD"G46I"4%*!, Y
M$N\^ZQ9JU;+63#Z517]E;2;<9I_Z0:M!MN$#\@G#,]AZ2F!K"&2VR5Q8:,]C
M_=D-$F2<?K!!6];,?5J=N!%0=@RT5=%3HVZ)9'ECUDR@#5G6@0J<YD)&KCD6
MK*#K5>!:3S8\2.(!T1DJ\F,T0^3%]U * $OJM0I]N6D<30#HK(;:YG1D2D[#
M!'==+#\ZN<:1+%+^L%:A$R*V:RP*\+H*9BE89OX 99:]@27\R\.SN'2#5Y<L
M1+=<FC0$G>E036!3S2SIM;L3S%2Z</'%)<2E=GB+23;F1!-R';B^[&##L!GH
M%(;:_;(1/."D=OJ\0/>Q92I2VGVRT(9G?0YSAQC$_W:7-/  C\CYQ.8>X!$Q
M(=$"MU:=^!UQ"! H,W;CA+!,TMOX<3KRSY+UVB5O="KPZ=I[26N$<9:NC&T6
M<>![Q1ML>U$T?W$NG%U($?W'>#!_?!BR$)K)=/@PF(\FXYDS&-\XL\?[^\'#
M?WAPS>C3>'0[NAZ,Y\[@^GKR.)Z/QI^<Z>1N=#T:SF#":JH::[QO(JD#TU,G
M9.6&V6, UY1>*M:"_X,]%1=-EM."/5TED<\N+-^@R"/^)G].H*+3G-K9%17W
M5S$0'7\6^ TGM6F41I&CL&!'Z-V48#J6Q&]49C;I;=@@6S]4_+4\5$P?V! Q
M_P\?'EATW92%W\'T_ER-:< &OX(NZD% HRI0DAZ18#L6-+JV62O /56;QG*>
MG@90V='_^*KSXDGHP-WK@C^6NR /<[VX&LR&-\[UY'XZ',_XE W3"7>B\;CC
MK3*9RX$[A?@"C:N;9UM0]]!#VP5Z0D=7ZJNBU!H]^N"&@3MY.V92?EVG';3M
M&!1NT%,\>0K\5>D*='$PN/R^/!C<#*_FSN3J;O0I7;8##0)4=I/[-J+R4.]>
M/9E-K\(*T)U,2D/E:2JIUG9T"IZK1] 7+LM]X6Y(YT2@'I *JK;\<CD8BT^E
MF"SOZ!X&(2/;UZ@*W OJJ2A9OS8"=O2#PJW,^L[PH=P91F.Z-APZ\\&_H;K$
M5F:3F4%:"?@:L%$_D=<"[B(:U(BN!5O?55B(J9^>7M--X37/OK%"H= =>OFQ
MW'5HQ[D?S=-KA<S-<3WAOL[A&,[1*5'*Z)ZS63-P-T&40FKT0--V@/MD(XIK
MKI280V='OYTE3Q'Z+6'!Y>QY+D%G_5/%&_)X-1O^ZY%V5F?XF7791AU4$&ZR
M^U)9.D7V%)V*4"E[]N71Z$B2*E!]1A?C^O-"%01V=(@#SOVDYW^7/W1P_N?\
M(?\FT W[\S@*K'(NB9BI*7MJAVYB?<'CEK)COY)*;^E_-49-W?K0MX>,.3,#
M!IS'+'=?.=.J+HV:U:%O$!FS: 0+.(GE)SAN_="/T9W_@A:IR+*-N+(J]-T?
M8_*TX0 GKOY2P20/F1B%'H6'RLT.<2,5E8T:@[[R8TSN 9"==-QI?H-[B@B'
M0'N(5E:$OJ9C; *:4(#W[L>(KMV&4>ROW5CVID"Y'/15&&-"ZA4%Q_\!T0UL
M@FZI?LS9PQ3XXL?/UTD4XS4BVCW(M!WHFS#&_#4#"IS?,7HMJ$IP2/_JI4GS
M#'<CYBU!7XLQWTLV! N<Y5O7)_SZ]CW/E,%%-J37H GHFS7&O!K# T[H:+VA
M,O.D@B3/"#]9WF'V=C!=HJ=K=FUNF[4&?@?'?%-S &HG[['E*?4$_MH_=^*O
M3;_X+7MK!8<^,^\9+9* 7;-$7D)X!EY9-V65%'5.QBVKH8LE8^Q.RO)FB?DG
M/?[V1I"P2\_,SG5.N9HV>'(.W .AZ^AJ_TZJ,8IG+AV;KMX^(;PB[N:YSB>T
M;ZJU=4['*:NAC$T37=T%(MD,5KEQ6'^-"'A2^J;N$QURB\B>F:WUNT.6KBP%
M-X9D?:YR=4]T;PBXU_47B.J7-96+*SQ92S$=$]L4IQTMBI)U^C/SU4X[WX&^
M^=#%]:)NN+!HY:S.^)6]0?)VB%F9M@V]GCZ:+34#O?/EM[Z @S6?QI3&4=I5
M'MH^]+*^70-I&1Q;!IE:/>@^DS]_&'IIJM*(CZ.%S"W&XTV[GX$.!.EFZ.F"
M"G@#VW:91_YX%BJ\SLJ[RV/HQ]$##H);3)AJYE-8PX:A TXZGK\.@MLBLRD\
MOU&P^H,,QKA)Z,"4CDVE(<1V;+G3&Z*R'78E,T=Z 1EX/WV"-Y&9G>GV-F&%
MD[EU+-86?'3,#B[#%1>4_R>_^*G'CG8#T)L\+;H,X;",OF;W^TW:@-Z(-2"Q
MX97_8P^*3,*2]?GNDQ_0]?@]"S(PV"(U:@QZ(Z0YFC:&R8XEQBU=">%7*OKN
MH/T+(FB,64KA(*%MC4*V+$O2+TZ6V;EL)>$I74[-J>VA>QS&S]&027%/E7O^
M>,EL:Q NZ!\?KY#G)A$:+I?(B[_@)%A<H4$8^Q<+UJK_@F[84UI!_6+G0R7S
MT/P9.<M< 2?::N"\4A6<$,>.GRE!_^+$M+2W4\7!2V>1*N-$7!L'[]2A[1)>
M(V9*.6NNE</!=;A>SL?+/SI,M3\ZM ;[VT?G*56/UT-<1^>5*4E_00L5U/S)
M^4.F:1_\4I=@?[WO;Q+X\^H*GE28BUC3CCRL18_+=L<L0%=0%GK59(:P5.&.
M0*[S2@@PKB\*O:8Q@UBF;D<(LRDCGX>V@[X 8D%9Z-6%&<92A>U82-"YF%*&
M"<KD_(+\U3/]<_!"UT8K-$[8>XO9X4)QW; +]1JCF#U@D >"L67(S%VC0<1#
MP@S:*S6DM3)Y)UUY5/*\;;7]XW8-\9H)Z+BIA$[(163+C)KE!5LSY#5#%#NT
MY<BAR\BT;+J 8<N(B"+@N)'SQ#!H\(V:MK57-MN%S;M^N=+JP^Q[CY=+7F+/
MRMGQTK=YC&=)C6*X/S !=^7G'"0D%,K:042]&8G +XB_73? $R![O%?"17VU
M4Z2E7I/"XAGH O2^6#=X[?J25PX%Q2TCQ."E:(%"NUTC7#ZZ;*.H>KJ[IBCT
M6E=J5#7IXVHU!?>(=OJ(&/@#1N?WAICNAB&]<*)<3C9L#MI=HFT !\$%WCF-
MI&^)9'A'33?D=NR\N<E\X.DAP&19^/Q>C&&X$(3Y"!P]+;0+/5'JO:[:&H"V
M]EK1$9-QOQ4W!!T@=VC/54$$3FWY6J=Z@A77@ Y1TR9+I?1)KZ=J+^KJTVDV
M9<*_0"Y5U[KNE8T'^G1L*T#G46I,2$EE.TY!MN$4W F4YMWP?T<1W5YE^9^*
M-ZJU3B:D!Q.5-S?V0R)B)H43;<7@QP$D$\1Y>G-6N2A-XAWZ*(;^6* _%K"%
M"-N.!2(2%\"G_]H!3_^Q ST?#=E *C@&H.4EQ4\!?KD&W;C]502@55D:H;N?
MB2\N#DR '-LJ#V)%VG3S1\A[M\(O[_GH2-Y2)K)_[(C(?O#+XZP&]>R7['=@
M;D0Y8/O@%N2U9)D\QN%CI#HQV2L$Y@(R ;I.<$L0SU>Y8KAW)4[E;*2L4\O;
M^-/*$IBM^,<N835?=C/=WKZD\J!9*_D"LV\[VX_W^XY#!L?,E_B -ICPG6(V
M ,E.-R5U3B;T6D,72T93]C3&8^B'K!,M!FNFG^3DOZXP]/ECHT=!!"J#TS$*
M8T3QRT[*=Y&XC[,YX8F!Y6^ *.M"GR<V>01$$Y"N(\'I9*!Q8T1<'/KHKV$\
MN$#M8Z"M'7A?*@Q]]'8 TI:&WM>EPKRFUN!'<319;EW2@UCJ2JX\:YDWR_V]
M*&_8\;*66=!YO.=M=F-PC_ YYL_<);,0IXQ4>(ZU6[##E]8TI::^GO!.9Z&$
ME=VH@:G>6>>4-K1=W1RI=S9%M0NEO'J;T\_*8]NU*I\WF45-P2/@Q:K1CZKB
MX;4JVT&F@=%J)RXN*'F@*UVP +U-2.@SUQ7][&2Y]#VT_;C0R\LJ:M2#WB@;
MV%UQ?:J-"/CFF>?&>,;!8K3>$/R2OHJD\LU+*T'OV1I0IJ-6IUNX>S=,EG0%
M13<RX6JWK@H7<TQW0^%*VHUT*T,'[#7L2V;8@'<HH9:?B/2&BJJ>K?GT*PMC
MW7EI#P]PV@:>EZP3GMSP!E%L/9\C2_\>H.Q]U<$:D]C_/4V2*M)*>M30TA>L
MG115MM VR.9'?C^FOID0K9@0H)&[0NW&J(D_A->"=E6W/TH4P+#7K:=W^OJ#
M[ELWMARHGJ/;KCCNB,7?+V7KU*OPN]6I:D<?$L5C9YG%?13=8C))2/$0A;W*
M._?7:;[RSRB*=;/;R7/(5)Y05(1J,]^ZNQ63QV?CA#@1D]3!J:C.*Y75B:FP
M#D^/[+RDXC:)Y@9/\M*_PF/R1,J CMCA*MTY7KW5OPZC?2QP\"?L\&F!/)MB
M@!+\J8-2!9$&E665[D,89FW;84>M]SVMYS#,D++@V(.N$L8L09O\?&.OU+?!
M[[[.\$<:F3C*TXM2.3O(JC,S =[='CX4UHCL@Q^^O_Q!ZBV5E ?WJ]1:Q-YS
M4"IEX?UHO!<JSU=+Q>RPZ:X'H)+2!6>,I<L.H98[3<*%[CC6S=?LL)Q:JS==
M7C32OYM!=;O1SE)9I/M:Z;@JKP(]M'9IZL4!6@>X;L9HQ;W"!Z:H^")GX==V
M]*C.QN)]90N'T4?F0MB9<@%UNT['?.SC58]E+FHG"1D58-[[H;].UC(X2T4@
M+Q/64%\ LU87D.'BWOVJ1'6_"%@ N1K5.EW %\J-O0VWKD_8H]*H\*#T\.L&
ML41B-_Z+OT#AXL&-91[&[C\-?8FT-8=:6SXB4];.TSX_XX VPUYA K#0\L>M
M7Y-:9:3UU)V7F9;2^H%8JT(&Z B/TS!:+2+/RW;+DTE^C@:T#-A]'CH>^#0L
M5D6?'<;ZI-;VR43;.2+K2X6%=O1-Z NOW9IEIT3988MM];P'/_KUEB"4WYH_
MXEQ?_VGH./W3&#!EM-D=Y<8R'"719%F,;I/&J/VE08Q:Q#^2WP;?"T\#OP[>
MAY3U(65]2)FE4V1E$.]#ROJ0LCZD3![BU(>4]2%E?4A9'U+6AY3U(65]2%D?
M4G8>(67'V&YDZA0>RTH3P':P^Q!_JH]6,&2E<:[M#2(^IFL.E\2@E^];1*9T
MUCC\BHCG1VA*?*\+/[*I -8/DQ88MPZ%W[S)?Z(%XV@43KD^BFPVG7RLCWTP
MI\;^E8%PF52K7$>C;9M"?+L!#^U3V?*C'L=^P0Q[OXZB*$&+&YZ]+-4[7<<7
M3_]RU24O139IZWQ#'!H#>_K#8:X2](AH*,>W&]30":&G/2X>N-RYQ62)>'K5
M+6;=K41K/P;^7K*M*U$)-:<_]-8H!S3X&DL"_IZTM<-O0U*_Z0$8TEO[RP=M
M:_[K^5ES$[1:\5\-0]ALJ=^*P]; O'_\ELU;A6%O]+NM!8L?Z'J<KOF4]LG#
M-V?'0E[L7R/K:P8SS&H+H&N=W][!F"&'W_1*6.K1YK^\<6.TO;]RK ,S#4%T
M[?];/TW3YA1\[!X$O-TL4*@" +O*%T82$]2MKVLYIW? 98:@C;?,IFGCU'J7
MF*SY-Z@9QZX?LA*XNHX>Q(6,Z=);:'_5N866*1<Y_DX 9[.5P(GQ-DDZW@GA
MN'$I 7I_1TW0;G]'K;^CUM]1Z^^H]7?4^CMJ_1VU_HZ:W]]1LV+OU=]1Z^^H
MM7S6W]]1Z^^H]7?4NN[WJ<2#)'[&+'O.XC&DE)0F'(K2GNM;EDQ=BOR!'[.C
MU\-L2 Z$KIM$[\>QOJI.S2:= S]FB?5UUXO;LT,QB-U,7'O?NY1.6/5%[9RH
M6ND=Q7E*AM,IST]5#-*X@LFRX.K/9N4CC1HR ;ZM^]:=,6B'Q3ZUI&]5S]+1
MZP-:IZ=(USCD/O+$#5A>T@\*B[9!0#O'U\ZRS8*9P#?6)?:J7*&5'S)PKES:
M')W?;.D7*BG/^UZW-3#;U$/:GB0+,6LPRYPZ ;ZQB^"=46B'R;;5CZMZROKQ
ML09Q8ZG.]W*Y!62W'%,+'I:V2WX^\&+_Q8]]Q"[>31+R&+Z@B,(Q180'C-&I
M*G4D[Z#EK+'B<]J=T3U=^3U'0R9-(7)M$"[H'Q_?22/8?FR01]W=RDM+$@<G
MQ$DRD5E<6RZSPPUF+\^ZXW*Y>3764LRD=]9<?(>C68IY^Z-#9W>'J]%'O_71
M;WWT6Q_]UD>_]=%O??A)%^$G< %P??A)'WY2?XI760-K1Z%HU;3>!]U2,(H!
MC(=Z%D3!F>I))=_W%"^>B4(WF[9V=L=L!Z%QX,ZZI32NS2VF'JM,O5QEPTO7
MFH"V\&GK!Y^NC+$UVL[4<M/;MAW99M[X^9TPM8E.)S['H]A6>PEGZ_SL6ABW
M*L+YG1@='\/3M68%"I_Y5-'12)DW?G['.FVB<[JVI>IBJ8:@(Z61".>73_CX
M&$+O@:6:%/)R=C3D[7WA_#+ZM@[1^0Y^ACE@.QL!S>4XO[R^0$!"CX7=^P//
M,W'N@8"TXEHY,$WHM^D2/,]$M\=$KR/;M3A8[('B0K6/L_"P-#",G0E%20OQ
M81^_;R<^C&RES.+!LD P%MTUG3WV$6%]1%@?$=9'A/4187;&"_418>?.<!\1
MUD>$G49$6.V"5QH))JUA?1!&2Q%@&K"!WRGK$U8:):R$2Q?7)ZQLQYU5SN'X
M09ZG1E(>>AAKD+"RK*REAVZ5]\-R7U1'CD+)][[5X-7#^#G3($'-A[^.9ZUZ
M4D /5-8;L0F99VK:^[%MGPB.HH[-6/K%/E*V(4GG&!>A'W=YJ,EV(4D?3-LR
MJ:=HXD;Q<KQC=QI@6_I2'VUK2,HIFF![,9OPD;=]X&UK))ZB*9N'W76\EI5^
ML8_I;4C2*9IFRR&A72]H&XO31_QV0>\I6ORI^'*_Z<#CYI!U%-YIF6F>CCNW
M#UAN$<B.C-OBV&4*[1J'_&#PBTM2'TP4)6S/<(W#$'E,GB]^_$S+WF$WO/5#
M-_38"\TK@C@+[)<_1T]>"Y'.E^U$.GM<IRS*^373RO&Y6HX?TM_GBCFO5'A>
M)Z"Z.<M<.<?-M4M+_#R[NN[CH_OXZ#X^NH^/[N.CK0S/ZN.CSYWA/CZZCX\^
MC?CHFD6U-*A04M[Z6)V68J.5D/61T=8.S'UD=!\9W4=&0[LL^\AHNWV0?62T
M[:YT^('*>B/N(Z/[R.A3,-D^,KJ/C#X54^XCH_O(:,M-M(^,[B.C3\QD^\CH
M/C+Z1$RUCXSN(Z/[R.AO?FEKC2^WCXSN(Z//P)W;1T;WD=$UD='\J._BJ8Q>
M%J<[9L$'L?^R6_7O12A_*$<HS^:3ZW]>7 UFPQOG>G(_'8YG@_EH,MX&_CK;
M%OL0X#X$N \![D. ^Q#@/@2XCS-K*\X,+OZWCS/K)L[L\@>S.+-=>>CPC09Q
M9F5ENXHS.WHP7V>GM!8'\^U_-V+LIO<>+^DP^$0GF84)Z++ZT$Y%8Q+48'03
MX!V1N#"6TW_MQG'ZCU_F;'<W68[H7OC%7R1N()AU:5E!43M&\\ZF7K'BW<1Y
MF_+%;A_S?0CS:SS[FSD>AG3+_B:<E.L44C4"S+&8 S57*M6ZF=/'.!RN-P%^
M0^C&)\BC]6C?O\+L6LCBQ8\PD0Z$^M7!#K>;8%T=)$UQ ADCN3B392Y@=/WL
M^F3MAD(*:255';"3WL-YT]"N2[+ZRZ0=7B;]:*\'J;],^HU>)IW[ZU0,+E"4
M'>%(YT]Y%>B]P[&NE.H !SY&3Q%98C9W>"@54TALOO,25=!U?L#=!&B!5Q4(
MEK!:>NE)Q:F@N"ZC<-'&[3$J1:PC?PW -7VXT,53N:<OBV#)4I,]AA1,)NHH
MG./8#=+?Y1NIU/'T&B+"UO*LF"P<I7&3YWO=]4"4.S6 P8OK!VQ9?XL)$W,[
M U2@D))NT@STH4*73)O#V1&[8QRBW+(0>?$]%,VI@I'+T_2Q" .QJTA9\3RO
M2.I#!KX<NLE"Q413TX0%GP7!#8H\XF\$O3</1FG0%O215?L&<  8W1^!530M
MG 4);^MI5#S3RW?:D$'&O!\\!@SWQZIZ+.F8EH:<<M@BONXH_IZ-:F,<_P?%
M#\C#J]#_O3;8./MFAY\\OTMUW6-FR634SF57NED:?MT@MF&=8_:C+'*:+:8&
MJQ5!*S=&HY#N:</(]SZ[02*+&(43Z?RNW,%C:HFAYUWY"H5HZ<<1U45[JU0:
M#32:L-ZK?.B(J UC1TNKQY!L!]/R8"M85,FKG.<5+QV8:A@"N(AR@Y[BR5/@
MK]*#9[T+*!_+%U!NAE=S9W)U-_K$[YW,++IX0O7;B:IQH410'OZB"";Q')$U
M$]#@[D>UEAT'I')>)-<TJ@K9</.B(%5E8*A;:M67MX,:':.KK'/J%6KW(D.$
MO'<K_/)^@?R4%?J7'1GT'[_<T:50D,;-",)-:*E*H=.#O4Z+5J\BJ*%61#C2
M(E:%+]8A5L'T&%&)@\EX2M#:3];I*S;H[NY:>N GJP!V+% !J[H&4BO:T1J5
MO9/SF<K.LCH\S@:CT)/B*RX.YE_10%>E)/C&CXU=HY!.ZPE?,DN#_^K*GMZ@
M+%$&/!WYOE ZT7GB&G8P([8O*1_=A\I-J:1^%&'R-L8QD@X]]46ASWI5ME(<
MAF3*@@]!UX3N=N-;U_,#\8(P*UQ7U@Y#;S $U2D#'ER\+Y1J^*DO;0<C8KN2
M\M#2L--"7. +#E[\<+4OGCH^4%H-^C!*9EZ5,#\- #I:G++NRY^P5*'.@X<%
MA:'/2W2PELEOR?S IJQHZK[)O6G[I< C[F2>II*=U^G76>A4C+(O,>E$ 1;5
M8M"+'3U ZV6WQ(SWUVNW!/V6H-![FRS3A(:^EQU;Z*[U92W 1[$9V+\I,.!,
M3N)G1.YPN,HU'./02PB1DB>M!!]T9L"7AOK@%#$=HLDRG0&O5=S4EX8/(3,@
M1:9P1Y-)W2<O!3.*H"ST:E1_6I$J:\<9,3O!QB$/Y5S>(3="+!HEC- 71- @
M2A]YCZ1OJO^I[DUU;]NL@Y=.P!IV4-JR\TJ;=MPH>W<]^@GZ"7.NMD8^PG(Y
MH'ED@]BA>[CBX@AB,_)!MZ8L\"*W'NSR9"'4$7R.V'9^#?CKRD*OB;7P%RL)
MCK\&[.9H=[:DU4*[=9 %4V]^5)=_[E(RY+$*DO+02T\YK@KA+;'DHH0/+$?R
M9/D8T3DW0O%@3?N?_[LB=E*[ ; UJ1X1N)E6%M(X"F.ZMF$QO'REHT==I1+8
M^O90N@3J'VDXTQS% #VL1OC6RV[3UF&6;#8!CZ-U@VLW>KZEJ_E1R-,FL"]D
MR9OG.!VLO[B1WG[BATH&],)W'(]^R%G21AQ_]RF'I-]R8ISN-2+GE6XP^CU&
MT^.\C,WM.GS@Q?Z+'_LHND-T)-:(M35HXA1V),:(@,]+^WNH/&>Z[EYQ5QYZ
MPV*.O&PO6<8!G*:Z^3,3<D(':?>)'ZZ9K23JZD/OA ZET0PG^R;(*S=(<Q\@
M%+<P2?Y9.DD^I1]S(O:U?J(T#N-EFPUV#2NW*Y\E]]H.(XH)D,?'FK1@]?QG
MK(TEX^K^L%_:2.K.@I5J8)-A4QID<Z$ %,NHVX[MR@,Y53VP*; +\D2PG'0*
M!X&*6B?EZJI@3LM.^9>>HY^-"1@3#^SU[(SNCIUJ=7*GXF8+\ 8+'T%]Z&/\
M9NL>*1C@4^>48&HV\1M+EQ>SU!*_)?Z&[Y%8^(VX$ZGJ@;I,S6G 1LJ=!'<#
MSTO6"=^\W2 *O^<K3H<:-@>69:-[IA40FD^;/Z;39LASM!STJF['QC.6;7DT
MJH(E\NC>*,:U&Y_36S<5_6/Z6R9Y+4W:.WO;6,LSKZ/X^3&KLR525M3V9MA'
M\)GM>FIU-&16GT_8X#*IKN"KL'1F*3G*4(A>W8 %Q,D<THJ*X,\G: :C:>EO
M"4][P4([*>L"RO?T$]?390DHM$U3"ZM(VC<F=FJ%DS!^H&MFL]ZT7Q/\[8K&
MW:D. 4NH*EJ4"5'B>KHT ;EY-+6PZ53YWHT3DCH4EWN3*/W)0/?2QE_*Y\>[
M5G<7-H)=PX[;W]EH=QS<+GWRD)2;!(VI-<Q?4?""[G$8/TNB=9JW:/5I\\':
M63*:UJYQ&Q%MWA)TP%;S3< I,*MKFO]!+IF_XL-[\+8AZ BN5GMN"1YP6E7V
MJ*13NP&[K\Z8:F,)?49F1[]IN/-0- 5]Y[O]GEF$")Q<+6.4DVK0A-W'TN;Z
M6$*BB?G=XD1R5FW>$G1*I=;[9Q$@<&9U;%'.J'X+T&] M-8YK6+0R/0*#P<<
MV#=Y2]!O1+3?-XLO*T SJV6*4D;U6SC=TV*;&=0UO<$R1J2]#EIJ[C1.B@_"
M"IQIE6EJ,FS8S F?&7?-J"B#E::5\4?K:GCBB:',VK#\Z+B!1D=@*+69K2S-
M:3)KR/(#Y*9J';U+C=:;)$:+_*ZG04>JU+3\J%A;CPH'1X]3->AP)OPI:EI^
MAJRM!SQ_IW<]YQ+6*Z-_"Z</.I3S:*%/IB,6 6)"4@ST'GC\:SGTXVXXF TM
M>M;QM&([9I1$GG=!]7!CJ9P=SUUH=9ZRZ!8\RIA+=*?Q(&--63O KS<=$?AW
M73V]>$ :SI";39+&G<H?X1'7."$RQ$JT^D)C6XRH'N*1U;&#%96=:?#3[8M@
M_(N34/X66+F0%2%:4EO9W]O4J=B9*X!^;/Z*U7@6"ED1&F6&9T7%3O%DH0 :
MB!:+61&G9(AI5<TC.JP>$!/.3U^X,'!7E>I!/T(D7%FIW%6U^A_!PXL,T9?4
M@AZ73<!7*F_';8512/^*YNY7W>WIC^7MZ6A\/;D?.O/!OVW:I&[U$C]T7UUO
M22M!/3"5^CNVHF7)FZ]0B):^]%TI147@@4R#H,J34EI0@!\4YW)2"=/<")_=
M($EA99=SV*B@IDU:&7H<;,Z=!B;@_ V72\22GZ*MFNR2V0/R<,B>4DRECF\1
MQ=@-V)204!G>]@J+^6VE<>CUM#G_+6)J-&]FOV'_>:(3,?W)_P=02P$"% ,4
M    " !K@*%8/+K/)MX&   -'0  "P              @ $     97A?,S$M
M,2YH=&U02P$"% ,4    " !K@*%8&UQS]=4&   -'0  "P
M@ $'!P  97A?,S$M,BYH=&U02P$"% ,4    " !K@*%88W9A/GT#  "6"P
M"P              @ $%#@  97A?,S(M,2YH=&U02P$"% ,4    " !K@*%8
M"+2;A7<#  "6"P  "P              @ &K$0  97A?,S(M,BYH=&U02P$"
M% ,4    " !K@*%8 #]!\_;0  #I? < #0              @ %+%0  9F]R
M;5\Q,"UQ+FAT;5!+ 0(4 Q0    ( &N H5C'\MB2^1$  #ZY   1
M      "  6SF  !K<FUD+3(P,C0P,S,Q+GAS9%!+ 0(4 Q0    ( &N H5AC
M:(L]T!$  &:X   5              "  93X  !K<FUD+3(P,C0P,S,Q7V-A
M;"YX;6Q02P$"% ,4    " !K@*%8*^FS+8\<  "G] $ %0
M@ &7"@$ :W)M9"TR,#(T,#,S,5]D968N>&UL4$L! A0#%     @ :X"A6".=
ML@AZ6   "2\% !4              ( !62<! &MR;60M,C R-# S,S%?;&%B
M+GAM;%!+ 0(4 Q0    ( &N H5@U;6=)@#8  $J[ P 5              "
M 0:  0!K<FUD+3(P,C0P,S,Q7W!R92YX;6Q02P4&      H "@!J @  N;8!
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>form_10-q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:krmd="http://korumedical.com/20240331"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="krmd-20240331.xsd" xlink:type="simple"/>
    <context id="From2024-01-01to2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-05-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
        </entity>
        <period>
            <instant>2024-05-01</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_FurnitureAndOfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_FurnitureAndOfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_ManufacturingEquipmentAndToolingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:ManufacturingEquipmentAndToolingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ManufacturingEquipmentAndToolingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:ManufacturingEquipmentAndToolingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_StockOptionPlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_StockOptionPlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_StockOptionPlan2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_StockOptionPlan2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_NonEmployeeDirectorAndBoardAdvisorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">krmd:NonEmployeeDirectorAndBoardAdvisorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_srt_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_StockOptionPlans2015And2021CombinedMember_custom_TimeBasedSharesOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlans2015And2021CombinedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_StockOptionPlans2015And2021CombinedMember_custom_TimeBasedSharesOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlans2015And2021CombinedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_StockOptionPlans2015And2021CombinedMember_custom_TimeBasedSharesOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlans2015And2021CombinedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_StockOptionPlans2015And2021CombinedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlans2015And2021CombinedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_StockOptionPlans2015And2021CombinedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlans2015And2021CombinedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">krmd:ExercisePrice1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">krmd:ExercisePrice1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PerformanceBasedSharesOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:PerformanceBasedSharesOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_PerformanceBasedSharesOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:PerformanceBasedSharesOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_PerformanceBasedSharesOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:PerformanceBasedSharesOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_PerformanceBasedSharesOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:PerformanceBasedSharesOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_PerformanceBasedSharesOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:PerformanceBasedSharesOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_PerformanceBasedSharesOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:PerformanceBasedSharesOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-07-28_custom_AONPremiumFinanceLLCMember_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">krmd:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krmd:AONPremiumFinanceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-28</instant>
        </period>
    </context>
    <context id="From2023-07-262023-07-28_custom_AONPremiumFinanceLLCMember_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">krmd:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krmd:AONPremiumFinanceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-26</startDate>
            <endDate>2023-07-28</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_AONPremiumFinanceLLCMember_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">krmd:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krmd:AONPremiumFinanceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_AONPremiumFinanceLLCMember_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">krmd:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krmd:AONPremiumFinanceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-08_custom_HSBCVenturesUSAIncMember_us-gaap_RevolvingCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krmd:HSBCVenturesUSAIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-08</instant>
        </period>
    </context>
    <context id="AsOf2024-03-08_custom_HSBCVenturesUSAIncMember_custom_TermLoanFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">krmd:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krmd:HSBCVenturesUSAIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-08</instant>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_LeaseOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">krmd:LeaseOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_LeaseTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">krmd:LeaseTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_LeaseThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">krmd:LeaseThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="N">
        <measure>krmd:Number</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2024-01-01to2024-03-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2024-01-01to2024-03-31" id="Fact000004">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2024-01-01to2024-03-31" id="Fact000005">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2024-01-01to2024-03-31" id="Fact000006">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2024-01-01to2024-03-31" id="Fact000007">0000704440</dei:EntityCentralIndexKey>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="AsOf2024-03-31"
      id="xdx2ixbrl0084"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0085"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-03-31"
      id="xdx2ixbrl0213"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="From2024-01-01to2024-03-31"
      id="xdx2ixbrl0252"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2024-01-01to2024-03-31"
      id="xdx2ixbrl0330"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2023-01-012023-03-31"
      id="xdx2ixbrl0331"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0349"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-012024-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0350"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0355"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0357"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-012024-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0358"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0361"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0363"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2024-01-012024-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0364"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0367"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0369"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2024-01-012024-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0370"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0373"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0374"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0376"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0397"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0398"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0403"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0405"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0406"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0417"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0418"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0420"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NumberOfReportableSegments
      contextRef="From2024-01-01to2024-03-31"
      decimals="INF"
      id="xdx2ixbrl0435"
      unitRef="N">1</us-gaap:NumberOfReportableSegments>
    <krmd:AntiDilutiveStockOptions
      contextRef="From2024-01-01to2024-03-31"
      decimals="INF"
      id="xdx2ixbrl0452"
      unitRef="Shares">0</krmd:AntiDilutiveStockOptions>
    <krmd:CommonStockOptions
      contextRef="From2024-01-01to2024-03-31"
      id="xdx2ixbrl0462"
      unitRef="Shares"
      xsi:nil="true"/>
    <krmd:PerformanceStockUnits
      contextRef="From2023-01-012023-03-31"
      id="xdx2ixbrl0466"
      unitRef="Shares"
      xsi:nil="true"/>
    <krmd:DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock
      contextRef="From2024-01-01to2024-03-31"
      id="xdx2ixbrl0485"
      unitRef="Shares"
      xsi:nil="true"/>
    <krmd:DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock
      contextRef="From2023-01-012023-03-31"
      id="xdx2ixbrl0486"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-01-012024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      id="xdx2ixbrl0591">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2023-01-012023-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      id="xdx2ixbrl0593">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2024-01-012024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      id="xdx2ixbrl0619"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      id="xdx2ixbrl0621"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-01-012023-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      id="xdx2ixbrl0623"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      id="xdx2ixbrl0625"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2023-01-012023-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      id="xdx2ixbrl0631"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      id="xdx2ixbrl0633"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member"
      id="xdx2ixbrl0667">P6Y10M25D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <krmd:ShareBasedCompensationArrangementByUnvestedAwardOptions
      contextRef="AsOf2022-12-31_custom_PerformanceBasedSharesOptionsMember"
      id="xdx2ixbrl0689"
      unitRef="Shares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_PerformanceBasedSharesOptionsMember"
      id="xdx2ixbrl0690"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementByUnvestedAwardOptions
      contextRef="AsOf2023-03-31_custom_PerformanceBasedSharesOptionsMember"
      id="xdx2ixbrl0716"
      unitRef="Shares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice
      contextRef="AsOf2023-03-31_custom_PerformanceBasedSharesOptionsMember"
      id="xdx2ixbrl0717"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2023-01-012023-03-31_us-gaap_PerformanceSharesMember"
      decimals="0"
      id="xdx2ixbrl0721"
      unitRef="USD">0</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested
      contextRef="From2024-01-012024-03-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0735"
      unitRef="Shares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested
      contextRef="From2024-01-012024-03-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0737"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested
      contextRef="From2023-01-012023-03-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0739"
      unitRef="Shares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested
      contextRef="From2023-01-012023-03-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0741"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross
      contextRef="From2024-01-012024-03-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0743"
      unitRef="Shares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-03-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0745"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested
      contextRef="From2024-01-012024-03-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0751"
      unitRef="Shares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested
      contextRef="From2024-01-012024-03-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0753"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested
      contextRef="From2023-01-012023-03-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0755"
      unitRef="Shares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested
      contextRef="From2023-01-012023-03-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0757"
      unitRef="Shares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested
      contextRef="AsOf2023-12-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0778"
      unitRef="Shares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested
      contextRef="AsOf2023-12-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0780"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested
      contextRef="AsOf2022-12-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0782"
      unitRef="Shares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested
      contextRef="AsOf2022-12-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0784"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested
      contextRef="From2023-01-012023-03-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0790"
      unitRef="Shares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested
      contextRef="From2023-01-012023-03-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0792"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross
      contextRef="From2023-01-012023-03-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0798"
      unitRef="Shares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-03-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0800"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested
      contextRef="From2024-01-012024-03-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0802"
      unitRef="Shares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested
      contextRef="From2024-01-012024-03-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0804"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested
      contextRef="From2023-01-012023-03-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0806"
      unitRef="Shares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested
      contextRef="From2023-01-012023-03-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0808"
      unitRef="Shares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested
      contextRef="AsOf2023-03-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0814"
      unitRef="Shares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested
      contextRef="AsOf2023-03-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0816"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <krmd:UnrecognizedCompensationCost
      contextRef="From2023-01-012023-03-31_custom_CommonStockWarrantsMember"
      decimals="0"
      id="xdx2ixbrl0820"
      unitRef="USD">0</krmd:UnrecognizedCompensationCost>
    <krmd:LesseeOperatingLeaseRemainingTerm
      contextRef="From2024-01-012024-03-31_custom_LeaseOneMember"
      id="xdx2ixbrl0840">P8Y4M24D</krmd:LesseeOperatingLeaseRemainingTerm>
    <krmd:LesseeOperatingLeaseRemainingTerm
      contextRef="From2024-01-012024-03-31_custom_LeaseTwoMember"
      id="xdx2ixbrl0842">P4Y9M18D</krmd:LesseeOperatingLeaseRemainingTerm>
    <krmd:LesseeFinanceLeaseRemainingTerm
      contextRef="From2024-01-012024-03-31_custom_LeaseOneMember"
      id="xdx2ixbrl0844">P3Y2M12D</krmd:LesseeFinanceLeaseRemainingTerm>
    <krmd:LesseeFinanceLeaseRemainingTerm
      contextRef="From2024-01-012024-03-31_custom_LeaseTwoMember"
      id="xdx2ixbrl0846">P2Y9M0D</krmd:LesseeFinanceLeaseRemainingTerm>
    <krmd:LesseeFinanceLeaseRemainingTerm
      contextRef="From2024-01-012024-03-31_custom_LeaseThreeMember"
      id="xdx2ixbrl0848">P4Y6M0D</krmd:LesseeFinanceLeaseRemainingTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="AsOf2024-03-31" id="xdx2ixbrl0923">P6Y7M6D</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="AsOf2023-12-31" id="xdx2ixbrl0924">P6Y10M25D</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeFinanceLeaseRenewalTerm1 contextRef="AsOf2024-03-31" id="xdx2ixbrl0926">P3Y7M6D</us-gaap:LesseeFinanceLeaseRenewalTerm1>
    <us-gaap:LesseeFinanceLeaseRenewalTerm1 contextRef="AsOf2023-12-31" id="xdx2ixbrl0927">P6Y8M12D</us-gaap:LesseeFinanceLeaseRenewalTerm1>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="AsOf2024-03-31"
      id="xdx2ixbrl0959"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="xdx2ixbrl0975"
      unitRef="USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <dei:DocumentType contextRef="From2024-01-01to2024-03-31" id="Fact000014">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2024-01-01to2024-03-31" id="Fact000015">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2024-01-01to2024-03-31" id="Fact000016">2024-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2024-01-01to2024-03-31" id="Fact000017">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2024-01-01to2024-03-31" id="Fact000018">0-12305</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2024-01-01to2024-03-31" id="Fact000019">KORU MEDICAL SYSTEMS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2024-01-01to2024-03-31" id="Fact000020">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2024-01-01to2024-03-31" id="Fact000021">13-3044880</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2024-01-01to2024-03-31" id="Fact000022">100 Corporate Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2024-01-01to2024-03-31" id="Fact000023">Mahwah</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2024-01-01to2024-03-31" id="Fact000024">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2024-01-01to2024-03-31" id="Fact000025">07430</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2024-01-01to2024-03-31" id="Fact000026">845</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2024-01-01to2024-03-31" id="Fact000027">469-2042</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2024-01-01to2024-03-31" id="Fact000028">Common stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2024-01-01to2024-03-31" id="Fact000029">KRMD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2024-01-01to2024-03-31" id="Fact000030">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2024-01-01to2024-03-31" id="Fact000031">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2024-01-01to2024-03-31" id="Fact000032">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2024-01-01to2024-03-31" id="Fact000033">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2024-01-01to2024-03-31" id="Fact000034">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2024-01-01to2024-03-31" id="Fact000035">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2024-01-01to2024-03-31" id="Fact000036">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2024-05-01"
      decimals="INF"
      id="Fact000037"
      unitRef="Shares">45764225</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityListingParValuePerShare
      contextRef="From2024-01-01to2024-03-31"
      decimals="INF"
      id="Fact000039"
      unitRef="USDPShares">0.01</dei:EntityListingParValuePerShare>
    <us-gaap:TreasuryStockCommonShares
      contextRef="AsOf2024-05-01"
      decimals="INF"
      id="Fact000041"
      unitRef="Shares">3420502</us-gaap:TreasuryStockCommonShares>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000049"
      unitRef="USD">10820317</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000050"
      unitRef="USD">11482240</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000055"
      unitRef="USD">24777</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000057"
      unitRef="USD">24777</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000052"
      unitRef="USD">4392511</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000053"
      unitRef="USD">4045211</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000059"
      unitRef="USD">3147312</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000060"
      unitRef="USD">3481301</us-gaap:InventoryNet>
    <us-gaap:OtherReceivables
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000062"
      unitRef="USD">288714</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000063"
      unitRef="USD">28889</us-gaap:OtherReceivables>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000065"
      unitRef="USD">830408</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000066"
      unitRef="USD">1218288</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000068"
      unitRef="USD">19479262</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000069"
      unitRef="USD">20255929</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000071"
      unitRef="USD">3755530</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000072"
      unitRef="USD">3837657</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000077"
      unitRef="USD">406801</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000079"
      unitRef="USD">390341</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000074"
      unitRef="USD">737901</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000075"
      unitRef="USD">754361</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000081"
      unitRef="USD">3428885</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000082"
      unitRef="USD">3514055</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredRentReceivablesNetNoncurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000086"
      unitRef="USD">6391452</us-gaap:DeferredRentReceivablesNetNoncurrent>
    <us-gaap:DeferredRentReceivablesNetNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000087"
      unitRef="USD">6002777</us-gaap:DeferredRentReceivablesNetNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000089"
      unitRef="USD">98970</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000090"
      unitRef="USD">98970</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000092"
      unitRef="USD">27500548</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000093"
      unitRef="USD">28460972</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000101"
      unitRef="USD">1774185</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000102"
      unitRef="USD">975193</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000104"
      unitRef="USD">1459405</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000105"
      unitRef="USD">1711427</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000107"
      unitRef="USD">159031</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000108"
      unitRef="USD">314344</us-gaap:NotesPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000110"
      unitRef="USD">457653</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000111"
      unitRef="USD">512520</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000113"
      unitRef="USD">519441</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000114"
      unitRef="USD">462941</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000116"
      unitRef="USD">111103</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000117"
      unitRef="USD">109540</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000119"
      unitRef="USD">372109</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000120"
      unitRef="USD">368313</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000122"
      unitRef="USD">4852927</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000123"
      unitRef="USD">4454278</us-gaap:LiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000125"
      unitRef="USD">288253</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000126"
      unitRef="USD">316623</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000128"
      unitRef="USD">3241837</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000129"
      unitRef="USD">3336300</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000131"
      unitRef="USD">8383017</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000132"
      unitRef="USD">8107201</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000139"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000140"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000141"
      unitRef="Shares">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000142"
      unitRef="Shares">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000144"
      unitRef="Shares">49143589</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000145"
      unitRef="Shares">49089864</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000146"
      unitRef="Shares">45723087</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000147"
      unitRef="Shares">45669362</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000137"
      unitRef="USD">491436</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000138"
      unitRef="USD">490899</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000149"
      unitRef="USD">47717888</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000150"
      unitRef="USD">47018707</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:TreasuryStockPreferredShares
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000155"
      unitRef="Shares">3420502</us-gaap:TreasuryStockPreferredShares>
    <us-gaap:TreasuryStockPreferredShares
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000157"
      unitRef="Shares">3420502</us-gaap:TreasuryStockPreferredShares>
    <us-gaap:TreasuryStockValue
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000152"
      unitRef="USD">3843562</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000153"
      unitRef="USD">3843562</us-gaap:TreasuryStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000159"
      unitRef="USD">-25248231</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000160"
      unitRef="USD">-23312273</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000162"
      unitRef="USD">19117531</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000163"
      unitRef="USD">20353771</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000165"
      unitRef="USD">27500548</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000166"
      unitRef="USD">28460972</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000168"
      unitRef="USD">8197798</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000169"
      unitRef="USD">7392605</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000171"
      unitRef="USD">3094500</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000172"
      unitRef="USD">3245570</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000174"
      unitRef="USD">5103298</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000175"
      unitRef="USD">4147035</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000180"
      unitRef="USD">5357620</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000181"
      unitRef="USD">5425877</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000183"
      unitRef="USD">1475674</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000184"
      unitRef="USD">1564869</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000186"
      unitRef="USD">231370</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000187"
      unitRef="USD">213117</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000189"
      unitRef="USD">7064664</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000190"
      unitRef="USD">7203863</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000192"
      unitRef="USD">-1961366</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000193"
      unitRef="USD">-3056828</us-gaap:OperatingIncomeLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000198"
      unitRef="USD">-11479</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000199"
      unitRef="USD">-680</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000201"
      unitRef="USD">-300</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000202"
      unitRef="USD">-56279</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000204"
      unitRef="USD">37187</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000205"
      unitRef="USD">125502</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000207"
      unitRef="USD">25408</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000208"
      unitRef="USD">68543</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000210"
      unitRef="USD">-1935958</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000211"
      unitRef="USD">-2988285</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000214"
      unitRef="USD">-577400</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000216"
      unitRef="USD">-1935958</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000217"
      unitRef="USD">-2410885</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-01to2024-03-31"
      decimals="INF"
      id="Fact000222"
      unitRef="USDPShares">-0.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-03-31"
      decimals="INF"
      id="Fact000223"
      unitRef="USDPShares">-0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-01to2024-03-31"
      decimals="INF"
      id="Fact000225"
      unitRef="USDPShares">-0.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-03-31"
      decimals="INF"
      id="Fact000226"
      unitRef="USDPShares">-0.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-01to2024-03-31"
      decimals="INF"
      id="Fact000231"
      unitRef="Shares">45712224</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-03-31"
      decimals="INF"
      id="Fact000232"
      unitRef="Shares">45487593</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-01to2024-03-31"
      decimals="INF"
      id="Fact000234"
      unitRef="Shares">45712224</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-03-31"
      decimals="INF"
      id="Fact000235"
      unitRef="Shares">45487593</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000240"
      unitRef="USD">-1935958</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000241"
      unitRef="USD">-2410885</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000246"
      unitRef="USD">699718</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000247"
      unitRef="USD">881222</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000249"
      unitRef="USD">231370</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000250"
      unitRef="USD">213117</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000253"
      unitRef="USD">-577400</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000255"
      unitRef="USD">-300</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000256"
      unitRef="USD">-56279</us-gaap:GainLossOnSaleOfOtherAssets>
    <krmd:RouLandlordCredit
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000258"
      unitRef="USD">-5497</krmd:RouLandlordCredit>
    <krmd:RouLandlordCredit
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000259"
      unitRef="USD">-5497</krmd:RouLandlordCredit>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000264"
      unitRef="USD">607125</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000265"
      unitRef="USD">647994</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000267"
      unitRef="USD">-333989</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000268"
      unitRef="USD">233551</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000270"
      unitRef="USD">-387880</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000271"
      unitRef="USD">-288786</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000273"
      unitRef="USD">-54867</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000274"
      unitRef="USD">4207</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000276"
      unitRef="USD">798992</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000277"
      unitRef="USD">-888679</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000279"
      unitRef="USD">56500</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000280"
      unitRef="USD">-41984</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000282"
      unitRef="USD">-252022</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000283"
      unitRef="USD">-1298204</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000285"
      unitRef="USD">-346720</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000286"
      unitRef="USD">-4660583</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000291"
      unitRef="USD">133083</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000292"
      unitRef="USD">272605</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000294"
      unitRef="USD">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000295"
      unitRef="USD">11232</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000297"
      unitRef="USD">-133083</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000298"
      unitRef="USD">-283837</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <krmd:PaymentsOnIndebtedness
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000303"
      unitRef="USD">155313</krmd:PaymentsOnIndebtedness>
    <krmd:PaymentsOnIndebtedness
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000304"
      unitRef="USD">214892</krmd:PaymentsOnIndebtedness>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000306"
      unitRef="USD">26807</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000307"
      unitRef="USD">24080</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000309"
      unitRef="USD">-182120</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000310"
      unitRef="USD">-238972</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000312"
      unitRef="USD">-661923</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000313"
      unitRef="USD">-5183392</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000315"
      unitRef="USD">11482240</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000316"
      unitRef="USD">17408257</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000318"
      unitRef="USD">10820317</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact000319"
      unitRef="USD">12224865</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000327"
      unitRef="USD">12296</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000328"
      unitRef="USD">12326</us-gaap:InterestPaidNet>
    <krmd:IssuanceOfCommonStockCompensation
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000336"
      unitRef="USD">123804</krmd:IssuanceOfCommonStockCompensation>
    <krmd:IssuanceOfCommonStockCompensation
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000337"
      unitRef="USD">175776</krmd:IssuanceOfCommonStockCompensation>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000345"
      unitRef="Shares">49089864</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000339"
      unitRef="USD">490899</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000340"
      unitRef="USD">47018707</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000341"
      unitRef="USD">-23312273</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="Fact000342"
      unitRef="USD">-3843562</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000343"
      unitRef="USD">20353771</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000353"
      unitRef="Shares">53725</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000347"
      unitRef="USD">537</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000348"
      unitRef="USD">123267</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000351"
      unitRef="USD">123804</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000356"
      unitRef="USD">393113</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000359"
      unitRef="USD">393113</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000362"
      unitRef="USD">130676</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000365"
      unitRef="USD">130676</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000368"
      unitRef="USD">52125</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000371"
      unitRef="USD">52125</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000375"
      unitRef="USD">-1935958</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000377"
      unitRef="USD">-1935958</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000385"
      unitRef="Shares">49143589</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000379"
      unitRef="USD">491436</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000380"
      unitRef="USD">47717888</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000381"
      unitRef="USD">-25248231</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="Fact000382"
      unitRef="USD">-3843562</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000383"
      unitRef="USD">19117531</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000393"
      unitRef="Shares">48861891</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000387"
      unitRef="USD">488619</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000388"
      unitRef="USD">44252117</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000389"
      unitRef="USD">-9571211</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="Fact000390"
      unitRef="USD">-3843562</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000391"
      unitRef="USD">31325963</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000401"
      unitRef="Shares">48875</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000395"
      unitRef="USD">489</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000396"
      unitRef="USD">175287</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000399"
      unitRef="USD">175776</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000404"
      unitRef="USD">535059</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000407"
      unitRef="USD">535059</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <krmd:CompensationeExpenseRelatedToRestrictedStockAwards
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000415"
      unitRef="Shares">50000</krmd:CompensationeExpenseRelatedToRestrictedStockAwards>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000409"
      unitRef="USD">500</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000410"
      unitRef="USD">169887</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000413"
      unitRef="USD">170387</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000419"
      unitRef="USD">-2410885</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000421"
      unitRef="USD">-2410885</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000429"
      unitRef="Shares">48960766</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000423"
      unitRef="USD">489608</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000424"
      unitRef="USD">45132350</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000425"
      unitRef="USD">-11982096</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="Fact000426"
      unitRef="USD">-3843562</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact000427"
      unitRef="USD">29796300</us-gaap:StockholdersEquity>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000431">&lt;p id="xdx_808_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zHbZTY15EU52" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 1 &#x2014; &lt;span id="xdx_825_zps1R66qG5Q4"&gt;NATURE OF OPERATIONS AND SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--NatureOfOperations_zuNRR9X8WuT5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_860_zL58AmV7DqSg"&gt;NATURE OF OPERATIONS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;KORU MEDICAL SYSTEMS, INC. (the &#x201c;Company,&#x201d;
&#x201c;KORU Medical,&#x201d; &#x201c;we,&#x201d; &#x201c;us&#x201d; or &#x201c;our&#x201d;) designs, manufactures and markets proprietary portable
and innovative medical devices primarily for the subcutaneous drug delivery market as governed by the United States Food and Drug Administration
(the &#x201c;FDA&#x201d;) quality and regulatory system and international regulations and standards for quality system management. The Company
operates as &lt;span id="xdx_903_eus-gaap--NumberOfReportableSegments_dxH_uN_c20240101__20240331_zHYjAdyxPnMa" title="Number of segment::XDX::1"&gt;one&lt;/span&gt; segment.&lt;/p&gt;

&lt;p id="xdx_85A_zlKzyNhotq45" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zxTa5f2NTFU5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_863_z3u1ztSDWWPc"&gt;BASIS OF PRESENTATION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying financial statements should be read
in conjunction with the Company&#x2019;s annual report on Form 10-K for the year ended December 31, 2023 (&#x201c;Annual Report&#x201d;).
&#160;In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;), the Company has
omitted footnote disclosures that would substantially duplicate the disclosures contained in the audited financial statements of the Company.
The accompanying interim financial statements are unaudited and reflect all adjustments which are in the opinion of management necessary
for a fair statement of the Company&#x2019;s financial position, results of operations, and cash flows for the periods presented. &#160;All
such adjustments are of a normal, recurring nature. &#160;The Company&#x2019;s results of operations and cash flows for the interim periods
are not necessarily indicative of the results of operations and cash flows that it may achieve in future periods.&lt;/p&gt;

&lt;p id="xdx_858_zjxYcOOJfiPk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zZ86aZl4CBLi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_86B_zxJfOor2QNue"&gt;CASH AND CASH EQUIVALENTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For purposes of the statements of cash flows, the
Company considers all short-term investments with an original maturity of three months or less to be cash equivalents. &#160;The Company
has historically held cash balances in excess of $&lt;span id="xdx_90E_eus-gaap--CashUninsuredAmount_iI_c20240331_znGjeFWwJNr7" title="FDIC cash uninsured amount"&gt;250,000&lt;/span&gt; at its primary commercial bank, which exceeds FDIC insurance limits. To reduce
the risk of uninsured deposits, the Company entered an insured cash sweep program with KeyBank during the second quarter of 2023 to automatically
invest its uninsured bank cash balances over $250,000 into FDIC insured banks so there is no more than $250,000 maintained at any one
bank. As of March 31, 2024 the Company has an investment balance of $&lt;span id="xdx_907_eus-gaap--InterestIncomeSecuritiesUSTreasury_dm_c20240101__20240331_zAroHWx5QOCk" title="Investment securities treasury bill"&gt;10.2 million&lt;/span&gt; in a US Treasury bill that matures every 90 days.&lt;/p&gt;

&lt;p id="xdx_853_zwcCH9ltGUkf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zpHXUHJP89Z8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_868_zfJNXKfqZn1b"&gt;PATENTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Costs incurred in obtaining patents have been capitalized
and are being amortized over the legal life of the patents.&lt;/p&gt;

&lt;p id="xdx_852_zT8HRlDMNaOc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zqiFo0vrTd6d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_864_zLIdpY0GWn3i"&gt;STOCK-BASED COMPENSATION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company maintains a stock option plan and an omnibus
equity incentive plan under which it grants stock options to certain executives, key employees and consultants. The fair value of each
option grant is estimated on the date of the grant using the Black-Scholes option-pricing model. &#160;All options are charged against
income at their fair value. &#160;The entire compensation expense of the award is recognized over the vesting period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company also maintains a non-employee director
compensation plan. Shares of stock granted for director fees are recorded at the fair value of the shares at the grant date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company issues restricted stock awards. Restricted
stock awards are equity classified and measured at the fair market value of the underlying stock at the grant date. The fair value of
restricted stock awards vesting at certain market capitalization thresholds were estimated on the date of grant using the Brownian Motion
Monte Carlo lattice model. The fair value of restricted stock awards with time-based vesting were estimated on the date of grant at the
current stock price. The fair value of restricted stock awards vesting at certain annual sales growth thresholds were estimated as of
the date of Board acknowledgement of the achievement, at the current stock price. We recognize restricted stock expense using the straight-line
attribution method over the requisite service period and account for forfeitures as they occur.&lt;/p&gt;

&lt;p id="xdx_858_zPuK4iHPQXOj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zEjvUKTCnSuj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_86B_zzX85zWjkZU3"&gt;NET LOSS PER COMMON SHARE&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic net loss per common share is calculated by dividing
net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed
by dividing net loss by the weighted average number of common and common equivalent shares outstanding during the period. The Company&#x2019;s
potentially dilutive common shares are those that result from diluted common stock options and unvested restricted stock awards. The calculation
of diluted net loss per share excluded stock options of &lt;span id="xdx_90A_ecustom--AntiDilutiveStockOptions_pid_dxL_uShares_c20240101__20240331_zAyKVLY6I0Kb" title="Anti-dilutive stock options::XDX::0"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0452"&gt;zero&lt;/span&gt;&lt;/span&gt; and &lt;span id="xdx_906_ecustom--AntiDilutiveStockOptions_pid_uShares_c20230101__20230331_z2JVos5KlZMg" title="Anti-dilutive stock options"&gt;14,626&lt;/span&gt;, respectively, in weighted-average shares for each of the three
months ended March 31, 2024 and 2023, as their effect was anti-dilutive as a result of the net loss incurred for those periods.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The calculation of diluted net loss per share excluded
stock options, performance-based restricted stock and performance-based restricted stock units (PSUs) of &lt;span id="xdx_90C_ecustom--AntiDilutiveSecurities_pid_uShares_c20240101__20240331_zLD40VIT7Xpi" title="Anti-dilutive securities"&gt;904,496&lt;/span&gt; and &lt;span id="xdx_904_ecustom--AntiDilutiveSecurities_pid_uShares_c20230101__20230331_zYK7EYycKdx4" title="Anti-dilutive Securities"&gt;914,626&lt;/span&gt; respectively,
in weighted-average shares for each of the three months ended March 31, 2024 and 2023, as their effect was anti-dilutive as a result of
the net loss incurred for those periods.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89F_ecustom--ScheduleOfSecuritiesTextBlock_zzpQsQwqywxl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B1_zFRbRMeqbCI6"&gt;The following securities were not included in the
computation of diluted shares outstanding for the three months ended March 31, 2024, and 2023 because the effect would be anti-dilutive:&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.25in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 64%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_491_20240101__20240331_z5gHa56Js7j9" style="width: 15%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_495_20230101__20230331_znrL5Y2snEGd" style="width: 15%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="text-align: center"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--CommonStockOptions_pid_uShares_zXCYQ9M0n2Ak" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Common stock options&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0462"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;14,626&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--PerformanceStockUnits_pid_uShares_zTxSUpVHYgl1" style="vertical-align: bottom"&gt;
    &lt;td&gt;PSUs&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;54,496&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0466"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--RestrictedStockUnits_pid_zd0Ut9uoSEBj" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Restricted stock &lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;850,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;900,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--AntiDilutedSecurities_pid_zwi8ws9Cj7l8" style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;904,496&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;914,626&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A9_znhncoWTWmPj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zBaLzXTzUa93" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B6_z7l4QIjCFLal"&gt;Therefore, diluted weighted average number of shares
outstanding and diluted net loss per share were the same as basic weighted average number of shares outstanding and net loss per share
for the three months ended March 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.25in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49E_20240101__20240331_zKWPQDLuseWi" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20230101__20230331_zwiXwTi9WQqb" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="text-align: center"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 64%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 15%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 15%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--NetIncomeLoss_zRGQTXHoMhT9" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Net loss&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(1,935,958&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(2,410,885&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasicAbstract_iB_zgy58JSQ1or" style="vertical-align: bottom"&gt;
    &lt;td&gt;Weighted Average Outstanding Shares:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_uShares_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJkv6CGHEuqk" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Basic weighted average shares outstanding&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;45,712,224&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;45,487,593&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock_pid_uShares_zU067aM1fsOl" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Dilutive effect of outstanding stock options and unvested restricted stock&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0485"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0486"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_uShares_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zd27J1f9JnPk" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Diluted weighted average shares outstanding&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;45,712,224&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;45,487,593&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--EarningsPerShareAbstract_iB_zOB9mDzjNIdh" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Net loss per share&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--EarningsPerShareBasic_pid_uUSDPShares_zcSlm2QFwCO3" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Basic&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;(0.04&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;(0.05&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--EarningsPerShareDiluted_pid_uUSDPShares_zpl67c48EQjj" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Diluted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;(0.04&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;(0.05&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zOZuMH9KPgh" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;
&lt;p id="xdx_850_zWUC8JD5Vj4h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--UseOfEstimates_zwBJwuyIaRwk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_867_zXdhu3aGikK9"&gt;USE OF ESTIMATES IN THE FINANCIAL STATEMENTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of financial statements in conformity
with United States generally accepted accounting principles (&#x201c;GAAP&#x201d;) requires management to make estimates and assumptions
that affect the amounts reported in the financial statements and accompanying notes. &#160;Actual results could differ from those estimates.
Important estimates include but are not limited to asset lives, deferred tax valuation allowances, inventory valuation, and customer rebate
and incentive accruals. The results of operations for the three months ended March 31, 2024 are not necessarily indicative of the results
that may be expected for the entire 2024 fiscal year.&lt;/p&gt;

&lt;p id="xdx_853_zDMfURqrRNTe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;p id="xdx_848_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zBnku6HMugG2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_861_zAVc8rBfNITh"&gt;REVENUE RECOGNITION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our revenues are derived from three business sources:
(i) domestic core (which consists of US and Canada), (ii) international core, and (iii) novel therapies. &#160;Our core domestic and international
revenues consist of sales of our syringe drivers, tubing and needles (&#x201c;Product Revenue&#x201d;) for the delivery of subcutaneous
drugs that are FDA cleared for use with the KORU Medical infusion system, with the primary delivery for immunoglobulin to treat Primary
Immunodeficiency Diseases (&#x201c;PIDD&#x201d;) and Chronic Inflammatory Demyelinating Polyneuropathy (&#x201c;CIDP&#x201d;). Novel therapies
consist of Product Revenue for feasibility/clinical trials (pre-clinical studies, Phase I, Phase II, Phase III) of biopharmaceutical companies
in the drug development process as well as non-recurring engineering services (&#x201c;NRE&#x201d;) revenues (including testing and registration
services) received from biopharmaceutical companies to ready or customize the FREEDOM System for clinical and commercial use across multiple
drug categories.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For Product Revenue, we recognize revenues when shipment
occurs, and at which point the customer obtains control and ownership of the goods. &#160;Shipping costs generally are billed to customers
and are included in Product Revenue.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company generally does not accept return of goods
shipped unless it is a Company error. &#160;The only credits provided to customers are for defective merchandise. &#160;The Company warrants
the syringe driver from defects in materials and workmanship under normal use and the warranty does not include a performance obligation.
&#160;The costs under the warranty are expensed as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Rebates are provided to distributors for the difference
in selling price to distributor and pricing specified to select customers. &#160;In addition, rebates are provided to customers for meeting
growth targets. &#160;Provisions for both distributor pricing and customer growth rebates are variable consideration and are recorded
as a reduction of revenue in the same period the related sales are recorded or when it is probable the growth target will be achieved.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We recognize NRE revenue under an input method, which
recognizes revenue on the basis of our efforts or inputs (for example, resources consumed, labor hours expended, costs incurred, or time
elapsed) to the satisfaction of a performance obligation relative to the total expected inputs to the satisfaction of that performance
obligation (i.e. completion milestone). The input method that we use is based on costs incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Contracts are often modified to account for changes
in contract specifications and requirements. Contract modifications exist when the modification either creates new, or changes existing,
enforceable rights and obligations. Generally, when contract modifications create new performance obligations, the modification is considered
to be a separate contract and revenue is recognized prospectively. When contract modifications change existing performance obligations,
the impact on the existing transaction price and measure of progress for the performance obligation to which it relates is generally recognized
as an adjustment to revenue (either as an increase in or a reduction of revenue) on a cumulative catch-up basis. Contract assets primarily
represent revenue earnings over time that are not yet billable based on the terms of the contracts. Contract liabilities (i.e., deferred
revenue) consist of fees invoiced or paid by the Company&#x2019;s customers for which the associated performance obligations have not been
satisfied and revenue has not been recognized based on the Company&#x2019;s revenue recognition criteria described above. As of March 31,
2024, the Company has recognized a contract asset of zero.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89B_ecustom--ScheduleOfNetSalesByGeography_zDNyTfMVxHZc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8BB_zofRxwMyRalc"&gt;The following table summarizes net revenues by geography
for the three months ended March 31, 2024, and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Three Months Ended March 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 46%"&gt;&lt;b&gt;Revenues&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 22%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 6%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 22%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Domestic&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--Revenues_c20240101__20240331__srt--StatementGeographicalAxis__country--US_zfekj6YiphU1" style="text-align: right" title="Net Revenue"&gt;6,384,083&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--Revenues_c20230101__20230331__srt--StatementGeographicalAxis__country--US_zU239wHzX3td" style="text-align: right" title="Net Revenue"&gt;6,283,965&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.2in"&gt;International&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--Revenues_c20240101__20240331__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zszLQcyBXTo6" style="border-bottom: black 1pt solid; text-align: right" title="Net Revenues"&gt;1,813,715&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--Revenues_c20230101__20230331__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zligqYQgmNRk" style="border-bottom: black 1pt solid; text-align: right" title="Net Revenues"&gt;1,108,640&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--Revenues_c20240101__20240331_zBlWjzy5lZTl" style="border-bottom: black 2.25pt double; text-align: right" title="Revenues"&gt;8,197,798&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--Revenues_c20230101__20230331_zgjEkojcqhJ3" style="border-bottom: black 2.25pt double; text-align: right" title="Revenues"&gt;7,392,605&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_z4HPq9rP1jhi" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;
&lt;p id="xdx_857_z8UF6jlgSFE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;



&lt;p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zJbmPfiRquv2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_86F_zQB5mnbGtWH1"&gt;ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company considers the applicability and
impact of all recently issued accounting pronouncements. &#160;Recent accounting pronouncements not specifically identified in our disclosures
are either not applicable to the Company or are not expected to have a material effect on our financial condition or results of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;i&gt;Financial
Instruments &#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/i&gt;, which amends guidance on reporting
credit losses for assets held at amortized cost basis and available for sale debt securities. &#160;For assets held at amortized cost
basis, Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its
current estimate of all expected credit losses. &#160;The allowance for credit losses is a valuation account that is deducted from the
amortized cost basis of the financial assets to present the net amount expected to be collected. &#160;For available for sale debt securities,
credit losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as
an allowance rather than as a write-down. &#160;This ASU affects entities holding financial assets and net investment in leases that are
not accounted for at fair value through net income. &#160;The amendments affect loans, debt securities, trade receivables, net investments
in leases, off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that
have the contractual right to receive cash. &#160;The Company adopted the pronouncement on January 1, 2023, and there was no impact on
its financial statements.&lt;/p&gt;

&lt;p id="xdx_853_zVK9dDlVTpoc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zjylkD9Qp3Wb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_864_zsUqUv4pUBy"&gt;FAIR VALUE MEASUREMENTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Fair value is the exit price that would be received
to sell an asset or paid to transfer a liability. &#160;Fair value is a market-based measurement that should be determined using assumptions
that market participants would use in pricing an asset or liability. Valuation techniques used to measure fair value should maximize the
use of observable inputs and minimize the use of unobservable inputs. &#160;To measure fair value, the Company uses the following fair
value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in; text-align: center"&gt;&#x2022;&lt;/td&gt;
    &lt;td style="width: 7in; text-align: justify"&gt;Level 1 &#x2013; Quoted prices in active markets for identical assets or liabilities.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: center"&gt;&#x2022;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Level 2 &#x2013; Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data by correlation or other means.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: center"&gt;&#x2022;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Level 3 &#x2013; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. &#160;Value is determined using pricing models, discounted cash flow methodologies, or similar techniques and includes instruments for which the determination of fair value requires significant judgment or estimation.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The carrying amounts of cash and cash equivalents,
including investments in short-term U.S. Treasury bills, accounts receivable, prepaid expenses, accounts payable and accrued expenses
are considered to be representative of their fair values because of the short-term nature of those instruments. &#160;There were no transfers
between levels in the fair value hierarchy during the three months ended March 31, 2024 and 2023.&lt;/p&gt;

&lt;p id="xdx_85A_z4NSgm49D4Wd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z50C5i0C6KEg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_86B_zEgjNVcrMTh8"&gt;IMPAIRMENT OF LONG-LIVED ASSETS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company reviews long-lived assets for impairment
whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. &#160;An impairment
loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition
are less than the carrying amount. &#160;The impairment loss, if recognized, would be based on the excess of the carrying value of the
impaired asset over its respective fair value. &#160;The Company did not record any impairment losses through March 31, 2024.&lt;/p&gt;

&lt;p id="xdx_85F_z5G37SYemi95" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:NatureOfOperations contextRef="From2024-01-01to2024-03-31" id="Fact000433">&lt;p id="xdx_84C_eus-gaap--NatureOfOperations_zuNRR9X8WuT5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_860_zL58AmV7DqSg"&gt;NATURE OF OPERATIONS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;KORU MEDICAL SYSTEMS, INC. (the &#x201c;Company,&#x201d;
&#x201c;KORU Medical,&#x201d; &#x201c;we,&#x201d; &#x201c;us&#x201d; or &#x201c;our&#x201d;) designs, manufactures and markets proprietary portable
and innovative medical devices primarily for the subcutaneous drug delivery market as governed by the United States Food and Drug Administration
(the &#x201c;FDA&#x201d;) quality and regulatory system and international regulations and standards for quality system management. The Company
operates as &lt;span id="xdx_903_eus-gaap--NumberOfReportableSegments_dxH_uN_c20240101__20240331_zHYjAdyxPnMa" title="Number of segment::XDX::1"&gt;one&lt;/span&gt; segment.&lt;/p&gt;

</us-gaap:NatureOfOperations>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000437">&lt;p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zxTa5f2NTFU5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_863_z3u1ztSDWWPc"&gt;BASIS OF PRESENTATION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying financial statements should be read
in conjunction with the Company&#x2019;s annual report on Form 10-K for the year ended December 31, 2023 (&#x201c;Annual Report&#x201d;).
&#160;In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;), the Company has
omitted footnote disclosures that would substantially duplicate the disclosures contained in the audited financial statements of the Company.
The accompanying interim financial statements are unaudited and reflect all adjustments which are in the opinion of management necessary
for a fair statement of the Company&#x2019;s financial position, results of operations, and cash flows for the periods presented. &#160;All
such adjustments are of a normal, recurring nature. &#160;The Company&#x2019;s results of operations and cash flows for the interim periods
are not necessarily indicative of the results of operations and cash flows that it may achieve in future periods.&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000439">&lt;p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zZ86aZl4CBLi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_86B_zxJfOor2QNue"&gt;CASH AND CASH EQUIVALENTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For purposes of the statements of cash flows, the
Company considers all short-term investments with an original maturity of three months or less to be cash equivalents. &#160;The Company
has historically held cash balances in excess of $&lt;span id="xdx_90E_eus-gaap--CashUninsuredAmount_iI_c20240331_znGjeFWwJNr7" title="FDIC cash uninsured amount"&gt;250,000&lt;/span&gt; at its primary commercial bank, which exceeds FDIC insurance limits. To reduce
the risk of uninsured deposits, the Company entered an insured cash sweep program with KeyBank during the second quarter of 2023 to automatically
invest its uninsured bank cash balances over $250,000 into FDIC insured banks so there is no more than $250,000 maintained at any one
bank. As of March 31, 2024 the Company has an investment balance of $&lt;span id="xdx_907_eus-gaap--InterestIncomeSecuritiesUSTreasury_dm_c20240101__20240331_zAroHWx5QOCk" title="Investment securities treasury bill"&gt;10.2 million&lt;/span&gt; in a US Treasury bill that matures every 90 days.&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashUninsuredAmount
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000441"
      unitRef="USD">250000</us-gaap:CashUninsuredAmount>
    <us-gaap:InterestIncomeSecuritiesUSTreasury
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000443"
      unitRef="USD">10200000</us-gaap:InterestIncomeSecuritiesUSTreasury>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2024-01-01to2024-03-31" id="Fact000445">&lt;p id="xdx_842_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zpHXUHJP89Z8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_868_zfJNXKfqZn1b"&gt;PATENTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Costs incurred in obtaining patents have been capitalized
and are being amortized over the legal life of the patents.&lt;/p&gt;

</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2024-01-01to2024-03-31" id="Fact000447">&lt;p id="xdx_84B_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zqiFo0vrTd6d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_864_zLIdpY0GWn3i"&gt;STOCK-BASED COMPENSATION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company maintains a stock option plan and an omnibus
equity incentive plan under which it grants stock options to certain executives, key employees and consultants. The fair value of each
option grant is estimated on the date of the grant using the Black-Scholes option-pricing model. &#160;All options are charged against
income at their fair value. &#160;The entire compensation expense of the award is recognized over the vesting period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company also maintains a non-employee director
compensation plan. Shares of stock granted for director fees are recorded at the fair value of the shares at the grant date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company issues restricted stock awards. Restricted
stock awards are equity classified and measured at the fair market value of the underlying stock at the grant date. The fair value of
restricted stock awards vesting at certain market capitalization thresholds were estimated on the date of grant using the Brownian Motion
Monte Carlo lattice model. The fair value of restricted stock awards with time-based vesting were estimated on the date of grant at the
current stock price. The fair value of restricted stock awards vesting at certain annual sales growth thresholds were estimated as of
the date of Board acknowledgement of the achievement, at the current stock price. We recognize restricted stock expense using the straight-line
attribution method over the requisite service period and account for forfeitures as they occur.&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000450">&lt;p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zEjvUKTCnSuj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_86B_zzX85zWjkZU3"&gt;NET LOSS PER COMMON SHARE&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic net loss per common share is calculated by dividing
net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed
by dividing net loss by the weighted average number of common and common equivalent shares outstanding during the period. The Company&#x2019;s
potentially dilutive common shares are those that result from diluted common stock options and unvested restricted stock awards. The calculation
of diluted net loss per share excluded stock options of &lt;span id="xdx_90A_ecustom--AntiDilutiveStockOptions_pid_dxL_uShares_c20240101__20240331_zAyKVLY6I0Kb" title="Anti-dilutive stock options::XDX::0"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0452"&gt;zero&lt;/span&gt;&lt;/span&gt; and &lt;span id="xdx_906_ecustom--AntiDilutiveStockOptions_pid_uShares_c20230101__20230331_z2JVos5KlZMg" title="Anti-dilutive stock options"&gt;14,626&lt;/span&gt;, respectively, in weighted-average shares for each of the three
months ended March 31, 2024 and 2023, as their effect was anti-dilutive as a result of the net loss incurred for those periods.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The calculation of diluted net loss per share excluded
stock options, performance-based restricted stock and performance-based restricted stock units (PSUs) of &lt;span id="xdx_90C_ecustom--AntiDilutiveSecurities_pid_uShares_c20240101__20240331_zLD40VIT7Xpi" title="Anti-dilutive securities"&gt;904,496&lt;/span&gt; and &lt;span id="xdx_904_ecustom--AntiDilutiveSecurities_pid_uShares_c20230101__20230331_zYK7EYycKdx4" title="Anti-dilutive Securities"&gt;914,626&lt;/span&gt; respectively,
in weighted-average shares for each of the three months ended March 31, 2024 and 2023, as their effect was anti-dilutive as a result of
the net loss incurred for those periods.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89F_ecustom--ScheduleOfSecuritiesTextBlock_zzpQsQwqywxl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B1_zFRbRMeqbCI6"&gt;The following securities were not included in the
computation of diluted shares outstanding for the three months ended March 31, 2024, and 2023 because the effect would be anti-dilutive:&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.25in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 64%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_491_20240101__20240331_z5gHa56Js7j9" style="width: 15%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_495_20230101__20230331_znrL5Y2snEGd" style="width: 15%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="text-align: center"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--CommonStockOptions_pid_uShares_zXCYQ9M0n2Ak" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Common stock options&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0462"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;14,626&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--PerformanceStockUnits_pid_uShares_zTxSUpVHYgl1" style="vertical-align: bottom"&gt;
    &lt;td&gt;PSUs&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;54,496&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0466"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--RestrictedStockUnits_pid_zd0Ut9uoSEBj" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Restricted stock &lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;850,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;900,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--AntiDilutedSecurities_pid_zwi8ws9Cj7l8" style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;904,496&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;914,626&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A9_znhncoWTWmPj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zBaLzXTzUa93" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B6_z7l4QIjCFLal"&gt;Therefore, diluted weighted average number of shares
outstanding and diluted net loss per share were the same as basic weighted average number of shares outstanding and net loss per share
for the three months ended March 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.25in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49E_20240101__20240331_zKWPQDLuseWi" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20230101__20230331_zwiXwTi9WQqb" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="text-align: center"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 64%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 15%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 15%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--NetIncomeLoss_zRGQTXHoMhT9" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Net loss&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(1,935,958&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(2,410,885&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasicAbstract_iB_zgy58JSQ1or" style="vertical-align: bottom"&gt;
    &lt;td&gt;Weighted Average Outstanding Shares:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_uShares_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJkv6CGHEuqk" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Basic weighted average shares outstanding&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;45,712,224&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;45,487,593&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock_pid_uShares_zU067aM1fsOl" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Dilutive effect of outstanding stock options and unvested restricted stock&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0485"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0486"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_uShares_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zd27J1f9JnPk" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Diluted weighted average shares outstanding&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;45,712,224&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;45,487,593&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--EarningsPerShareAbstract_iB_zOB9mDzjNIdh" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Net loss per share&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--EarningsPerShareBasic_pid_uUSDPShares_zcSlm2QFwCO3" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Basic&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;(0.04&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;(0.05&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--EarningsPerShareDiluted_pid_uUSDPShares_zpl67c48EQjj" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Diluted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;(0.04&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;(0.05&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zOZuMH9KPgh" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;
</us-gaap:EarningsPerSharePolicyTextBlock>
    <krmd:AntiDilutiveStockOptions
      contextRef="From2023-01-012023-03-31"
      decimals="INF"
      id="Fact000454"
      unitRef="Shares">14626</krmd:AntiDilutiveStockOptions>
    <krmd:AntiDilutiveSecurities
      contextRef="From2024-01-01to2024-03-31"
      decimals="INF"
      id="Fact000456"
      unitRef="Shares">904496</krmd:AntiDilutiveSecurities>
    <krmd:AntiDilutiveSecurities
      contextRef="From2023-01-012023-03-31"
      decimals="INF"
      id="Fact000458"
      unitRef="Shares">914626</krmd:AntiDilutiveSecurities>
    <krmd:ScheduleOfSecuritiesTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000460">&lt;p id="xdx_89F_ecustom--ScheduleOfSecuritiesTextBlock_zzpQsQwqywxl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B1_zFRbRMeqbCI6"&gt;The following securities were not included in the
computation of diluted shares outstanding for the three months ended March 31, 2024, and 2023 because the effect would be anti-dilutive:&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.25in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 64%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_491_20240101__20240331_z5gHa56Js7j9" style="width: 15%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_495_20230101__20230331_znrL5Y2snEGd" style="width: 15%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="text-align: center"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--CommonStockOptions_pid_uShares_zXCYQ9M0n2Ak" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Common stock options&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0462"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;14,626&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--PerformanceStockUnits_pid_uShares_zTxSUpVHYgl1" style="vertical-align: bottom"&gt;
    &lt;td&gt;PSUs&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;54,496&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0466"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--RestrictedStockUnits_pid_zd0Ut9uoSEBj" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Restricted stock &lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;850,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;900,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--AntiDilutedSecurities_pid_zwi8ws9Cj7l8" style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;904,496&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;914,626&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</krmd:ScheduleOfSecuritiesTextBlock>
    <krmd:CommonStockOptions
      contextRef="From2023-01-012023-03-31"
      decimals="INF"
      id="Fact000463"
      unitRef="Shares">14626</krmd:CommonStockOptions>
    <krmd:PerformanceStockUnits
      contextRef="From2024-01-01to2024-03-31"
      decimals="INF"
      id="Fact000465"
      unitRef="Shares">54496</krmd:PerformanceStockUnits>
    <krmd:RestrictedStockUnits
      contextRef="From2024-01-01to2024-03-31"
      decimals="INF"
      id="Fact000468"
      unitRef="Shares">850000</krmd:RestrictedStockUnits>
    <krmd:RestrictedStockUnits
      contextRef="From2023-01-012023-03-31"
      decimals="INF"
      id="Fact000469"
      unitRef="Shares">900000</krmd:RestrictedStockUnits>
    <krmd:AntiDilutedSecurities
      contextRef="From2024-01-01to2024-03-31"
      decimals="INF"
      id="Fact000471"
      unitRef="Shares">904496</krmd:AntiDilutedSecurities>
    <krmd:AntiDilutedSecurities
      contextRef="From2023-01-012023-03-31"
      decimals="INF"
      id="Fact000472"
      unitRef="Shares">914626</krmd:AntiDilutedSecurities>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000474">&lt;p id="xdx_897_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zBaLzXTzUa93" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B6_z7l4QIjCFLal"&gt;Therefore, diluted weighted average number of shares
outstanding and diluted net loss per share were the same as basic weighted average number of shares outstanding and net loss per share
for the three months ended March 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.25in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49E_20240101__20240331_zKWPQDLuseWi" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20230101__20230331_zwiXwTi9WQqb" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="text-align: center"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 64%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 15%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 15%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--NetIncomeLoss_zRGQTXHoMhT9" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Net loss&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(1,935,958&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(2,410,885&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasicAbstract_iB_zgy58JSQ1or" style="vertical-align: bottom"&gt;
    &lt;td&gt;Weighted Average Outstanding Shares:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_uShares_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJkv6CGHEuqk" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Basic weighted average shares outstanding&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;45,712,224&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;45,487,593&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock_pid_uShares_zU067aM1fsOl" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Dilutive effect of outstanding stock options and unvested restricted stock&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0485"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0486"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_uShares_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zd27J1f9JnPk" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Diluted weighted average shares outstanding&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;45,712,224&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;45,487,593&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--EarningsPerShareAbstract_iB_zOB9mDzjNIdh" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Net loss per share&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--EarningsPerShareBasic_pid_uUSDPShares_zcSlm2QFwCO3" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Basic&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;(0.04&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;(0.05&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--EarningsPerShareDiluted_pid_uUSDPShares_zpl67c48EQjj" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Diluted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;(0.04&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;(0.05&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000476"
      unitRef="USD">-1935958</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000477"
      unitRef="USD">-2410885</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000482"
      unitRef="Shares">45712224</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000483"
      unitRef="Shares">45487593</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000488"
      unitRef="Shares">45712224</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000489"
      unitRef="Shares">45487593</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-01to2024-03-31"
      decimals="INF"
      id="Fact000494"
      unitRef="USDPShares">-0.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-03-31"
      decimals="INF"
      id="Fact000495"
      unitRef="USDPShares">-0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-01to2024-03-31"
      decimals="INF"
      id="Fact000497"
      unitRef="USDPShares">-0.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-03-31"
      decimals="INF"
      id="Fact000498"
      unitRef="USDPShares">-0.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:UseOfEstimates contextRef="From2024-01-01to2024-03-31" id="Fact000500">&lt;p id="xdx_848_eus-gaap--UseOfEstimates_zwBJwuyIaRwk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_867_zXdhu3aGikK9"&gt;USE OF ESTIMATES IN THE FINANCIAL STATEMENTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of financial statements in conformity
with United States generally accepted accounting principles (&#x201c;GAAP&#x201d;) requires management to make estimates and assumptions
that affect the amounts reported in the financial statements and accompanying notes. &#160;Actual results could differ from those estimates.
Important estimates include but are not limited to asset lives, deferred tax valuation allowances, inventory valuation, and customer rebate
and incentive accruals. The results of operations for the three months ended March 31, 2024 are not necessarily indicative of the results
that may be expected for the entire 2024 fiscal year.&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000503">&lt;p id="xdx_848_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zBnku6HMugG2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_861_zAVc8rBfNITh"&gt;REVENUE RECOGNITION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our revenues are derived from three business sources:
(i) domestic core (which consists of US and Canada), (ii) international core, and (iii) novel therapies. &#160;Our core domestic and international
revenues consist of sales of our syringe drivers, tubing and needles (&#x201c;Product Revenue&#x201d;) for the delivery of subcutaneous
drugs that are FDA cleared for use with the KORU Medical infusion system, with the primary delivery for immunoglobulin to treat Primary
Immunodeficiency Diseases (&#x201c;PIDD&#x201d;) and Chronic Inflammatory Demyelinating Polyneuropathy (&#x201c;CIDP&#x201d;). Novel therapies
consist of Product Revenue for feasibility/clinical trials (pre-clinical studies, Phase I, Phase II, Phase III) of biopharmaceutical companies
in the drug development process as well as non-recurring engineering services (&#x201c;NRE&#x201d;) revenues (including testing and registration
services) received from biopharmaceutical companies to ready or customize the FREEDOM System for clinical and commercial use across multiple
drug categories.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For Product Revenue, we recognize revenues when shipment
occurs, and at which point the customer obtains control and ownership of the goods. &#160;Shipping costs generally are billed to customers
and are included in Product Revenue.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company generally does not accept return of goods
shipped unless it is a Company error. &#160;The only credits provided to customers are for defective merchandise. &#160;The Company warrants
the syringe driver from defects in materials and workmanship under normal use and the warranty does not include a performance obligation.
&#160;The costs under the warranty are expensed as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Rebates are provided to distributors for the difference
in selling price to distributor and pricing specified to select customers. &#160;In addition, rebates are provided to customers for meeting
growth targets. &#160;Provisions for both distributor pricing and customer growth rebates are variable consideration and are recorded
as a reduction of revenue in the same period the related sales are recorded or when it is probable the growth target will be achieved.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We recognize NRE revenue under an input method, which
recognizes revenue on the basis of our efforts or inputs (for example, resources consumed, labor hours expended, costs incurred, or time
elapsed) to the satisfaction of a performance obligation relative to the total expected inputs to the satisfaction of that performance
obligation (i.e. completion milestone). The input method that we use is based on costs incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Contracts are often modified to account for changes
in contract specifications and requirements. Contract modifications exist when the modification either creates new, or changes existing,
enforceable rights and obligations. Generally, when contract modifications create new performance obligations, the modification is considered
to be a separate contract and revenue is recognized prospectively. When contract modifications change existing performance obligations,
the impact on the existing transaction price and measure of progress for the performance obligation to which it relates is generally recognized
as an adjustment to revenue (either as an increase in or a reduction of revenue) on a cumulative catch-up basis. Contract assets primarily
represent revenue earnings over time that are not yet billable based on the terms of the contracts. Contract liabilities (i.e., deferred
revenue) consist of fees invoiced or paid by the Company&#x2019;s customers for which the associated performance obligations have not been
satisfied and revenue has not been recognized based on the Company&#x2019;s revenue recognition criteria described above. As of March 31,
2024, the Company has recognized a contract asset of zero.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89B_ecustom--ScheduleOfNetSalesByGeography_zDNyTfMVxHZc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8BB_zofRxwMyRalc"&gt;The following table summarizes net revenues by geography
for the three months ended March 31, 2024, and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Three Months Ended March 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 46%"&gt;&lt;b&gt;Revenues&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 22%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 6%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 22%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Domestic&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--Revenues_c20240101__20240331__srt--StatementGeographicalAxis__country--US_zfekj6YiphU1" style="text-align: right" title="Net Revenue"&gt;6,384,083&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--Revenues_c20230101__20230331__srt--StatementGeographicalAxis__country--US_zU239wHzX3td" style="text-align: right" title="Net Revenue"&gt;6,283,965&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.2in"&gt;International&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--Revenues_c20240101__20240331__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zszLQcyBXTo6" style="border-bottom: black 1pt solid; text-align: right" title="Net Revenues"&gt;1,813,715&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--Revenues_c20230101__20230331__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zligqYQgmNRk" style="border-bottom: black 1pt solid; text-align: right" title="Net Revenues"&gt;1,108,640&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--Revenues_c20240101__20240331_zBlWjzy5lZTl" style="border-bottom: black 2.25pt double; text-align: right" title="Revenues"&gt;8,197,798&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--Revenues_c20230101__20230331_zgjEkojcqhJ3" style="border-bottom: black 2.25pt double; text-align: right" title="Revenues"&gt;7,392,605&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_z4HPq9rP1jhi" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;
</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <krmd:ScheduleOfNetSalesByGeography contextRef="From2024-01-01to2024-03-31" id="Fact000505">&lt;p id="xdx_89B_ecustom--ScheduleOfNetSalesByGeography_zDNyTfMVxHZc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8BB_zofRxwMyRalc"&gt;The following table summarizes net revenues by geography
for the three months ended March 31, 2024, and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Three Months Ended March 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 46%"&gt;&lt;b&gt;Revenues&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 22%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 6%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 22%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Domestic&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--Revenues_c20240101__20240331__srt--StatementGeographicalAxis__country--US_zfekj6YiphU1" style="text-align: right" title="Net Revenue"&gt;6,384,083&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--Revenues_c20230101__20230331__srt--StatementGeographicalAxis__country--US_zU239wHzX3td" style="text-align: right" title="Net Revenue"&gt;6,283,965&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.2in"&gt;International&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--Revenues_c20240101__20240331__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zszLQcyBXTo6" style="border-bottom: black 1pt solid; text-align: right" title="Net Revenues"&gt;1,813,715&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--Revenues_c20230101__20230331__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zligqYQgmNRk" style="border-bottom: black 1pt solid; text-align: right" title="Net Revenues"&gt;1,108,640&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--Revenues_c20240101__20240331_zBlWjzy5lZTl" style="border-bottom: black 2.25pt double; text-align: right" title="Revenues"&gt;8,197,798&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--Revenues_c20230101__20230331_zgjEkojcqhJ3" style="border-bottom: black 2.25pt double; text-align: right" title="Revenues"&gt;7,392,605&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</krmd:ScheduleOfNetSalesByGeography>
    <us-gaap:Revenues
      contextRef="From2024-01-012024-03-31_country_US"
      decimals="0"
      id="Fact000507"
      unitRef="USD">6384083</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-01-012023-03-31_country_US"
      decimals="0"
      id="Fact000509"
      unitRef="USD">6283965</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-01-012024-03-31_us-gaap_NonUsMember"
      decimals="0"
      id="Fact000511"
      unitRef="USD">1813715</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-01-012023-03-31_us-gaap_NonUsMember"
      decimals="0"
      id="Fact000513"
      unitRef="USD">1108640</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000515"
      unitRef="USD">8197798</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000517"
      unitRef="USD">7392605</us-gaap:Revenues>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000520">&lt;p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zJbmPfiRquv2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_86F_zQB5mnbGtWH1"&gt;ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company considers the applicability and
impact of all recently issued accounting pronouncements. &#160;Recent accounting pronouncements not specifically identified in our disclosures
are either not applicable to the Company or are not expected to have a material effect on our financial condition or results of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;i&gt;Financial
Instruments &#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/i&gt;, which amends guidance on reporting
credit losses for assets held at amortized cost basis and available for sale debt securities. &#160;For assets held at amortized cost
basis, Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its
current estimate of all expected credit losses. &#160;The allowance for credit losses is a valuation account that is deducted from the
amortized cost basis of the financial assets to present the net amount expected to be collected. &#160;For available for sale debt securities,
credit losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as
an allowance rather than as a write-down. &#160;This ASU affects entities holding financial assets and net investment in leases that are
not accounted for at fair value through net income. &#160;The amendments affect loans, debt securities, trade receivables, net investments
in leases, off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that
have the contractual right to receive cash. &#160;The Company adopted the pronouncement on January 1, 2023, and there was no impact on
its financial statements.&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000522">&lt;p id="xdx_848_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zjylkD9Qp3Wb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_864_zsUqUv4pUBy"&gt;FAIR VALUE MEASUREMENTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Fair value is the exit price that would be received
to sell an asset or paid to transfer a liability. &#160;Fair value is a market-based measurement that should be determined using assumptions
that market participants would use in pricing an asset or liability. Valuation techniques used to measure fair value should maximize the
use of observable inputs and minimize the use of unobservable inputs. &#160;To measure fair value, the Company uses the following fair
value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in; text-align: center"&gt;&#x2022;&lt;/td&gt;
    &lt;td style="width: 7in; text-align: justify"&gt;Level 1 &#x2013; Quoted prices in active markets for identical assets or liabilities.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: center"&gt;&#x2022;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Level 2 &#x2013; Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data by correlation or other means.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: center"&gt;&#x2022;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Level 3 &#x2013; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. &#160;Value is determined using pricing models, discounted cash flow methodologies, or similar techniques and includes instruments for which the determination of fair value requires significant judgment or estimation.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The carrying amounts of cash and cash equivalents,
including investments in short-term U.S. Treasury bills, accounts receivable, prepaid expenses, accounts payable and accrued expenses
are considered to be representative of their fair values because of the short-term nature of those instruments. &#160;There were no transfers
between levels in the fair value hierarchy during the three months ended March 31, 2024 and 2023.&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000524">&lt;p id="xdx_84B_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z50C5i0C6KEg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_86B_zEgjNVcrMTh8"&gt;IMPAIRMENT OF LONG-LIVED ASSETS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company reviews long-lived assets for impairment
whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. &#160;An impairment
loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition
are less than the carrying amount. &#160;The impairment loss, if recognized, would be based on the excess of the carrying value of the
impaired asset over its respective fair value. &#160;The Company did not record any impairment losses through March 31, 2024.&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000526">&lt;p id="xdx_80F_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zJchNRUsOyHk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 2 &#x2014; &lt;span id="xdx_82F_zmPySt8BEpfh"&gt;PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--PropertyPlantAndEquipmentTextBlock_zYohctDB84N3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8BC_zZFzrzgyaOqi"&gt;Property and equipment consists of the following at:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 6in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;March 31, 2024&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 55%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 19%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 19%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Furniture and office equipment&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20240331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zxn6LKV20sN3" style="text-align: right"&gt;1,423,093&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zWUXpZxHSpy7" style="text-align: right"&gt;1,412,164&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Leasehold improvements&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20240331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z6zGUIqg1786" style="text-align: right"&gt;1,953,653&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zO7mQR53vrZ" style="text-align: right"&gt;1,953,653&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Manufacturing equipment and tooling&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20240331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentAndToolingMember_zqNOXgZ6cnze" style="border-bottom: black 1pt solid; text-align: right"&gt;3,311,833&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentAndToolingMember_zUgaSnHXixM9" style="border-bottom: black 1pt solid; text-align: right"&gt;3,193,113&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Total property and equipment&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20240331_zSlcSOC85Vi9" style="text-align: right" title="Total property and equipment"&gt;6,688,579&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231_zsEKGEvpY8Zi" style="text-align: right" title="Total property and equipment"&gt;6,558,930&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Less: accumulated depreciation and amortization&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20240331_zOTht4UYY9Ec" style="border-bottom: black 1pt solid; text-align: right" title="Less: accumulated depreciation and amortization"&gt;(2,933,049&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20231231_zJITZYSBPNy5" style="border-bottom: black 1pt solid; text-align: right" title="Less: accumulated depreciation and amortization"&gt;(2,721,273&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Property and equipment, net&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20240331_z4cl2qc71P59" style="border-bottom: black 2.25pt double; text-align: right" title="Property and equipment, net"&gt;3,755,530&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20231231_zlbjEsW8Rbb3" style="border-bottom: black 2.25pt double; text-align: right" title="Property and equipment, net"&gt;3,837,657&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AB_zo8Dra3pFcp1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Depreciation and amortization expense was $&lt;span id="xdx_904_eus-gaap--Depreciation_c20240101__20240331_zIsc01H3fYM2" title="Depreciation and amortization expense"&gt;214,910&lt;/span&gt;
and $&lt;span id="xdx_900_eus-gaap--Depreciation_c20230101__20230331_zq4sM5F5JsF8" title="Depreciation and amortization expense"&gt;197,233&lt;/span&gt; for the three months ended March 31, 2024 and 2023, respectively.&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000528">&lt;p id="xdx_891_eus-gaap--PropertyPlantAndEquipmentTextBlock_zYohctDB84N3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8BC_zZFzrzgyaOqi"&gt;Property and equipment consists of the following at:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 6in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;March 31, 2024&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 55%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 19%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 19%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Furniture and office equipment&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20240331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zxn6LKV20sN3" style="text-align: right"&gt;1,423,093&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zWUXpZxHSpy7" style="text-align: right"&gt;1,412,164&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Leasehold improvements&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20240331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z6zGUIqg1786" style="text-align: right"&gt;1,953,653&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zO7mQR53vrZ" style="text-align: right"&gt;1,953,653&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Manufacturing equipment and tooling&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20240331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentAndToolingMember_zqNOXgZ6cnze" style="border-bottom: black 1pt solid; text-align: right"&gt;3,311,833&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentAndToolingMember_zUgaSnHXixM9" style="border-bottom: black 1pt solid; text-align: right"&gt;3,193,113&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Total property and equipment&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20240331_zSlcSOC85Vi9" style="text-align: right" title="Total property and equipment"&gt;6,688,579&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231_zsEKGEvpY8Zi" style="text-align: right" title="Total property and equipment"&gt;6,558,930&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Less: accumulated depreciation and amortization&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20240331_zOTht4UYY9Ec" style="border-bottom: black 1pt solid; text-align: right" title="Less: accumulated depreciation and amortization"&gt;(2,933,049&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20231231_zJITZYSBPNy5" style="border-bottom: black 1pt solid; text-align: right" title="Less: accumulated depreciation and amortization"&gt;(2,721,273&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Property and equipment, net&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20240331_z4cl2qc71P59" style="border-bottom: black 2.25pt double; text-align: right" title="Property and equipment, net"&gt;3,755,530&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20231231_zlbjEsW8Rbb3" style="border-bottom: black 2.25pt double; text-align: right" title="Property and equipment, net"&gt;3,837,657&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-03-31_custom_FurnitureAndOfficeEquipmentMember"
      decimals="0"
      id="Fact000529"
      unitRef="USD">1423093</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_custom_FurnitureAndOfficeEquipmentMember"
      decimals="0"
      id="Fact000530"
      unitRef="USD">1412164</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-03-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      id="Fact000531"
      unitRef="USD">1953653</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      id="Fact000532"
      unitRef="USD">1953653</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-03-31_custom_ManufacturingEquipmentAndToolingMember"
      decimals="0"
      id="Fact000533"
      unitRef="USD">3311833</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_custom_ManufacturingEquipmentAndToolingMember"
      decimals="0"
      id="Fact000534"
      unitRef="USD">3193113</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000536"
      unitRef="USD">6688579</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000538"
      unitRef="USD">6558930</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000540"
      unitRef="USD">2933049</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000542"
      unitRef="USD">2721273</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000544"
      unitRef="USD">3755530</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000546"
      unitRef="USD">3837657</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000548"
      unitRef="USD">214910</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000550"
      unitRef="USD">197233</us-gaap:Depreciation>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000552">&lt;p id="xdx_805_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zo3NqYgGZ74e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 3 &#x2014; &lt;span id="xdx_82F_z2ZimLmWL1qg"&gt;STOCK-BASED COMPENSATION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company maintains a stock option plan and omnibus
equity incentive plan under which it grants stock options to certain executives, key employees and consultants. It also has granted stock
options outside of the plans as inducement awards. The fair value of each option grant is estimated on the date of the grant using the
Black-Scholes option-pricing model. &#160;All options are charged against income at their fair value. &#160;The entire compensation expense
of the award is recognized over the vesting period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company issues performance share units (PSUs) under its omnibus equity
incentive plan. Performance share units are equity classified and measured at the fair market value of the underlying stock at the grant
date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Shares of stock granted for director fees under the
non-employee director compensation plan and under its omnibus equity incentive plan are recorded at the fair value of the shares at the
grant date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company issues restricted stock awards under its
omnibus equity incentive plan and outside the plan as incentive awards. Restricted stock awards are equity classified and measured at
the fair market value of the underlying stock at the grant date. The fair value of restricted stock awards vesting at certain market capitalization
thresholds were estimated on the date of grant using the Brownian Motion Monte Carlo lattice model. The fair value of other restricted
stock awards were estimated on the date of grant at the current stock price. We recognize restricted stock expense using the straight-line
attribution method over the requisite service period and account for forfeitures as they occur.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has three equity incentive plans: the
2015 Stock Option Plan, as amended (the &#x201c;2015 Plan&#x201d;), the 2021 Omnibus Equity Incentive Plan (the &#x201c;2021 Plan&#x201d;),
and the Non-Employee Director Compensation Plan. The Company has also issued restricted stock and stock options as employment inducement
awards to its Chief Executive Officer and Chief Commercial Officer, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The 2015 plan provides for the grant of incentive
stock options and nonqualified stock options. As of March 31, 2024, there were &lt;span id="xdx_90D_ecustom--SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan_pid_uShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z8JkAgpVAmZh" title="Shares issued under plan"&gt;2,120,000&lt;/span&gt; shares reserved for outstanding awards and &lt;span id="xdx_90F_ecustom--SharesAvailableForIssuanceShareBasedCompensation_iI_pid_uShares_c20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zCq5W8k1PF11" title="Shares available for issuance"&gt;604,250&lt;/span&gt;
shares available for issuance under the 2015 Plan. Additional options may be issued under the 2015 Plan as outstanding options are forfeited.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The 2021 Plan provides for the grant of incentive
stock options, nonqualified stock options, stock awards, restricted stock awards, restricted stock units and/or stock appreciation rights
to employees, consultants and directors. As of March 31, 2024, there were &lt;span id="xdx_90D_ecustom--SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan_pid_uShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zAaNyZXEewM" title="Shares issued under plan"&gt;656,744&lt;/span&gt; shares reserved for outstanding awards and &lt;span id="xdx_909_ecustom--SharesAvailableForIssuanceShareBasedCompensation_iI_pid_uShares_c20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zibuOTaz1fv2" title="Shares available for issuance"&gt;152,811&lt;/span&gt; shares
available for issuance under the 2021 Plan. Additional awards may be issued under the 2021 Plan as outstanding awards are forfeited.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Each non-employee director of the Company (other than
the Chairman of the Board) is eligible to receive $&lt;span id="xdx_909_ecustom--NonemployeeServicesTransactionCost_pid_uShares_c20240101__20240331__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorAndBoardAdvisorMember_zc2412wPPQ9" title="Nonemployee services transaction cost"&gt;110,000&lt;/span&gt; annually, &lt;span id="xdx_900_eus-gaap--DeferredCompensationArrangementsOverallDescription_c20240101__20240331__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorAndBoardAdvisorMember_zPH2ZzmWWyi3" title="Share-based goods and non-employee services transaction"&gt;to be paid quarterly $12,500 in cash and $15,000 in common stock.&lt;/span&gt;
&#160;The Chairman of the Board is eligible to receive $&lt;span id="xdx_902_ecustom--NonemployeeServicesTransactionCost_pid_uShares_c20240101__20240331__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zd3co86c6aQc" title="Nonemployee services transaction cost"&gt;140,000&lt;/span&gt; annually, &lt;span id="xdx_90E_eus-gaap--DeferredCompensationArrangementsOverallDescription_c20240101__20240331__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zGmDiHNjbIV" title="Share-based goods and non-employee services transaction"&gt;to be paid quarterly $12,500 in cash and $22,500 in common stock.
&lt;/span&gt;Non-employee director compensation is paid pursuant to the Non-Employee Director Compensation Plan. All payments were and are pro-rated
for partial service.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Time Based Stock Options&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zlWrq3Mfyb6b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8BD_zvPKrWKfE2Hk"&gt;The following table summarizes the activities for
our stock options with time based vesting for the three months ended March 31, 2024, and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 4.5in; border-collapse: collapse"&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 44%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 22%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 4%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 22%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Dividend yield&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zZSuCsvVBIS8" title="Dividend yield"&gt;0.00&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zfjBMFk5KbQ" title="Dividend yield"&gt;0.00&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Expected Volatility&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zDaUabp6Fyul" title="Expected volatility"&gt;46.18&lt;/span&gt; - &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zg0C9AWaVRP4" title="Expected volatility"&gt;46.21&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zuoZ3Pq4ySTa" title="Expected volatility"&gt;61.3&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Weighted-average volatility&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp0_uPure_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zV5OjUQjvGC6" title="Weighted-average volatility"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp0_uPure_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zVyys5zzYZ89" title="Weighted-average volatility"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Expected dividends&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_d0_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zB6E6iySGl1c" title="Expected dividends"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_d0_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z4DBuV6Vbh0e" title="Expected dividends"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Expected term (in years)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zZeIzhdCHAfb" title="Expected term (in years)::XDX::P10Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0591"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z1byDkyDfC2i" title="Expected term (in years)::XDX::P10Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0593"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Risk-free rate&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zcSsb2JN5pRg" title="Risk-free rate"&gt;4.2&lt;/span&gt;% - &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zPRdMSdg4Jm6" title="Risk-free rate"&gt;4.3&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zMcAlCg3jvX7" title="Risk-free rate"&gt;3.53&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A0_z2l7PKyaBFtk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z9u1GmXy9bRd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B2_zJ8DmKTKjUPd"&gt;The following table summarizes the status of the stock
options:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="9" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Three Months Ended March 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="4" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="4" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 54%"&gt;Outstanding at January 1&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zYoiTVrmYcPf" style="width: 9%; text-align: right" title="Outstanding at beginning"&gt;3,256,250&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zxKkDVi3IAXf" style="width: 9%; text-align: right" title="Outstanding at beginning"&gt;3.66&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zAAYvVJlyYVa" style="width: 9%; text-align: right" title="Outstanding at beginning"&gt;3,035,000&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zhNzoga14ma6" style="width: 9%; text-align: right" title="Outstanding at beginning"&gt;3.93&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_ziK7kuxQgc29" style="text-align: right" title="Granted"&gt;65,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zwe0tBog49Ag" style="text-align: right" title="Granted"&gt;2.21&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z2neB2rU5jE2" style="text-align: right" title="Granted"&gt;40,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zrO57WfTOI1a" style="text-align: right" title="Granted"&gt;3.91&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zNFGcmXnfZei" style="text-align: right" title="Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0619"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zdOs5FzRoU5i" style="text-align: right" title="Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0621"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zrmoyx70kaA9" style="text-align: right" title="Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0623"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zDYgCzgwe9oe" style="text-align: right" title="Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0625"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zuML3OHLNHic" style="text-align: right" title="Forfeited"&gt;381,250&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zAQujz4UAVL9" style="text-align: right" title="Forfeited"&gt;7.0&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zcdYDgDNjF92" style="text-align: right" title="Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0631"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z2FoRJB8U7gj" style="text-align: right" title="Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0633"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Outstanding at March 31&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zSkdBzXYYMvk" style="text-align: right" title="Outstanding at ending"&gt;2,940,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zUMNnfyoqoXg" style="text-align: right" title="Outstanding at ending"&gt;3.19&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zmLssqaTjuyl" style="text-align: right" title="Outstanding at ending"&gt;3,075,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zJz1aNHxEbHe" style="text-align: right" title="Outstanding at ending"&gt;3.92&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Options exercisable at March 31&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zwxrpXUOKwrc" style="text-align: right" title="Options exercisable"&gt;1,393,750&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zOKzHkx1nZw6" style="text-align: right" title="Options exercisable"&gt;3.59&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zQkyiePyAbxj" style="text-align: right" title="Options exercisable"&gt;1,010,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zrDnZxmsiV75" style="text-align: right" title="Options exercisable"&gt;4.63&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 0.1in; text-indent: -0.1in"&gt;Weighted average fair value of options granted during the period&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zZmrFPqZ2UWa" style="text-align: right" title="Weighted average fair value of options granted during the period"&gt;1.39&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zY8ko5SEmoPj" style="text-align: right" title="Weighted average fair value of options granted during the period"&gt;2.83&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Stock-based compensation expense&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zQAFevKilFAh" style="text-align: right" title="Stock-based compensation expense"&gt;393,113&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zvRaPBX5SuA3" style="text-align: right" title="Stock-based compensation expense"&gt;535,059&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AF_zRbcbz427Ulg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Total stock-based compensation expense was $&lt;span id="xdx_906_ecustom--StockBasedCompensationStockOptions_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zTiGHoCLI8r7" title="Stock-based compensation expense"&gt;393,113&lt;/span&gt;
and $&lt;span id="xdx_906_ecustom--StockBasedCompensationStockOptions_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zwgMAJ6yWV0d" title="Stock-based compensation expense"&gt;535,059&lt;/span&gt; for the three months ended March 31, 2024, and 2023, respectively. No cash was received from option exercises for the three
months ended March 31, 2024, and 2023, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89E_ecustom--ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock_zPvoFlRomfAk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table presents information pertaining
to options outstanding at March 31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;b&gt;Range of Exercise Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Number&lt;br/&gt;
Outstanding&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Remaining&lt;br/&gt;
Contractual&lt;br/&gt;
Life&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Number&lt;br/&gt;
Exercisable&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 29%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;$2.18 - $4.37&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_uShares_c20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zsp8OekKpoVc" style="text-align: right" title="Number outstanding"&gt;2,940,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dxL_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zrPHLUL09Mje" title="Weighted average remaining contractual life::XDX::P6Y10M25D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0667"&gt;6.9&lt;/span&gt;&lt;/span&gt; years&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_uUSDPShares_c20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zaUD8pR3q3Sa" style="text-align: right" title="Weighted average exercise price"&gt;3.19&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_uShares_c20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_z0inQJXrmbri" style="text-align: right" title="Number exercisable"&gt;1,393,750&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_uUSDPShares_c20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zcgmIrpLA4ic" style="text-align: right" title="Weighted average exercise price"&gt;3.59&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A3_z7lVE1Cfr7Xh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of March 31, 2024, there was $&lt;span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20240331__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z0n9toIWnu0i" title="Total unrecognized compensation cost"&gt;2,719,478&lt;/span&gt; of total
unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the Plans. &#160;That cost is
expected to be recognized over a weighted-average period of 46 months. &#160;The total fair value of shares vested as of March 31, 2024,
and March 31, 2023, was $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_c20240331__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember_zjVbUYwyoaZ1" title="Fair value of shares"&gt;3,884,426&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_c20230331__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember_zneaG83Fw18k" title="Fair value of shares"&gt;3,511,874&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;div id="xdx_235_zrZVBeJ1vi28"&gt;
&lt;p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center"&gt;- 12 -&lt;/p&gt;


&lt;hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/&gt;&lt;p style="break-before: always"&gt;&lt;/p&gt;

&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;&lt;a href="#toc"&gt;&lt;span style="color: Blue"&gt;Table of Contents&lt;/span&gt;&lt;/a&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p id="xdx_234_zIIQrbiZSOd2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;/div&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Performance Based Stock Options&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_zfdU1nleHWD3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;span id="xdx_8B8_zXaeFjqp7yzf"&gt;The following table summarizes the activities
for our unvested performance based stock option awards for the three months ended March 31, 2024, and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="9" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Three Months Ended March 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="4" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="4" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Grant-Date&lt;br/&gt;
Fair Value&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Grant-Date&lt;br/&gt;
Fair Value&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 41%"&gt;Unvested at January 1&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByUnvestedAwardOptions_iS_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zotXsiT7eLUi" style="width: 12%; text-align: right" title="Unvested at beginning"&gt;200,000&lt;/td&gt;
    &lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zJQQjo9OzeD5" style="width: 11%; text-align: right" title="Unvested at beginning"&gt;1.48&lt;/td&gt;
    &lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByUnvestedAwardOptions_iS_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zR9hL9pdviS8" style="width: 12%; text-align: right" title="Outstanding at beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0689"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zprybgccS3Z" style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0690"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_pid_d0_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zTEEWu3cIbFi" style="text-align: right" title="Granted"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zeya2LFwdaRd" style="text-align: right" title="Granted"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_pid_d0_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zXWOaTaNmEe1" style="text-align: right" title="Granted"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zsi3lmH5hgo2" style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Vested&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested_pid_d0_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zUsOlgAh1JPh" style="text-align: right" title="Vested"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zpuvY05Z4xj5" style="text-align: right" title="Vested"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested_pid_d0_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zK59qA2YlLx3" style="text-align: right" title="Forfeited"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zWxMuPh3Rqcj" style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Forfeited/canceled&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures_pid_d0_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zpZ0uITitbJl" style="text-align: right" title="Forfeited/canceled"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zk41Ro850OGl" style="text-align: right" title="Forfeited/canceled"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures_pid_d0_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zFpVkK1Ao6x6" style="text-align: right" title="Forfeited"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zbsX2bw9yNdd" style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Unvested at March 31&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByUnvestedAwardOptions_iE_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zA0woV7FpRF1" style="text-align: right" title="Unvested at ending"&gt;200,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_z11bZTkeKju3" style="text-align: right" title="Unvested at ending"&gt;1.48&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByUnvestedAwardOptions_iE_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zL8NJNwlP4Oc" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0716"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zy5RGvR7rdu5" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0717"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A6_zfCIxTX6T4ci" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Total stock-based compensation expense was $&lt;span id="xdx_903_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zS1xOOjuCjil" title="Total stock-based compensation expense"&gt;8,121&lt;/span&gt;
and &lt;span id="xdx_90A_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_dxL_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zkkRoYDuQnf4" title="Total stock-based compensation expense::XDX::0"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0721"&gt;zero&lt;/span&gt;&lt;/span&gt; for the three months ended March 31, 2024, and 2023, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of March 31, 2024, there was $&lt;span id="xdx_905_ecustom--UnrecognizedCompensationCost_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zDZFp88xtrTf" title="Unrecognized compensation cost"&gt;168,223&lt;/span&gt; of unrecognized
compensation cost related to unvested employee performance based options. This amount is expected to be recognized over a weighted-average
period of 36 months.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Restricted Stock Awards and PSUs&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_z9ygRDHDD4y4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B1_zutCAf93qVe5"&gt;The following table summarizes the activities for
our restricted stock awards and PSUs for the three months ended March 31, 2024, and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="9" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Three Months Ended March 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="4" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="4" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Grant-Date Fair Value&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Grant-Date Fair Value&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 41%"&gt;Unvested at January 1&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zKYWgn2mgeg7" style="width: 12%; text-align: right" title="Outstanding at beginning"&gt;904,496&lt;/td&gt;
    &lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_znguJnC4jSch" style="width: 11%; text-align: right" title="Outstanding at beginning"&gt;1.80&lt;/td&gt;
    &lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_ziNpjHxQAwWe" style="width: 12%; text-align: right" title="Outstanding at beginning"&gt;950,000&lt;/td&gt;
    &lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_pid_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zCIwRk1DycGk" style="width: 11%; text-align: right" title="Outstanding at beginning"&gt;3.04&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zR0yXwCX9oBb" style="text-align: right" title="Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0735"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zzILKzaYeEi6" style="text-align: right" title="Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0737"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zKrUnVs8DfHf" style="text-align: right" title="Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0739"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z9q5qkqj6DKj" style="text-align: right" title="Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0741"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Vested&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z2bO08kSVx91" style="text-align: right" title="Vested"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0743"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_ze8tsIucLVlg" style="text-align: right" title="Vested"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0745"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zgTceYgH9i3g" style="text-align: right" title="Vested"&gt;50,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zZVhFi4utnhl" style="text-align: right" title="Vested"&gt;3.31&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Forfeited/canceled&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z8APshZWAndi" style="text-align: right" title="Forfeited/canceled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0751"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z1FZxq0fktp9" style="text-align: right" title="Forfeited/canceled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0753"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zHJ4BQvdTDKd" style="text-align: right" title="Forfeited/canceled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0755"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zxVVVZJpYx27" style="text-align: right" title="Forfeited/canceled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0757"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Unvested at March 31&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zLmPv1DufjFf" style="text-align: right" title="Outstanding at ending"&gt;904,496&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zIuBm8uUqbT5" style="text-align: right" title="Outstanding at ending"&gt;1.80&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zkPMoHvDvW7a" style="text-align: right" title="Outstanding at ending"&gt;900,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_pid_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zuylbHtfoaT3" style="text-align: right" title="Outstanding at ending"&gt;2.93&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A1_zKkyMje4eMt8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Total stock-based compensation expense was $&lt;span id="xdx_905_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zDGx7mNi5eIg" title="Total stock-based compensation expense"&gt;122,551&lt;/span&gt;
and $&lt;span id="xdx_901_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zlfXfy1yf1Fb" title="Total stock-based compensation expense"&gt;170,387&lt;/span&gt; for the three months ended March 31, 2024, and 2023, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of March 31, 2024, and 2023, there was $&lt;span id="xdx_906_ecustom--UnrecognizedCompensationCost_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zVLYduJ3g3u2" title="Unrecognized compensation cost"&gt;755,513&lt;/span&gt;
and $&lt;span id="xdx_90D_ecustom--UnrecognizedCompensationCost_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zpR1pnKUb0G" title="Unrecognized compensation cost"&gt;1,447,790&lt;/span&gt; of unrecognized compensation cost related to unvested employee restricted stock awards and PSUs. This amount is expected
to be recognized over a weighted-average period of 21 months.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Common Stock Warrants&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_zIKqcXIf9dk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B4_zELoc4sie5I8"&gt;The following table summarizes the activities for
our common stock warrants issued in connection with our loan financing agreement with HSBC for the three months ended March 31, 2024,
and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="9" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Three Months Ended March 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="4" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="4" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Grant-Date Fair Value&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Grant-Date Fair Value&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 41%"&gt;Unvested at January 1&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z32p3x7EvNAi" style="width: 12%; text-align: right" title="Outstanding at beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0778"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z6WNsuByy9Hb" style="width: 11%; text-align: right" title="Outstanding at beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0780"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zAxpnMBih8G7" style="width: 12%; text-align: right" title="Outstanding at beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0782"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_pid_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zfk2gwBzJGb9" style="width: 11%; text-align: right" title="Outstanding at beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0784"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zSA31aYSHUY8" style="text-align: right" title="Granted"&gt;76,104&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zc5SR8rOvrJf" style="text-align: right" title="Granted"&gt;1.37&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zzCkLpkxkpX2" style="text-align: right" title="Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0790"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z8GphMB98u8h" style="text-align: right" title="Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0792"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Vested&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_ziSVH8pmo6B6" style="text-align: right" title="Vested"&gt;38,052&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zjFtWrc3Q9D6" style="text-align: right" title="Vested"&gt;1.37&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zFmp0xx4pNtk" style="text-align: right" title="Vested"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0798"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zxbtd3qnDml7" style="text-align: right" title="Vested"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0800"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Forfeited/canceled&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zLxCz4v7LCIk" style="text-align: right" title="Forfeited/canceled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0802"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z2l0CNeiBtLb" style="text-align: right" title="Forfeited/canceled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0804"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z0tyiOTYMoB1" style="text-align: right" title="Forfeited/canceled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0806"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zoF53Nge4OY3" style="text-align: right" title="Forfeited/canceled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0808"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Unvested at March 31&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zdQalfv0smS7" style="text-align: right" title="Outstanding at ending"&gt;38,052&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z0AnyDlHUsy4" style="text-align: right" title="Outstanding at ending"&gt;1.37&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z3qLHiDO5Hm8" style="text-align: right" title="Outstanding at ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0814"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_pid_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zXGxwUbpLKxa" style="text-align: right" title="Outstanding at ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0816"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AF_zVLUdOWcsDWh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of March 31, 2024, and 2023, there was $&lt;span id="xdx_904_ecustom--UnrecognizedCompensationCost_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember_z7HXh3eYmTX7" title="Unrecognized cost"&gt;52,125&lt;/span&gt;
and &lt;span id="xdx_901_ecustom--UnrecognizedCompensationCost_dxL_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember_zb5XL6m2x191" title="Unrecognized cost::XDX::0"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0820"&gt;zero&lt;/span&gt;&lt;/span&gt; of unrecognized cost related to unvested warrants.&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <krmd:SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan
      contextRef="From2024-01-012024-03-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      id="Fact000554"
      unitRef="Shares">2120000</krmd:SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan>
    <krmd:SharesAvailableForIssuanceShareBasedCompensation
      contextRef="AsOf2024-03-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      id="Fact000556"
      unitRef="Shares">604250</krmd:SharesAvailableForIssuanceShareBasedCompensation>
    <krmd:SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan
      contextRef="From2024-01-012024-03-31_custom_StockOptionPlan2021Member"
      decimals="INF"
      id="Fact000558"
      unitRef="Shares">656744</krmd:SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan>
    <krmd:SharesAvailableForIssuanceShareBasedCompensation
      contextRef="AsOf2024-03-31_custom_StockOptionPlan2021Member"
      decimals="INF"
      id="Fact000560"
      unitRef="Shares">152811</krmd:SharesAvailableForIssuanceShareBasedCompensation>
    <krmd:NonemployeeServicesTransactionCost
      contextRef="From2024-01-012024-03-31_custom_NonEmployeeDirectorAndBoardAdvisorMember"
      decimals="INF"
      id="Fact000562"
      unitRef="Shares">110000</krmd:NonemployeeServicesTransactionCost>
    <us-gaap:DeferredCompensationArrangementsOverallDescription
      contextRef="From2024-01-012024-03-31_custom_NonEmployeeDirectorAndBoardAdvisorMember"
      id="Fact000564">to be paid quarterly $12,500 in cash and $15,000 in common stock.</us-gaap:DeferredCompensationArrangementsOverallDescription>
    <krmd:NonemployeeServicesTransactionCost
      contextRef="From2024-01-012024-03-31_srt_BoardOfDirectorsChairmanMember"
      decimals="INF"
      id="Fact000566"
      unitRef="Shares">140000</krmd:NonemployeeServicesTransactionCost>
    <us-gaap:DeferredCompensationArrangementsOverallDescription
      contextRef="From2024-01-012024-03-31_srt_BoardOfDirectorsChairmanMember"
      id="Fact000568">to be paid quarterly $12,500 in cash and $22,500 in common stock.</us-gaap:DeferredCompensationArrangementsOverallDescription>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000571">&lt;p id="xdx_898_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zlWrq3Mfyb6b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8BD_zvPKrWKfE2Hk"&gt;The following table summarizes the activities for
our stock options with time based vesting for the three months ended March 31, 2024, and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 4.5in; border-collapse: collapse"&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 44%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 22%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 4%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 22%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Dividend yield&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zZSuCsvVBIS8" title="Dividend yield"&gt;0.00&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zfjBMFk5KbQ" title="Dividend yield"&gt;0.00&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Expected Volatility&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zDaUabp6Fyul" title="Expected volatility"&gt;46.18&lt;/span&gt; - &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zg0C9AWaVRP4" title="Expected volatility"&gt;46.21&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zuoZ3Pq4ySTa" title="Expected volatility"&gt;61.3&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Weighted-average volatility&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp0_uPure_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zV5OjUQjvGC6" title="Weighted-average volatility"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp0_uPure_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zVyys5zzYZ89" title="Weighted-average volatility"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Expected dividends&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_d0_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zB6E6iySGl1c" title="Expected dividends"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_d0_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z4DBuV6Vbh0e" title="Expected dividends"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Expected term (in years)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zZeIzhdCHAfb" title="Expected term (in years)::XDX::P10Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0591"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z1byDkyDfC2i" title="Expected term (in years)::XDX::P10Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0593"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Risk-free rate&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zcSsb2JN5pRg" title="Risk-free rate"&gt;4.2&lt;/span&gt;% - &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zPRdMSdg4Jm6" title="Risk-free rate"&gt;4.3&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zMcAlCg3jvX7" title="Risk-free rate"&gt;3.53&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2024-01-012024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="Fact000573"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2023-01-012023-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="Fact000575"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-01-012024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000577"
      unitRef="Pure">0.4618</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-01-012024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000579"
      unitRef="Pure">0.4621</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-01-012023-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="Fact000581"
      unitRef="Pure">0.613</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="From2024-01-012024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="Fact000583"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="From2023-01-012023-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="Fact000585"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
      contextRef="From2024-01-012024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="0"
      id="Fact000587"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
      contextRef="From2023-01-012023-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="0"
      id="Fact000589"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-01-012024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000595"
      unitRef="Pure">0.042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-01-012024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000597"
      unitRef="Pure">0.043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-01-012023-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="Fact000599"
      unitRef="Pure">0.0353</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000601">&lt;p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z9u1GmXy9bRd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B2_zJ8DmKTKjUPd"&gt;The following table summarizes the status of the stock
options:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="9" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Three Months Ended March 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="4" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="4" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 54%"&gt;Outstanding at January 1&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zYoiTVrmYcPf" style="width: 9%; text-align: right" title="Outstanding at beginning"&gt;3,256,250&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zxKkDVi3IAXf" style="width: 9%; text-align: right" title="Outstanding at beginning"&gt;3.66&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zAAYvVJlyYVa" style="width: 9%; text-align: right" title="Outstanding at beginning"&gt;3,035,000&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zhNzoga14ma6" style="width: 9%; text-align: right" title="Outstanding at beginning"&gt;3.93&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_ziK7kuxQgc29" style="text-align: right" title="Granted"&gt;65,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zwe0tBog49Ag" style="text-align: right" title="Granted"&gt;2.21&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z2neB2rU5jE2" style="text-align: right" title="Granted"&gt;40,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zrO57WfTOI1a" style="text-align: right" title="Granted"&gt;3.91&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zNFGcmXnfZei" style="text-align: right" title="Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0619"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zdOs5FzRoU5i" style="text-align: right" title="Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0621"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zrmoyx70kaA9" style="text-align: right" title="Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0623"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zDYgCzgwe9oe" style="text-align: right" title="Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0625"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zuML3OHLNHic" style="text-align: right" title="Forfeited"&gt;381,250&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zAQujz4UAVL9" style="text-align: right" title="Forfeited"&gt;7.0&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zcdYDgDNjF92" style="text-align: right" title="Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0631"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z2FoRJB8U7gj" style="text-align: right" title="Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0633"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Outstanding at March 31&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zSkdBzXYYMvk" style="text-align: right" title="Outstanding at ending"&gt;2,940,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zUMNnfyoqoXg" style="text-align: right" title="Outstanding at ending"&gt;3.19&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zmLssqaTjuyl" style="text-align: right" title="Outstanding at ending"&gt;3,075,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zJz1aNHxEbHe" style="text-align: right" title="Outstanding at ending"&gt;3.92&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Options exercisable at March 31&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zwxrpXUOKwrc" style="text-align: right" title="Options exercisable"&gt;1,393,750&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zOKzHkx1nZw6" style="text-align: right" title="Options exercisable"&gt;3.59&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zQkyiePyAbxj" style="text-align: right" title="Options exercisable"&gt;1,010,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zrDnZxmsiV75" style="text-align: right" title="Options exercisable"&gt;4.63&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 0.1in; text-indent: -0.1in"&gt;Weighted average fair value of options granted during the period&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zZmrFPqZ2UWa" style="text-align: right" title="Weighted average fair value of options granted during the period"&gt;1.39&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zY8ko5SEmoPj" style="text-align: right" title="Weighted average fair value of options granted during the period"&gt;2.83&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Stock-based compensation expense&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zQAFevKilFAh" style="text-align: right" title="Stock-based compensation expense"&gt;393,113&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20230331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zvRaPBX5SuA3" style="text-align: right" title="Stock-based compensation expense"&gt;535,059&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="Fact000603"
      unitRef="Shares">3256250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="Fact000605"
      unitRef="USDPShares">3.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="Fact000607"
      unitRef="Shares">3035000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="Fact000609"
      unitRef="USDPShares">3.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-01-012024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="Fact000611"
      unitRef="Shares">65000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="Fact000613"
      unitRef="USDPShares">2.21</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-012023-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="Fact000615"
      unitRef="Shares">40000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="Fact000617"
      unitRef="USDPShares">3.91</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2024-01-012024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="Fact000627"
      unitRef="Shares">381250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="Fact000629"
      unitRef="USDPShares">7.0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="Fact000635"
      unitRef="Shares">2940000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="Fact000637"
      unitRef="USDPShares">3.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="Fact000639"
      unitRef="Shares">3075000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="Fact000641"
      unitRef="USDPShares">3.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="Fact000643"
      unitRef="Shares">1393750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="Fact000645"
      unitRef="USDPShares">3.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2023-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="Fact000647"
      unitRef="Shares">1010000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="Fact000649"
      unitRef="USDPShares">4.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="Fact000651"
      unitRef="USDPShares">1.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="Fact000653"
      unitRef="USDPShares">2.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="0"
      id="Fact000655"
      unitRef="USD">393113</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="0"
      id="Fact000657"
      unitRef="USD">535059</us-gaap:AllocatedShareBasedCompensationExpense>
    <krmd:StockBasedCompensationStockOptions
      contextRef="From2024-01-012024-03-31_custom_StockOptionPlans2015And2021CombinedMember_custom_TimeBasedSharesOptionsMember"
      decimals="0"
      id="Fact000659"
      unitRef="USD">393113</krmd:StockBasedCompensationStockOptions>
    <krmd:StockBasedCompensationStockOptions
      contextRef="From2023-01-012023-03-31_custom_StockOptionPlans2015And2021CombinedMember_custom_TimeBasedSharesOptionsMember"
      decimals="0"
      id="Fact000661"
      unitRef="USD">535059</krmd:StockBasedCompensationStockOptions>
    <krmd:ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000663">&lt;p id="xdx_89E_ecustom--ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock_zPvoFlRomfAk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table presents information pertaining
to options outstanding at March 31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;b&gt;Range of Exercise Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Number&lt;br/&gt;
Outstanding&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Remaining&lt;br/&gt;
Contractual&lt;br/&gt;
Life&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Number&lt;br/&gt;
Exercisable&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 29%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;$2.18 - $4.37&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_uShares_c20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zsp8OekKpoVc" style="text-align: right" title="Number outstanding"&gt;2,940,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dxL_c20240101__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zrPHLUL09Mje" title="Weighted average remaining contractual life::XDX::P6Y10M25D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0667"&gt;6.9&lt;/span&gt;&lt;/span&gt; years&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_uUSDPShares_c20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zaUD8pR3q3Sa" style="text-align: right" title="Weighted average exercise price"&gt;3.19&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_uShares_c20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_z0inQJXrmbri" style="text-align: right" title="Number exercisable"&gt;1,393,750&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_uUSDPShares_c20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zcgmIrpLA4ic" style="text-align: right" title="Weighted average exercise price"&gt;3.59&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</krmd:ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member"
      decimals="INF"
      id="Fact000665"
      unitRef="Shares">2940000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member"
      decimals="INF"
      id="Fact000669"
      unitRef="USDPShares">3.19</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member"
      decimals="INF"
      id="Fact000671"
      unitRef="Shares">1393750</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2024-03-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member"
      decimals="INF"
      id="Fact000673"
      unitRef="USDPShares">3.59</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2024-03-31_custom_StockOptionPlans2015And2021CombinedMember_custom_TimeBasedSharesOptionsMember"
      decimals="0"
      id="Fact000675"
      unitRef="USD">2719478</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="AsOf2024-03-31_custom_StockOptionPlans2015And2021CombinedMember"
      decimals="0"
      id="Fact000677"
      unitRef="USD">3884426</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="AsOf2023-03-31_custom_StockOptionPlans2015And2021CombinedMember"
      decimals="0"
      id="Fact000679"
      unitRef="USD">3511874</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000683">&lt;p id="xdx_89D_eus-gaap--ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_zfdU1nleHWD3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;span id="xdx_8B8_zXaeFjqp7yzf"&gt;The following table summarizes the activities
for our unvested performance based stock option awards for the three months ended March 31, 2024, and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="9" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Three Months Ended March 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="4" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="4" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Grant-Date&lt;br/&gt;
Fair Value&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Grant-Date&lt;br/&gt;
Fair Value&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 41%"&gt;Unvested at January 1&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByUnvestedAwardOptions_iS_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zotXsiT7eLUi" style="width: 12%; text-align: right" title="Unvested at beginning"&gt;200,000&lt;/td&gt;
    &lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zJQQjo9OzeD5" style="width: 11%; text-align: right" title="Unvested at beginning"&gt;1.48&lt;/td&gt;
    &lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByUnvestedAwardOptions_iS_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zR9hL9pdviS8" style="width: 12%; text-align: right" title="Outstanding at beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0689"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zprybgccS3Z" style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0690"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_pid_d0_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zTEEWu3cIbFi" style="text-align: right" title="Granted"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zeya2LFwdaRd" style="text-align: right" title="Granted"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_pid_d0_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zXWOaTaNmEe1" style="text-align: right" title="Granted"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zsi3lmH5hgo2" style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Vested&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested_pid_d0_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zUsOlgAh1JPh" style="text-align: right" title="Vested"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zpuvY05Z4xj5" style="text-align: right" title="Vested"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested_pid_d0_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zK59qA2YlLx3" style="text-align: right" title="Forfeited"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zWxMuPh3Rqcj" style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Forfeited/canceled&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures_pid_d0_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zpZ0uITitbJl" style="text-align: right" title="Forfeited/canceled"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zk41Ro850OGl" style="text-align: right" title="Forfeited/canceled"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures_pid_d0_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zFpVkK1Ao6x6" style="text-align: right" title="Forfeited"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zbsX2bw9yNdd" style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Unvested at March 31&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByUnvestedAwardOptions_iE_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zA0woV7FpRF1" style="text-align: right" title="Unvested at ending"&gt;200,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_z11bZTkeKju3" style="text-align: right" title="Unvested at ending"&gt;1.48&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByUnvestedAwardOptions_iE_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zL8NJNwlP4Oc" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0716"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zy5RGvR7rdu5" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0717"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock>
    <krmd:ShareBasedCompensationArrangementByUnvestedAwardOptions
      contextRef="AsOf2023-12-31_custom_PerformanceBasedSharesOptionsMember"
      decimals="INF"
      id="Fact000685"
      unitRef="Shares">200000</krmd:ShareBasedCompensationArrangementByUnvestedAwardOptions>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_custom_PerformanceBasedSharesOptionsMember"
      decimals="INF"
      id="Fact000687"
      unitRef="USDPShares">1.48</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants
      contextRef="From2024-01-012024-03-31_custom_PerformanceBasedSharesOptionsMember"
      decimals="INF"
      id="Fact000692"
      unitRef="Shares">0</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1
      contextRef="From2024-01-012024-03-31_custom_PerformanceBasedSharesOptionsMember"
      decimals="INF"
      id="Fact000694"
      unitRef="USDPShares">0</krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants
      contextRef="From2023-01-012023-03-31_custom_PerformanceBasedSharesOptionsMember"
      decimals="INF"
      id="Fact000696"
      unitRef="Shares">0</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1
      contextRef="From2023-01-012023-03-31_custom_PerformanceBasedSharesOptionsMember"
      decimals="INF"
      id="Fact000697"
      unitRef="USDPShares">0</krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested
      contextRef="From2024-01-012024-03-31_custom_PerformanceBasedSharesOptionsMember"
      decimals="INF"
      id="Fact000699"
      unitRef="Shares">0</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1
      contextRef="From2024-01-012024-03-31_custom_PerformanceBasedSharesOptionsMember"
      decimals="INF"
      id="Fact000701"
      unitRef="USDPShares">0</krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested
      contextRef="From2023-01-012023-03-31_custom_PerformanceBasedSharesOptionsMember"
      decimals="INF"
      id="Fact000703"
      unitRef="Shares">0</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1
      contextRef="From2023-01-012023-03-31_custom_PerformanceBasedSharesOptionsMember"
      decimals="INF"
      id="Fact000704"
      unitRef="USDPShares">0</krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures
      contextRef="From2024-01-012024-03-31_custom_PerformanceBasedSharesOptionsMember"
      decimals="INF"
      id="Fact000706"
      unitRef="Shares">0</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1
      contextRef="From2024-01-012024-03-31_custom_PerformanceBasedSharesOptionsMember"
      decimals="INF"
      id="Fact000708"
      unitRef="USDPShares">0</krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures
      contextRef="From2023-01-012023-03-31_custom_PerformanceBasedSharesOptionsMember"
      decimals="INF"
      id="Fact000710"
      unitRef="Shares">0</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1
      contextRef="From2023-01-012023-03-31_custom_PerformanceBasedSharesOptionsMember"
      decimals="INF"
      id="Fact000711"
      unitRef="USDPShares">0</krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1>
    <krmd:ShareBasedCompensationArrangementByUnvestedAwardOptions
      contextRef="AsOf2024-03-31_custom_PerformanceBasedSharesOptionsMember"
      decimals="INF"
      id="Fact000713"
      unitRef="Shares">200000</krmd:ShareBasedCompensationArrangementByUnvestedAwardOptions>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice
      contextRef="AsOf2024-03-31_custom_PerformanceBasedSharesOptionsMember"
      decimals="INF"
      id="Fact000715"
      unitRef="USDPShares">1.48</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2024-01-012024-03-31_us-gaap_PerformanceSharesMember"
      decimals="0"
      id="Fact000719"
      unitRef="USD">8121</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <krmd:UnrecognizedCompensationCost
      contextRef="From2024-01-012024-03-31_us-gaap_PerformanceSharesMember"
      decimals="0"
      id="Fact000723"
      unitRef="USD">168223</krmd:UnrecognizedCompensationCost>
    <us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000725">&lt;p id="xdx_892_eus-gaap--ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_z9ygRDHDD4y4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B1_zutCAf93qVe5"&gt;The following table summarizes the activities for
our restricted stock awards and PSUs for the three months ended March 31, 2024, and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="9" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Three Months Ended March 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="4" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="4" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Grant-Date Fair Value&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Grant-Date Fair Value&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 41%"&gt;Unvested at January 1&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zKYWgn2mgeg7" style="width: 12%; text-align: right" title="Outstanding at beginning"&gt;904,496&lt;/td&gt;
    &lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_znguJnC4jSch" style="width: 11%; text-align: right" title="Outstanding at beginning"&gt;1.80&lt;/td&gt;
    &lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_ziNpjHxQAwWe" style="width: 12%; text-align: right" title="Outstanding at beginning"&gt;950,000&lt;/td&gt;
    &lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_pid_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zCIwRk1DycGk" style="width: 11%; text-align: right" title="Outstanding at beginning"&gt;3.04&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zR0yXwCX9oBb" style="text-align: right" title="Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0735"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zzILKzaYeEi6" style="text-align: right" title="Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0737"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zKrUnVs8DfHf" style="text-align: right" title="Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0739"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z9q5qkqj6DKj" style="text-align: right" title="Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0741"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Vested&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z2bO08kSVx91" style="text-align: right" title="Vested"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0743"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_ze8tsIucLVlg" style="text-align: right" title="Vested"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0745"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zgTceYgH9i3g" style="text-align: right" title="Vested"&gt;50,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zZVhFi4utnhl" style="text-align: right" title="Vested"&gt;3.31&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Forfeited/canceled&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z8APshZWAndi" style="text-align: right" title="Forfeited/canceled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0751"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z1FZxq0fktp9" style="text-align: right" title="Forfeited/canceled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0753"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zHJ4BQvdTDKd" style="text-align: right" title="Forfeited/canceled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0755"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zxVVVZJpYx27" style="text-align: right" title="Forfeited/canceled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0757"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Unvested at March 31&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zLmPv1DufjFf" style="text-align: right" title="Outstanding at ending"&gt;904,496&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zIuBm8uUqbT5" style="text-align: right" title="Outstanding at ending"&gt;1.80&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zkPMoHvDvW7a" style="text-align: right" title="Outstanding at ending"&gt;900,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_pid_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zuylbHtfoaT3" style="text-align: right" title="Outstanding at ending"&gt;2.93&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested
      contextRef="AsOf2023-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      decimals="INF"
      id="Fact000727"
      unitRef="Shares">904496</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested
      contextRef="AsOf2023-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      decimals="INF"
      id="Fact000729"
      unitRef="USDPShares">1.80</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested
      contextRef="AsOf2022-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      decimals="INF"
      id="Fact000731"
      unitRef="Shares">950000</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested
      contextRef="AsOf2022-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      decimals="INF"
      id="Fact000733"
      unitRef="USDPShares">3.04</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross
      contextRef="From2023-01-012023-03-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      decimals="INF"
      id="Fact000747"
      unitRef="Shares">50000</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-03-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      decimals="INF"
      id="Fact000749"
      unitRef="USDPShares">3.31</krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested
      contextRef="AsOf2024-03-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      decimals="INF"
      id="Fact000759"
      unitRef="Shares">904496</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested
      contextRef="AsOf2024-03-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      decimals="INF"
      id="Fact000761"
      unitRef="USDPShares">1.80</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested
      contextRef="AsOf2023-03-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      decimals="INF"
      id="Fact000763"
      unitRef="Shares">900000</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested
      contextRef="AsOf2023-03-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      decimals="INF"
      id="Fact000765"
      unitRef="USDPShares">2.93</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2024-01-012024-03-31_us-gaap_RestrictedStockMember"
      decimals="0"
      id="Fact000767"
      unitRef="USD">122551</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2023-01-012023-03-31_us-gaap_RestrictedStockMember"
      decimals="0"
      id="Fact000769"
      unitRef="USD">170387</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <krmd:UnrecognizedCompensationCost
      contextRef="From2024-01-012024-03-31_us-gaap_RestrictedStockMember"
      decimals="0"
      id="Fact000771"
      unitRef="USD">755513</krmd:UnrecognizedCompensationCost>
    <krmd:UnrecognizedCompensationCost
      contextRef="From2023-01-012023-03-31_us-gaap_RestrictedStockMember"
      decimals="0"
      id="Fact000773"
      unitRef="USD">1447790</krmd:UnrecognizedCompensationCost>
    <us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000776">&lt;p id="xdx_898_eus-gaap--ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_zIKqcXIf9dk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B4_zELoc4sie5I8"&gt;The following table summarizes the activities for
our common stock warrants issued in connection with our loan financing agreement with HSBC for the three months ended March 31, 2024,
and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="9" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Three Months Ended March 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="4" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="4" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Grant-Date Fair Value&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Grant-Date Fair Value&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 41%"&gt;Unvested at January 1&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z32p3x7EvNAi" style="width: 12%; text-align: right" title="Outstanding at beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0778"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z6WNsuByy9Hb" style="width: 11%; text-align: right" title="Outstanding at beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0780"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zAxpnMBih8G7" style="width: 12%; text-align: right" title="Outstanding at beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0782"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_pid_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zfk2gwBzJGb9" style="width: 11%; text-align: right" title="Outstanding at beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0784"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zSA31aYSHUY8" style="text-align: right" title="Granted"&gt;76,104&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zc5SR8rOvrJf" style="text-align: right" title="Granted"&gt;1.37&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zzCkLpkxkpX2" style="text-align: right" title="Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0790"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z8GphMB98u8h" style="text-align: right" title="Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0792"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Vested&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_ziSVH8pmo6B6" style="text-align: right" title="Vested"&gt;38,052&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zjFtWrc3Q9D6" style="text-align: right" title="Vested"&gt;1.37&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zFmp0xx4pNtk" style="text-align: right" title="Vested"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0798"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zxbtd3qnDml7" style="text-align: right" title="Vested"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0800"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Forfeited/canceled&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zLxCz4v7LCIk" style="text-align: right" title="Forfeited/canceled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0802"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z2l0CNeiBtLb" style="text-align: right" title="Forfeited/canceled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0804"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z0tyiOTYMoB1" style="text-align: right" title="Forfeited/canceled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0806"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zoF53Nge4OY3" style="text-align: right" title="Forfeited/canceled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0808"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Unvested at March 31&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pid_uShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zdQalfv0smS7" style="text-align: right" title="Outstanding at ending"&gt;38,052&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z0AnyDlHUsy4" style="text-align: right" title="Outstanding at ending"&gt;1.37&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pid_uShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z3qLHiDO5Hm8" style="text-align: right" title="Outstanding at ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0814"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_pid_uUSDPShares_c20230101__20230331__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zXGxwUbpLKxa" style="text-align: right" title="Outstanding at ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0816"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested
      contextRef="From2024-01-012024-03-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member"
      decimals="INF"
      id="Fact000786"
      unitRef="Shares">76104</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested
      contextRef="From2024-01-012024-03-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member"
      decimals="INF"
      id="Fact000788"
      unitRef="USDPShares">1.37</krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross
      contextRef="From2024-01-012024-03-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member"
      decimals="INF"
      id="Fact000794"
      unitRef="Shares">38052</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-03-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member"
      decimals="INF"
      id="Fact000796"
      unitRef="USDPShares">1.37</krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested
      contextRef="AsOf2024-03-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member"
      decimals="INF"
      id="Fact000810"
      unitRef="Shares">38052</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested
      contextRef="AsOf2024-03-31_custom_CommonStockWarrantsMember_custom_StockOptionPlan2021Member"
      decimals="INF"
      id="Fact000812"
      unitRef="USDPShares">1.37</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested>
    <krmd:UnrecognizedCompensationCost
      contextRef="From2024-01-012024-03-31_custom_CommonStockWarrantsMember"
      decimals="0"
      id="Fact000818"
      unitRef="USD">52125</krmd:UnrecognizedCompensationCost>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000822">&lt;p id="xdx_807_eus-gaap--DebtDisclosureTextBlock_z3cf6wwfzpNb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 4 &#x2014; &lt;span id="xdx_824_zkyWV8c7dytc"&gt;DEBT OBLIGATIONS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On July 28, 2023, the Company entered into a
commercial insurance premium finance and security agreement with AON Premium Finance, LLC in the aggregate principal amount of
$&lt;span id="xdx_906_eus-gaap--NotesPayable_iI_dm_c20230728__dei--LegalEntityAxis__custom--AONPremiumFinanceLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_z27QFGKX2xac" title="Notes payable"&gt;0.57
million&lt;/span&gt; bearing an annual percentage rate of &lt;span id="xdx_901_ecustom--NotePayableTerms_pid_dp_uPure_c20230726__20230728__dei--LegalEntityAxis__custom--AONPremiumFinanceLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zEt4adGtrBvk" title="Note payable terms"&gt;9.5&lt;/span&gt;%,
to finance its insurance premiums. &lt;span id="xdx_908_eus-gaap--DebtInstrumentFrequencyOfPeriodicPayment_c20230726__20230728__dei--LegalEntityAxis__custom--AONPremiumFinanceLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zrZ35925XQj8" title="Description of the frequency of periodic payments"&gt;Monthly
payments are due on the first of each month beginning August 1, 2023 through June 1, 2024.&lt;/span&gt; The balance of the AON note was
$&lt;span id="xdx_906_eus-gaap--OtherLongTermDebtNoncurrent_iI_c20231231__dei--LegalEntityAxis__custom--AONPremiumFinanceLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zaQRudaPpskk" title="Balance of AON note"&gt;314,344&lt;/span&gt;
as of December 31, 2023 and $&lt;span id="xdx_903_eus-gaap--OtherLongTermDebtNoncurrent_iI_c20240331__dei--LegalEntityAxis__custom--AONPremiumFinanceLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zg1HcVxIsuOe" title="Balance of AON note"&gt;159,031&lt;/span&gt;
as of March 31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On March 8, 2024, the Company entered into a loan
and security agreement with HSBC Ventures USA Inc., as lender, providing for a $&lt;span id="xdx_90A_eus-gaap--LinesOfCreditCurrent_iI_c20240308__dei--LegalEntityAxis__custom--HSBCVenturesUSAIncMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zDHRn3zBUwmk" title="Revolving credit facility"&gt;5,000,000&lt;/span&gt; revolving credit facility and a $&lt;span id="xdx_905_ecustom--LinesOfCreditCurrent1_iI_c20240308__dei--LegalEntityAxis__custom--HSBCVenturesUSAIncMember__us-gaap--CreditFacilityAxis__custom--TermLoanFacilityMember_zKis0mgO2FS9" title="Term loan facility"&gt;5,000,000&lt;/span&gt; term
loan facility. Borrowings are secured by a first-priority lien on substantially all of the assets of the Company, subject to customary
exceptions. The revolving credit facility matures on December 31, 2025 and the term loan matures on December 1, 2028. Our former revolving
credit facility with Key Bank expired during the quarter ended September 30, 2023. As of March 31, 2024, there were no outstanding borrowings
under the term loan nor the revolving credit facility.&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:NotesPayable
      contextRef="AsOf2023-07-28_custom_AONPremiumFinanceLLCMember_custom_PromissoryNoteMember"
      decimals="0"
      id="Fact000824"
      unitRef="USD">570000</us-gaap:NotesPayable>
    <krmd:NotePayableTerms
      contextRef="From2023-07-262023-07-28_custom_AONPremiumFinanceLLCMember_custom_PromissoryNoteMember"
      decimals="INF"
      id="Fact000826"
      unitRef="Pure">0.095</krmd:NotePayableTerms>
    <us-gaap:DebtInstrumentFrequencyOfPeriodicPayment
      contextRef="From2023-07-262023-07-28_custom_AONPremiumFinanceLLCMember_custom_PromissoryNoteMember"
      id="Fact000828">Monthly
payments are due on the first of each month beginning August 1, 2023 through June 1, 2024.</us-gaap:DebtInstrumentFrequencyOfPeriodicPayment>
    <us-gaap:OtherLongTermDebtNoncurrent
      contextRef="AsOf2023-12-31_custom_AONPremiumFinanceLLCMember_custom_PromissoryNoteMember"
      decimals="0"
      id="Fact000830"
      unitRef="USD">314344</us-gaap:OtherLongTermDebtNoncurrent>
    <us-gaap:OtherLongTermDebtNoncurrent
      contextRef="AsOf2024-03-31_custom_AONPremiumFinanceLLCMember_custom_PromissoryNoteMember"
      decimals="0"
      id="Fact000832"
      unitRef="USD">159031</us-gaap:OtherLongTermDebtNoncurrent>
    <us-gaap:LinesOfCreditCurrent
      contextRef="AsOf2024-03-08_custom_HSBCVenturesUSAIncMember_us-gaap_RevolvingCreditFacilityMember"
      decimals="0"
      id="Fact000834"
      unitRef="USD">5000000</us-gaap:LinesOfCreditCurrent>
    <krmd:LinesOfCreditCurrent1
      contextRef="AsOf2024-03-08_custom_HSBCVenturesUSAIncMember_custom_TermLoanFacilityMember"
      decimals="0"
      id="Fact000836"
      unitRef="USD">5000000</krmd:LinesOfCreditCurrent1>
    <us-gaap:LeasesOfLesseeDisclosureTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000838">&lt;p id="xdx_801_eus-gaap--LeasesOfLesseeDisclosureTextBlock_zk5BZxcXN6ff" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 5 &#x2014; &lt;span id="xdx_82B_zpMVH4UhthY9"&gt;LEASES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We have finance and operating leases for our corporate
office and certain office and computer equipment. &#160;Our two operating leases have remaining lease terms of &lt;span id="xdx_90A_ecustom--LesseeOperatingLeaseRemainingTerm_dxL_c20240101__20240331__us-gaap--LeaseContractualTermAxis__custom--LeaseOneMember_zS39fX1ATpHh" title="Operating lease remaining term::XDX::P8Y4M24D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0840"&gt;8.4&lt;/span&gt;&lt;/span&gt; years and &lt;span id="xdx_908_ecustom--LesseeOperatingLeaseRemainingTerm_dxL_c20240101__20240331__us-gaap--LeaseContractualTermAxis__custom--LeaseTwoMember_zuxS5Y2FwZri" title="Operating lease remaining term::XDX::P4Y9M18D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0842"&gt;4.8&lt;/span&gt;&lt;/span&gt; years,
respectively. Our three finance leases have remaining lease terms of &lt;span id="xdx_902_ecustom--LesseeFinanceLeaseRemainingTerm_dxL_c20240101__20240331__us-gaap--LeaseContractualTermAxis__custom--LeaseOneMember_zTn177XUF3r6" title="Finance lease remaining term::XDX::P3Y2M12D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0844"&gt;3.2&lt;/span&gt;&lt;/span&gt; years, &lt;span id="xdx_905_ecustom--LesseeFinanceLeaseRemainingTerm_dxL_c20240101__20240331__us-gaap--LeaseContractualTermAxis__custom--LeaseTwoMember_zPLpD3ncnP1c" title="Finance lease remaining term::XDX::P2Y9M0D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0846"&gt;2.75&lt;/span&gt;&lt;/span&gt; years, and &lt;span id="xdx_900_ecustom--LesseeFinanceLeaseRemainingTerm_dxL_c20240101__20240331__us-gaap--LeaseContractualTermAxis__custom--LeaseThreeMember_zpkUK7LeVvpe" title="Finance lease remaining term::XDX::P4Y6M0D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0848"&gt;4.5&lt;/span&gt;&lt;/span&gt; years, respectively, as of March 31,
2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--LeaseCostTableTextBlock_zauTH8fo6kWa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8BE_z1UUuMP6ctD5"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 4.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_496_20240101__20240331_zPZhZXkiyey3" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20230101__20230331_zB4RJACsSBi2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="text-align: center"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 62%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 15%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 4%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 15%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingLeaseCost_maLCzGTc_zFrhS2aSiqqb" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Operating lease cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;111,548&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;112,522&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ShortTermLeaseCost_maLCzGTc_zSXcYUba4MP6" style="vertical-align: bottom"&gt;
    &lt;td&gt;Short-term lease cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;3,460&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;52,894&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LeaseCost_zKRTYi0GRENg" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Total lease cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;115,008&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;165,416&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--FinanceLeaseCost1Abstract_iB_zZm9UtAhC4va" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 7.95pt; text-indent: -7.95pt"&gt;Finance lease cost:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_i01_maFLCzAT2_z6I3gfDgKNQ5" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Amortization of right-of-use assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;28,896&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;27,223&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--FinanceLeaseInterestExpense_i01_maFLCzAT2_zMns9RB1ItPk" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Interest on lease liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;6,053&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;6,720&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--FinanceLeaseCost_i01_zqGwjQy9Sim2" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Total finance lease cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;34,949&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;33,943&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A3_zfUOYrNp5RPd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;p id="xdx_89F_eus-gaap--OperatingLeaseLeaseIncomeTableTextBlock_zKNpO7m0QyU3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B8_zC6gKwzRWUK5"&gt;Supplemental cash flow information related to leases
was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 6.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_495_20240101__20240331_zVppJ63WtQ94" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20230101__20230331_zpl9Na4lfwZ6" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="text-align: center"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--CashFlowOperatingActivitiesLesseeAbstract_iB" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 70%; padding-left: 8.25pt; text-indent: -8.25pt"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingLeasePayments_i01_zsEqvrMPSCH6" style="vertical-align: bottom"&gt;
    &lt;td&gt;Operating cash flows from operating leases&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;120,365&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;113,813&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--FinanceLeaseInterestPaymentOnLiability_i01_zc6FMQiffytl" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Financing cash flows from finance leases&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;32,859&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;30,800&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A2_znLkcIgBIoLb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_zvPao6Y57qB7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B2_zHobzA7gJrza"&gt;Supplemental balance sheet information related to
leases was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20240331_zd6RSgwy3vY7" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20231231_zfj7QKjQoz3f" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;March 31,&lt;br/&gt;
2024&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;br/&gt;
2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 55%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 17%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 17%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--AssetsAndLiabilitiesOperatingLesseeAbstract_iB_zUKGoupTq6x7" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 7.95pt; text-indent: -7.95pt"&gt;&lt;b&gt;Operating Leases&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_z7iI4XVnolG1" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 24.7pt; text-indent: -8.25pt"&gt;Operating lease right-of-use assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;3,428,885&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;3,514,055&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 24.7pt; text-indent: -8.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityCurrent_i01I_z2Bc90rfh79b" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 24.7pt; text-indent: -8.25pt"&gt;Operating lease current liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;372,109&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;368,313&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_zpCmZ4XeYpzd" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 24.7pt; text-indent: -8.25pt"&gt;Operating lease long term liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;3,241,837&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;3,336,300&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OperatingLeaseLiability_i01I_zloCrfDY96a4" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 7.95pt; text-indent: -7.95pt"&gt;Total operating lease liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;3,613,946&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;3,704,613&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 7.95pt; text-indent: -7.95pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--AssetsAndLiabilitiesLesseeFinanceAbstract_iB_zYpNM6sUPA98" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 7.95pt; text-indent: -7.95pt"&gt;&lt;b&gt;Finance Leases&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentOther_i01I_z2bIO0JnclQ6" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 24.7pt; text-indent: -8.25pt"&gt;Property and equipment, at cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;577,929&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;577,929&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentOtherAccumulatedDepreciation_i01NI_di_z1PbQqb7pPHk" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 24.7pt; text-indent: -8.25pt"&gt;Accumulated depreciation&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(190,358&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(161,461&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentOtherNet_i01I_zohKRMyBndKd" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 24.7pt; text-indent: -8.25pt"&gt;Property and equipment, net&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;387,571&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;416,468&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FinanceLeaseLiabilityCurrent_iI_zQQS7vFSwB8i" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 24.7pt; text-indent: -8.25pt"&gt;Finance lease current liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;111,103&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;109,540&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_zumSjJzwUjP6" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 24.7pt; text-indent: -8.25pt"&gt;Finance lease long term liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;288,253&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;316,623&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--FinanceLeaseLiability_iI_zYz94yTFuF22" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 7.95pt; text-indent: -7.95pt"&gt;Total finance lease liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;399,356&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;426,163&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5in; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 55%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 19%; text-align: center"&gt;&lt;b&gt;March 31,&lt;br/&gt;
2024&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: top; width: 19%; text-align: center"&gt;&lt;b&gt;December 31,&lt;br/&gt;
2023&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 2%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;b&gt;Weighted Average Remaining Lease Term&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-left: 0.2in"&gt;Operating leases&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dxL_c20240331_z8uD2GUNGQ71" title="Operating leases term::XDX::P6Y7M6D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0923"&gt;6.6&lt;/span&gt;&lt;/span&gt; Years&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dxL_c20231231_z8y6Zc5zuA8f" title="::XDX::P6Y10M25D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0924"&gt;6.9&lt;/span&gt;&lt;/span&gt; Years&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 0.2in"&gt;Finance leases&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dxL_c20240331_zjyamX7bpi3a" title="Finance leases  term::XDX::P3Y7M6D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0926"&gt;3.6&lt;/span&gt;&lt;/span&gt; Years&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dxL_c20231231_ziSWWq7j83ck" title="::XDX::P6Y8M12D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0927"&gt;3.7&lt;/span&gt;&lt;/span&gt; Years&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;b&gt;Weighted Average Discount Rate&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-left: 0.2in"&gt;Operating leases&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20240331_zSIydO3clCqg" title="Operating leases discount rate"&gt;5.73&lt;/span&gt;%&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20231231_zWAR3Jqmunb1"&gt;5.76&lt;/span&gt;%&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 0.2in"&gt;Finance leases&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_pid_dp_uPure_c20240331_z6TiDvQXNJu3" title="Finance leases discount rate"&gt;6.17&lt;/span&gt;%&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_pid_dp_uPure_c20231231_z9i6Vxe0410h"&gt;6.19&lt;/span&gt;%&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AD_zvGn0RGtdUqh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zZh9W77sRRAa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B6_zQqUwkv5Smyl"&gt;Maturities of lease liabilities are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&lt;b&gt;Year Ending December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Operating Leases&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Finance Leases&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom; width: 52%"&gt;Remainder of 2024&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 2%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20240331_zanzfq8GuNhb" style="vertical-align: bottom; width: 18%; text-align: right" title="2024 - Operating Leases"&gt;384,041&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20240331_zN3jqj0wcU1i" style="vertical-align: bottom; width: 18%; text-align: right" title="2024 - Finance Leases"&gt;98,578&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 2%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;2025&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_c20240331_z7s6l8TSl4Wg" style="text-align: right" title="2025 - Operating Leases"&gt;512,055&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_c20240331_zRUoU2hVhPb2" style="text-align: right" title="2025 - Finance Leases"&gt;131,437&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;2026&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_c20240331_zg5vTq2XkmZg" style="vertical-align: bottom; text-align: right" title="2026 - Operating Leases"&gt;512,055&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_c20240331_zoX17dI2XQ79" style="vertical-align: bottom; text-align: right" title="2026 - Finance Leases"&gt;131,437&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom"&gt;2027&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_c20240331_z2KRKq1vCqLj" style="vertical-align: bottom; text-align: right" title="2027 - Operating Leases"&gt;512,055&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_c20240331_zounU9bLy9Pl" style="vertical-align: bottom; text-align: right" title="2027 - Finance Leases"&gt;74,194&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;2028&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_c20240331_zpTHKbaDDgVb" style="vertical-align: bottom; text-align: right" title="2028 - Operating Leases"&gt;511,009&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_iI_c20240331_zweTlmwMVuXk" style="vertical-align: bottom; text-align: right" title="2028 - Finance Leases"&gt;6,179&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom"&gt;Thereafter&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_c20240331_zsGbBJNckw15" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Thereafter - Operating Leases"&gt;1,833,604&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--FinanceLeaseLiabilityPaymentsDueAfterYearFive_iI_c20240331_zHAmz4lUIWrk" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Thereafter - Finance Leases"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0959"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;Total undiscounted lease payments&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueTotal_iI_c20240331_zxoLT9s7r5pi" style="vertical-align: bottom; text-align: right" title="Total undiscounted lease payments - Operating Leases"&gt;4,264,819&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal_iI_c20240331_zWaFrJrbLQSk" style="vertical-align: bottom; text-align: right" title="Total undiscounted lease payments - Finance Leases"&gt;441,825&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-left: 16.45pt"&gt;Less: imputed interest&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--LesseeOperatingLeaseImputedInterest_iNI_di_c20240331_zydmttaezh5g" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Less: imputed interest - Operating Leases"&gt;(650,873&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--LesseeFinancingLeaseImputedInterest_iNI_di_c20240331_zmxAZ4l6Q9g2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Less: imputed interest - Finance Leases"&gt;(42,469&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;Total lease liabilities&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; vertical-align: bottom"&gt;$&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--OperatingLeaseLiability_iI_c20240331_z5NJJfYHuG68" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Total lease liabilities - Operating Leases"&gt;3,613,946&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; vertical-align: bottom"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--FinanceLeaseLiability_iI_c20240331_zuHy3SmrjCza" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Total lease liabilities - Finance Leases"&gt;399,356&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zuNGCSXdVu49" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;
</us-gaap:LeasesOfLesseeDisclosureTextBlock>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000850">&lt;p id="xdx_89E_eus-gaap--LeaseCostTableTextBlock_zauTH8fo6kWa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8BE_z1UUuMP6ctD5"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 4.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_496_20240101__20240331_zPZhZXkiyey3" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20230101__20230331_zB4RJACsSBi2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="text-align: center"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 62%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 15%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 4%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 15%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingLeaseCost_maLCzGTc_zFrhS2aSiqqb" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Operating lease cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;111,548&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;112,522&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ShortTermLeaseCost_maLCzGTc_zSXcYUba4MP6" style="vertical-align: bottom"&gt;
    &lt;td&gt;Short-term lease cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;3,460&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;52,894&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LeaseCost_zKRTYi0GRENg" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Total lease cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;115,008&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;165,416&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--FinanceLeaseCost1Abstract_iB_zZm9UtAhC4va" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 7.95pt; text-indent: -7.95pt"&gt;Finance lease cost:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_i01_maFLCzAT2_z6I3gfDgKNQ5" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Amortization of right-of-use assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;28,896&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;27,223&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--FinanceLeaseInterestExpense_i01_maFLCzAT2_zMns9RB1ItPk" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Interest on lease liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;6,053&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;6,720&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--FinanceLeaseCost_i01_zqGwjQy9Sim2" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Total finance lease cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;34,949&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;33,943&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000852"
      unitRef="USD">111548</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000853"
      unitRef="USD">112522</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000855"
      unitRef="USD">3460</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000856"
      unitRef="USD">52894</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000858"
      unitRef="USD">115008</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000859"
      unitRef="USD">165416</us-gaap:LeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000864"
      unitRef="USD">28896</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000865"
      unitRef="USD">27223</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000867"
      unitRef="USD">6053</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000868"
      unitRef="USD">6720</us-gaap:FinanceLeaseInterestExpense>
    <krmd:FinanceLeaseCost
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000870"
      unitRef="USD">34949</krmd:FinanceLeaseCost>
    <krmd:FinanceLeaseCost
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000871"
      unitRef="USD">33943</krmd:FinanceLeaseCost>
    <us-gaap:OperatingLeaseLeaseIncomeTableTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000874">&lt;p id="xdx_89F_eus-gaap--OperatingLeaseLeaseIncomeTableTextBlock_zKNpO7m0QyU3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B8_zC6gKwzRWUK5"&gt;Supplemental cash flow information related to leases
was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 6.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_495_20240101__20240331_zVppJ63WtQ94" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20230101__20230331_zpl9Na4lfwZ6" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="text-align: center"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--CashFlowOperatingActivitiesLesseeAbstract_iB" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 70%; padding-left: 8.25pt; text-indent: -8.25pt"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingLeasePayments_i01_zsEqvrMPSCH6" style="vertical-align: bottom"&gt;
    &lt;td&gt;Operating cash flows from operating leases&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;120,365&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;113,813&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--FinanceLeaseInterestPaymentOnLiability_i01_zc6FMQiffytl" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Financing cash flows from finance leases&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;32,859&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;30,800&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:OperatingLeaseLeaseIncomeTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000879"
      unitRef="USD">120365</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000880"
      unitRef="USD">113813</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000882"
      unitRef="USD">32859</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000883"
      unitRef="USD">30800</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000885">&lt;p id="xdx_899_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_zvPao6Y57qB7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B2_zHobzA7gJrza"&gt;Supplemental balance sheet information related to
leases was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20240331_zd6RSgwy3vY7" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20231231_zfj7QKjQoz3f" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;March 31,&lt;br/&gt;
2024&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;br/&gt;
2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 55%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 17%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 17%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--AssetsAndLiabilitiesOperatingLesseeAbstract_iB_zUKGoupTq6x7" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 7.95pt; text-indent: -7.95pt"&gt;&lt;b&gt;Operating Leases&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_z7iI4XVnolG1" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 24.7pt; text-indent: -8.25pt"&gt;Operating lease right-of-use assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;3,428,885&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;3,514,055&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 24.7pt; text-indent: -8.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityCurrent_i01I_z2Bc90rfh79b" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 24.7pt; text-indent: -8.25pt"&gt;Operating lease current liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;372,109&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;368,313&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_zpCmZ4XeYpzd" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 24.7pt; text-indent: -8.25pt"&gt;Operating lease long term liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;3,241,837&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;3,336,300&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OperatingLeaseLiability_i01I_zloCrfDY96a4" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 7.95pt; text-indent: -7.95pt"&gt;Total operating lease liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;3,613,946&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;3,704,613&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 7.95pt; text-indent: -7.95pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--AssetsAndLiabilitiesLesseeFinanceAbstract_iB_zYpNM6sUPA98" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 7.95pt; text-indent: -7.95pt"&gt;&lt;b&gt;Finance Leases&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentOther_i01I_z2bIO0JnclQ6" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 24.7pt; text-indent: -8.25pt"&gt;Property and equipment, at cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;577,929&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;577,929&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentOtherAccumulatedDepreciation_i01NI_di_z1PbQqb7pPHk" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 24.7pt; text-indent: -8.25pt"&gt;Accumulated depreciation&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(190,358&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(161,461&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentOtherNet_i01I_zohKRMyBndKd" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 24.7pt; text-indent: -8.25pt"&gt;Property and equipment, net&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;387,571&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;416,468&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FinanceLeaseLiabilityCurrent_iI_zQQS7vFSwB8i" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 24.7pt; text-indent: -8.25pt"&gt;Finance lease current liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;111,103&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;109,540&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_zumSjJzwUjP6" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 24.7pt; text-indent: -8.25pt"&gt;Finance lease long term liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;288,253&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;316,623&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--FinanceLeaseLiability_iI_zYz94yTFuF22" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 7.95pt; text-indent: -7.95pt"&gt;Total finance lease liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;399,356&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;426,163&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5in; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 55%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 19%; text-align: center"&gt;&lt;b&gt;March 31,&lt;br/&gt;
2024&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: top; width: 19%; text-align: center"&gt;&lt;b&gt;December 31,&lt;br/&gt;
2023&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 2%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;b&gt;Weighted Average Remaining Lease Term&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-left: 0.2in"&gt;Operating leases&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dxL_c20240331_z8uD2GUNGQ71" title="Operating leases term::XDX::P6Y7M6D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0923"&gt;6.6&lt;/span&gt;&lt;/span&gt; Years&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dxL_c20231231_z8y6Zc5zuA8f" title="::XDX::P6Y10M25D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0924"&gt;6.9&lt;/span&gt;&lt;/span&gt; Years&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 0.2in"&gt;Finance leases&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dxL_c20240331_zjyamX7bpi3a" title="Finance leases  term::XDX::P3Y7M6D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0926"&gt;3.6&lt;/span&gt;&lt;/span&gt; Years&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dxL_c20231231_ziSWWq7j83ck" title="::XDX::P6Y8M12D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0927"&gt;3.7&lt;/span&gt;&lt;/span&gt; Years&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;b&gt;Weighted Average Discount Rate&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-left: 0.2in"&gt;Operating leases&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20240331_zSIydO3clCqg" title="Operating leases discount rate"&gt;5.73&lt;/span&gt;%&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20231231_zWAR3Jqmunb1"&gt;5.76&lt;/span&gt;%&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 0.2in"&gt;Finance leases&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_pid_dp_uPure_c20240331_z6TiDvQXNJu3" title="Finance leases discount rate"&gt;6.17&lt;/span&gt;%&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_pid_dp_uPure_c20231231_z9i6Vxe0410h"&gt;6.19&lt;/span&gt;%&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000890"
      unitRef="USD">3428885</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000891"
      unitRef="USD">3514055</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000893"
      unitRef="USD">372109</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000894"
      unitRef="USD">368313</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000896"
      unitRef="USD">3241837</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000897"
      unitRef="USD">3336300</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000899"
      unitRef="USD">3613946</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000900"
      unitRef="USD">3704613</us-gaap:OperatingLeaseLiability>
    <us-gaap:PropertyPlantAndEquipmentOther
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000905"
      unitRef="USD">577929</us-gaap:PropertyPlantAndEquipmentOther>
    <us-gaap:PropertyPlantAndEquipmentOther
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000906"
      unitRef="USD">577929</us-gaap:PropertyPlantAndEquipmentOther>
    <us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000908"
      unitRef="USD">190358</us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation>
    <us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000909"
      unitRef="USD">161461</us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation>
    <us-gaap:PropertyPlantAndEquipmentOtherNet
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000911"
      unitRef="USD">387571</us-gaap:PropertyPlantAndEquipmentOtherNet>
    <us-gaap:PropertyPlantAndEquipmentOtherNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000912"
      unitRef="USD">416468</us-gaap:PropertyPlantAndEquipmentOtherNet>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000914"
      unitRef="USD">111103</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000915"
      unitRef="USD">109540</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000917"
      unitRef="USD">288253</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000918"
      unitRef="USD">316623</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiability
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000920"
      unitRef="USD">399356</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000921"
      unitRef="USD">426163</us-gaap:FinanceLeaseLiability>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000929"
      unitRef="Pure">0.0573</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000930"
      unitRef="Pure">0.0576</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeFinanceLeaseDiscountRate
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000932"
      unitRef="Pure">0.0617</us-gaap:LesseeFinanceLeaseDiscountRate>
    <us-gaap:LesseeFinanceLeaseDiscountRate
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000933"
      unitRef="Pure">0.0619</us-gaap:LesseeFinanceLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000935">&lt;p id="xdx_892_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zZh9W77sRRAa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B6_zQqUwkv5Smyl"&gt;Maturities of lease liabilities are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&lt;b&gt;Year Ending December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Operating Leases&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Finance Leases&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom; width: 52%"&gt;Remainder of 2024&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 2%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20240331_zanzfq8GuNhb" style="vertical-align: bottom; width: 18%; text-align: right" title="2024 - Operating Leases"&gt;384,041&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20240331_zN3jqj0wcU1i" style="vertical-align: bottom; width: 18%; text-align: right" title="2024 - Finance Leases"&gt;98,578&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 2%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;2025&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_c20240331_z7s6l8TSl4Wg" style="text-align: right" title="2025 - Operating Leases"&gt;512,055&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_c20240331_zRUoU2hVhPb2" style="text-align: right" title="2025 - Finance Leases"&gt;131,437&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;2026&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_c20240331_zg5vTq2XkmZg" style="vertical-align: bottom; text-align: right" title="2026 - Operating Leases"&gt;512,055&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_c20240331_zoX17dI2XQ79" style="vertical-align: bottom; text-align: right" title="2026 - Finance Leases"&gt;131,437&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom"&gt;2027&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_c20240331_z2KRKq1vCqLj" style="vertical-align: bottom; text-align: right" title="2027 - Operating Leases"&gt;512,055&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_c20240331_zounU9bLy9Pl" style="vertical-align: bottom; text-align: right" title="2027 - Finance Leases"&gt;74,194&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;2028&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_c20240331_zpTHKbaDDgVb" style="vertical-align: bottom; text-align: right" title="2028 - Operating Leases"&gt;511,009&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_iI_c20240331_zweTlmwMVuXk" style="vertical-align: bottom; text-align: right" title="2028 - Finance Leases"&gt;6,179&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom"&gt;Thereafter&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_c20240331_zsGbBJNckw15" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Thereafter - Operating Leases"&gt;1,833,604&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--FinanceLeaseLiabilityPaymentsDueAfterYearFive_iI_c20240331_zHAmz4lUIWrk" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Thereafter - Finance Leases"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0959"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;Total undiscounted lease payments&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueTotal_iI_c20240331_zxoLT9s7r5pi" style="vertical-align: bottom; text-align: right" title="Total undiscounted lease payments - Operating Leases"&gt;4,264,819&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal_iI_c20240331_zWaFrJrbLQSk" style="vertical-align: bottom; text-align: right" title="Total undiscounted lease payments - Finance Leases"&gt;441,825&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-left: 16.45pt"&gt;Less: imputed interest&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--LesseeOperatingLeaseImputedInterest_iNI_di_c20240331_zydmttaezh5g" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Less: imputed interest - Operating Leases"&gt;(650,873&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--LesseeFinancingLeaseImputedInterest_iNI_di_c20240331_zmxAZ4l6Q9g2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Less: imputed interest - Finance Leases"&gt;(42,469&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;Total lease liabilities&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; vertical-align: bottom"&gt;$&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--OperatingLeaseLiability_iI_c20240331_z5NJJfYHuG68" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Total lease liabilities - Operating Leases"&gt;3,613,946&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; vertical-align: bottom"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--FinanceLeaseLiability_iI_c20240331_zuHy3SmrjCza" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Total lease liabilities - Finance Leases"&gt;399,356&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000937"
      unitRef="USD">384041</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000939"
      unitRef="USD">98578</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000941"
      unitRef="USD">512055</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000943"
      unitRef="USD">131437</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000945"
      unitRef="USD">512055</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000947"
      unitRef="USD">131437</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000949"
      unitRef="USD">512055</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000951"
      unitRef="USD">74194</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000953"
      unitRef="USD">511009</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000955"
      unitRef="USD">6179</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000957"
      unitRef="USD">1833604</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <krmd:LesseeOperatingLeaseLiabilityPaymentsDueTotal
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000961"
      unitRef="USD">4264819</krmd:LesseeOperatingLeaseLiabilityPaymentsDueTotal>
    <krmd:LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000963"
      unitRef="USD">441825</krmd:LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal>
    <krmd:LesseeOperatingLeaseImputedInterest
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000965"
      unitRef="USD">650873</krmd:LesseeOperatingLeaseImputedInterest>
    <krmd:LesseeFinancingLeaseImputedInterest
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000967"
      unitRef="USD">42469</krmd:LesseeFinancingLeaseImputedInterest>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000969"
      unitRef="USD">3613946</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000971"
      unitRef="USD">399356</us-gaap:FinanceLeaseLiability>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000973">&lt;p id="xdx_803_eus-gaap--IncomeTaxDisclosureTextBlock_z0BD5KGS1Mw2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 6 &#x2014; &lt;span id="xdx_822_zJwD9oNZlMie"&gt;INCOME TAXES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For interim income tax reporting, the Company estimates
its annual effective tax rate and applies it to fiscal year-to-date pretax loss, excluding unusual or infrequently occurring discrete
items. Tax jurisdictions with losses for which tax benefits cannot be realized are excluded. The Company reported an income tax expense
of &lt;span id="xdx_902_eus-gaap--DeferredIncomeTaxExpenseBenefit_dmxL_c20240101__20240331_zJQ3QkPBTldk" title="Income tax expense::XDX::0"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0975"&gt;zero&lt;/span&gt;&lt;/span&gt; and income tax benefit of $&lt;span id="xdx_906_eus-gaap--DeferredIncomeTaxExpenseBenefit_dm_c20230101__20230331_zd6i30huUq2f" title="Income tax benefit"&gt;0.6 million&lt;/span&gt; for the periods ended March 31, 2024 and 2023, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We evaluate our deferred tax assets to determine if
they are more likely than not to be realized by assessing both positive and negative evidence in accordance with ASC Topic 740, Income
Taxes.&#160; After considering our cumulative pretax loss (the three-year period ending with the current year), as well as analyzing all
available evidence,&#160;we have recorded a valuation allowance of $&lt;span id="xdx_902_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_dm_c20231231_zpyTEC5j3tVi" title="Valuation Allowance"&gt;6.0 million&lt;/span&gt; against our net deferred tax assets during the year ended
December 31, 2023.&#160; As of March 31, 2024, the valuation allowance is $&lt;span id="xdx_90A_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_dm_c20240331_zXoUjDjdRf8g" title="Valuation Allowance"&gt;6.4 million&lt;/span&gt; As we continue to assess the realizability of our
deferred tax assets, reported pretax income and new evidence may result in a partial or full reduction of the valuation allowance in future
periods.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Recurring items cause our effective tax rate to differ
from the U.S. federal statutory rate of &lt;span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20240101__20240331_zH6tqN3GBnFi" title="Statutory rate"&gt;21&lt;/span&gt;%, including U.S. federal R&amp;amp;D credits, U.S. state tax rates, and stock-based compensation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Beginning in 2022, certain research and development
costs are required to be capitalized and amortized over a five-year period under the Tax Cuts and Jobs Act enacted in December 2017. This
change will impact the expected U.S. federal and state income tax expense and cash taxes to be paid for our fiscal 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company files income tax returns in the U.S. federal
jurisdiction and in various state jurisdictions. Income tax returns for years prior to fiscal 2020 are no longer subject to examination
by tax authorities.&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000977"
      unitRef="USD">600000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000979"
      unitRef="USD">6000000.0</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000981"
      unitRef="USD">6400000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2024-01-01to2024-03-31"
      decimals="INF"
      id="Fact000983"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000985">&lt;p id="xdx_80B_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zLsfjh654rbc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 7 &#x2014; &lt;span id="xdx_823_z9rHQQEUoJdf"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;LEGAL PROCEEDINGS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has been and may again become involved
in legal proceedings, claims and litigation arising in the ordinary course of business. &#160;KORU Medical Systems Inc. is not presently a party to
any litigation or other legal proceeding that is believed to be material to its financial condition.&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000987">&lt;p id="xdx_809_eus-gaap--SubsequentEventsTextBlock_zN7pEo3Y175" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 8 &#x2014; &lt;span id="xdx_828_zHS0OdBt4v4k"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On April 8, 2024, the Company&#x2019;s appeal to BSI
in connection with a prior audit matter was upheld resulting in no disruption of sales of the Company to the market and patients. Our
products remain certified, marketed and sold in the EU. The Company intends to address the identified nonconformance through the routine
BSI assessment process.&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
